,symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund,sharesout,cash,debt,enterprisevalue,revenuePerShareTTM,netIncomePerShareTTM,operatingCashFlowPerShareTTM,freeCashFlowPerShareTTM,cashPerShareTTM,bookValuePerShareTTM,tangibleBookValuePerShareTTM,shareholdersEquityPerShareTTM,interestDebtPerShareTTM,marketCapTTM,enterpriseValueTTM,peRatioTTM,priceToSalesRatioTTM,pocfratioTTM,pfcfRatioTTM,pbRatioTTM,ptbRatioTTM,evToSalesTTM,enterpriseValueOverEBITDATTM,evToOperatingCashFlowTTM,evToFreeCashFlowTTM,earningsYieldTTM,freeCashFlowYieldTTM,debtToEquityTTM,debtToAssetsTTM,netDebtToEBITDATTM,currentRatioTTM,interestCoverageTTM,incomeQualityTTM,dividendYieldTTM,dividendYieldPercentageTTM,payoutRatioTTM,salesGeneralAndAdministrativeToRevenueTTM,researchAndDevelopementToRevenueTTM,intangiblesToTotalAssetsTTM,capexToOperatingCashFlowTTM,capexToRevenueTTM,capexToDepreciationTTM,stockBasedCompensationToRevenueTTM,grahamNumberTTM,roicTTM,returnOnTangibleAssetsTTM,grahamNetNetTTM,workingCapitalTTM,tangibleAssetValueTTM,netCurrentAssetValueTTM,investedCapitalTTM,averageReceivablesTTM,averagePayablesTTM,averageInventoryTTM,daysSalesOutstandingTTM,daysPayablesOutstandingTTM,daysOfInventoryOnHandTTM,receivablesTurnoverTTM,payablesTurnoverTTM,inventoryTurnoverTTM,roeTTM,capexPerShareTTM,dividendPerShareTTM,debtToMarketCapTTM,dividendYielTTM,dividendYielPercentageTTM,peRatioTTM,pegRatioTTM,payoutRatioTTM,currentRatioTTM,quickRatioTTM,cashRatioTTM,daysOfSalesOutstandingTTM,daysOfInventoryOutstandingTTM,operatingCycleTTM,daysOfPayablesOutstandingTTM,cashConversionCycleTTM,grossProfitMarginTTM,operatingProfitMarginTTM,pretaxProfitMarginTTM,netProfitMarginTTM,effectiveTaxRateTTM,returnOnAssetsTTM,returnOnEquityTTM,returnOnCapitalEmployedTTM,netIncomePerEBTTTM,ebtPerEbitTTM,ebitPerRevenueTTM,debtRatioTTM,debtEquityRatioTTM,longTermDebtToCapitalizationTTM,totalDebtToCapitalizationTTM,interestCoverageTTM,cashFlowToDebtRatioTTM,companyEquityMultiplierTTM,receivablesTurnoverTTM,payablesTurnoverTTM,inventoryTurnoverTTM,fixedAssetTurnoverTTM,assetTurnoverTTM,operatingCashFlowPerShareTTM,freeCashFlowPerShareTTM,cashPerShareTTM,operatingCashFlowSalesRatioTTM,freeCashFlowOperatingCashFlowRatioTTM,cashFlowCoverageRatiosTTM,shortTermCoverageRatiosTTM,capitalExpenditureCoverageRatioTTM,dividendPaidAndCapexCoverageRatioTTM,priceBookValueRatioTTM,priceToBookRatioTTM,priceToSalesRatioTTM,priceEarningsRatioTTM,priceToFreeCashFlowsRatioTTM,priceToOperatingCashFlowsRatioTTM,priceCashFlowRatioTTM,priceEarningsToGrowthRatioTTM,priceSalesRatioTTM,enterpriseValueMultipleTTM,priceFairValueTTM,dividendPerShareTTM,symbol,date,calendarYear,period,revenueGrowth,grossProfitGrowth,ebitgrowth,operatingIncomeGrowth,netIncomeGrowth,epsgrowth,epsdilutedGrowth,weightedAverageSharesGrowth,weightedAverageSharesDilutedGrowth,dividendsperShareGrowth,operatingCashFlowGrowth,freeCashFlowGrowth,tenYRevenueGrowthPerShare,fiveYRevenueGrowthPerShare,threeYRevenueGrowthPerShare,tenYOperatingCFGrowthPerShare,fiveYOperatingCFGrowthPerShare,threeYOperatingCFGrowthPerShare,tenYNetIncomeGrowthPerShare,fiveYNetIncomeGrowthPerShare,threeYNetIncomeGrowthPerShare,tenYShareholdersEquityGrowthPerShare,fiveYShareholdersEquityGrowthPerShare,threeYShareholdersEquityGrowthPerShare,tenYDividendperShareGrowthPerShare,fiveYDividendperShareGrowthPerShare,threeYDividendperShareGrowthPerShare,receivablesGrowth,inventoryGrowth,assetGrowth,bookValueperShareGrowth,debtGrowth,rdexpenseGrowth,sgaexpensesGrowth,revenue+1,revenue+2,revenue+3,ebitda+1,ebitda+2,ebitda+3,eps+1,eps+2,eps+3
0,A,134.51,1.072,1750384,38648489280,0.944,124.16-155.35,1.32,"Agilent Technologies, Inc.",USD,0001090872,US00846U1016,00846U101,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.agilent.com,"Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.",Mr. Rodney  Gonsalves,Healthcare,US,17400,800 227 9770,5301 Stevens Creek Boulevard,Santa Clara,CA,95051,43.1821,91.32789834256609,https://images.financialmodelingprep.com/symbol/A.png,1999-11-18,False,False,True,False,False,286000000.0,1329000000,3390000000,39329660000,22.762237762237763,4.506993006993007,6.1223776223776225,4.800699300699301,4.646853146853147,20.622377622377623,3.055944055944056,20.622377622377623,11.965034965034965,38648489280.0,40709489280.0,29.844732350659427,5.936787907834101,21.970222729868645,28.148936110706483,6.522526280094947,6.522526280094947,6.253377769585254,23.4907612694749,23.24928,29.650028608885652,0.03350675047946626,0.035525321314706766,0.5747711088504578,0.2861725476954246,1.189267166762839,2.0891820580474936,47.0,1.3584173778122575,0.0070180655713329865,0.7018065571332986,0.2125678820791311,0.0,0.07235023041474654,0.424109404018234,0.2158766419189035,0.05806451612903226,1.4708171206225682,0.01966205837173579,45.730301922921555,0.1372300851529633,0.1889475227206098,-10.979020979020978,2064000000,874000000,-1989000000,8866000000,1275500000.0,518500000.0,975000000.0,74.23348694316437,66.36363636363636,119.45454545454545,4.9169184290030215,5.5,3.0555555555555554,0.21303144238317565,1.3216783216783217,0.944,0.08771364840266274,0.0070180655713329865,0.7018065571332986,29.844732350659427,-3.6112126144297956,0.2125678820791311,2.0891820580474936,1.5762532981530344,0.7013192612137203,74.23348694316437,119.45454545454545,193.68803239770983,66.36363636363636,127.32439603407347,0.543778801843318,0.23102918586789556,0.23364055299539171,0.19800307219662058,0.1525312294543064,0.10881310146885025,0.21303144238317565,0.15114058888553913,0.8474687705456936,1.0113031914893618,0.23102918586789556,0.2861725476954246,0.5747711088504578,0.361895488477767,0.3649870801033592,47.0,0.516519174041298,2.008477449983045,4.9169184290030215,5.5,3.0555555555555554,3.661417322834646,0.5495525915920986,6.1223776223776225,4.800699300699301,4.646853146853147,0.26897081413210444,0.7841233580810966,0.516519174041298,38.91111111111111,4.632275132275132,2.6855828220858897,6.522526280094947,6.522526280094947,5.936787907834101,29.844732350659427,28.148936110706483,21.970222729868645,21.970222729868645,-3.6112126144297956,5.936787907834101,23.4907612694749,6.522526280094947,0.944,A,2024-10-31,2024,FY,-0.047270598565783695,0.020202020202020204,0.10222222222222223,0.10222222222222223,0.03951612903225806,0.052132701421801105,0.05727923627684948,-0.013605442176870748,-0.016891891891891893,0.04822381262199089,-0.011851015801354402,0.18792401628222524,0.0708030170561475,0.36524474543669466,0.0799613644673153,1.819959375151134,0.8569151271572832,0.2360478346685242,1.9781239159092485,0.30315206542387063,0.11671701339412939,0.2817053433918921,0.3450106033756499,0.1472872582079714,0.7876567398119123,0.4401740877134249,0.21706604324956172,0.025561580170410533,-0.05722599418040737,0.1006225030196042,0.022985752632665706,0.23948811700182815,-0.004158004158004158,-0.04039167686658507,6827342312.0,7265798987.0,7732901752.0,1768810750.0,1882405008.0,2003420822.0,5.56256,6.10726,6.71343
0,ABT,114.23,0.722,5007693,198127365800,2.2,99.71-121.64,1.81,Abbott Laboratories,USD,0000001800,US0028241000,002824100,New York Stock Exchange,NYSE,Medical - Devices,https://www.abbott.com,"Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.",Mr. Robert B. Ford,Healthcare,US,114000,224 667 6100,100 Abbott Park Road,North Chicago,IL,60064-6400,-5.08655,119.31655262180269,https://images.financialmodelingprep.com/symbol/ABT.png,1980-03-17,False,False,True,False,False,1734455938.0,7558000000,14979000000,205166321491,23.76364777967626,3.3249619512675106,5.032125526385093,3.739501164543276,4.490168835871574,23.078130221143734,5.199324930905221,22.94437069752763,8.922106154996484,198127365800.0,205548365800.0,34.355280353344895,4.806933202319431,22.70014915189505,30.546926580326858,4.9785632173519945,4.9785632173519945,4.9869802702768276,19.111888963272897,23.55045437671861,31.691083225408573,0.029107607032018826,0.032736517612348935,0.37639461252387174,0.20144978212921621,0.6900046490004649,1.5972352704334989,13.903225806451612,1.5192341166231507,0.019259388952114157,1.9259388952114158,0.6530258366568407,0.0,0.06744789771210909,0.4170477163914143,0.2568744271310724,0.05439503117645632,0.6954094292803971,0.01640099958754883,41.43073847053384,0.10711819685644983,0.13304572509574125,-9.358986668014163,8900000000,9018000000,-10526000000,50531000000,8027500000.0,4079500000.0,6813500000.0,81.48009316544145,78.86080017138877,133.18756360130683,4.4796217802412786,4.628408527516113,2.74049611037722,0.14737393548716834,1.292624361841817,2.2,0.07560288271899086,0.019259388952114157,1.9259388952114158,34.355280353344895,9.190037494519752,0.6530258366568407,1.5972352704334989,1.1400483156623271,0.5071802442625151,81.48009316544145,133.18756360130683,214.66765676674828,78.86080017138877,135.8068565953595,0.5470073028119465,0.16730960525996555,0.16444670888225732,0.13991799500206226,0.14915904396577162,0.07755930926892247,0.14737393548716834,0.1159888317018199,0.8508409560342284,0.9828886310904872,0.16730960525996555,0.20144978212921621,0.37639461252387174,0.24372398852169286,0.27346417161113645,13.903225806451612,0.5826824220575473,1.8684289878379736,4.4796217802412786,4.628408527516113,2.74049611037722,3.880708031258827,0.5543197589972565,5.032125526385093,3.739501164543276,4.490168835871574,0.21175728461557125,0.7431255728689276,0.5826824220575473,4.051996285979573,3.892952720785013,1.4527296937416778,4.9785632173519945,4.9785632173519945,4.806933202319431,34.355280353344895,30.546926580326858,22.70014915189505,22.70014915189505,9.190037494519752,4.806933202319431,19.111888963272897,4.9785632173519945,2.2,ABT,2023-12-31,2023,FY,-0.08118571461297047,-0.09697686752886459,-0.2253049509686678,-0.2253049509686678,-0.1745276215202654,-0.1624365482233503,-0.1636828644501279,-0.010795003993154592,-0.008503401360544218,0.08637230115617149,-0.24214591378770484,-0.351742696053306,0.63893020689236,0.3279903446131078,0.18496589403721572,0.9501397480231146,0.16685810400304235,-0.06037428580034557,0.9833903679799277,1.4468323139506936,0.30177092760928964,0.36914958704535195,0.28038851950872434,0.20392555804542944,2.599345030303062,0.8237981189954574,0.42024184871563774,0.05580572531360566,0.06431232787947513,-0.016443214487224266,0.06356080716244915,-0.10403025513659968,-0.05090027700831025,-0.026582503556187766,42000760347.0,45000213557.0,48327024484.0,11267522461.0,12072184237.0,12964666100.0,4.67462,5.16092,5.70724
0,ADPT,6.39,1.447,1245768,943029810,0.0,2.28-7.067,0.39,Adaptive Biotechnologies Corporation,USD,0001478320,US00650F1093,00650F109,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.adaptivebiotech.com,"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.",Mr. Chad M. Robins M.B.A.,Healthcare,US,709,206 659 0067,1165 Eastlake Avenue East,Seattle,WA,98109,0.0401863,9.31981,https://images.financialmodelingprep.com/symbol/ADPT.png,2019-06-27,False,False,True,False,False,147516398.0,38084000,91825000,809024957,1.2017782592549473,-1.323520657005196,-0.7433275316280431,-0.7764221574878747,1.6495047553967526,1.5155874399807403,0.6829681402605831,1.5169364425506104,0.07890648197632917,943029810.0,996770810.0,-4.828031936017537,5.319377094121231,-8.596479651445925,-8.233551403501114,4.21243752919253,4.21243752919253,5.622515596620074,-6.0962711232072415,-9.090228356725307,-8.702761688566813,-0.20712373349064103,-0.12145427300967294,0.0,0.0,-0.3286810800892939,3.5188355187328106,-14.301202749140893,0.5614046764523677,0.0,0.0,0.0,0.4257397818165409,0.5707460430274929,0.21991706445409717,-0.04452226569268511,0.027538046727812186,0.24168316831683168,0.31776491691203845,6.721099324834699,-0.759688783691084,-0.4481283324267067,-0.37294158985633585,220718000,100749000,-26587000,441387000,38212000.0,8609000.0,12584500.0,84.03058404124502,32.78969301461603,53.32618419123039,4.3436565884255405,11.13154672833628,6.844667503136763,-0.7447057656805456,0.03309462585983153,0.0,0.0,0.0,0.0,-4.828031936017537,-0.5459389958419835,0.0,3.5188355187328106,3.3824049665057574,0.4346149017996736,84.03058404124502,53.32618419123039,137.35676823247542,32.78969301461603,104.56707521785938,0.5384302974921312,-0.9389898579664038,-1.101741857605397,-1.1013018806195778,-0.021216573912420194,-0.34957726506071557,-0.7447057656805456,-0.35352181770688434,0.9996006532902585,1.1733266853291362,-0.9389898579664038,0.0,0.0,0.0,0.0,-14.301202749140893,0.0,2.495859643477989,4.3436565884255405,11.13154672833628,6.844667503136763,1.8118842238665631,0.3174218361127723,-0.7433275316280431,-0.7764221574878747,1.6495047553967526,-0.6185230311029885,1.0445222656926851,0.0,0.0,-22.460671855796804,-22.460671855796804,4.21243752919253,4.21243752919253,5.319377094121231,-4.828031936017537,-8.233551403501114,-8.596479651445925,-8.596479651445925,-0.5459389958419835,5.319377094121231,-6.0962711232072415,4.21243752919253,0.0,ADPT,2023-12-31,2023,FY,-0.08111900187795454,-0.256485529713734,-0.13412026815061992,-0.13412026815061992,-0.5811011904761905,-0.56,-0.56,0.013102936424988937,0.013102936424988937,0,0.15015901492293893,0.16612080242044194,2.2340144892007223,1.2338247863174705,0.5729292440415258,-2.274805181825687,-2.538645309156508,0.05087246062295098,-2.840332792130158,-2.5413545292425095,-0.4660057861570246,2.0026158073366642,1.8725032241071013,-0.6229142777931177,0,0,0,-0.0521257208477919,-0.00034594893793676054,-0.22820350284899785,-0.34433913583243975,1.124331030906835,-0.13854087304946527,-0.06309129419431923,177705789.0,211241264.0,265223499.0,-168337212.0,-200104710.0,-251241023.0,-1.115,-0.9375,-0.67667
0,ADTX,0.1861,1.081,3004767,2648985,0.0,0.185-338.8,-0.0399,"Aditxt, Inc.",USD,0001726711,US0070256047,007025109,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.aditxt.com,"Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.",Mr. Amro A. Albanna,Healthcare,US,47,909 488 0844,737 North Fifth Street,Richmond,VA,23219,,0.0,https://images.financialmodelingprep.com/symbol/ADTX.png,2020-06-30,False,False,True,False,False,115672.0,328596,10110295,10277931,1.8336935472715956,-347.4312798257141,-120.37824192544436,-120.37824192544436,2.840756622173041,38.46292101805104,38.402889203956015,40.73344456739747,164.01028771007677,2648985.0,12430684.0,-0.0005356454954008616,12.488908899753426,-0.00154596044121711,-0.1902406223553603,0.004568727294645541,0.004568727294645541,58.60572258341308,-0.4180462414414114,-0.8927272372107882,-0.8927272372107882,-1866.9063934750893,-5.256500886188483,1.8761061514916317,0.29624323052556123,-0.3289603775513248,0.08569598252723902,-2.977142068670915,0.34613792148886224,0.0,0.0,0.0,70.2449706987511,68.33068215570444,0.00023271338206842183,0.0,0.0,0.0,3.6493326481445685,564.2886118819122,-2.217685866817255,-1.347131168436452,-208.32462480116192,-22280585,4442139,-23301881,-19168874,816483.0,6569511.0,327247.5,2110.377215273423,0.0,29.027830527165214,0.1729548619831503,0.0,12.574139829651438,-4.313814995488069,0.0,0.0,3.3370083258304595,0.0,0.0,-0.0005356454954008616,6.463896924062679e-06,0.0,0.08569598252723902,0.08204403300567256,0.013484234948295988,2110.377215273423,29.027830527165214,2139.4050458005886,0.0,2139.4050458005886,-4.2757476179475455,-142.20911615363943,-190.70896764368928,-189.47074353981716,0.0036730383970791907,-1.3468176729861554,-4.313814995488069,-5.513977916338155,0.9935072581055259,1.3410460088764753,-142.20911615363943,0.29624323052556123,1.8761061514916317,0.0,0.652307687085412,-2.977142068670915,-1.5752135964120892,6.332992481088112,0.1729548619831503,0.0,12.574139829651438,0.06831655966454166,0.007108314707716986,-120.37824192544436,-120.37824192544436,2.840756622173041,-65.64796069908112,1.0,-1.5752135964120892,-1.5752135964120892,0.0,0.0,0.004568727294645541,0.004568727294645541,12.488908899753426,-0.0005356454954008616,-0.1902406223553603,-0.00154596044121711,-0.00154596044121711,6.463896924062679e-06,12.488908899753426,-0.4180462414414114,0.004568727294645541,0.0,ADTX,2023-12-31,2023,FY,-0.30902256041725795,-1.6688790913883165,-0.04516593573348904,-0.04516593573348904,-0.14850864093804406,0.8221334122755082,0.8221334122755082,5.520790200138026,5.520790200138026,0,0.1703820104371176,0.18312981387432756,0,0,0,0,0.6876000572501767,0.9448064188421978,-0.30043339256299967,0.9630293604275472,0.9265581298672784,3.292829744704586,1.0678690466703857,-0.9687163959813636,0,0,0,10.085959000759527,-0.21533786692460632,3.1525191451078594,-0.5273304778176483,4.3869741464679635,-0.026656956633962954,0.05839155028322941,1475000.0,1200000.0,1260000.0,-294999.0,-239999.0,-251999.0,-451.6,-3678.8,-3741.2
0,AKYA,2.49,1.346,228017,123412866,0.0,1.88-6.31,-0.06,"Akoya Biosciences, Inc.",USD,0001711933,US00974H1041,00974H104,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.akoyabio.com,"Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.",Mr. Brian  McKelligon,Healthcare,US,330,855 896 8401,100 Campus Drive,Marlborough,MA,01752,5.021,-0.03099895265852369,https://images.financialmodelingprep.com/symbol/AKYA.png,2021-04-16,False,False,True,False,False,49503272.0,12557000,84919000,207010899,1.7537224610122741,-1.170993303230542,-0.9428063664155372,-0.9833693417275529,0.7251237857570304,0.2753959374644973,-0.40201383052013206,0.2753959374644973,1.738026528832276,123412866.0,195774866.0,-2.1263998633728955,1.421561550423314,-2.6410513215632503,-2.535186236647494,9.041527710701972,9.041527710701972,2.2550811034959395,-4.919955418174507,-4.194696306136441,-4.021669391947412,-0.4702784350323461,-0.39444833896005627,5.567519988263772,0.5839828272025729,-1.8185062324085244,2.7457221448219196,-4.468528018942384,0.805133866961082,0.0,0.0,0.0,0.0,0.23021367275240454,0.258007432312865,-0.04302365443949263,0.023129643494787768,0.25392008093070306,0.11200829349766746,2.6936876148555213,-0.5070237663095167,-0.6010846234407242,-1.176659595349576,48868000,-19901000,-39479000,96375000,14669999.5,9272500.0,25004000.0,53.756724068421356,82.87713841368584,238.5272161741835,6.7898482715470045,4.404109589041096,1.5302237029985721,-1.8947660878447394,0.04056297531201574,0.0,0.6150250169216555,0.0,0.0,-2.1263998633728955,-0.523094366389732,0.0,2.7457221448219196,1.8450684099596328,0.4485764298217412,53.756724068421356,238.5272161741835,292.28394024260484,82.87713841368584,209.40680182891901,0.5556067499856016,-0.5217185970166446,-0.6661982376317457,-0.6677187122041122,-0.0022823155128293797,-0.4460003231440376,-1.8947660878447394,-0.4441361051186507,1.0022823155128293,1.2769302099662199,-0.5217185970166446,0.5839828272025729,5.567519988263772,0.8477355224213995,0.8477355224213995,-4.468528018942384,-0.6148981581513003,9.533704980561872,6.7898482715470045,4.404109589041096,1.5302237029985721,6.213053746511129,0.6679464196410023,-0.9428063664155372,-0.9833693417275529,0.7251237857570304,-0.5376029487991707,1.0430236544394926,-0.6148981581513003,0.0,-23.243027888446214,-23.243027888446214,9.041527710701972,9.041527710701972,1.421561550423314,-2.1263998633728955,-2.535186236647494,-2.6410513215632503,-2.6410513215632503,-0.523094366389732,1.421561550423314,-4.919955418174507,9.041527710701972,0.0,AKYA,2023-12-31,2023,FY,0.29086682963972266,0.2976492279327034,0.12898743354277428,0.12898743354277428,0.1035942299797568,0.2352941176470589,0.2352941176470589,0.1771709025757469,0.1771709025757469,0,0.04854568565874084,0.10358879978966741,0.9108157379336587,0.9108157379336587,0.9014964424608533,-2.0857607033518195,-2.0857607033518195,-5.21210572108354,-2.5852227791741966,-2.5852227791741966,-2.1656663004668126,2.4890155303364043,2.4890155303364043,1.4181368466649953,0,0,0,0.7467365607976154,0.2340880850476322,0.02464338667621044,-0.2202709104286549,0.1309247334529716,-0.05695575373745207,0.03424855309906721,81967878.0,91597919.0,105596203.0,-38765093.0,-43319432.0,-49939644.0,-1.095,-0.62125,-0.44429
0,AWH,0.77,1.438,94058,12833821,0.0,0.67-5.65,0.005,Aspira Women's Health Inc.,USD,0000926617,US04537Y2081,04537Y109,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://aspirawh.com,"Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.",Ms. Nicole  Sandford CPA,Healthcare,US,64,512 519 0400,Building III,Austin,TX,78738,,0.0,https://images.financialmodelingprep.com/symbol/AWH.png,2000-10-02,False,False,True,False,False,15405730.0,2133000,2142000,12487641,0.5817965133752182,-0.9603569580928655,-0.9439344970994559,-0.9471151318373099,0.13845497746617655,-0.16357550080392166,-0.16357550080392166,-0.16357550080392166,0.10275397530659047,12833821.0,12842821.0,-0.8017852044609666,1.4318666741046524,-0.8157345688350984,-0.8795710369405798,-4.707306388888889,-4.707306388888889,1.4328708021867678,-0.7603801657785672,-0.8831536927520286,-0.8801878555273799,-1.247216828692033,-1.136917836083268,-0.6202380952380953,0.32843034250893044,-0.0005328596802841918,0.752469813391877,-849.1,0.9828996282527881,0.0,0.0,0.0,1.1432556063817918,0.4287626910632601,0.0,-0.003369550268188695,0.005466919558183644,0.4260869565217391,0.14347874595559523,1.8800384526221408,18.649048735222546,-3.108846396301744,-0.2635707623072714,-1353000,-2520000,-3166000,-739000,1349500.0,2247000.0,258000.0,51.066607162780315,248.0327650506127,28.196590303676082,7.147527910685805,1.4715797726381812,12.944827586206896,5.94355729637441,0.003180634737854032,0.0,0.12178757986417295,0.0,0.0,-0.8017852044609666,-0.04650354185873606,0.0,0.752469813391877,0.6994145627515551,0.3902305159165752,51.066607162780315,28.196590303676082,79.2631974664564,248.0327650506127,-168.7695675841563,0.5811670199709918,-1.8946781211647885,-1.6506749972107553,-1.6506749972107553,-0.05094450827982427,-3.108846396301744,5.94355729637441,24.019801980198018,1.0,0.8712165822635732,-1.8946781211647885,0.32843034250893044,-0.6202380952380953,-1.1247892074198989,-1.6332288401253918,-849.1,-9.303902751119642,-1.8884920634920634,7.147527910685805,1.4715797726381812,12.944827586206896,14.59771986970684,1.8833788611052742,-0.9439344970994559,-0.9471151318373099,0.13845497746617655,-1.6224478411246235,1.0033695502681887,-9.303902751119642,-63.50218340611354,-296.7755102040816,-296.7755102040816,-4.707306388888889,-4.707306388888889,1.4318666741046524,-0.8017852044609666,-0.8795710369405798,-0.8157345688350984,-0.8157345688350984,-0.04650354185873606,1.4318666741046524,-0.7603801657785672,-4.707306388888889,0.0,AWH,2023-12-31,2023,FY,0.11852394916911047,0.21833757814308868,0.4246299404852739,0.4246299404852739,0.22641946697566628,0.956553048487758,0.956553048487758,16.826979959068616,16.826979959068616,0,0.5061674693180053,0.5089613474411574,-0.46098736978812704,0.5172804705686506,0.4313504663280639,0.7079919711135567,0.14135340397601956,0.21549817466394114,0.7140555446088442,0.2572555056253147,0.3115293358373376,-1.013350340949937,-1.167334466492625,-1.176966466015768,0,0,0,0.1718875502008032,-0.28164556962025317,-0.6395556323029989,-1.0197094170056162,-0.25554685460715215,-0.32219049218881235,-0.3550159005492917,10139950.0,17908750.0,32661000.0,-10139950.0,-17908750.0,-32661000.0,-1.1346,-0.53445,-0.26
0,AXDX,1.16,0.598,64614,29050808,0.0,0.73-4.41,-0.03,"Accelerate Diagnostics, Inc.",USD,0000727207,US00430H2013,00430H102,NASDAQ Capital Market,NASDAQ,Medical - Devices,https://acceleratediagnostics.com,"Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.",Mr. Jack  Phillips,Healthcare,US,134,520 365 3100,3950 South Country Club Road,Tucson,AZ,85714,0.712337,1.73234,https://images.financialmodelingprep.com/symbol/AXDX.png,1994-04-07,False,False,True,False,False,24915000.0,19691000,58974000,81887650,0.47690146498093516,-2.145574954846478,-1.0789082881798113,-1.083323299217339,0.8393337346979731,-1.9458559100943207,-1.9458559100943207,-1.9458559100943207,2.759983945414409,29050808.0,68333808.0,-0.5406476233234188,2.4449426022555123,-1.0751608943119675,-1.0763146233929828,-0.5961386935087972,-0.5961386935087972,5.751035852550076,-1.76582272985684,-2.5420857854990513,-2.531725686339891,-1.8496335817642056,-0.9290963611063761,-1.1964480930673873,1.7949868482129043,-1.0151170603131945,1.5026837550662724,-3.325278810408922,0.5028621670158635,0.0,0.0,0.0,0.0,1.558155192728497,0.0,-0.0040921096685391165,0.009257700723783875,0.03204194581998252,0.40245749873758624,9.692112432017256,-3.8547550331555613,-1.6542472535974007,-2.2827513546056593,9178000,-48481000,-53360000,13294000,2158000.0,4236500.0,3100500.0,62.26687426359199,190.73384325462808,120.4932934264494,5.861864824864331,1.9136614340263047,3.029214237743452,1.657118943550637,0.004415011037527594,0.0,1.996674240523706,0.0,0.0,-0.5406476233234188,0.017217547388915018,0.0,1.5026837550662724,1.3395771716507832,1.078486143060576,62.26687426359199,120.4932934264494,182.76016769004138,190.73384325462808,-7.973675564586699,0.2407843797340515,-3.011277562699882,-4.451354990742299,-4.498990069011951,-0.026067270424079712,-1.6542472535974007,1.657118943550637,-2.5453510706409617,1.010701253521393,1.4782280603689213,-3.011277562699882,1.7949868482129043,-1.1964480930673873,6.090403191936161,6.090403191936161,-3.325278810408922,-0.46342556676148605,-0.6665497823889771,5.861864824864331,1.9136614340263047,3.029214237743452,2.8867832847424686,0.3676930218164939,-1.0789082881798113,-1.083323299217339,0.8393337346979731,-2.2623295741457667,1.0040921096685391,-0.46342556676148605,0.0,-244.37272727272727,-244.37272727272727,-0.5961386935087972,-0.5961386935087972,2.4449426022555123,-0.5406476233234188,-1.0763146233929828,-1.0751608943119675,-1.0751608943119675,0.017217547388915018,2.4449426022555123,-1.76582272985684,-0.5961386935087972,0.0,AXDX,2023-12-31,2023,FY,-0.0543444165621079,-0.22797456857402362,0.13975001990287397,0.13975001990287397,0.014001568175635672,0.3508541392904073,0.3508541392904073,0.518603717092051,0.518603717092051,0.0,0.17509440157609588,0.16336595511545798,74.260167182297,-0.07110473606533016,-0.5151493687929005,-0.2424847565998663,0.7408963144526681,0.6419370350815664,-0.21506247532563078,0.6953104586247086,0.6463189301866991,-1.1443555773085148,-1.1513933939276155,0.857864066264784,0,0,0,0.08526490066225166,-0.3627262225644975,-0.5175574867338306,0.4117750257311398,-0.49419654371937066,-0.05803455322310979,-0.20330160998137423,11900000.0,12300000.0,22400000.0,-11900000.0,-12300000.0,-22400000.0,-2.3,-2.0,-0.36
0,AZTA,50.43,1.483,740023,2304242517,0.0,38.82-69.16,0.93,"Azenta, Inc.",USD,0000933974,US1143401024,114340102,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.azenta.com,"Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.",Mr. John P.  Marotta,Healthcare,US,3300,978 262 2626,15 Elizabeth Drive,Chelmsford,MA,01824,65.94415,-15.514146649537016,https://images.financialmodelingprep.com/symbol/AZTA.png,1995-02-02,False,False,True,False,False,52963000.0,310929000,58792000,2313390720,11.925050874557876,-2.982884345171762,0.9137252289355104,0.23433184747323027,8.395955472648868,32.14121929357042,15.072096516304084,32.14121929357042,0.0,2304242517.0,2052105517.0,-16.906455016141805,3.5108361538449815,55.191646682177016,178.66500093044894,1.5690132828933496,1.5690132828933496,3.1266701258374305,96.7289897242517,40.806250213764436,159.11495053113126,-0.059149005456509265,0.005597067107671983,0.0,0.0,-11.88484562809333,4.065666206142385,0.0,-0.30632271425960894,0.0,0.0,0.0,0.0,0.051080032240223186,0.44734317091904396,0.7435423253594226,0.05697194826327891,0.4120603015075377,0.02204250041519191,46.44517894221408,-0.040289166338272196,-0.14145245312346524,5.78113492659528,627968000,829528000,501733000,1834053000,170162000.0,41774000.0,115263000.0,96.04952896668256,40.58468256550137,105.2737418983509,3.8001227484062974,8.993540836765467,3.4671513847435276,-0.07793588815438113,0.6793933814622801,0.0,0.0,0.0,0.0,-16.906455016141805,7.917856432559738,0.0,4.065666206142385,3.5029999170079917,1.5179189509810143,96.04952896668256,105.2737418983509,201.32327086503346,40.58468256550137,160.7385882995321,0.3911382048168356,-0.11067568864720571,-0.25494002190994375,-0.2501359848733017,0.018843793142604422,-0.07817466420893687,-0.07793588815438113,-0.03832784051515353,0.9811562068573956,2.3034871074767,-0.11067568864720571,0.0,0.0,0.0,0.0,0.0,0.0,1.1871566852292892,3.8001227484062974,8.993540836765467,3.4671513847435276,2.461402008655671,0.3125286601547303,0.9137252289355104,0.23433184747323027,8.395955472648868,0.07662233382039027,0.25645767464057745,0.0,0.0,1.344913350449294,1.344913350449294,1.5690132828933496,1.5690132828933496,3.5108361538449815,-16.906455016141805,178.66500093044894,55.191646682177016,55.191646682177016,7.917856432559738,3.5108361538449815,96.7289897242517,1.5690132828933496,0.0,AZTA,2024-09-30,2024,FY,-0.013154966680299276,0.0008626586607889336,-1.7442770013401525,-1.7442770013401525,-10.515045240934278,-13.045454545454543,-13.045454545454543,-0.19739483495087015,-0.19739483495087015,0.0,1.8753001715265867,1.5876697348036088,0.7036752326417557,0.13648207842079607,0.7834939198223473,0.17198957722523472,-0.2509765539209605,-0.5315512581797185,-7.561203661856836,-23.47368280041434,-6.938312090298861,2.44876306866557,1.1021426617439458,0.8632044082889965,-1.0,-1.0,-1.0,0.10333791164915195,-0.10095321299864272,-0.27226446086245376,-0.13038807734134028,-0.0272023297372427,-0.012692896689833902,-0.042825706173604566,596369167.0,634540400.0,664183500.0,30285007.0,32223431.0,33728776.0,0.385,0.67833,0.925
0,BDSX,1.57,1.213,423222,228383190,0.0,1.11-2.21,0.21,"Biodesix, Inc.",USD,0001439725,US09075X1081,09075X108,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.biodesix.com,"Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.",Mr. Scott  Hutton,Healthcare,US,217,303 417 0500,2970 Wilderness Place,Boulder,CO,80301,,0.0,https://images.financialmodelingprep.com/symbol/BDSX.png,2020-10-28,False,False,True,False,False,146296000.0,31406000,61956000,290956880,0.44814622409361843,-0.2995228851096407,-0.3830590036638049,-0.4210436375567343,0.21467435883414449,0.19041532236014655,0.04366489856181987,0.19041532236014655,0.3116968338163723,228383190.0,258933190.0,-5.2416695953809995,3.4834689301729664,-4.098585296216988,-3.707699887981558,8.245134795563054,8.245134795563054,3.949440071992923,-8.741541136355963,-4.620506602426838,-4.203665600597432,-0.19077890771314693,-0.26970899215480787,1.319775998851276,0.35783459700417547,-1.0313628844400933,3.3955874411787397,-3.9117147707979627,1.2788972820009585,0.0,0.0,0.0,0.5375064824135932,0.13779323388548245,0.20895827452965166,-0.09916131334760885,0.08475946432384614,1.0361737833302256,0.09844117019004911,1.13281035537898,-0.5109752396561429,-0.5391515121687133,-0.2560083665992235,31054000,6388000,-30869000,83124000,9082000.0,2378500.0,600000.0,44.738415545590435,63.40328654570353,0.0,8.158536585365853,5.756799369333859,0.0,-2.773573858691352,0.0379846338929294,0.0,0.16097944861878846,0.0,0.0,-5.2416695953809995,-0.34445257341075136,0.0,3.3955874411787397,3.3955874411787397,2.4227416493095735,44.738415545590435,0.0,44.738415545590435,63.40328654570353,-18.664871000113095,0.7772337634605412,-0.5271346206644093,-0.6683597205698423,-0.6683597205698423,0.04455318469157215,-0.42649134247588644,-2.773573858691352,-0.3849409668077523,1.0,1.2679108796296297,-0.5271346206644093,0.35783459700417547,1.319775998851276,0.5645234410417546,0.5689238958868497,-3.9117147707979627,-1.5242758057935537,3.688229170406002,8.158536585365853,5.756799369333859,0.0,2.142479003954119,0.638116465355304,-0.3830590036638049,-0.4210436375567343,0.21467435883414449,-0.8547634300356914,1.0991613133476088,-1.5242758057935537,-85.81929555895866,-10.084578009717474,-10.084578009717474,8.245134795563054,8.245134795563054,3.4834689301729664,-5.2416695953809995,-3.707699887981558,-4.098585296216988,-4.098585296216988,-0.34445257341075136,3.4834689301729664,-8.741541136355963,8.245134795563054,0.0,BDSX,2023-12-31,2023,FY,0.28459646184444676,0.49958433785019535,0.18144378885676948,0.18144378885676948,0.35132109270040307,0.6649214659685865,0.6649214659685865,0.9502885780110681,0.9502885780110681,0,0.4914613537312105,0.05306560013194244,-0.22345583566447919,-0.22345583566447919,-0.6514604096608082,0.5818152874628859,0.5818152874628859,0.6537548619752327,0.3558393180908386,0.3558393180908386,0.5375228746896745,1.007475582526565,1.007475582526565,-0.9640111846207002,0,0,0,0.5160908193484699,0.0,0.06662648268141994,-0.8860346298953008,0.9055259026687598,-0.23767363761257823,0.09640102827763496,70729200.0,92250700.0,113466667.0,-54662155.0,-71294770.0,-87691258.0,-0.34797,-0.21658,-0.15
0,BDX,227.68,0.45,1648685,65827296960,3.89,218.75-249.89,3.85,"Becton, Dickinson and Company",USD,0000010795,US0758871091,075887109,New York Stock Exchange,NYSE,Medical - Instruments & Supplies,https://www.bd.com,"Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.",Mr. Thomas E. Polen Jr.,Healthcare,US,70000,201 847 6800,1 Becton Drive,Franklin Lakes,NJ,07417-1880,-236.78359,464.46358669879544,https://images.financialmodelingprep.com/symbol/BDX.png,1973-02-21,False,False,True,False,False,289607000.0,1717000000,20110000000,88217247700,69.67373026204477,5.959800695425179,13.11432389410477,10.610931365609257,7.4652891677342055,89.39355747616598,-39.688267203486106,197.80599225847442,71.26208965943503,65827296960.0,84220296960.0,38.20261979142526,3.2623301100208146,17.361169499736704,21.42118352098926,1.151026808644346,1.151026808644346,4.173867427891763,19.770022760563382,22.174907045813583,27.40653985030914,0.026176215282085292,0.04668276143660145,0.35104563069510875,0.35104563069510875,4.317605633802817,1.1700011176930816,4.9981060606060606,2.227565982404692,0.017085382993675333,1.708538299367533,0.6373117033603708,0.0,0.05897512141936763,0.6525678176168698,0.1908899420747762,0.03593022103280801,0.4264705882352941,0.009713549410248786,162.86465709287504,0.02895091293379239,0.08672059488519318,-86.45768230740279,1521000000,-11494000000,-20929000000,45725000000,2814500000.0,948000000.0,3549000000.0,54.86396074933095,62.61105582194879,126.90626979100696,6.652818991097923,5.82964135021097,2.8761384335154827,0.051470917142558935,2.503392528495513,3.8899999999999997,0.30549636592582335,0.017085382993675333,1.7085382993675333,38.20261979142526,1.7226551702244537,0.6373117033603708,1.1700011176930816,0.7404716664803845,0.19190790209008607,54.86396074933095,126.90626979100696,181.7702305403379,62.61105582194879,119.15917471838912,0.452225195757756,0.13078600455942116,0.1008028545941124,0.0855387055208643,0.15093411996066863,0.030129525538525992,0.051470917142558935,0.05459359937110821,0.8485742379547689,0.7707464948844259,0.13078600455942116,0.35104563069510875,0.35104563069510875,0.23848137611995854,0.2598325494857615,4.9981060606060606,0.18886126305320736,1.0,6.652818991097923,5.82964135021097,2.8761384335154827,2.9582172701949863,0.3522326571937297,13.11432389410477,10.610931365609257,7.4652891677342055,0.18822479928635147,0.8091100579252238,0.18886126305320736,1.7502304147465437,5.238620689655172,2.081095890410959,1.151026808644346,1.151026808644346,3.2623301100208146,38.20261979142526,21.42118352098926,17.361169499736704,17.361169499736704,1.7226551702244537,3.2623301100208146,19.770022760563382,1.151026808644346,3.8899999999999997,BDX,2024-09-30,2024,FY,0.041606442287838115,0.11689106487148103,0.13548081477972526,0.13548081477972526,0.14892183288409702,0.1830985915492958,0.18623481781376516,0.012159339392626851,0.009074454215096119,-0.024429616351296406,0.2860488457678153,0.47470449172576834,0.5937262229694409,0.08720706308182959,-0.005090735108356518,0.47035965045397593,0.07539567673401193,-0.17415566099116245,-0.040173556066793494,0.30194816362925875,-0.18632646107454773,2.4207517199413697,0.13985308353300432,0.09255922864048122,0.7429995189040681,0.04142195097541029,0.047897712036472674,0.19692186266771902,0.17415215398716774,0.08537324744221296,-0.008489802838901106,0.2664525473896341,-0.03799514955537591,0.029243483788938335,21998483874.0,23106251820.0,24329917840.0,4715164088.0,4952603526.0,5214884604.0,14.41339,15.71118,16.53696
0,BIM.PA,102.2,0.219,102615,12052357290,0.85,88.25-111.5,0.9,bioMérieux S.A.,EUR,,FR0013280286,F1149Y232,Paris,EURONEXT,Medical - Diagnostics & Research,https://www.biomerieux.com,"bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.",Mr. Pierre  Boulud,Healthcare,FR,13409,33 4 78 87 20 00,376 Chemin De l'Orme,Marcy l'Étoile,,69280,-32.09722,134.2972217712783,https://images.financialmodelingprep.com/symbol/BIM.PA.png,2004-07-07,False,False,True,False,False,117929352.0,272200000,558500000,10864562874,32.27779967789529,3.487681336534436,4.1940364431070565,1.3262177511159392,2.3081615847427024,32.90190214900867,22.349821781434024,32.7976024153851,3.364726366002588,12052357290.0,12338657290.0,29.303135848285923,3.1662570051228163,24.367933227658714,77.06110799232736,3.116081435027665,3.116081435027665,3.241470455799291,14.83368272421255,24.946739365143554,78.89167065217391,0.03412604047489663,0.012976714532829784,0.10176327628109003,0.07399748077682315,0.3441933157008896,2.2104684846668663,152.25,1.2025285679552637,0.008317025440313111,0.8317025440313112,0.24361779722830051,0.03911729935636411,0.12462892420859056,0.23394935233404146,0.6837848766680146,0.08884802311835019,0.9988186650915535,0.0030211480362537764,50.73185075583528,0.09353520839429907,0.10093994649912877,-5.599962933740194,1211800000,2635700000,773900000,4032300000,432750000.0,240400000.0,960650000.0,0.0,43.976149248729264,206.48606378819193,0.0,8.299953639313863,1.767673775671406,0.10795275590551182,2.867818691991117,0.85,0.032657511765484676,0.008317025440313111,0.831702544031311,29.303135848285923,0.2930313584828592,0.24361779722830051,2.2104684846668663,1.198781340525422,0.2719009090000999,0.0,206.48606378819193,206.48606378819193,43.976149248729264,162.50991453946267,0.5296729278865099,0.12799159332720347,0.1281229475896493,0.10805201628792854,0.1818741029321304,0.0773251113910248,0.10795275590551182,0.1128300138953219,0.8433463194586837,1.0010262725779968,0.12799159332720347,0.07399748077682315,0.10176327628109003,0.057783191230207066,0.09236401182709908,152.25,1.2566056910569106,1.3752262267955944,0.0,8.299953639313863,1.767673775671406,2.4151386333354483,0.7156285837829708,4.1940364431070565,1.3262177511159392,2.3081615847427024,0.12993563641140154,0.3162151233319854,1.2566056910569106,3.162404092071611,1.462448255470136,1.1281934306569343,3.116081435027665,3.116081435027665,3.1662570051228163,29.303135848285923,77.06110799232736,24.367933227658714,24.367933227658714,0.2930313584828592,3.1662570051228163,14.83368272421255,3.116081435027665,0.85,BIM.PA,2023-12-31,2023,FY,0.02384999024825165,0.04905410228953139,-0.21561271882815292,-0.21561271882815292,-0.20954907161803712,-0.21093750000000003,-0.21204188481675396,0.0017642543402817078,0.0030552107718534796,-0.011625167512941693,-0.0625131551252368,-0.4315286624203822,1.3206225088772794,0.5130001657567735,0.17839159732182364,0.8571239537896704,0.11063948989482265,-0.23580818025042705,1.1825575617365456,0.3893336237496079,-0.11578459278483241,1.984321025581026,0.9401916796484685,0.5433160427158771,1.5963456911140381,1.4848910778174123,3.453043302251671,-1.0,0.18371335504885994,0.013997609223768944,0.028189580655164373,0.026513652552433715,0.030228392297357815,0.06892217450508013,3946797417.0,4237677888.0,4565863589.0,907273580.5,975745137.0,1051311428.0,4.08405,4.59817,5.22759
0,BIO,327.47,0.936,193490,9180847404,0.0,262.12-387.99,1.53,"Bio-Rad Laboratories, Inc.",USD,0000012208,US0905722072,090572207,New York Stock Exchange,NYSE,Medical - Devices,https://www.bio-rad.com,"Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.",Mr. Norman D. Schwartz,Healthcare,US,7700,510 724 7000,1000 Alfred Nobel Drive,Hercules,CA,94547,182.6249,144.8450953476257,https://images.financialmodelingprep.com/symbol/BIO.png,1980-02-27,False,False,True,False,False,27949000.0,411753000,1388115000,10327538420,92.31847293284196,-27.861104153994777,14.72245876417761,7.983720347776307,58.09989623957923,267.91151740670506,242.0644387992415,267.91151740670506,44.69483702458049,9180847404.0,10157209404.0,-11.75366195790366,3.5581797459043045,22.242887906522345,41.1444422215948,1.2223065404944191,1.2223065404944191,3.9365839759492354,-13.371522947809089,24.68469615386485,45.52005899514648,-0.08507986732828893,0.02430461919046618,0.16027278291431502,0.11317990937308081,-1.2853379672597303,6.136485501352564,6.409670714809683,-0.528442379363575,0.0,0.0,-109.7621261349189,0.0,0.10715759847361202,0.06812862805692324,0.4577182741240115,0.07299447447861782,0.9584783715012722,0.006278561155317263,409.81336061281286,0.02804807887636662,-0.07880622669281227,-26.590790368170598,2557677000,6765459000,-59993000,3999247000,458623000.0,124439000.0,803984500.0,65.34668315628696,37.91594011669576,249.57957730732574,5.585593367103953,9.626558088145027,1.4624594044830381,-0.09715738022683426,6.7387384164013024,0.0,0.13071778096182374,0.0,0.0,-11.75366195790366,-0.28013291684658825,-109.7621261349189,6.136485501352564,4.5212885812231525,0.8269078990968846,65.34668315628696,249.57957730732574,314.9262604636127,37.91594011669576,277.01032034691696,0.5441373160081219,0.12191299231961442,-0.3895773559428713,-0.3017933818539506,0.22533130519473413,-0.07343726658588809,-0.09715738022683426,0.031127613408461843,0.7746686948052659,-3.195536000966426,0.12191299231961442,0.11317990937308081,0.16027278291431502,0.13813370896432636,0.13813370896432636,6.409670714809683,0.3428697608532622,1.4160886309424363,5.585593367103953,9.626558088145027,1.4624594044830381,3.5877595005353395,0.24333623929973125,14.72245876417761,7.983720347776307,58.09989623957923,0.15947467821405165,0.5422817258759886,0.3428697608532622,0.0,2.1847500013273797,0.004803674420196143,1.2223065404944191,1.2223065404944191,3.5581797459043045,-11.75366195790366,41.1444422215948,22.242887906522345,22.242887906522345,-0.28013291684658825,3.5581797459043045,-13.371522947809089,1.2223065404944191,0.0,BIO,2023-12-31,2023,FY,-0.046743526360434065,-0.0867615626575131,-0.24226299998342368,-0.24226299998342368,0.824309345051116,0.8208391493554479,0.8208391493554479,-0.01933859325163673,-0.01933859325163673,0,0.9282529429613211,1.7184331797235024,0.22581417657256636,0.19147310196124526,0.06943614014739795,1.0911453694437165,0.34150462489718336,-0.3358247200048292,-9.018132014008419,-2.803357345752144,-1.170288953946025,2.912108170795299,1.2234521204816158,-0.098332555449317,0,0,0,-0.011377856846829544,0.08508221699503417,-0.08907019326355725,-0.07298241378876137,0.17298054300644058,-0.11663403259773676,-0.008699906381179597,2579007750.0,2654943709.0,2782778612.0,914151487.0,941067641.0,986379822.0,10.28511,11.51256,13.0823
0,BIOPOR.CO,1.484,1.146,362560,637610988,0.0,1.21-2.85,-0.108,BioPorto A/S,DKK,,DK0011048619,,Copenhagen,CPH,Medical - Diagnostics & Research,https://bioporto.com,"BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.","Mr. Peter Moerch Eriksen B.B.A., BBA",Healthcare,DK,27,45 45 29 00 00,"Tuborg Havnevej 15, st.",Hellerup,,2900,2.61607,-1.1320668218243084,https://images.financialmodelingprep.com/symbol/BIOPOR.CO.png,2000-01-13,False,False,True,False,False,429657000.0,76342000,4625000,731741590,0.08124154849100562,-0.14267892760969797,-0.1599648091384523,-0.16005557921784122,0.17768126668482068,0.20142811591571883,0.2007042827185406,0.20142811591571883,0.004131202331161834,637610988.0,565893988.0,-10.4009752866907,18.26651544147138,-9.27704041903099,-9.271779261004232,7.367392547229765,7.367392547229765,16.21194029679711,-8.640526285251859,-8.233580503419176,-8.228911108202825,-0.09614482992567248,-0.10785416389342399,0.0,0.0,1.0950330569679203,5.154992010721097,-26.748732394366197,1.1082087747303246,0.0,0.0,0.0,1.025783532916977,0.8294849023090586,0.0028558834873000424,-0.0005674378000872981,0.0011172864264023378,0.016175860638739114,-0.11364808342405316,0.8041391796879293,-0.5013135131481758,-0.5645519261053349,0.13114647265144055,80611000,86234000,77659000,81473000,6677000.0,4213000.0,4506000.0,0.0,102.5216925026811,167.892171200156,0.0,3.560222145088511,2.1740144128868164,-0.836244586161034,9.07700793889079e-05,0.0,0.0,0.0,0.0,-10.4009752866907,0.6760633936348959,0.0,5.154992010721097,4.911808669656203,3.934951806607907,0.0,167.892171200156,167.892171200156,102.5216925026811,65.37047869747491,0.7061536698561852,-1.360195954850169,-1.9219045436314675,-1.756231020454936,0.08620278448558566,-0.5629396315818472,-0.836244586161034,-0.5305094025498062,0.9137972155144143,1.4129615198298195,-1.360195954850169,0.0,0.0,0.0,0.0,-26.748732394366197,0.0,1.258281818707031,0.0,3.560222145088511,2.1740144128868164,63.3502722323049,0.3205384855552903,-0.1599648091384523,-0.16005557921784122,0.17768126668482068,-1.969002463759812,1.0005674378000873,0.0,0.0,-1762.3076923076924,-1762.3076923076924,7.367392547229765,7.367392547229765,18.26651544147138,-10.4009752866907,-9.271779261004232,-9.27704041903099,-9.27704041903099,0.6760633936348959,18.26651544147138,-8.640526285251859,7.367392547229765,0.0,BIOPOR.CO,2023-12-31,2023,FY,0.06865960164313577,0.05986766095998319,0.2144948379475063,0.2144948379475063,0.25809043372890955,0.30434782608695654,0.30434782608695654,0.08241601033671088,0.08241601033671088,0,-0.05660664951891017,-0.04794546415892439,-0.48238291556673146,-0.34528419561412116,-0.20529780335839495,0.07361272830295802,0.1972458674052093,0.07253448059325204,0.24077613709525017,0.18545899709856653,0.45498809980032157,-0.6098489717122878,-0.4110001987537087,-0.6448928733271743,0,0,0,0.16861081654294804,0.48045347928068804,-0.17331553755522827,-0.20850785288692655,-0.31892907468294973,-0.2716812639532887,-0.1292348686714884,,,,,,,,,
0,BJDX,3.84,0.728,635146,2122959,0.0,3.03-1260.0,-0.06,"Bluejay Diagnostics, Inc.",USD,0001704287,US0956333019,095633103,NASDAQ Capital Market,NASDAQ,Medical - Devices,https://www.bluejaydx.com,"Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.",Mr. Indranil  Dey,Healthcare,US,10,844 327 7078,360 Massachusetts Avenue,Acton,MA,01720,-8.92785,13.537854855066648,https://images.financialmodelingprep.com/symbol/BJDX.png,2021-11-10,False,False,True,False,False,9555855.0,5755741,241652,55165590,0.15166241011400863,-0.8987731605387482,-0.9270295541319955,-0.9682139379469445,0.6023261131526169,0.749742853988471,0.749742853988471,0.749742853988471,0.11690790619991617,2122959.0,-3391130.0,-4.272490733588665,1.4648531944490444,-4.142262760538959,-0.22945669053725246,5.121756052187793,5.121756052187793,-2.3398980448006714,0.43637529255712043,0.3828082668063433,0.3665249620843327,-0.2340555105569657,-4.358120905773498,0.0,0.0,0.709560589113658,6.259427951664384,-7.225216733577704,1.0314388489041102,0.0,0.0,0.0,2.66214506121728,2.9017321895803665,0.0,-0.044426182133439296,0.27155300897559037,1.8057979792418026,0.004905945362611644,3.8937895392005437,-1.1266334171380266,-1.028148504622663,0.4779022913177314,5518439,7164434,5378710,7280565,0.0,403353.0,0.0,0.0,703.1700595013567,0.0,0.0,0.5190778462024317,0.0,-1.5567714869362903,0.04118438381494906,0.0,0.0,0.0,0.0,-4.272490733588665,-0.11531325686778371,0.0,6.259427951664384,6.259427951664384,5.4855920483928,0.0,0.0,0.0,703.1700595013567,-703.1700595013567,0.8865865708387154,-5.569507694940328,-5.926143200962696,-5.926143200962696,-4.657365752014369e-07,-1.028148504622663,-1.5567714869362903,-1.1050803493843169,1.0,1.0640335781107468,-5.569507694940328,0.0,0.0,0.0,0.0,-7.225216733577704,0.0,1.1659553287810314,0.0,0.5190778462024317,0.0,0.8224519699499355,0.1734936989804164,-0.9270295541319955,-0.9682139379469445,0.6023261131526169,-6.112454321641882,1.0444261821334393,0.0,0.0,-22.50924909541814,-22.50924909541814,5.121756052187793,5.121756052187793,1.4648531944490444,-4.272490733588665,-0.22945669053725246,-4.142262760538959,-4.142262760538959,-0.11531325686778371,1.4648531944490444,0.43637529255712043,5.121756052187793,0.0,BJDX,2023-12-31,2023,FY,-1,-16.966858170963587,-0.10661771650230699,-0.10661771650230699,-0.07867444005882603,0.008194482381862801,0.008194482381862801,0.08758649146194376,0.08759442645845236,0,-0.07392238264140209,-0.00863149340281805,0,0,0,-1.8474483807981845,-1.8474483807981845,-8.460249970430826,-6.604242347470224,-6.604242347470224,-4.118392289490198,1.5714346669670543,1.5714346669670543,1.3983898741044496,0,0,0,0,0.0,-0.6399352427454088,-0.7693740107631437,-0.28347147198353295,0.37629210105988414,-0.11849417062115797,0.0,5054000.0,7862000.0,0.0,3032400.0,4717200.0,-396.0,-128.0,-116.0
0,BLFS,27.39,1.883,377312,1270545408,0.0,14.5-28.88,1.28,"BioLife Solutions, Inc.",USD,0000834365,US09062W2044,09062W204,NASDAQ Capital Market,NASDAQ,Medical - Instruments & Supplies,https://www.biolifesolutions.com,"BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.",Mr. Roderick  de Greef,Healthcare,US,409,425 402 1400,3303 Monte Villa Parkway,Bothell,WA,98021,37.69216,-10.30216163937811,https://images.financialmodelingprep.com/symbol/BLFS.png,1989-11-22,False,False,True,False,False,46175345.0,23977000,39267000,1171520638,2.6715122539961533,-0.9967656982313831,0.19700989781451553,0.1223813270913298,0.7403951177841768,7.048371809674622,1.7824447223946025,7.048371809674622,0.4633641611123858,1270545408.0,1285835408.0,-27.47887497392778,10.299659592405844,139.0285478234583,224.8354995576004,3.8860038516135575,3.8860038516135575,10.423607775742148,-59.35629451137885,141.347192261185,227.54121536011323,-0.03639159175726116,0.004447696213309993,0.06161721373682254,0.052545250647186445,-0.7058117527581591,2.7788037057762853,-20.726527570789866,-0.1526367892078726,0.0,0.0,0.0,0.3903030204769857,0.10023670941487378,0.6371144393321665,0.3788061998461031,0.027934953549830575,0.3689507494646681,0.23155368926214756,12.572805696659605,-0.0806521291122173,-0.3323272874306839,0.16296575585953932,57217000,82305000,33192000,332514000,17991000.0,4025500.0,32337500.0,53.01699119635532,21.01010858479813,176.15536324914513,6.884585333184507,17.372589890568005,2.072034556698468,-0.13968744380566794,0.07462857072318571,0.0,0.015783772759107875,0.0,0.0,-27.47887497392778,-0.71532309455939,0.0,2.7788037057762853,1.778399552322328,0.7454144127339427,53.01699119635532,176.15536324914513,229.17235444550045,21.01010858479813,208.1622458607023,0.45949188540670244,-0.22548193064089886,-0.26259342726049384,-0.3731091619513935,-0.001852252029759516,-0.120596774024504,-0.13968744380566794,-0.07958830968908626,1.4208625320285246,1.1645874528132303,-0.22548193064089886,0.052545250647186445,0.06161721373682254,0.023472473926141067,0.058040895474870846,-20.726527570789866,0.453625211927795,1.17265048654063,6.884585333184507,17.372589890568005,2.072034556698468,3.838026197069164,0.3232211543500362,0.19700989781451553,0.1223813270913298,0.7403951177841768,0.07374471051735598,0.6211938001538969,0.453625211927795,0.7437658408960838,2.6398723157283808,2.6398723157283808,3.8860038516135575,3.8860038516135575,10.299659592405844,-27.47887497392778,224.8354995576004,139.0285478234583,139.0285478234583,-0.71532309455939,10.299659592405844,-59.35629451137885,3.8860038516135575,0.0,BLFS,2023-12-31,2023,FY,-0.11429348598841486,-0.13135892386013154,-0.7745289637201844,-0.7745289637201844,0.524859625907514,0.5379939209726444,0.5379939209726444,0.029146140934869582,0.029146140934869582,0.0,-0.47225821651549066,-0.00026491469746741547,0.83381913532528,1.6984922422345052,0.8608901645043922,-10.805257849524724,-2.9792308745737768,-2.1981639049755697,-6.018485956566324,-8.562797778909122,-16.556495058212423,3.9144388815403537,1.9098917543933744,0.027540396437281296,0,-1,0,-0.4502298444130127,0.24501489800595921,-0.08332426387460604,-0.09909127462098509,-0.023379772607691075,0.2701716448168671,0.15984979780473715,107761400.0,98212667.0,129045400.0,-13328103.0,-12147100.0,-15960542.0,-0.51,-0.17857,0.1175
0,BMRA,0.2789,-1.137,882144,4691544,0.0,0.24-1.35,0.0129,"Biomerica, Inc.",USD,0000073290,US09061H3075,09061H307,NASDAQ Capital Market,NASDAQ,Medical - Devices,https://www.biomerica.com,"Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.",Mr. Zackary S. Irani,Healthcare,US,64,949 645 2111,17571 Von Karman Avenue,Irvine,CA,92614,0.19521,0.24789488495953368,https://images.financialmodelingprep.com/symbol/BMRA.png,1984-09-07,False,False,True,False,False,16821646.0,2820000,707000,5288524,0.3273757514573782,-0.36631373647977133,-0.29907893674614244,-0.3021701919063093,0.16764114522443285,0.3178048093509993,0.3054992359249505,0.3178048093509993,0.019855369682610133,4691544.0,2578544.0,-0.7613692095748134,0.8519238881285434,-0.9325297295567481,-0.9229872122762148,0.8775826916199027,0.8775826916199027,0.4682303374306042,-0.4289708867077025,-0.5125311071357583,-0.5072878221522723,-1.3134232215122674,-1.083438629159185,0.06247661803217359,0.04243964421855146,0.3515222092829812,2.99628079962808,0.0,0.8164556962025317,0.0,0.0,0.0,0.0,0.2391502159343047,0.026302414231257943,-0.0103359173126615,0.009442529406669585,0.13720316622691292,0.13510080535696484,1.6184455541208773,-1.1493604729861497,-0.8041237113402062,0.14447159332683615,4294000,5139000,3921000,5351000,1249000.0,688500.0,2159000.0,102.79918336647602,79.14874551971326,141.14496216646754,3.550611863313991,4.6115702479338845,2.5859938208032958,-0.846196099972535,0.003091255160166847,0.0,0.07119191464473103,0.0,0.0,-0.7613692095748134,0.2664792233511844,0.0,2.99628079962808,2.093444909344491,1.3110181311018132,102.79918336647602,141.14496216646754,243.94414553294354,79.14874551971326,164.79540001323028,0.08806956384048735,-1.1810425242495959,-1.1147632312989344,-1.1189397346903458,-0.0037465385241896073,-0.7829733163913596,-0.846196099972535,-1.1372617590487848,1.0037465385241897,0.943880688806888,-1.1810425242495959,0.04243964421855146,0.06247661803217359,0.0,0.05880281690140845,0.0,-15.062874251497005,1.4721286943509166,3.550611863313991,4.6115702479338845,2.5859938208032958,6.478822352941177,0.6997457433290979,-0.29907893674614244,-0.3021701919063093,0.16764114522443285,-0.9135647200952823,1.0103359173126616,-15.062874251497005,-15.062874251497005,-96.75,-96.75,0.8775826916199027,0.8775826916199027,0.8519238881285434,-0.7613692095748134,-0.9229872122762148,-0.9325297295567481,-0.9325297295567481,0.2664792233511844,0.8519238881285434,-0.4289708867077025,0.8775826916199027,0.0,BMRA,2024-05-31,2024,FY,0.014234875444839857,0.36995515695067266,0.11851031427384744,0.11851031427384744,0.1627450980392157,0.28,0.28,0.18845035374133415,0.18845035374133415,0,0.020643039824625502,0.013688760806916427,-0.5480711536182801,-0.4297702647674668,-0.46659379940449075,-1.656934428163542,-0.3083595400158775,0.27610541195020927,-10.845847201097975,-0.36808796278426303,0.3446855506988018,-0.5237715152586608,-0.09327809975692662,-0.4934490784909996,0,0,0,0.31163434903047094,0.1556420233463035,-0.35976200359762006,-0.5269637124293693,-0.2744916820702403,-0.058712121212121215,-0.09827444535743632,,,,,,,,,
0,BNGO,0.195,2.376,2869919,19888635,0.0,0.195-2.27,-0.0055,"Bionano Genomics, Inc.",USD,0001411690,US09075F3055,09075F107,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://www.bionanogenomics.com,"Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.","Dr. Robert Erik Holmlin M.B.A., Ph.D.",Healthcare,US,344,858 888 7600,9540 Towne Centre Drive,San Diego,CA,92121,0.473774,2.32377,https://images.financialmodelingprep.com/symbol/BNGO.png,2018-08-21,False,False,True,False,False,85870000.0,8794000,22453000,52635393,0.38819145219517875,-1.5812623733550717,-1.126330499592407,-1.1362058926283918,0.2673110515896122,0.5690928147199255,0.44046814952835683,0.5690928147199255,0.23338767904972632,19888635.0,33547635.0,-0.12331919312432335,0.5966471170576588,-0.1731285799954507,-0.20384801057745527,0.34265060980600803,0.34265060980600803,1.0064089218215637,-0.2788502331535156,-0.3468603052172295,-0.34384555070413875,-8.10903781207729,-4.9056156945914084,0.3059875583203733,0.1711613745106568,-0.11353454079978721,1.4257966616084978,-21.242924528301888,0.7122982994925727,0.0,0.0,0.0,0.0,0.9908201835963281,0.12642796639271078,-0.008767757811369134,0.025439491210175795,0.05516164704351786,0.3351532969340613,4.4997126279825155,-1.6934992568626435,-1.779197295491175,-0.05114126004425294,14030000,37823000,8486000,51254000,5785500.0,8717000.0,16899000.0,58.20903581928361,93.58147212393459,154.06522129093275,6.2705041384499625,3.9003447126436783,2.3691265098093974,-1.7626544381809155,0.009875393035984628,0.0,0.7518364131072847,0.0,0.0,-0.12331919312432335,-0.00229282351660779,0.0,1.4257966616084978,0.9911077389984826,0.26688922610015176,58.20903581928361,154.06522129093275,212.27425711021635,93.58147212393459,118.69278498628177,-0.017969610607787845,-3.242455150896982,-4.073528529429411,-4.073408531829363,2.9457900977265863e-05,-1.5542569996108149,-1.7626544381809155,-1.9864000588105566,0.9999705420990227,1.2563099071092854,-3.242455150896982,0.1711613745106568,0.3059875583203733,0.0,0.2342959214051801,-21.242924528301888,-6.468133484919414,1.7877138413685847,6.2705041384499625,3.9003447126436783,2.3691265098093974,1.2733106688567173,0.38156177743183534,-1.126330499592407,-1.1362058926283918,0.2673110515896122,-2.9014819703605927,1.0087677578113692,-6.468133484919414,-6.468133484919414,-114.05424528301887,-114.05424528301887,0.34265060980600803,0.34265060980600803,0.5966471170576588,-0.12331919312432335,-0.20384801057745527,-0.1731285799954507,-0.1731285799954507,-0.00229282351660779,0.5966471170576588,-0.2788502331535156,0.34265060980600803,0.0,BNGO,2023-12-31,2023,FY,0.29904323429969065,0.6090832632464256,-0.6343832100715273,-0.6343832100715273,-0.7533937675344656,-0.4868995633187772,-0.4868995633187772,0.18080287680232357,0.18080287680232357,0,-0.002924304576336367,0.009725409388220235,-0.9186139691933631,-0.9376325984513683,0.2966391701409409,0.9184476998545292,0.8699245508070941,0.0026042999316302656,0.8111883504150449,0.7395114057231381,-0.7253749604248378,1.0539970185031629,-0.8034277209235205,-0.16327015168597817,0,0,0,0.3758188550270578,-0.23080541648466113,-0.3027557544341175,-0.6734794372256886,5.806050737058622,0.10163720512977348,0.07184297259469953,28904333.0,30860800.0,37478550.0,-28904333.0,-30860800.0,-37478550.0,-1.5535,-0.3101,-0.2561
0,BRKR,57.0,1.204,1389885,8641086000,0.2,48.07-94.86,1.71,Bruker Corporation,USD,0001109354,US1167941087,116794108,NASDAQ Global Select,NASDAQ,Medical - Devices,https://www.bruker.com,"Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.",Dr. Frank H. Laukien Ph.D.,Healthcare,US,9707,978 663 3660,40 Manning Road,Billerica,MA,01821,20.32344,36.6765559701596,https://images.financialmodelingprep.com/symbol/BRKR.png,2000-08-04,False,False,True,False,False,148100000.0,148100000,2297300000,12376986000,21.88588791357191,2.0587440918298445,1.801485482781904,1.0580688723835245,1.0,12.444969615124915,-4.442943956785955,12.323430114787305,15.771775827143822,8641086000.0,10790286000.0,27.686782551656282,2.665932187702465,31.640554722638683,55.14413529036376,4.625335598049422,4.625335598049422,3.328999475519082,20.221675412293852,40.443350824587704,68.8595149968092,0.03611831740052359,0.018134294693977124,1.2587255492849707,0.37581180781625745,4.027736131934033,1.6575145601694274,8.52987012987013,0.8736083824492469,0.0035087719298245615,0.3508771929824561,0.09806493932436865,0.36179927806744205,0.10967821553080555,0.4091511393937411,0.4126686656671664,0.03396785240489927,0.654577883472057,0.007620399222534168,23.892315734303946,0.06180593026233606,0.08441774184617089,-20.98379473328832,869300000,-658000000,-2078400000,4064300000,616350000.0,223900000.0,1198150000.0,60.62876006540586,50.119205697730564,268.859246740705,6.020245170876672,7.282637362637363,1.357587676171747,0.19036024224261722,0.7434166103983795,0.2,0.2658577868568835,0.0035087719298245615,0.3508771929824561,27.686782551656282,-2.0851608109216118,0.09806493932436865,1.6575145601694274,0.7344376370925043,0.11201875803645715,60.62876006540586,268.859246740705,329.48800680611083,50.119205697730564,279.36880110838024,0.48884706753463114,0.10131737265911825,0.12084657390553173,0.09406719526116064,0.22415113607352566,0.04987812658476337,0.19036024224261722,0.06854805042999082,0.7784018381414348,1.1927527405602922,0.10131737265911825,0.37581180781625745,1.2587255492849707,0.5537216353677621,0.5572724626431205,8.52987012987013,0.11613633395725417,3.349350720508465,6.020245170876672,7.282637362637363,1.357587676171747,4.671134169188644,0.530239329941599,1.801485482781904,1.0580688723835245,1.0,0.0823126523308549,0.5873313343328336,0.11613633395725417,8.134146341463415,2.4232515894641233,1.9057142857142857,4.625335598049422,4.625335598049422,2.665932187702465,27.686782551656282,55.14413529036376,31.640554722638683,31.640554722638683,-2.0851608109216118,2.665932187702465,20.221675412293852,4.625335598049422,0.2,BRKR,2023-12-31,2023,FY,0.17141502351128146,0.15899517500191468,0.009706494106771435,0.009706494106771435,0.4403236682400539,0.45999999999999996,0.457286432160804,-0.014804845222072678,-0.014725568942436412,0.0014027945868632285,0.33625954198473285,0.7006993006993008,0.8329407798694157,0.6685710624662003,0.5628906760147094,1.7459793668739396,0.5583464986971418,0.1009596461535432,5.065573770491803,1.536431392940876,1.8366681210912341,0.842252160533105,0.6234555490955022,0.47914076135296874,0.0,0.24972242178825677,0.25226576036252163,0.044515370401478245,0.20480278710961802,0.1744921926212519,0.2674837548498594,0.13156167979002625,0.24968206867316659,0.2008561080013171,3348876885.0,3602861616.0,3805717423.0,648226273.0,697388898.0,736654738.0,2.38725,2.73542,3.10608
0,CDIO,0.9738,4.679,6843757,39380287,0.0,0.19-3.56,-0.0462,"Cardio Diagnostics Holdings, Inc.",USD,0001870144,US14159C1036,14159C103,NASDAQ Capital Market,NASDAQ,Biotechnology,https://cardiodiagnosticsinc.com,"Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.",Dr. Meeshanthini V. Dogan Ph.D.,Healthcare,US,7,855 226 9991,400 N Aberdeen St,Chicago,IL,60642,0.97694,-0.0031429340819327804,https://images.financialmodelingprep.com/symbol/CDIO.png,2022-01-14,False,False,True,False,False,24442853.0,1982590,720468,4188634,0.0014600586928211695,-0.3376477369478923,-0.2172060683750788,-0.24933803758505604,0.08111123525555712,0.15080829557826167,0.12377397188454228,0.15080829557826167,0.014134397486250888,39380287.0,38118165.0,-2.8840708627355096,1103.4601826944631,-4.483300154940465,-6.461575809007844,6.457204467871254,6.457204467871254,1068.094737726967,-4.816600862733661,-7.179730374207781,-6.254484962178399,-0.3467321184513168,-0.15476101024860484,0.06344526929603371,0.05218632941355509,0.15948138936056167,8.511016298484833,-75.18301467557833,0.4770686289988294,0.0,0.0,0.0,229.47721923335575,0.8646884106702533,0.14745102099516208,-0.14793311002016146,22.00731338264963,3.651361943681223,142.57332997085854,1.0703746043263545,-2.1406515492866385,-2.1601145350351314,0.04900774062667725,2318493,3025389,1831896,4159932,10810.0,63444.5,0.0,144.20813718897108,188.27213867571314,0.0,2.531063829787234,1.9386830285530958,0.0,-2.58811450508673,0.03213196920997725,0.0,0.005938783534005224,0.0,0.0,-2.8840708627355096,-0.1384354014113045,0.0,8.511016298484833,8.511016298484833,6.422821118378639,144.20813718897108,0.0,144.20813718897108,188.27213867571314,-44.06400148674206,-3.0638029589778077,-235.13441492938804,-231.25627661959203,-231.25627661959203,3.63500920933744e-07,-1.8416034413777114,-2.58811450508673,-2.011002971159289,1.0,0.983506717589764,-235.13441492938804,0.05218632941355509,0.06344526929603371,0.0,0.059660117100367956,-75.18301467557833,-22.70113011018895,1.2157450046592886,2.531063829787234,1.9386830285530958,0.0,0.030227596318277414,0.007963474411581403,-0.2172060683750788,-0.24933803758505604,0.08111123525555712,-148.76529926025555,1.1479331100201615,-22.70113011018895,-22.70113011018895,-6.759811916775847,-6.759811916775847,6.457204467871254,6.457204467871254,1103.4601826944631,-2.8840708627355096,-6.461575809007844,-4.483300154940465,-4.483300154940465,-0.1384354014113045,1103.4601826944631,-4.816600862733661,6.457204467871254,0.0,CDIO,2023-12-31,2023,FY,16.96315789473684,2.1338870431893686,-0.5922913097228045,-0.5922913097228045,-0.7972239773352628,0.5629139072847682,0.5629139072847682,3.108301597022751,3.108301597022751,0,-0.11416433966978382,-0.2473314932374347,0,0,0,-165.5280431567133,-165.5280431567133,-165.5280431567133,-9.382665479396058,-9.382665479396058,-9.382665479396058,35.75642015155247,35.75642015155247,35.75642015155247,0,0,0,0,0,-0.28596196354319514,-0.8326163131637508,0.48525379490996806,2.5893492879746836,0.579175210602025,55000.0,525000.0,25000000.0,-27500.0,-262500.0,-12500000.0,-0.36,-0.23,-0.55
0,CDMO,12.3,1.405,1870344,786748590,0.0,5.65-12.48,-0.03,"Avid Bioservices, Inc.",USD,0000704562,US05368M1062,05368M106,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.avidbio.com,"Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.","Mr. Nicholas Stewart Green B.Sc., MBA",Healthcare,US,371,714 508 6100,2642 Michelle Drive,Tustin,CA,92780,0.97927,17.3693,https://images.financialmodelingprep.com/symbol/CDMO.png,1994-04-04,False,False,True,False,False,63838000.0,33415000,205526000,807937480,2.3566684419937967,-2.381810207086688,-0.05661204924966321,0.0024593502302703717,0.5234343181177356,0.7019016886493937,0.7019016886493937,0.7019016886493937,3.351311131301106,786748590.0,958859590.0,-5.164139427819797,5.22947648642361,-217.26823464305477,5011.137515923567,17.523821638993038,17.523821638993038,6.373489248562597,-67.86945002831257,-265.3180935251799,6107.385923566879,-0.1936431062672104,0.0001995554895115859,4.586814854490269,0.6353552902479891,-12.182262174405436,1.3013781757376341,-2.421865715983363,0.022611241803894087,0.0,0.0,0.0,0.03984180265213201,0.0,0.0,-1.04344216934145,0.02506563860547044,0.26220275344180227,0.0771710591910665,6.1331414172446275,-0.35138464345119647,-0.47004160973408105,-3.2670509727748365,22349000,44808000,-182169000,244914000,32692500.0,14625000.0,28634500.0,73.30326697464189,24.31073336501217,73.77312914884732,4.979314225193619,15.013944438439088,4.947600897659673,-1.765441810376107,0.05907139947993358,0.0,0.2612346594736191,0.0,0.0,-5.164139427819797,0.9768830417625773,0.0,1.3013781757376341,0.9228113706240898,0.4506041318301958,73.30326697464189,73.77312914884732,147.0763961234892,24.31073336501217,122.76566275847702,0.07677888929509123,-0.1354647877962046,-0.23415866263418525,-1.0106683505600054,-3.3161689565118655,-0.47004160973408105,-1.765441810376107,-0.081740372043028,4.3161689565118655,1.7285574092247302,-0.1354647877962046,0.6353552902479891,4.586814854490269,0.8199679375143136,0.8210071344683503,-2.421865715983363,-0.017584149937234218,7.219291198000357,4.979314225193619,15.013944438439088,4.947600897659673,0.675959831959203,0.4650799735379403,-0.05661204924966321,0.0024593502302703717,0.5234343181177356,-0.024022067865332845,-0.04344216934144992,-0.017584149937234218,-2.501038062283737,-0.958366481039512,-0.958366481039512,17.523821638993038,17.523821638993038,5.22947648642361,-5.164139427819797,5011.137515923567,-217.26823464305477,-217.26823464305477,0.9768830417625773,5.22947648642361,-67.86945002831257,17.523821638993038,0.0,CDMO,2024-04-30,2024,FY,-0.06267334825077378,-0.7675349110546379,-6.1645569620253164,-6.1645569620253164,-252.34464285714284,-248.77777777777777,-254.40909090909088,0.014951499967880774,-0.009140509861716472,0.0,1.8498486847210367,0.7696437448218724,1.2811950312478244,1.312031119038088,0.3444823550291745,1.1415765928970378,1.836668836817434,-0.6764313914082852,-0.45378037757253875,-28.579511148473244,-12.565155713766588,-0.6715006230187752,0.016335351808132104,-0.2784049169187007,-1,-1.0,-1.0,0.03945246712294406,-0.30821262640065594,-0.2538432205456553,-0.6833692448531331,0.09829680869615764,0.0,-0.06754187739875893,163112000.0,190489250.0,224973850.0,6447561.0,7529741.0,8892863.0,-0.28667,-0.13,0.14
0,CDNA,20.61,1.801,831401,1105394679,0.0,7.42-34.84,0.06,"CareDx, Inc",USD,0001217234,US14167L1035,14167L103,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.caredx.com,"CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.",Mr. John Walter Hanna Jr.,Healthcare,US,635,415 287 2300,1 Tower Place,South San Francisco,CA,94080,27.36722,-6.757224203154625,https://images.financialmodelingprep.com/symbol/CDNA.png,2014-07-17,False,False,True,False,False,52903338.0,95400000,29965000,1586736245,5.912197827668265,-2.713590567763418,0.14702285893566866,0.11689243502933595,4.5526994912872985,5.165004900068877,3.6396380130115795,5.165004900068877,0.02340116988459216,1105394679.0,1039959679.0,-7.59510305085821,3.534152918231956,140.18228287220367,178.75075663001294,3.9903156722513775,3.9903156722513775,3.3249450211813603,-25.9866483170494,133.70528143481613,168.169417690815,-0.13166378300647347,0.005594381913973371,0.004530715911669338,0.002595469459207313,1.6350983282940603,4.102247053045186,0.0,-0.05418019197815517,0.0,0.0,0.0,0.35055551115018785,0.2370745743745504,0.16918142079939621,0.20493700179994856,0.0050963152425865235,0.08826135105204873,0.16039964830948766,17.758193687246788,-0.21073903081001052,-0.36225674004764213,1.8281596900369501,252647000,192549000,130348000,393182000,66394000.0,6056500.0,19248500.0,77.75191431540244,20.89839125606835,64.52407609643286,4.694418178816396,17.465459208206443,5.65680319784042,-0.5440543882790466,0.030130423906332717,0.0,0.0011199619679008786,0.0,0.0,-7.59510305085821,-0.7830813145540017,0.0,4.102247053045186,3.8657170923379174,1.1714145383104126,77.75191431540244,64.52407609643286,142.27599041183532,20.89839125606835,121.37759915576697,0.6516121812804732,-0.18454799776196948,-0.4580097514187515,-0.458981692910239,-0.0021221047928853647,-0.3009696300722245,-0.5440543882790466,-0.1459302987017912,1.0021220978122776,2.4817920376979314,-0.18454799776196948,0.002595469459207313,0.004530715911669338,0.0,0.004510281109281415,0.0,6.282714054927302,1.745624821589337,4.694418178816396,17.465459208206443,5.65680319784042,5.227029646712791,0.6557334088074048,0.14702285893566866,0.11689243502933595,4.5526994912872985,0.02486771640955959,0.7950629982000514,6.282714054927302,6.282714054927302,4.879548306148055,4.879548306148055,3.9903156722513775,3.9903156722513775,3.534152918231956,-7.59510305085821,178.75075663001294,140.18228287220367,140.18228287220367,-0.7830813145540017,3.534152918231956,-25.9866483170494,3.9903156722513775,0.0,CDNA,2023-12-31,2023,FY,-0.12886855835894503,-0.14913565638106507,-1.6331783869171705,-1.6331783869171705,-1.4837038100583453,-1.4583333333333335,-1.4583333333333335,0.008309574211213555,0.008309574211213555,0,0.2714449859344665,0.4426804913965263,0.7395487639904552,1.4268057348499774,0.260973224534821,-3.6181831001332942,-2.0418854730175497,-1.4755219146163099,-6.366870077668111,-1.697693642556844,-7.790651356093984,1.2378372106978839,0.8057942228460546,-0.18636744867144,0,0,0,-0.22998853902762698,0.01242720465890183,-0.14026935989730954,-0.39854315546354574,-0.1224709593045619,-0.09428242687082355,0.024324929743819494,329043922.0,364446122.0,424784783.0,-50869203.0,-56342277.0,-65670454.0,-0.7,-0.53,-0.072
0,CDXS,5.28,2.071,623379,429674784,0.0,2.53-6.08,0.16,"Codexis, Inc.",USD,0001200375,US1920051067,192005106,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.codexis.com,"Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.","Dr. Stephen George Dilly MBBS, Ph.D.",Healthcare,US,174,650 421 8100,200 Penobscot Drive,Redwood City,CA,94063,8.28897,-3.00897441017533,https://images.financialmodelingprep.com/symbol/CDXS.png,2010-04-22,False,False,True,False,False,72032000.0,37452000,41846000,226252560,0.8946856952465571,-0.8620057752110173,-0.6105480897378943,-0.6404098178587294,1.2529847845402045,1.0189915593069747,0.9847984229231452,1.0189915593069747,0.5361367170146601,429674784.0,434068784.0,-6.125248985376539,6.667206405362629,-8.64796743900498,-9.31443277693475,5.181593460490463,5.181593460490463,6.735387518232318,-10.332510925970007,-9.869910275358695,-9.40968532408411,-0.16325866954754115,-0.10736026808592054,0.4456675749318801,0.2207540676055958,-0.10459414425136872,3.21392581627715,-8.588285085491789,0.7082877021194357,0.0,0.0,0.0,0.1655339353877665,0.6725941097973497,0.01662133982980504,-0.04890970690556857,0.03337678056046923,0.3766415689021187,0.1974366135989821,4.445612860204155,-0.4785901931389736,-0.4261048586329948,0.4016062305641937,77773000,70937000,38119000,104274000,14464000.0,3948500.0,2167500.0,93.6768767650436,80.0593657241056,39.97266052179347,3.896372430471584,4.5591168091168095,9.131241084165477,-0.8258864293101098,0.029861728120835183,0.0,0.07613199847445551,0.0,0.0,-6.125248985376539,-0.3150128049622219,0.0,3.21392581627715,3.1540607475305302,1.0661277007600558,93.6768767650436,39.97266052179347,133.64953728683707,80.0593657241056,53.59017156273147,0.7020296061819198,-0.7871861713682773,-0.9624646991279521,-0.9634732954721783,-0.0010479307398391024,-0.41902242497452474,-0.8258864293101098,-0.4487324641321846,1.001047930739839,1.2226646429205024,-0.7871861713682773,0.2207540676055958,0.4456675749318801,0.28061079475845574,0.3082780458383595,-8.588285085491789,-1.3444301785277575,2.018841961852861,3.896372430471584,4.5591168091168095,9.131241084165477,2.681005075297446,0.4349081878488086,-0.6105480897378943,-0.6404098178587294,1.2529847845402045,-0.6824162865034292,1.0489097069055686,-1.3444301785277575,-10.776525361431021,-20.445839144583914,-20.445839144583914,5.181593460490463,5.181593460490463,6.667206405362629,-6.125248985376539,-9.31443277693475,-8.64796743900498,-8.64796743900498,-0.3150128049622219,6.667206405362629,-10.332510925970007,5.181593460490463,0.0,CDXS,2023-12-31,2023,FY,-0.49388123241215093,-0.42983581451316166,-1.1463391562086145,-1.1463391562086145,-1.2695879971421766,-1.1960784313725492,-1.1960784313725492,0.04265121576045568,0.04265121576045568,0,-5.664835164835165,-20.16560295599597,0.23300585218815767,-0.11300320469017631,-0.11502287156037463,-0.28434057969912874,-1.8617549934588429,-1.7855640649061726,-0.03579112335501942,-4.370332429757864,-1.7665584902828038,0.17163907624887992,0.1787067496322439,-0.5563604403544673,0,0,0,-0.5124409757052333,0.3233119763430261,-0.45461334781723134,-0.42628726295032543,-0.6327971034419543,-0.2648472515262363,0.020662424288890594,65294000.0,66600986.0,84746760.0,-18623341.0,-18996123.0,-24171713.0,-0.79375,-0.68714,-0.48
0,CERS,1.58,1.2,1535931,293429700,0.0,1.38-2.59,0.0,Cerus Corporation,USD,0001020214,US1570851014,157085101,NASDAQ Global Market,NASDAQ,Medical - Devices,https://www.cerus.com,"Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.",Mr. William M. Greenman,Healthcare,US,625,925 288 6000,1220 Concord Avenue,Concord,CA,94520,1.0174,4.1374,https://images.financialmodelingprep.com/symbol/CERS.png,1997-01-31,False,False,True,False,False,185424000.0,21575000,97898000,398960760,0.9504109500388299,-0.10637781516955734,-0.04629929243247907,-0.05630339114677712,0.40752545517300887,0.29273988264733797,0.28564263525757183,0.2884685909051687,0.5106189004659591,293429700.0,369752700.0,-14.852720912547527,1.6650477503702568,-34.125791496796744,-28.106293103448277,5.477199424180673,5.477199424180673,2.098137650443457,-44.023419454696985,-43.06962143273151,-35.41692528735632,-0.06732773111997299,-0.03557922050835345,1.6008524930359513,0.4517698151831549,-9.087153232527681,2.587395344557917,-3.1861261460289407,0.4351903482536625,0.0,0.0,0.0,0.0,0.3240386088555232,0.006943162093289507,-0.2160745486313337,0.010526076865896078,0.8548387096774194,0.12634696900056178,0.8309330990064636,-0.20909031486250457,-0.10479590698267481,-0.12486652213305721,86267000,52965000,5354000,103956000,24050500.0,16301500.0,36414000.0,50.45574224446601,73.5003808073115,169.28624016247778,7.234062641106687,4.965960665658094,2.1561114456182606,-0.38484425757738344,0.010004098714298042,0.0,0.2918177641867882,0.0,0.0,-14.852720912547527,-0.965426859315589,0.0,2.587395344557917,1.9150611831815254,0.3970006440334897,50.45574224446601,169.28624016247778,219.7419824069438,73.5003808073115,146.2416015996323,0.5529680132100846,-0.16367340222097385,-0.11134376294480477,-0.11192822974652299,-0.008459891958006319,-0.1040682920137808,-0.38484425757738344,-0.21335266357974467,1.0052492100703292,0.6802801275828595,-0.16367340222097385,0.4517698151831549,1.6008524930359513,0.5479904640007307,0.6155106824867607,-3.1861261460289407,-0.10025926216026607,3.5435136196227264,7.234062641106687,4.965960665658094,2.1561114456182606,10.763390948512795,0.9297769852114868,-0.04629929243247907,-0.05630339114677712,0.40752545517300887,-0.04871502420146514,1.2160745486313338,-0.10025926216026607,-0.41311775179250276,-4.6280323450134775,-4.6280323450134775,5.477199424180673,5.477199424180673,1.6650477503702568,-14.852720912547527,-28.106293103448277,-34.125791496796744,-34.125791496796744,-0.965426859315589,1.6650477503702568,-44.023419454696985,5.477199424180673,0.0,CERS,2023-12-31,2023,FY,-0.03505751382306477,-0.007968401956506763,0.11818902027522667,0.11818902027522667,0.12460011675423234,0.125,0.125,0.02109943640431618,0.02109943640431618,0,-0.6852625414796018,-0.7296759007785624,0.4779143961097297,0.8631404375110968,0.5471071800456169,0.39619071846261533,-0.0026337661245157172,0.036405666612098445,0.6757581678262924,0.5273629985375784,0.43039443606011013,-0.5388636288469504,-0.5479162961446447,-0.5387236035144439,0,0,0,0.03119735083948179,0.37461641899113884,-0.09328173431395925,-0.23660828713886217,0.10043903389616791,0.055095387399191974,-0.09382612347753044,198332000.0,221927667.0,244196600.0,-85515551.0,-95689383.0,-105291162.0,-0.106835,-0.076,-0.0225
0,CRL,185.77,1.376,690241,9499571874,0.0,176.48-275.0,3.62,"Charles River Laboratories International, Inc.",USD,0001100682,US1598641074,159864107,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.criver.com,"Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.",Mr. James C. Foster J.D.,Healthcare,US,20400,781 222 6000,251 Ballardvale Street,Wilmington,MA,01887,11.52079,174.2492123556704,https://images.financialmodelingprep.com/symbol/CRL.png,2000-06-23,False,False,True,False,False,51394000.0,210171000,2759489000,12741262140,79.01537144413744,8.037514106705062,15.491263571623147,10.905631007510605,4.089407323812118,74.47789625248083,-1.465852044985796,73.5936685216173,47.28524730513289,9499571874.0,12048889874.0,23.112867676963305,2.339268252285937,11.991920422830644,16.948872535166036,2.524266064348079,2.524266064348079,2.9670374550963374,12.166171769861466,15.133792380406906,21.49729497006159,0.043265942330328155,0.05900097472118984,0.6077245085164397,0.28718457960564436,2.5741326386364554,1.4766765360528975,4.277496618489643,1.885758950248108,0.0,0.0,0.0,0.0,0.0,0.487647432320628,0.29601410775248127,0.058034689710400315,0.6928511161219576,0.017773576207929444,115.36454546523466,0.07639525006055971,0.10073183477618575,-62.890585476903915,482502000,-75336000,-2681402000,6410666000,758214000.0,134532000.0,342655500.0,67.78902961794827,18.433750446668355,45.58171635055053,5.384352041283096,19.800636937990483,8.007596668649613,0.11208006013165228,4.585632564112542,0.0,0.2419666939192422,0.0,0.0,23.112867676963305,-5.470045350214657,0.0,1.4766765360528975,1.1445356300649758,0.2076335108637343,67.78902961794827,45.58171635055053,113.3707459684988,18.433750446668355,94.93699552183044,0.33705745206253956,0.13861650918167231,0.12770788659504406,0.10172089252769573,0.1747379056749664,0.051610214194633026,0.11208006013165228,0.08051208725415751,0.7965122220701065,0.9213035831660479,0.13861650918167231,0.28718457960564436,0.6077245085164397,0.3780028887394581,0.3780028887394581,4.277496618489643,0.3463694976898781,2.1161460317644973,5.384352041283096,19.800636937990483,8.007596668649613,2.0052806981938276,0.5073708351564161,15.491263571623147,10.905631007510605,4.089407323812118,0.19605379672960485,0.7039858922475187,0.3463694976898781,0.0,3.378217368059268,3.378217368059268,2.524266064348079,2.524266064348079,2.339268252285937,23.112867676963305,16.948872535166036,11.991920422830644,11.991920422830644,-5.470045350214657,2.339268252285937,12.166171769861466,2.524266064348079,0.0,CRL,2023-12-30,2023,FY,0.03856807995855193,0.027282653209822438,-0.05179000729674719,-0.05179000729674719,-0.02386133197319765,-0.031347962382445214,-0.02742616033755272,0.008167362040462882,0.0029239196117034757,0.0,0.10370214963527209,0.23893295174410917,2.3017841647074344,0.7055800663629302,0.3660456695312716,2.07689694060027,0.45103340503174383,0.21028125229276703,3.301518527379193,0.9624002233130491,0.26017393071259987,4.229528005780225,1.5556034440418687,0.6452893541302314,0,0.0,0.0,0.03719480588524569,0.48649578396381676,0.07789674026703425,0.2003802665173163,-0.009974894068207032,0,0.12442827974223347,4031897566.0,4068077722.0,4310718974.0,994544297.0,1003468821.0,1063320906.0,10.19848,10.30693,11.46945
0,CSTL,27.53,0.985,380623,771040969,0.0,16.965-35.84,0.44,"Castle Biosciences, Inc.",USD,0001447362,US14843C1053,14843C105,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://castlebiosciences.com,"Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.",Mr. Derek J. Maetzold,Healthcare,US,710,866 788 9007,505 South Friendswood Drive,Friendswood,TX,77546,7.87567,33.8757,https://images.financialmodelingprep.com/symbol/CSTL.png,2019-07-25,False,False,True,False,False,27840000.0,94959000,26740000,725777800,11.202514367816091,0.2182112068965517,2.3196479885057473,1.437751436781609,10.04974856321839,15.842492816091953,11.870905172413794,15.842492816091953,0.4399066091954023,771040969.0,702821969.0,126.16217283950618,2.4722518709238868,11.868180058532959,19.26302168536238,1.737731575427101,1.737731575427101,2.2535156984461873,28.02543938910599,10.88313490453553,17.55869710445449,0.007926306098676051,0.05191293538125858,0.026663341306639762,0.02285425553622963,-2.720272749023048,7.783542160514731,-2.131416837782341,10.63028806584362,0.0,0.0,0.0,0.2377660495450144,0.16910137938552897,0.21487858676746377,0.3801855092212639,0.0787230904392102,1.8250204415372036,0.16250905802910112,8.81945084725296,-0.0012503039906106243,0.01503727759680789,8.881348778735632,300477000,330486000,271262000,467333000,48124500.0,8175000.0,7292500.0,58.82192716382688,38.530040922619044,37.18346974206349,6.205169017727463,9.473127753303965,9.816189896530737,0.014650212608949652,0.881896551724138,0.0,0.015252107829305242,0.0,0.0,126.16217283950618,0.4823847785039943,0.0,7.783542160514731,7.635173270120781,2.143785980358957,58.82192716382688,37.18346974206349,96.00539690589036,38.530040922619044,57.47535598327132,0.7931498855321633,-0.0033282244980409005,0.03571268252329436,0.019478770544892554,0.45456994074340096,0.011806088637975765,0.014650212608949652,-0.0022072426478406022,0.545430059256599,-10.730250481695569,-0.0033282244980409005,0.02285425553622963,0.026663341306639762,0.022202762320704103,0.02597087110630169,-2.131416837782341,5.49141156462585,1.1666685560757728,6.205169017727463,9.473127753303965,9.816189896530737,5.540853127720433,0.6061002983102232,2.3196479885057473,1.437751436781609,10.04974856321839,0.20706494206067758,0.6198144907787361,5.49141156462585,37.0080229226361,2.6302948843271423,2.6302948843271423,1.737731575427101,1.737731575427101,2.4722518709238868,126.16217283950618,19.26302168536238,11.868180058532959,11.868180058532959,0.4823847785039943,2.4722518709238868,28.02543938910599,1.737731575427101,0.0,CSTL,2023-12-31,2023,FY,0.6038354045198812,0.6643435208987908,0.2541638322617454,0.2541638322617454,0.14406148529893653,0.1705426356589147,0.1705426356589147,0.028709603131956706,0.028709603131956706,0,0.8649381826911535,0.5929748133736545,4.833598298630472,2.833009308929704,1.4777090222967693,0.8321177823056538,0.8181608519371695,-1.4027755567257447,-0.6959638462532128,-2.586538093529608,-2.9464751174835553,11.008569937549032,16.441216303601024,-0.3352393758374374,0,0,0,0.6315385926052138,0.9954773869346734,0.013437537025321408,-0.047101786505637164,0.1521412471825695,0.19408502772643252,0.2597777668999951,325994556.0,267378667.0,304841167.0,-64201633.0,-52657772.0,-60035667.0,0.35166,-1.97483,-1.26167
0,CTKB,6.32,1.321,649736,814085520,0.0,4.66-9.87,0.13,"Cytek Biosciences, Inc.",USD,0001831915,US23285D1090,23285D109,NASDAQ Global Select,NASDAQ,Medical - Devices,https://cytekbio.com,"Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.",Dr. Wenbin  Jiang Ph.D.,Healthcare,US,645,877 922 9835,47215 Lakeview Boulevard,Fremont,CA,94538,8.09473,-1.774726409504358,https://images.financialmodelingprep.com/symbol/CTKB.png,2021-07-23,False,False,True,False,False,131003744.0,162272000,8992000,572480741,1.5359103019223634,-0.07754740200402212,0.2510920603918007,0.21909297493054855,2.120374513876489,2.9423815551408974,2.662427724203058,2.9423815551408974,0.01773995100475907,814085520.0,660805520.0,-81.49853943104637,4.045949604890413,25.170051136377456,28.36337258727615,2.147919935454246,2.147919935454246,3.2841584414293523,-124.84517664840355,20.088937800206722,23.022978189673196,-0.012270158544940207,0.035256738137290536,0.003206533441601399,0.0025161534609324425,28.95900245607406,6.213529308724939,-21.733455882352942,-3.2375984251968504,0.0,0.0,0.0,0.2226479797226778,0.20152079916505145,0.07466013606771628,0.12743965464826412,0.020833954574822323,0.41203066640456065,0.12680284280105364,2.265814648063461,-0.05215397064563125,-0.022349527335766502,1.792998374153337,327394000,348788000,284428000,392701000,48693000.0,4290000.0,48435000.0,95.47939963222503,21.684801781540767,188.31856065617143,3.8228141505490747,16.83206531824086,1.9382051282051282,-0.026044310450026406,0.03199908546125216,0.0,0.001518268007027075,0.0,0.0,-81.49853943104637,-2.006592826900763,0.0,6.213529308724939,5.46827077726643,2.584072487539214,95.47939963222503,188.31856065617143,283.79796028839644,21.684801781540767,262.11315850685565,0.549187416132399,-0.11751900998956315,-0.05919686397296357,-0.05048953829332538,0.147090912006472,-0.02068090858382903,-0.026044310450026406,-0.055192342255076104,0.852909004037528,0.5037216019622769,-0.11751900998956315,0.0025161534609324425,0.003206533441601399,0.0031962844486280026,0.0031962844486280026,-21.733455882352942,26.613268608414238,1.2743791232880977,3.8228141505490747,16.83206531824086,1.9382051282051282,7.02745180217938,0.4096077976328614,0.2510920603918007,0.21909297493054855,2.120374513876489,0.16348094031111773,0.8725603453517359,26.613268608414238,0.0,7.846851145038168,7.846851145038168,2.147919935454246,2.147919935454246,4.045949604890413,-81.49853943104637,28.36337258727615,25.170051136377456,25.170051136377456,-2.006592826900763,4.045949604890413,-124.84517664840355,2.147919935454246,0.0,CTKB,2023-12-31,2023,FY,0.17666243995220562,0.08370471606552182,-14.249178532311062,-14.249178532311062,-5.71583850931677,-5.677083333333334,-5.827956989247312,0.005740898292420779,-0.023664961339972656,0,1.431771727577467,1.0205439160142993,2.278138093522729,2.278138093522729,1.0438443678559237,1.3776551836469904,1.3776551836469904,-0.6574540901560322,0.2902828435409263,0.2902828435409263,-1.615239327790265,10.26625004328099,10.26625004328099,25.10855334757054,0,0,0,0.14849377865094956,0.2642148108153009,-0.04816199400934788,-0.0816025995393265,-0.2187465458162927,0.26659590337942507,0.3489399293286219,204708671.0,227509163.0,254253636.0,242903.0,269958.0,301692.0,0.15773,0.21028,0.19023
0,CTLT,63.48,1.158,2227006,11522381760,0.0,42.11-63.5,0.0,"Catalent, Inc.",USD,0001596783,US1488061029,148806102,New York Stock Exchange,NYSE,Drug Manufacturers - Specialty & Generic,https://www.catalent.com,"Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.",Mr. Alessandro  Maselli,Healthcare,US,17000,732 537 6200,14 Schoolhouse Road,Somerset,NJ,08873,121.94199,-58.46198698258929,https://images.financialmodelingprep.com/symbol/CTLT.png,2014-07-31,False,False,True,False,False,182000000.0,335000000,4947000000,15635740000,24.296703296703296,-2.269230769230769,2.1923076923076925,0.5439560439560439,1.8406593406593406,19.46153846153846,2.0054945054945055,19.46153846153846,28.516483516483518,11522381760.0,16134381760.0,-27.97423728813559,2.6056946540027135,28.955789473684206,116.38769454545454,3.2618181818181817,3.2618181818181817,3.6486616372682046,35.382416140350884,40.437047017543854,162.9735531313131,-0.035747176578934614,0.008591973609456245,1.3929983060417843,0.5082406262875978,10.114035087719298,2.512024048096192,0.21875,-0.9661016949152542,0.0,0.0,0.0,0.0,0.002939846223428313,0.3272558714462299,0.7518796992481203,0.06784260515603799,0.6122448979591837,0.014925373134328358,31.522392716980576,0.007863531952568567,-0.0632368703108253,-24.51098901098901,1509000000,365000000,-3659000000,8357000000,1512000000.0,368000000.0,563500000.0,120.3459972862958,39.593578247035,58.38733005496094,3.0329218106995883,9.218666666666667,6.251356238698011,-0.1143727499307671,1.6483516483516483,0.0,0.42821007867734456,0.0,0.0,-27.97423728813559,-0.47487131198995597,0.0,2.512024048096192,1.9579158316633267,0.33567134268537074,120.3459972862958,58.38733005496094,178.73332734125674,39.593578247035,139.13974909422174,0.21822704658525555,0.012663952962460425,-0.07847127996381728,-0.09339665309814564,-0.19020172910662825,-0.04254223320972394,-0.1143727499307671,0.00642939150401837,1.1902017291066282,-6.196428571428571,0.012663952962460425,0.5082406262875978,1.3929983060417843,0.579734219269103,0.5821142048135913,0.21875,0.08086745034454804,2.740824392998306,3.0329218106995883,9.218666666666667,6.251356238698011,1.2045764096976301,0.45550061804697156,2.1923076923076925,0.5439560439560439,1.8406593406593406,0.09023066485753053,0.24812030075187969,0.08086745034454804,8.3125,1.33,1.33,3.2618181818181817,3.2618181818181817,2.6056946540027135,-27.97423728813559,116.38769454545454,28.955789473684206,28.955789473684206,-0.47487131198995597,2.6056946540027135,35.382416140350884,3.2618181818181817,0.0,CTLT,2024-06-30,2024,FY,0.024555659494855005,-0.1009433962264151,-4.467153284671533,-4.467153284671533,-3.4956896551724137,-3.4999999999999996,-3.4999999999999996,0.0,0.0,0.0,0.02681992337164751,0.8167701863354038,0.5534341593773172,0.38657255217900727,0.01709418245034121,-0.025890092742072983,-0.13774869778760176,-0.4255164406109247,-42.72475578405293,-7.04954410271257,-2.6548519620342823,7.282028558691627,0.7079972028218322,-0.14555576723608732,0,0,-1,0.08825573314801946,-0.2486910994764398,-0.09543683917640512,-0.22243797195253517,0.014229738090327902,-1.0,0.12515042117930206,4628151000.0,4990888899.0,5417350000.0,654062583.0,705325666.0,765594281.0,1.0727,1.69365,2.39
0,CYRX,7.86,1.633,418385,388524516,0.0,5.32-20.11,0.12,"Cryoport, Inc.",USD,0001124524,US2290503075,229050307,NASDAQ Capital Market,NASDAQ,Integrated Freight & Logistics,https://www.cryoport.com,"Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.",Mr. Jerrell W. Shelton,Industrials,US,1100,949 470 2300,112 Westwood Place,Brentwood,TN,37027,1.12505,21.9449,https://images.financialmodelingprep.com/symbol/CYRX.png,2005-08-22,False,False,True,False,False,49417757.0,44665000,233366000,589479009,4.575541540665231,-3.2067015910900207,-0.1691901961475103,-0.6604508577756777,5.5175713458625815,8.470072812086554,3.8184654961171143,8.470072812086554,4.818996540049359,388524516.0,577225516.0,-2.4511167555594824,1.7182758886043705,-46.456592515249376,-11.904054047429376,0.927973132507669,0.927973132507669,2.552818794142752,-4.674269339009388,-69.03785623729219,-17.685688951528892,-0.40797730166539703,-0.08400499493833744,0.5575289317011172,0.33254152030950535,-1.5280670623375745,5.702192418496395,-15.134575136040183,0.05276144079561804,0.0,0.0,-0.06310422293459879,0.0,0.08095067510492542,0.32756264561498505,-2.9036000478411674,0.1073666706469774,0.800903932435999,0.09348865390313693,24.720890137113617,-0.11084171751415099,-0.3358134153293225,0.684870217804503,288898000,188700000,67144000,637164000,41810500.0,12402500.0,23580500.0,70.15635987316077,0.0,61.672585354654956,5.2026644577897425,0.0,5.918350883152174,-0.3561318740589253,0.4912606616281674,0.0,0.6006467813217737,0.0,0.0,-2.4511167555594824,-0.34413679248055135,-0.06310422293459879,5.702192418496395,5.318852845912206,0.7269812334185126,70.15635987316077,61.672585354654956,131.82894522781572,0.0,131.82894522781572,0.3835427419033846,-0.31980912198767875,-0.7013307505539266,-0.7008354229964664,0.0007062681296506495,-0.22581348457104586,-0.3561318740589253,-0.11293153799783236,0.9992937318703493,2.1929666864879067,-0.31980912198767875,0.33254152030950535,0.5575289317011172,0.3515347469561459,0.3579573517727146,-15.134575136040183,-0.03582784124508283,1.676569383523026,5.2026644577897425,0.0,5.918350883152174,1.909834957852594,0.3222061516319566,-0.1691901961475103,-0.6604508577756777,5.5175713458625815,-0.036977086677899985,3.9036000478411674,-0.03582784124508283,-1.2948737803933716,-0.3444000494295012,-0.24392449747644193,0.927973132507669,0.927973132507669,1.7182758886043705,-2.4511167555594824,-11.904054047429376,-46.456592515249376,-46.456592515249376,-0.34413679248055135,1.7182758886043705,-4.674269339009388,0.927973132507669,0.0,CYRX,2023-12-31,2022,FY,-0.01695065261276904,-0.043716846533747945,-2.609484704112337,-2.609484704112337,-1.6675327458280877,-1.907894736842105,-1.907894736842105,-0.005101690142311389,-0.005101690142311389,-1.0,0.5910318746623446,-0.7528025184275184,6.854033806880562,5.879233537643106,1.3464199951347924,0.9845228651692862,0.8692945946323595,0.9596884777544832,0.544123215854014,-5.0324752999362605,-1.411433681044774,20.005865431654335,6.343354810800719,0.011580712694817058,0,0.0,-1,-0.040676729445027135,-0.05318303345617458,-0.07798056502744656,-0.11569443433976304,-0.04566330510107637,0.14743671288640123,0.22343925700720504,227449139.0,244960670.0,265423727.0,-90773625.0,-97762375.0,-105929062.0,-2.36833,-1.03117,-0.87312
0,DGX,153.1,0.891,830477,17088256500,2.96,123.04-165.32,1.58,Quest Diagnostics Incorporated,USD,0001022079,US74834L1008,74834L100,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.questdiagnostics.com,"Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.",Mr. James E. Davis,Healthcare,US,50000,973 520 2700,500 Plaza Drive,Secaucus,NJ,07094,-50.00359,203.10358788013667,https://images.financialmodelingprep.com/symbol/DGX.png,1996-12-17,False,False,True,False,False,112000000.0,764000000,6970000000,23594000000,85.16964285714286,7.508928571428571,12.473214285714286,9.133928571428571,6.821428571428571,61.794642857142854,-30.357142857142858,60.794642857142854,57.544642857142854,17088256500.0,23294256500.0,20.389060642092748,1.791409634133557,12.274302075876879,16.704063049853374,2.5183139961815244,2.5183139961815244,2.4420019394066466,13.08666095505618,16.67448568360773,22.77053421309873,0.04904590836987963,0.05986567441798407,0.9180496401821119,0.38838148493320906,3.486516853932584,1.2538240917782026,6.855670103092783,1.643529411764706,0.019333768778576094,1.9333768778576095,0.38882282996432815,0.0,0.0,0.6412550481515998,0.2677165354330709,0.03920746409476884,0.8008565310492506,0.008386623335779431,101.34746761338148,0.07942057460968727,0.1456529269137513,-65.05357142857143,531000000,-3400000000,-6551000000,13606000000,1347500000.0,1264000000.0,183000000.0,52.65122130202327,73.31655567601052,10.401115068917454,6.932412790697675,4.978411719352351,35.09239130434783,0.12856869864322568,3.3392857142857144,2.96,0.36580677496267683,0.019333768778576094,1.9333768778576093,20.389060642092748,76.35703210463896,0.38882282996432815,1.2538240917782026,1.1658699808795412,0.3652007648183556,52.65122130202327,10.401115068917454,63.05233637094073,73.31655567601052,-10.264219305069794,0.3230946640109026,0.13942761295733305,0.11667889715903135,0.08816437781738128,0.22012578616352202,0.05225225225225225,0.12856869864322568,0.09497964721845319,0.7556154537286612,0.8368421052631579,0.13942761295733305,0.38838148493320906,0.9180496401821119,0.45339969495063015,0.47863705972434917,6.855670103092783,0.2234842425211966,2.363783228080482,6.932412790697675,4.978411719352351,35.09239130434783,3.463689179375454,0.592668530599565,12.473214285714286,9.133928571428571,6.821428571428571,0.14645141000104833,0.7322834645669292,0.2234842425211966,2.316749585406302,3.735294117647059,1.992867332382311,2.5183139961815244,2.5183139961815244,1.791409634133557,20.389060642092748,16.704063049853374,12.274302075876879,12.274302075876879,76.35703210463896,1.791409634133557,13.08666095505618,2.5183139961815244,2.96,DGX,2023-12-31,2023,FY,-0.06384701001720125,-0.13748907660937956,-0.11624649859943978,-0.11624649859943978,-0.09725158562367865,-0.06527093596059107,-0.057644110275689324,-0.034482758620689655,-0.0423728813559322,0.06627634660421534,-0.259604190919674,-0.3424657534246575,0.7571068729758906,0.49177684617865214,0.17297415946351002,1.6476774758983348,0.2871428571428571,-0.2409690060562878,0.36513545347467613,0.4089673913043477,-0.2859888190076869,1.1680597771023304,0.46827070552147243,0.11641884894215122,1.3034749034749034,0.4334049409237379,0.26491101491101493,0.012552301255230125,-0.010416666666666666,0.09231128768403833,0.10657803990582418,0.18952834270878408,0,-0.13820704375667023,9829956670.0,10710937694.0,11134342281.0,2211382260.0,2409570906.0,2504821519.0,8.8992,9.72877,10.55615
0,DHR,228.55,0.881,2803134,165075951250,1.05,222.53-281.7,2.39,Danaher Corporation,USD,0000313616,US2358511028,235851102,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.danaher.com,"Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",Mr. Rainer M. Blair,Healthcare,US,61000,202 828 0850,"2200 Pennsylvania Avenue, NW",Washington,DC,20037-1701,2.84816,225.7018384637133,https://images.financialmodelingprep.com/symbol/DHR.png,1978-12-29,False,False,True,False,False,723000000.0,2627000000,17524000000,214040120000,27.704011065006917,5.383125864453666,8.697095435684647,6.929460580912863,3.6334716459197787,70.9612724757953,-14.8298755186722,70.95297372060857,24.645919778699863,165075951250.0,179972951250.0,42.45674460431655,8.241435409385922,26.278888358778627,32.94929166666667,3.221147585722919,3.221147585722919,8.985169807788319,25.146423256951234,28.621652552480917,35.92274476047904,0.02355338378671479,0.030349666090444535,0.34160509951461043,0.21737889970849097,2.0814587117507335,1.370758958986238,13.488135593220338,1.8775753956404897,0.004594180704441041,0.4594180704441041,0.1986125385405961,0.0,0.0689465801298053,0.7694225640389506,0.2032442748091603,0.06380429355966051,0.568,0.012830753869196205,92.70300820304838,0.051114664753551656,0.20938239724553476,-31.41597510373444,2721000000,-10722000000,-19250000000,69591000000,3402500000.0,1620500000.0,2674500000.0,63.90688966550175,71.99851687059696,120.80954146582621,5.711434274308526,5.069548872180451,3.0212845407020166,0.07480156060809902,1.7676348547717842,1.05,0.10615719532314372,0.004594180704441041,0.4594180704441041,42.45674460431655,-6.039471919964024,0.1986125385405961,1.370758958986238,1.0058591088704183,0.35795067447881185,63.90688966550175,120.80954146582621,184.71643113132797,71.99851687059696,112.717914260731,0.5960559161258113,0.19865202196704942,0.1891163255117324,0.19430853719420868,0.1158922914466737,0.0482788562922533,0.07480156060809902,0.05430154484415088,1.027455121436114,0.951997989444584,0.19865202196704942,0.21737889970849097,0.34160509951461043,0.24139715777176404,0.25462418086976735,13.488135593220338,0.3588221867153618,1.5714731281311527,5.711434274308526,5.069548872180451,3.0212845407020166,4.135866198637208,0.24846492588227997,8.697095435684647,6.929460580912863,3.6334716459197787,0.31392910634048926,0.7967557251908397,0.3588221867153618,5.24,4.92018779342723,3.0658215504631885,3.221147585722919,3.221147585722919,8.241435409385922,42.45674460431655,32.94929166666667,26.278888358778627,26.278888358778627,-6.039471919964024,8.241435409385922,25.146423256951234,3.221147585722919,1.05,DHR,2023-12-31,2023,FY,-0.24088843697372184,-0.25938044223969603,-0.40124309392265195,-0.40124309392265195,-0.33915938410320434,-0.34285714285714286,-0.33817427385892124,0.015721969383533305,0.00814000814000814,-0.011867900945627678,-0.15905622725672028,-0.21528437627256686,0.18089200120422652,0.14238699104021846,0.027964133436135023,0.8882807444723799,0.6943802973665208,0.10651888634598033,0.6705115076950979,0.7095263115881405,0.25288165587262984,1.2579467178885753,0.8032946020697996,0.28968358993800086,13.891619203239891,0.8019869103640956,0.2800384150481016,-0.06149796602057909,-0.16591639871382638,0.0016360403082394783,0.05134855020636998,-0.007165726482695533,-0.13868194842406878,-0.1484264913104744,23726210422.0,25094249375.0,27051559352.0,7189050942.0,7603567274.0,8196632955.0,7.49272,8.3358,9.34195
0,DIA.MI,100.25,0.192,107711,5344920880,1.15,82.72-112.35,0.81,DiaSorin S.p.A.,EUR,,IT0003492391,,Milan,MIL,Medical - Diagnostics & Research,https://diasoringroup.com,"DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.",Mr. Carlo  Rosa,Healthcare,IT,3184,39 01 614871,Via Crescentino snc,Saluggia,VC,13040,-168.57219,268.82219435133686,https://images.financialmodelingprep.com/symbol/DIA.MI.png,2007-07-19,False,False,True,False,False,53315904.0,169570000,1029118000,5832855525,21.7836689029975,3.167066247249601,6.012821239981226,3.937361729813303,4.067604293082979,30.287641751324333,-6.94770175893482,30.309717715749507,17.910115525753817,5344920880.0,6204468880.0,31.65390054188505,4.602072711242139,16.67270587281138,25.46121872677731,3.3075200811886214,3.3075200811886214,5.342158950797991,23.234364803376355,19.35394670268483,29.555786284560128,0.031591683264335174,0.03927541767465789,0.5909034090557491,0.30551592650550485,3.2188173047960453,3.11923264631903,0.0,2.697363881900563,0.011471321695760598,1.1471321695760597,0.3650350892777827,0.11336592573203745,0.07592456105305936,0.6351712502875528,0.21973055003602857,0.06065096399567425,0.6123919809434388,0.008641175943847855,46.47407759899387,0.07327634416730477,0.148082439617742,-18.44530292499589,564500000,-370423000,-679830000,2815433000,97698000.0,49333500.0,163857000.0,61.407402687753574,88.20406468820492,292.9622554170126,5.943908780118324,4.138131290096993,1.245894285871217,0.10674789845310217,1.32120051832939,1.15,0.1786544686887863,0.011471321695760598,1.14713216957606,31.65390054188505,14.018155954263413,0.3650350892777827,3.11923264631903,1.8889364417914931,0.6365957127304126,61.407402687753574,292.9622554170126,354.3696581047662,88.20406468820492,266.16559341656125,0.648448962301191,0.20613626383655814,0.1827493335721223,0.14538718254268926,0.21312803889789303,0.05402473130010978,0.10674789845310217,0.08373486565729661,0.7955551995778524,0.8865462591144132,0.20613626383655814,0.30551592650550485,0.5909034090557491,0.35857377042673366,0.37142632650870283,0.0,0.3357220801471158,1.9341165477509143,5.943908780118324,4.138131290096993,1.245894285871217,4.371204793430111,0.3715921194376731,6.012821239981226,3.937361729813303,4.067604293082979,0.2760242669293345,0.6548276711824542,0.3357220801471158,6.223143223201459,4.551028520321972,2.4271761597225905,3.3075200811886214,3.3075200811886214,4.602072711242139,31.65390054188505,25.46121872677731,16.67270587281138,16.67270587281138,14.018155954263413,4.602072711242139,23.234364803376355,3.3075200811886214,1.15,DIA.MI,2023-12-31,2023,FY,-0.15643380759335204,-0.17702054045411292,-0.3287365484256676,-0.3287365484256676,-0.3364700901177633,-0.31175059952038364,-0.30843373493975906,-0.03471663187641394,-0.03968904052323692,0.07073829702673055,-0.19951148222252474,-0.03431100469790136,1.5747142684919586,0.7086366487320633,0.2797542638365758,1.8212864812495315,0.4787632135581674,0.005173488124056759,0.8772907386350388,0.00666164894971388,-0.3665451010805182,2.6242987496526142,1.174135475322757,0.5830820067107393,-0.2083936252211324,-0.595776597227967,0.11274272359717873,-0.17730120322185025,0.02935035105577741,-0.05769902250004548,0.04838385427788197,-0.12443999008864744,-0.07423842153058698,0.018869797928391073,1191928316.0,1291418714.0,1405388794.0,446367426.0,483625768.0,526306632.0,3.79936,4.23468,4.91122
0,DNA,10.08,1.098,1158573,579387362,0.0,5.26-74.0,1.34,"Ginkgo Bioworks Holdings, Inc.",USD,0001830214,US37611X1000,37611X100,New York Stock Exchange,NYSE,Biotechnology,https://www.ginkgobioworks.com,"Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",Dr. Jason  Kelly Ph.D.,Healthcare,US,1218,877 422 5362,27 Drydock Avenue,Boston,MA,02210,15.95294,-7.932942849279252,https://images.financialmodelingprep.com/symbol/DNA.png,2021-04-19,False,False,True,False,False,52240000.0,616214000,445592000,255134000,4.1721094946401225,-12.465333078101072,-6.2347626339969375,-7.235470903522205,11.795826952526799,15.274559724349158,13.75147396630934,15.274559724349158,8.531489280245022,579387362.0,408765362.0,-0.8086426521332517,2.6583377089345768,-1.616741581313094,-1.5328478468494449,0.6599208214120558,0.6599208214120558,1.8754920234364603,-0.6732670912825277,-1.2550210068037237,-1.0814442048674404,-1.2366401863195506,-0.6523804708049534,0.5584258524731717,0.30089615452402385,0.28102718167398794,5.78954267786449,-6358.4946236559135,0.5001681539460894,0.0,0.0,-0.0008507514715389848,1.2759152286523117,2.0303462704919912,0.05372875507383095,-0.160504629970771,0.23985666503021322,0.8683165850012458,0.6176617680120761,65.45269802055985,-0.47527453915644224,-0.4646978520919963,-0.9411897013782542,548053000,718377000,-20460000,1244565000,21151000.0,19364500.0,0.0,39.20612890053269,72.48567489279887,0.0,9.309768912049892,5.035477707006369,0.0,-0.701063158923163,1.000708269525268,0.0,0.7690744210606375,0.0,0.0,-0.8086426521332517,-0.02167414515951698,-0.0008507514715389848,5.78954267786449,5.78954267786449,5.385215027921732,39.20612890053269,0.0,39.20612890053269,72.48567489279887,-33.27954599226618,0.6372716803318177,-2.713178650247074,-2.989392111070837,-2.9877770691577465,0.0005402576353598622,-0.43973021501361015,-0.701063158923163,-0.4327545124028875,0.9994597423646402,1.1018043765008285,-2.713178650247074,0.30089615452402385,0.5584258524731717,0.35832686655381635,0.35832686655381635,-6358.4946236559135,-0.7309466956318785,1.8558756703173034,9.309768912049892,5.035477707006369,0.0,0.35327403046619965,0.14717638057834415,-6.2347626339969375,-7.235470903522205,11.795826952526799,-1.4943909410830876,1.160504629970771,-0.7309466956318785,0.0,-6.230349867054345,-6.165016751528459,0.6599208214120558,0.6599208214120558,2.6583377089345768,-0.8086426521332517,-1.5328478468494449,-1.616741581313094,-1.616741581313094,-0.02167414515951698,2.6583377089345768,-0.6732670912825277,0.6599208214120558,0.0,DNA,2023-12-31,2023,FY,-0.4736197577589564,-0.27803575999122454,0.6086804964526165,0.6086804964526165,0.5758198970131534,0.6336989032901296,0.6334796488427773,0.15804011885214414,0.15750378458888023,0,-0.17169842742607,-0.10454923161307063,140.7762506131243,140.7762506131243,99.21269242497783,-201.12678484929378,-201.12678484929378,-65.4624058876832,-227.59319429620712,-227.59319429620712,-214.44550621032872,66.9796085035195,66.9796085035195,71.64840327102154,0,0,0,-0.6151336930819136,-0.9894592117323556,-0.34417822717175184,-0.4543374081058733,-0.4537402731208257,-0.44841603468602365,-0.7307138975478371,227748447.0,203813945.0,253020642.0,-227748447.0,-203813945.0,-253020642.0,-10.08,-5.81,-3.7825
0,DTIL,4.72,1.693,93423,36207394,0.0,4.13-19.43,0.12,"Precision BioSciences, Inc.",USD,0001357874,US74019P2074,74019P108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.precisionbiosciences.com,"Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",Mr. Michael  Amoroso,Healthcare,US,108,919 314 5512,302 East Pettigrew Street,Durham,NC,27701,13.98621,-0.4262143887721674,https://images.financialmodelingprep.com/symbol/DTIL.png,2019-03-28,False,False,True,False,False,7287173.0,98752000,30307000,-3151929,10.305230848780454,1.1833121019632715,-6.612303564084454,-6.632613223262299,13.887690054840197,8.901394271825302,8.848150030196896,8.901394271825302,3.502318388763379,36207394.0,-32237606.0,3.988803961498318,0.48214810376051986,-0.7138208272283906,-0.7491236629218133,0.5302540091881726,0.5302540091881726,-0.4292852615319058,-1.7126709876215267,0.6690382069108645,0.6669895516520804,0.2507017165176423,-1.3348930884117205,0.3631023957080751,0.15368202638687703,-3.636242894331403,9.224086129193791,-8.230573895378365,-4.198031015856421,0.0,0.0,0.0,0.4562293597528497,0.7348726962820923,0.0025316786073157683,-0.0030714952786136764,0.0019708106956429104,0.027529761904761904,0.15982209438585276,15.394653949973737,-0.1376688117955597,0.056407404984627464,1.9171014603331087,98541000,64478000,22131000,109885000,7682000.0,1051000.0,0.0,7.519108873974646,65.0427948368294,0.0,48.542986425339365,5.611689979123173,0.0,0.17629710652348363,0.020309659177845784,0.0,0.6505024912867244,0.0,0.0,3.988803961498318,-0.0638208633839731,0.0,9.224086129193791,9.224086129193791,8.241695877149057,7.519108873974646,0.0,7.519108873974646,65.0427948368294,-57.523685962854756,0.9284116464259081,-0.2158037711728987,0.15284435922019815,0.11482635559816767,0.2488869140965325,0.05626459956413368,0.17629710652348363,-0.11471162830204705,0.7512632862868095,-0.7082562014068864,-0.2158037711728987,0.15368202638687703,0.3631023957080751,0.25564582759570365,0.26637939809317,-8.230573895378365,-2.045811573897168,2.3626861529923224,48.542986425339365,5.611689979123173,0.0,6.854326396495071,0.48999725952315704,-6.612303564084454,-6.632613223262299,13.887690054840197,-0.6416453606050921,1.0030714952786137,-2.045811573897168,-37.792156862745095,-325.5743243243243,-325.5743243243243,0.5302540091881726,0.5302540091881726,0.48214810376051986,3.988803961498318,-0.7491236629218133,-0.7138208272283906,-0.7138208272283906,-0.0638208633839731,0.48214810376051986,-1.7126709876215267,0.5302540091881726,0.0,DTIL,2023-12-31,2023,FY,0.9414694397959997,1.5147259848390704,0.56423490026503,0.56423490026503,0.5010983825300225,0.6195470798569725,0.6195470798569725,0.31111654929072713,0.31111654929072713,0,-0.8384368238148319,-0.7605151613955005,3025.57310506099,0.9048874781797654,-0.09409181459049533,-398.18981993212157,0.30811667807343124,0.5654106858640137,-3237.155492987158,0.433322028041113,0.7460213104097506,1731.50044606045,-0.7991889912022464,-0.8083142200023468,0,0,0,16.775,-1.0,-0.32912763625828717,-0.7619603725261374,0.15653203136558663,-0.36412156446943617,-0.05868753762793498,72300000.0,20025000.0,31733333.0,-55426073.0,-15351412.0,-24327165.0,0.0675,-7.0225,-3.78667
0,DYAI,1.75,0.721,58736,51781450,0.0,0.93-2.67,-0.155,"Dyadic International, Inc.",USD,0001213809,US26745T1016,26745T101,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.dyadic.com,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.",Mr. Mark A. Emalfarb,Healthcare,US,7,561 743 8333,140 Intracoastal Pointe Drive,Jupiter,FL,33477-5094,0.653264,2.40326,https://images.financialmodelingprep.com/symbol/DYAI.png,2008-01-16,False,False,True,False,False,29503143.0,5921614,5369854,30131508,0.11404032444950017,-0.21455598815353333,-0.14241841962397023,-0.14241858909743954,0.3363182695484342,0.11565249166843004,0.11565249166843004,0.11565249166843004,0.2276893346583447,51781450.0,51229690.0,-8.156379204609866,15.390313944101852,-12.287736408117395,-12.323646840541521,15.131537373333583,15.131537373333583,15.226321633693441,-18.353548153187674,-12.192346073376806,-12.192331564883208,-0.12260342180201904,-0.08114481151068578,1.5596683227279762,0.4924974545761455,0.1976735312863074,5.14661444191537,-4.681423683252757,0.6637820778139156,0.0,0.0,0.0,1.886249505134122,0.6988724785617563,0.0,0.0,0.0,0.0,0.341600119837791,0.7472038070216261,-0.4867516146343601,-0.5858108144375368,0.09572602993518352,8613248,3412112,3296870,8718162,335867.5,383075.5,0.0,42.717680056875395,172.03787912474212,0.0,8.544471504867067,2.121625782978549,0.0,-1.4916512422236388,0.0,0.0,0.10277354149024409,0.0,0.0,-8.156379204609866,-0.4404444770489327,0.0,5.14661444191537,5.14661444191537,2.850800317353946,42.717680056875395,0.0,42.717680056875395,172.03787912474212,-129.32019906786672,0.6457405274051671,-1.9420959368093427,-1.8814045749978898,-1.8814045749978898,0.34939564706648074,-0.5858108144375368,-1.4916512422236388,-0.7486145942769025,1.0,0.9687495552299222,-1.9420959368093427,0.4924974545761455,1.5596683227279762,0.6069176082804488,0.6093243835067481,-4.681423683252757,-0.7895486890340664,3.1668556014573963,8.544471504867067,2.121625782978549,0.0,32.06958079951198,0.31136886888785936,-0.14241841962397023,-0.14241858909743954,0.3363182695484342,-1.2488426380007063,1.0000011899687538,-0.7895486890340664,-78.57339741192311,0.0,0.0,15.131537373333583,15.131537373333583,15.390313944101852,-8.156379204609866,-12.323646840541521,-12.287736408117395,-12.287736408117395,-0.4404444770489327,15.390313944101852,-18.353548153187674,15.131537373333583,0.0,DYAI,2023-12-31,2023,FY,-0.010748717794712696,0.14353309957750493,0.18644382626713168,0.18644382626713168,0.2748324491051218,0.27272727272727276,0.27272727272727276,0.015313200501951701,0.015313200501951701,0,0.16786959063061502,0.16786959063061502,-0.8073343961770639,1.1502265634615167,0.7261833219908461,-2.5033192345316304,-0.46666185367688684,0.023979646952773218,-17.079524475669725,-0.1472517057608189,0.30486968463386066,1.6067736846064784,-0.8669333542000545,-0.8028703771820843,0,0,0,0.2265237479589787,0.0,-0.4006165618182929,-0.47780852777940624,0.0,-0.2674964149763461,-0.09413556479361147,4300000.0,7450000.0,5500000.0,-4300000.0,-7450000.0,-5500000.0,-0.18,-0.19,-0.32
0,EDIT,1.31,2.006,2431944,108138011,0.0,1.28-11.58,-0.03,"Editas Medicine, Inc.",USD,0001650664,US28106W1036,28106W103,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.editasmedicine.com,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.",Dr. Gilmore  O'Neill M.D.,Healthcare,US,265,617 401 9000,11 Hurley Street,Cambridge,MA,02141,9.07885,0.001146781729575004,https://images.financialmodelingprep.com/symbol/EDIT.png,2016-02-03,False,False,True,False,False,82485199.0,95832000,38488000,223930528,0.7487161423954375,-2.552845874809613,-2.203571091584564,-2.3198707443259003,3.2137644476071396,2.1292789752498504,2.1292789752498504,2.1292789752498504,0.24079471518278087,108138011.0,50794011.0,-0.5131527966206334,1.7509960005181513,-0.5944895560678249,-0.565117248046824,0.6152317358256375,0.6152317358256375,0.8224685222967064,-0.2318270915132476,-0.2794534116041857,-0.2654438661127224,-1.9487373090149716,-1.7695442909524202,0.09333614220481228,0.05004472367485125,0.26172165721930624,3.7474465467914255,-65.87546843470741,0.8631821894648861,0.0,0.0,0.0,1.1348813109232812,3.4958547880436543,0.0,-0.05277780834277792,0.1553321027235338,9.869341563786008,0.3682437902781826,11.05910139145229,-1.2484541892673675,-0.6428364273568461,1.372967530817256,198786000,175634000,119206000,249933000,185000.0,13130000.0,0.5,0.7446808510638298,773.5349507974211,0.0,490.14285714285717,0.4718597390120887,0.0,-0.801309054930837,0.11629965274133605,0.0,0.15159331902267,0.0,0.0,-0.5131527966206334,0.060552030001234686,0.0,3.7474465467914255,3.7474465467914255,1.324506240238829,0.7446808510638298,0.0,0.7446808510638298,773.5349507974211,-772.7902699463573,0.9045629715988212,-3.700281744875158,-3.409631140904822,-3.409631140904822,-0.0490758552894022,-0.6428364273568461,-0.801309054930837,-0.895413261028,1.0,0.9214517639439529,-3.700281744875158,0.05004472367485125,0.09333614220481228,0.0,0.08536820342972602,-65.87546843470741,-11.087781370096993,1.8650546021840875,490.14285714285717,0.4718597390120887,0.0,1.2074608481435862,0.18853547518522928,-2.203571091584564,-2.3198707443259003,3.2137644476071396,-2.943132873473882,1.052777808342778,-11.087781370096993,-11.087781370096993,-18.947357448139268,-18.947357448139268,0.6152317358256375,0.6152317358256375,1.7509960005181513,-0.5131527966206334,-0.565117248046824,-0.5944895560678249,-0.5944895560678249,0.060552030001234686,1.7509960005181513,-0.2318270915132476,0.6152317358256375,0.0,EDIT,2023-12-31,2023,FY,2.9632203733766236,-8.441345794392523,0.2512458508519584,0.2512458508519584,0.25022020826808644,0.3221476510067114,0.3221476510067114,0.10632534662363212,0.10632534662363212,0,0.2547011824143356,0.24560939454556477,0,0.5165881375474883,-0.33569356248883775,0.8122031277503858,-0.7929134278632678,0.43295742169937895,0.886697775865719,0.13605827118991212,-0.08043264945481884,1.7832352301385705,-0.08352850995833744,-0.3156842943972981,0,0,0,0.9799805636540331,1.0,-0.02949130990179285,-0.12513469625090368,-0.16861602876257226,0.015392265572308782,-0.014864788413668251,37758647.0,19429059.0,8625000.0,-37758647.0,-19429059.0,-8625000.0,-2.65524,-1.41885,-1.3662
0,ERF.PA,47.96,0.735,391658,9178070813,0.5,39.47-62.1,0.28,Eurofins Scientific SE,EUR,,FR0014000MR3,F3322K104,Paris,EURONEXT,Medical - Diagnostics & Research,https://www.eurofins.com,"Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.",Dr. Gilles G. Martin Ph.D.,Healthcare,LU,62000,352 26 18 53 20,23 Val Fleuri,Luxembourg City,,1526,-71.12907,119.08906800322912,https://images.financialmodelingprep.com/symbol/ERF.PA.png,1997-10-27,False,False,True,False,False,194100000.0,681200000,3396900000,11634595000,43.15481710458526,2.1576506955177743,7.728490458526533,4.4829984441009785,3.509531169500258,27.289541473467285,-1.3060278207109737,27.011334363730036,18.26172076249356,9178070813.0,11893770813.0,22.22787965616046,1.0957124299963588,6.205610300920752,10.547688138936248,1.7755509355509356,1.7755509355509356,1.4199228557784713,6.016526703088247,7.9286519757731515,13.668644303094052,0.044988546612130406,0.09480750538201366,0.6479047855194644,0.3146093431630423,1.373751169790323,1.4188066670286117,7.206499661475965,3.269260102429988,0.010425354462051709,1.042535446205171,0.7268385864374403,0.0,0.0,0.5140592005334716,0.4199386713151639,0.0752057877237699,0.75164061567832,0.014326048935395488,36.21219474814001,0.0919215050438742,0.07982008081116108,-18.98737764039155,771400000,-253500000,-2887000000,8762200000,1416600000.0,588800000.0,142400000.0,61.72843780405547,30.82368802260373,7.454641940249272,5.912995905689679,11.841542119565217,48.9627808988764,0.08529184147285243,3.2454920144255537,0.5,0.3701104588546608,0.010425354462051709,1.0425354462051708,22.22787965616046,1.562302398690135,0.7268385864374403,1.4188066670286117,1.3414951951788914,0.3698354959552636,61.72843780405547,7.454641940249272,69.18307974430473,30.82368802260373,38.359391721701,0.16762074173118363,0.12707205405695798,0.09028992341533007,0.04999791078453025,0.2538675128917096,0.038787833882858516,0.08529184147285243,0.11885698971558742,0.5537485124950416,0.7105411499436303,0.12707205405695798,0.3146093431630423,0.6479047855194644,0.3915208207604104,0.3931688233523924,7.206499661475965,0.44160852483146396,2.0593946098533253,5.912995905689679,11.841542119565217,48.9627808988764,3.4323676446484184,0.7757890934686771,7.728490458526533,4.4829984441009785,3.509531169500258,0.17908754982778896,0.5800613286848361,0.44160852483146396,64.10683752136752,2.381300100007937,1.6055011483919301,1.7755509355509356,1.7755509355509356,1.0957124299963588,22.22787965616046,10.547688138936248,6.205610300920752,6.205610300920752,1.562302398690135,1.0957124299963588,6.016526703088247,1.7755509355509356,0.5,ERF.PA,2023-12-31,2023,FY,-0.029424472221808377,-0.8616753249648837,-0.36248105398157865,-0.36248105398157865,-0.4914782038675844,-0.49211356466876965,-0.4885993485342019,0.002077922077922078,-0.005527638190954774,-0.003112578796089897,-0.10419783507876441,-0.017433312329342573,3.1314760355561537,0.5809026120139168,0.15619773718114635,3.6720448324549606,0.7172403585067829,-0.1969388993791236,2.3413441656500416,0.2716532944542421,-0.4447120074471702,9.179492512133784,0.7454663540177207,0.3281150798893607,8.632079942244145,3.1333902846837374,616.4491100743045,0.012396694214876033,-0.04532967032967033,0.07984330837506819,0.056843335225916836,0.18072470305217261,0,0.868020304568528,6959930839.0,7471292262.0,8001268302.0,1486701633.5,1597076280.0,1710364869.0,3.01356,3.44215,3.91394
0,EXAS,59.4,1.272,2398217,10993514400,0.0,40.62-79.62,3.29,Exact Sciences Corporation,USD,0001124140,US30063P1057,30063P105,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://www.exactsciences.com,"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",Mr. Kevin T. Conroy J.D.,Healthcare,US,6500,608 284 5700,5505 Endeavor Lane,Madison,WI,53719,23.3089,44.1711,https://images.financialmodelingprep.com/symbol/EXAS.png,2001-02-01,False,False,True,False,False,184795000.0,588830000,2758393000,14757798400,14.569268649043535,-1.158245623528775,1.2609756757488026,0.5326280472956519,5.525750155577803,17.373365080224033,-5.526870315755296,17.373365080224033,14.026672799588733,10993514400.0,13163077400.0,-51.28445883441258,4.08327454901483,47.10638051342792,111.69206010545886,3.419026753062051,3.419026753062051,4.889106156456419,500.95438422895415,56.48856073675447,133.73441636949212,-0.0194990845711915,0.008953187890489324,0.8000371280459715,0.3806032417825937,82.568237174608,2.118553965801714,-10.022565976796566,-1.0886945308776945,0.0,0.0,0.0,0.47956563984774514,0.1658471776098603,0.6270733463425072,0.5776064062620697,0.04999205148852592,0.6234598210149895,0.08329557171340193,21.27813529372547,-0.0414816484830502,-0.08504634202744682,-12.174686815119456,809455000,-1021338000,-2004943000,5854088000,276392000.0,75316500.0,132180000.0,35.90161934207125,47.45005830857216,66.56263645270882,10.166672330912812,7.6922982396854165,5.483556833860147,-0.06751563545379959,0.7283476284531508,0.0,0.23364029977529296,0.0,0.0,-51.28445883441258,2.2145561769405435,0.0,2.118553965801714,1.929257028833903,0.8136809726087594,35.90161934207125,66.56263645270882,102.46425579478006,47.45005830857216,55.0141974862079,0.7209938759319072,-0.08759742497942301,-0.07821149577614614,-0.07949922892010186,-0.016464755355675757,-0.03171604773810634,-0.06751563545379959,-0.0391443256653337,1.0164647553556758,0.8928515398085999,-0.08759742497942301,0.3806032417825937,0.8000371280459715,0.4194375371722356,0.4444559034815304,-10.022565976796566,0.0907220010838893,2.10202394572079,10.166672330912812,7.6922982396854165,5.483556833860147,3.3124766235555816,0.39894786614825567,1.2609756757488026,0.5326280472956519,5.525750155577803,0.08655037573430875,0.42239359373793034,0.0907220010838893,0.9356885294613674,1.7312827371001895,1.7312827371001895,3.419026753062051,3.419026753062051,4.08327454901483,-51.28445883441258,111.69206010545886,47.10638051342792,47.10638051342792,2.2145561769405435,4.08327454901483,500.95438422895415,3.419026753062051,0.0,EXAS,2023-12-31,2023,FY,0.19934327410102007,0.22229043933809528,0.6277119239812862,0.6277119239812862,0.6725789326806799,0.6807909604519774,0.6807909604519774,0.02150824208538653,0.02150824208538653,0,1.6983346678058142,1.072893765367414,225.00525681717602,2.731453745744827,0.4062380162700068,2.4885293369975234,2.5277143699953686,-0.04030909627011842,-0.6443811857729327,0.20929246756375072,0.7981496459173664,7.708684251151602,2.133499013456314,-0.06539594528764545,0,0,0,0.28840252336389466,0.07793064375650056,0.03925903097750669,0.011802662675102991,0.04407833514721454,0.0825178309075843,0.02335921784357503,2740226801.0,3054244255.0,3421195076.0,-652832311.0,-727643907.0,-815066362.0,-1.2079,-0.2542,0.56501
0,FLGT,18.34,1.508,213165,560961912,0.0,16.56-30.68,-0.41,"Fulgent Genetics, Inc.",USD,0001674930,US3596641098,359664109,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.fulgentgenetics.com,"Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",Mr. Ming  Hsieh,Healthcare,US,1184,626 350 0537,4978 Santa Anita Avenue,Temple City,CA,91780,-30.87198,50.91197612068298,https://images.financialmodelingprep.com/symbol/FLGT.png,2016-09-29,False,False,True,False,False,30416000.0,58042000,412000,603309680,9.132068648079958,-5.423757233035245,0.3608298264071541,-0.9425302472382956,7.005161756970016,37.31253287743293,32.07943187795897,37.42914913203577,1.2128813782219885,560961912.0,503331912.0,-3.3814197818984173,2.019584866125914,50.827283826879274,-19.567528673084972,0.48999243705229506,0.48999243705229506,1.812104334301792,-7.463403202846975,45.8616776309795,-17.557273336123902,-0.2957337640695335,-0.051105073957320654,0.00036189714918155905,0.00033393771737359604,0.8545373665480427,4.413285579132316,-2.4307135612270074,-0.06620259502108228,0.0,0.0,0.0,0.3437163604681723,0.17516858018224302,0.12901181183095944,3.612118451025057,0.14272342049459788,1.5688392892476948,0.16382789520487037,67.58438364335922,-0.07079768783642885,-0.15351765738284168,5.309910902156759,252549000,975728000,227674000,518529000,60515000.0,19839000.0,7829000.0,75.3164591141305,39.47933961027613,17.207051730164277,4.846218267469249,9.245342085331988,21.212233549582947,-0.14544202627352912,1.3033600736454498,0.0,0.0007344527162835255,0.0,0.0,-3.3814197818984173,4.632545101200931,0.0,4.413285579132316,4.296621165022301,0.7844573591025814,75.3164591141305,17.207051730164277,92.52351084429478,39.47933961027613,53.04417123401865,0.34078578346132105,-0.3192312815694068,-0.6808551236494684,-0.5939242730260907,0.09069084948311874,-0.13371206625583681,-0.14544202627352912,-0.0764546165499628,0.8723210744784919,2.1327957595579115,-0.3192312815694068,0.00033393771737359604,0.00036189714918155905,0.0,0.00036176622701533206,-2.4307135612270074,26.638349514563107,1.0837264865672036,4.846218267469249,9.245342085331988,21.212233549582947,2.6005149330587023,0.22513319008594032,0.3608298264071541,-0.9425302472382956,7.005161756970016,0.03951238654814751,-2.612118451025057,26.638349514563107,26.638349514563107,0.276845849204147,0.276845849204147,0.48999243705229506,0.48999243705229506,2.019584866125914,-3.3814197818984173,-19.567528673084972,50.827283826879274,50.827283826879274,4.632545101200931,2.019584866125914,-7.463403202846975,0.48999243705229506,0.0,FLGT,2023-12-31,2023,FY,-0.5327496736503341,-0.7153019479369094,-1.4071933096954523,-1.4071933096954523,-2.170303271200742,-2.1827731092436977,-2.2159827213822894,-0.010399707612054358,-0.038108771476553414,0,-0.8934876932786368,-0.9795693199003174,96.01230140264994,7.1740241338832025,-0.47744756177143544,3.6326637988651336,25.147189840928764,-0.8536919427982277,-15.797646298739672,-21.56656219126863,-1.5966810521703412,288.2109324906548,12.119666482289603,0.5203284484851418,0,0,0,0.08902538436747616,-1.0,-0.10874403792639964,-0.09818234043256922,-0.2610233549762574,0.43341404358353514,-0.13018027628140166,281983317.0,324650522.0,365321342.0,91232783.0,105037316.0,118195938.0,0.32541,-0.15394,0.026196
0,GH,31.67,1.106,1770053,3912986850,0.0,15.81-38.53,0.54,"Guardant Health, Inc.",USD,0001576280,US40131M1099,40131M109,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://guardanthealth.com,"Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.",Dr. Helmy  Eltoukhy Ph.D.,Healthcare,US,1768,855 698 8887,505 Penobscot Drive,Redwood City,CA,94063,21.5581,53.0331,https://images.financialmodelingprep.com/symbol/GH.png,2018-10-04,False,False,True,False,False,123051000.0,688368000,1339415000,3473836940,5.625764926737694,-4.164208336380851,-2.0647780188702245,-2.229644618897855,8.119145720067289,-0.48838286564107564,-0.5740465335511292,-0.48838286564107564,9.300875246848868,3912986850.0,4564033850.0,-7.605287113834624,5.6525141710581055,-15.338210553659778,-14.26223520192448,-64.846664836262,-64.846664836262,6.5929856151481525,-9.774682496509067,-17.96347447387168,-16.63520137775186,-0.13148747509885855,-0.07011523690655899,-19.001281283280086,0.7421075993337349,-1.3943318398711568,6.216093643112316,-199.58930647036033,0.49583926933510275,0.0,0.0,-0.04136140980855175,0.23966278371007257,0.4970213331484306,0.006850467951754925,-0.07984713054909416,0.02930563259834512,0.47398425270437605,0.18542995654786668,6.764531026618406,-0.4762107267760785,-0.33530604258905655,-4.041058179128979,1029370000,-70637000,-372108000,1310044000,94492000.0,28960000.0,69640999.5,46.64419665557251,43.0884406161546,201.33187356470918,7.825196405358051,8.47094939572158,1.8129270519239813,-12.402517245552463,0.16486660002763082,0.0,0.2918233676149461,0.0,0.0,-7.605287113834624,2.073708286372236,-0.04136140980855175,6.216093643112316,5.849740302515898,3.488145126555018,46.64419665557251,201.33187356470918,247.97607022028168,43.0884406161546,204.88762960412708,0.8106610849165626,-0.7441466740627745,-0.740164043359682,-0.7402030462718994,-5.2694956702310574e-05,-0.3330090392902705,-12.402517245552463,-0.38403676208566984,1.0000526949567023,0.9946480568389175,-0.7441466740627745,0.7421075993337349,-19.001281283280086,1.055551601259007,1.055551601259007,-199.58930647036033,-0.22250002408264816,-25.604482827476037,7.825196405358051,8.47094939572158,1.8129270519239813,2.5626487693099325,0.44988877169244446,-2.0647780188702245,-2.229644618897855,8.119145720067289,-0.3670217376230759,1.0798471305490942,-0.22250002408264816,0.0,-12.523931581801154,-6.1250452014175165,-64.846664836262,-64.846664836262,5.6525141710581055,-7.605287113834624,-14.26223520192448,-15.338210553659778,-15.338210553659778,2.073708286372236,5.6525141710581055,-9.774682496509067,-64.846664836262,0.0,GH,2023-12-31,2023,FY,0.2545057370010989,0.1489804340189555,-0.0373766022873812,-0.0373766022873812,0.2675560810769522,0.3322932917316692,0.3322932917316692,0.09600892560042279,0.09600892560042279,0,-0.050125540048406435,0.10716057933857812,13.103960304907714,0.6891526788094073,0.7124459392948721,-4.589999466514816,-0.2222159373347794,-1.722528942979334,-5.561761455551543,-0.530194627001949,-0.694957940658786,0.25731128468556974,-0.9108350216234157,-0.8935994674692498,0,-1,0,-0.08712058896109237,0.20058917012287297,0.10958859865154023,1.4058406853708734,-0.01133439082031193,-0.017690947467543412,-0.027506339157883843,723903119.0,843271445.0,1015054484.0,-546113007.0,-636164553.0,-765757795.0,-3.44714,-2.96952,-2.53502
0,GRAL,18.35,1.31,773369,616574185,0.0,12.33-24.92,1.21,"GRAIL, LLC",USD,0001699031,US3847471014,,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://grail.com,"GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.",Mr. Robert P. Ragusa,Healthcare,US,1360,833-694-2553,1525 O’Brien Drive, Menlo Park,CA,94025,,0.0,https://images.financialmodelingprep.com/symbol/GRAL.png,2024-06-12,True,False,True,False,False,31880054.0,853551000,72191000,-342690456,3.690991238597024,-60.709840704786764,-19.214647503420164,-19.49068216760235,26.77382541447389,81.1678675324703,16.818133369535698,81.1678675324703,0.0,616574185.0,-164785815.0,-0.3022574229642669,5.239903330528856,-0.9550006054877532,-0.9922914507438474,0.2260746839586403,0.2260746839586403,-1.4004182494964688,0.24693191405190512,0.2690099565106666,0.265200132289608,-3.3084381855469625,-1.0077684326015044,0.0,0.0,1.1708697157191388,9.650103958925616,0.0,0.2892910677196234,0.0,0.0,0.0,1.9148968717334218,3.0436053675989427,0.6579548639909376,-0.014365845854473982,0.07478605240122717,0.05550509637703098,0.4626622134971828,332.97595549150225,-0.7541357253897027,-1.8147843233962913,10.937261900497408,815428000,536163000,379378000,3011412000,18677000.0,11782000.0,23359500.0,61.38082247660812,13.463046886421035,39.0312441713338,5.94648271679806,27.11124777914446,9.351482581435912,-0.8580802322815594,0.2760346641821874,0.0,0.0,0.0,0.0,-0.3022574229642669,-0.010594263004343017,0.0,9.650103958925616,9.425075317180804,9.054514787626767,61.38082247660812,39.0312441713338,100.41206664794191,13.463046886421035,86.94901976152087,-0.6858560878396179,-19.094349403836183,-18.93783409394148,-16.448112926939125,0.13146810530982825,-0.6207381507231986,-0.8580802322815594,-0.7430708744228072,0.8685318946901718,0.9918030561510904,-19.094349403836183,0.0,0.0,0.0,0.0,0.0,0.0,1.2049430445394946,5.94648271679806,27.11124777914446,9.351482581435912,0.8142563541875705,0.037739171264232894,-19.214647503420164,-19.49068216760235,26.77382541447389,-5.205823113989241,1.014365845854474,0.0,0.0,-69.60954545454545,-69.60954545454545,0.2260746839586403,0.2260746839586403,5.239903330528856,-0.3022574229642669,-0.9922914507438474,-0.9550006054877532,-0.9550006054877532,-0.010594263004343017,5.239903330528856,0.24693191405190512,0.2260746839586403,0.0,GRAL,2023-12-31,2023,FY,0.676057605760576,0.17893118757889856,-1.0410312219260591,-1.0410312219260591,0.7285315065590585,0.7622361534479783,0.7622361534479783,0.0,0.0,0,-0.061439874009688,-0.041965380059297605,0,0,0,-9.465249572770029,-9.465249572770029,-9.227381835796681,-18.53938254008735,-18.53938254008735,-17.699270180715434,14.364028871396389,14.364028871396389,24.84550814913117,0,0,0,0.2008058017727639,0.09820298658567451,-0.30136687978905063,-0.21522586066216826,-0.1208519945838975,0.027820593732553342,0.22306332564195983,,,,,,,,,
0,HBIO,2.11,1.313,151247,92031026,0.0,1.99-5.56,0.01,"Harvard Bioscience, Inc.",USD,0001123494,US4169061052,416906105,NASDAQ Global Market,NASDAQ,Medical - Instruments & Supplies,https://www.harvardbioscience.com,"Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.",Mr. James W. Green,Healthcare,US,391,508 893 8999,84 October Hill Road,Holliston,MA,01746,1.13885,0.9711519570606535,https://images.financialmodelingprep.com/symbol/HBIO.png,2001-03-19,False,False,True,False,False,43614000.0,4569000,45691000,158443660,2.24084009721649,-0.32652359334158754,0.09212638143715321,0.014078048333104049,0.10475993946897785,1.497730086669418,-0.10221488512862842,1.497730086669418,0.94024854404549,92031026.0,133153026.0,-6.462013903518011,0.9416672737690828,22.903320059731207,149.887664495114,1.408798567098374,1.408798567098374,1.3624301764007694,-38.46129045023384,33.13913041314087,216.86160586319218,-0.1547505181713685,0.006671663097616667,0.5795597195431861,0.2884660809667858,-11.878101710542545,2.056656850248341,-1.5,-0.28214310792781405,0.0,0.0,-0.033775717997331645,0.22485982073425284,0.11488560553349977,0.5317017045238077,0.8471876555500248,0.034829943109728645,0.48058732175631796,0.048714852862931285,3.3171515973030052,-0.04882085001634358,-0.23171545257814152,-0.888011876920255,24040000,-4458000,-19126000,105564000,12658500.0,5497000.0,25560000.0,47.91997503376581,43.13569559089994,212.20835290696374,7.616865404099447,8.46166950596252,1.7200076952674106,-0.20755315078974695,0.07804833310404916,0.0,0.4113612728820387,0.0,0.0,-6.462013903518011,0.2019379344849378,-0.033775717997331645,2.056656850248341,0.9142894817810207,0.20082633730385477,47.91997503376581,212.20835290696374,260.12832794072955,43.13569559089994,216.9926323498296,0.5425960790733844,-0.04834649858797528,-0.13667990013506323,-0.1457148119346785,-0.06610270998652493,-0.10851195147783814,-0.20755315078974695,-0.043553204040999924,1.066102709986525,2.827089947089947,-0.04834649858797528,0.2884660809667858,0.5795597195431861,0.34398537770904053,0.3669121922853266,-1.5,0.10613344603518411,2.009108722941735,7.616865404099447,8.46166950596252,1.7200076952674106,8.321866485013624,0.7446871737821836,0.09212638143715321,0.014078048333104049,0.10475993946897785,0.04111242991036713,0.1528123444499751,0.10613344603518411,1.1142540210759844,1.1803760282021152,1.0342342342342343,1.408798567098374,1.408798567098374,0.9416672737690828,-6.462013903518011,149.887664495114,22.903320059731207,22.903320059731207,0.2019379344849378,0.9416672737690828,-38.46129045023384,1.408798567098374,0.0,HBIO,2023-12-31,2023,FY,-0.009573388626637843,0.0863545931370131,1.2643036561540608,1.2643036561540608,0.6411307271963009,0.65,0.65,0.02431603602733441,0.02431603602733441,0.0,11.177083333333334,27.751141552511417,-0.23552263783462932,-0.21506797803155975,0.0014449045296302382,1.4748222211383701,4.054256721184065,0.3694116598456545,-0.3366383008324251,0.16692751265099276,0.6017038323550665,-0.4460452423579055,-0.2490781296799632,-0.1319563458282422,0,0,0,-0.03627656390302305,-0.06516887930708423,-0.05499449642267474,-0.01219453406748276,-0.08651546215615924,-0.0458269121583259,-0.0534178544030363,93750000.0,97800000.0,112000000.0,5500597.0,5738222.0,6571379.0,0.045,0.125,0.25
0,HOLX,71.65,0.986,1731753,16260322650,0.0,70.36-84.67,0.89,"Hologic, Inc.",USD,0000859737,US4364401012,436440101,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.hologic.com,"Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.",Mr. Stephen P. MacMillan,Healthcare,US,6990,508 263 2900,250 Campus Drive,Marlborough,MA,01752,-31.74084,103.3908417218265,https://images.financialmodelingprep.com/symbol/HOLX.png,1990-03-01,False,False,True,False,False,233772000.0,2160200000,2534600000,19267853040,17.239874749756172,3.3772222507400373,5.497664390945023,4.897934739831973,9.98237599028113,21.944458703351984,3.60308334616635,21.944458703351984,11.364491898088737,16260322650.0,16634722650.0,21.215660291323623,4.034619286884026,13.032807189542485,14.201155152838428,3.265061169590644,3.265061169590644,4.127517902337353,12.833453672272796,12.943294934640523,14.528142052401748,0.04713499303196144,0.07041680688913021,0.49407407407407405,0.2768239405854085,0.2888443141490511,3.686174315464713,7.661752653562654,1.6278657378087398,0.0,0.0,0.0,0.10158304798769292,0.06768894819115677,0.46829401485364786,0.10908807967631497,0.03478735546622996,0.4538685658789252,0.017145551089275967,40.83508993257685,0.11138843928031404,0.16217159994248506,-3.859315914651883,2786100000,842300000,-202700000,7611600000,614450000.0,202900000.0,672650000.0,54.37596149074488,41.9247026996562,139.84500929944204,6.712524983344437,8.706084396467125,2.6100323624595467,0.16129444152182684,0.5997296511130503,0.0,0.1558763657128292,0.0,0.0,21.215660291323623,1.604774304087301,0.0,3.686174315464713,3.0307558812186657,2.0827227150019283,54.37596149074488,139.84500929944204,194.22097079018693,41.9247026996562,152.29626809053073,0.559748895836435,0.2321224750632723,0.21465435958513226,0.1958959853109027,0.08738874118599006,0.08622761031017911,0.16129444152182684,0.11522638801300684,0.91261125881401,0.9247461260553139,0.2321224750632723,0.2768239405854085,0.49407407407407405,0.32739835586264765,0.3306891422905305,7.661752653562654,0.5070622583445119,1.7847953216374268,6.712524983344437,8.706084396467125,2.6100323624595467,7.493863889921904,0.44017038007863696,5.497664390945023,4.897934739831973,9.98237599028113,0.31889236266190263,0.890911920323685,0.5070622583445119,34.272,9.166904422253923,9.166904422253923,3.265061169590644,3.265061169590644,4.034619286884026,21.215660291323623,14.201155152838428,13.032807189542485,13.032807189542485,1.604774304087301,4.034619286884026,12.833453672272796,3.265061169590644,0.0,HOLX,2024-09-28,2024,FY,-2.481143310837634e-05,0.07545257060101376,0.32046678635547576,0.32046678635547576,0.731359649122807,0.8108108108108107,0.8142076502732238,-0.04477412348240481,-0.04532393471874485,0,0.2226027397260274,0.27081021087680357,0.8612931396517532,0.3679560752067317,-0.21970201426007127,1.95449488308286,1.2615601850526028,-0.39861978550790167,52.3364490294391,23.446191797806023,-0.5399858473289745,1.9062716420798616,1.5725899711667148,0.32604391562034685,0,0,0,-0.04028132992327366,0.10071243523316062,0.0018272734235663564,0.07047330593391421,-0.056844794549712585,-0.07305470608222901,0.007290400972053463,4175352371.0,4419187215.0,4693589856.0,1616842153.0,1711263514.0,1817521793.0,4.27086,4.69118,5.17068
0,HTL.V,1.45,0.539341,22211,212884638,0.0,1.05-1.73,0.06,Hamilton Thorne Ltd.,CAD,,CA4078911001,,Toronto Stock Exchange Ventures,TSXV,Medical - Devices,https://www.hamiltonthorne.ltd,"Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets under the Hamilton Thorne brand; test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand. The company also manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics under the Gynemed brand; and bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand. It sells its products and services through a direct sales force in the United States, Germany, France, and the United Kingdom, as well as through distributors to approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries. The company is headquartered in Beverly, Massachusetts.",Mr. David B. Wolf,Healthcare,US,,978 921 2050,100 Cummings Center,Beverly,MA,01915,,0.0,https://images.financialmodelingprep.com/symbol/HTL.V.png,2012-07-04,False,False,False,False,False,146132920.0,16352919,19773673,163272632,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,240593601.64744,258982362.64744,0.0,3.1532816455849675,0.0,142.71378223969316,0.0,0.0,3.3942894785003186,36.60016984871088,42.76374355981057,153.62151052108524,,0.00700703172676387,0.29939523044262173,0.1798869421090367,2.598755255096532,1.8349460385983754,0.1737462005861257,-2.896384564910059,0.0,0.0,0.0,0.2522347970790294,0.05454230570756666,0.5401049933650427,0.7216291949300873,0.05727792236673633,0.6375637250360887,0.02017716173592011,0.0,0.004902025299882518,-0.041819387480708334,0.0,15562535,6602382,-9195027,84841842,10221542.0,12640293.5,14228165.0,51.20498673954759,117.83426161025797,141.86315357359712,7.128211981707172,3.0975710715382054,2.5729020595234537,-0.03260440236790321,0.0,0.0,0.08128631794896318,0.0,0.0,0.0,0.0,0.0,1.8349460385983754,1.0541038451103335,0.36770082425687556,51.20498673954759,141.86315357359712,193.0681403131447,117.83426161025797,75.23387870288674,0.5092196687752581,0.003972912878657958,-0.0199652073430218,-0.027404187918408252,-0.37259721111719424,-0.019232527482910208,-0.03260440236790321,0.0033651632341903984,1.3725972111171942,-5.025332282082664,0.003972912878657958,0.1798869421090367,0.29939523044262173,0.18750822018613275,0.23041121240735718,0.1737462005861257,0.30966558824455814,1.664352214410017,7.128211981707172,3.0975710715382054,2.5729020595234537,7.225247094870378,0.7018097941881034,0.0,0.0,0.0,0.07937306690077238,0.27837080506991274,0.30966558824455814,1.351225862878728,1.3857532469939522,1.3857532469939522,0.0,0.0,3.1532816455849675,0.0,142.71378223969316,0.0,0.0,0.0,3.1532816455849675,36.60016984871088,0.0,0.0,HTL.V,2021-12-31,2021,FY,0.3161279611490666,0.28531395351688255,0.33715883469019853,0.33715883469019853,1.5061916014146937,1.0,1.0,0.047543417539995574,0.041593910219228036,0,-0.05620807078245423,-0.212145150925279,0.6145673966138122,1.5679119670752748,0.6056103164066348,1.6636006151795224,1.9189027082788706,0.16601891596614404,1.284107861618209,0.8490309390892344,-0.26331233857453495,5.4970054957059125,7.479902703566033,0.5120961154521786,0,0,0,0.2999267756895289,0.2868346165874469,0.07526249085393603,0.046046226320430504,-0.09614688672779778,0.26111901464161263,0.27976221313448235,,,,,,,,,
0,IDXG,2.84,0.625,11217,12509632,0.0,1.01-3.54,0.16,"Interpace Biosciences, Inc.",USD,0001054102,US46062X3035,46062X303,Other OTC,PNK,Medical - Diagnostics & Research,https://www.interpace.com,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",Dr. Thomas W. Burnell Ph.D.,Healthcare,US,108,855 776 6419,Morris Corporate Center 1,Parsippany,NJ,07054,2.03651,3.11651,https://images.financialmodelingprep.com/symbol/IDXG.png,1998-05-20,False,False,True,False,False,4393000.0,2113000,1189000,6983400,10.219212383337128,1.069883906214432,1.0475756885954928,0.8452082859094013,0.4809924880491691,-2.5372183018438426,-2.5372183018438426,-2.5372183018438426,0.17823810607785112,12509632.0,11585632.0,2.6544936170212767,0.2786544004633239,2.711021295089092,3.3691440883382713,-1.1193360846940605,-1.1193360846940605,0.25807212705767046,1.8771276733635773,2.517521077792264,3.1202887153245356,0.37671968528677185,0.2968112890930764,0.0,0.0,-0.14970836033700582,0.591933507379189,8.116219667943806,0.9585503020204124,0.0,0.0,0.0,0.19526429510168622,0.014122468981801172,0.0,0.19317687961755758,0.019802641837257478,1.5274914089347078,0.007729490120954269,7.815171343172673,-0.5680656617022792,0.3347816796068096,-4.006885954928295,-7659000,-11146000,-14075000,-4775000,6749500.0,1731000.0,615500.0,59.29532443810839,34.92714896489649,0.0,6.155628685040449,10.450323339212227,0.0,-0.3522116267306143,0.20236740268609152,0.0,0.0,0.0,0.0,2.6544936170212767,0.04012606630380999,0.0,0.591933507379189,0.591933507379189,0.11257925302360275,59.29532443810839,0.0,59.29532443810839,34.92714896489649,24.3681754732119,0.6040362640055242,0.14155881763303857,0.10917069476310338,0.10469338204174371,0.003672719853091206,0.3347816796068096,-0.3522116267306143,-1.3435517970401691,0.9589879616404815,0.7712037765538946,0.14155881763303857,0.0,0.0,0.0,0.0,8.116219667943806,0.0,-1.2595549973084514,6.155628685040449,10.450323339212227,0.0,15.56622746185853,3.1977348814018094,1.0475756885954928,0.8452082859094013,0.4809924880491691,0.102510413650235,0.8068231203824424,0.0,0.0,5.1766029246344205,5.1766029246344205,-1.1193360846940605,-1.1193360846940605,0.2786544004633239,2.6544936170212767,3.3691440883382713,2.711021295089092,2.711021295089092,0.04012606630380999,0.2786544004633239,1.8771276733635773,-1.1193360846940605,0.0,IDXG,2023-12-31,2023,FY,0.2630818518751178,0.3111732762876419,1.7302083333333333,1.7302083333333333,1.1367433930093778,1.1376811594202898,1.1304347826086956,0.01864086833411987,0.02973100519112789,0.0,1.4925897035881435,1.4141502370851011,-0.9091088200486168,0.19801730403011142,0.1584419906667256,1.3678212771144225,1.2849744083685464,1.2425560368634028,1.0598963470281404,1.042919721284982,1.0285674660471478,-1.1588821908574443,-1.2997536607655327,0.5142787158948902,0,0,0,-0.009737678855325914,0.0024509803921568627,-0.1851179673321234,0.764411861733378,-0.30445590702877384,-0.0953058321479374,-0.024977609712409195,,,,,,,,,
0,IDXX,412.26,1.357,626520,33757786422,0.0,398.5-583.39,3.23,"IDEXX Laboratories, Inc.",USD,0000874716,US45168D1046,45168D104,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.idexx.com,"IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",Mr. Jonathan J. Mazelsky,Healthcare,US,11000,207 556 0300,One IDEXX Drive,Westbrook,ME,04092,260.74839,151.5116101191816,https://images.financialmodelingprep.com/symbol/IDXX.png,1991-06-21,False,False,True,False,False,82304000.0,308636000,998280000,42271270880,46.71482552488336,10.524871209175739,11.139519342923794,9.63020024543157,3.749951399688958,19.659481920684293,13.354126166407465,19.659481920684293,11.01854101866252,33757786422.0,34447430422.0,39.17007551033837,8.780076248622496,37.00877814462271,42.590986645801706,20.97003378132003,20.97003378132003,8.959446033972487,27.46682041419387,37.572443243927154,43.46108571056784,0.025529692934497014,0.023479146146960003,0.5400919870412236,0.26080543971139736,0.5498908820098442,1.4206400164879154,33.77635569574184,1.058399587180905,0.0,0.0,0.0,0.1113642079714067,0.05562683477523118,0.15487682517967533,0.13549230007405977,0.03230920977513364,0.9861551040046608,0.015928196322477765,68.23162091891284,0.35415345149144867,0.30589587578262667,-9.584840955482115,424520000,1099098000,-298968000,1782274000,597689500.0,114035500.0,384881000.0,55.73240937084912,26.758873094172188,94.30771107113455,6.5491516358328035,13.640335253112484,3.8703091810243095,0.5542383939966822,1.509319097492224,0.0,0.02588730164577614,0.0,0.0,39.17007551033837,14.255109623226657,0.0,1.4206400164879154,1.0343987063327864,0.3058151609553479,55.73240937084912,94.30771107113455,150.04012044198367,26.758873094172188,123.28124734781149,0.6076114936029465,0.28965591860418843,0.28430793949360916,0.2253004499303868,0.2075478086486543,0.2585196937058571,0.5542383939966822,0.475615641316705,0.792452192266165,0.9815367863486083,0.28965591860418843,0.26080543971139736,0.5400919870412236,0.24489222572955538,0.35068813524498066,33.77635569574184,1.0491235819283258,2.0708616646910425,6.5491516358328035,13.640335253112484,3.8703091810243095,4.58372218341007,1.1474441963419708,11.139519342923794,9.63020024543157,3.749951399688958,0.23845790319799356,0.8645076999259402,1.0491235819283258,2.6259580683966317,7.380493204805013,7.380493204805013,20.97003378132003,20.97003378132003,8.780076248622496,39.17007551033837,42.590986645801706,37.00877814462271,37.00877814462271,14.255109623226657,8.780076248622496,27.46682041419387,20.97003378132003,0.0,IDXX,2023-12-31,2023,FY,0.08719950916514123,0.09261511780947125,0.22070619127358096,0.22070619127358096,0.2443759212709969,0.2524630541871922,0.2528019925280201,-0.006660846896188848,-0.007352245862884161,0,0.6694967070852916,0.9608952012705951,2.402713791369685,0.7297437769938183,0.3896350816739846,3.716589224711028,1.3693975893887558,0.4371261471951241,4.759253663772552,1.3437849502031944,0.4923201805258875,2.6667964619524995,164.1879204976477,1.412964606000721,0,0,0,0.07868153178937591,0.03387227008642744,0.1868234086279678,1.4550578208007325,-0.20841179232094478,-0.250643591554823,0.06010910334727001,3878800133.0,4158581370.0,4515198380.0,1177612058.0,1262554243.0,1370823934.0,10.45615,11.98467,13.57044
0,ILMN,136.02,1.131,1917061,21572772000,0.0,97.363815-156.66,2.02,"Illumina, Inc.",USD,0001110803,US4523271090,452327109,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.illumina.com,"Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.",Mr. Jacob  Thaysen Ph.D.,Healthcare,US,10590,858 202 4500,5200 Illumina Way,San Diego,CA,92122,78.29238,57.72762184381009,https://images.financialmodelingprep.com/symbol/ILMN.png,2000-07-28,False,False,True,False,False,159000000.0,869000000,2674000000,22540190000,27.61006289308176,-9.968553459119496,4.377358490566038,3.4339622641509435,5.90566037735849,13.364779874213836,4.446540880503145,13.364779874213836,13.081761006289309,21572772000.0,23377772000.0,-13.64490851735016,4.914071070615034,31.073534482758625,39.510571428571424,10.177496470588236,10.177496470588236,5.325232801822323,-22.24336060894386,33.588752873563216,42.816432234432234,-0.073287409639167,0.025309682038080223,0.9355294117647058,0.33056202194878614,-1.7174119885823025,2.433846153846154,12.054347826086957,-0.43883984867591425,0.0,0.0,0.0,0.0,0.2835990888382688,0.23578317259727302,0.21551724137931033,0.03416856492027335,0.38461538461538464,0.08769931662870159,54.75051834935412,0.27877893094763095,-0.3448651000870322,-13.45125786163522,1398000000,707000000,-1516000000,4101000000,678000000.0,195000000.0,567500000.0,58.117312072892936,44.06763590391908,132.43362831858406,6.280400572246066,8.282722513089006,2.7560975609756095,-0.42154255319148937,0.9433962264150944,0.0,0.09215320126685621,0.0,0.0,-13.64490851735016,-0.2843183655191332,0.0,2.433846153846154,1.8451282051282052,0.8912820512820513,58.117312072892936,132.43362831858406,190.55094039147698,44.06763590391908,146.48330448755792,0.639635535307517,0.25261958997722095,-0.3492027334851936,-0.36104783599088835,-0.033920417482061316,-0.26355171267043564,-0.42154255319148937,0.22008334987100614,1.0339204174820613,-1.382326420198377,0.25261958997722095,0.33056202194878614,0.9355294117647058,0.48334548991004134,0.48334548991004134,12.054347826086957,0.3501006036217304,2.8301176470588234,6.280400572246066,8.282722513089006,2.7560975609756095,3.4163424124513617,0.729963418689724,4.377358490566038,3.4339622641509435,5.90566037735849,0.15854214123006835,0.7844827586206896,0.3501006036217304,0.0,4.64,4.64,10.177496470588236,10.177496470588236,4.914071070615034,-13.64490851735016,39.510571428571424,31.073534482758625,31.073534482758625,-0.2843183655191332,4.914071070615034,-22.24336060894386,10.177496470588236,0.0,ILMN,2023-12-31,2023,FY,-0.017452006980802792,-0.07671601615074024,0.7441971763579803,0.7441971763579803,0.7363760217983651,0.7379679144385027,0.7379679144385027,0.006369426751592357,0.006369426751592357,0,0.2193877551020408,4.8108108108108105,1.5088044004714147,0.25725483940799143,0.2937420128888038,-0.02077143578465388,-0.6105766033385799,-0.5882208157524613,-8.334496711495282,-2.3077129371379534,-2.6466019604816307,1.9662486446211127,0.3901252654277295,0.13869442811453336,0,0,0,0.09302325581395349,0.03345070422535211,-0.1747469800848841,-0.1349235883457602,-0.34981316470250073,0.02498107494322483,0.24286815728604472,4316146451.0,4472899715.0,4746437211.0,-221283321.0,-229319861.0,-243343779.0,4.12114,4.41316,5.2051
0,INFIQ,0.0001,1.334,349,9076,0.0,1.0E-6-0.018,0.0,"Infinity Pharmaceuticals, Inc.",USD,,US45665G3039,,OTC Markets EXMKT,OTC,,,,Mr. Seth A. Tasker J.D.,,,30,,,,,,,0.0,https://images.financialmodelingprep.com/symbol/INFIQ.png,2000-07-27,True,False,False,False,True,89885492.0,17746000,633000,1807896,0.029053942347140604,-0.49714399074442017,-0.47542916611319824,-0.47561964703101595,0.4292879649618195,-0.21346188031445262,-0.21346188031445262,-0.21346188031445262,0.0020168567768936788,9076.0,-37386924.0,-0.00020114896662083885,0.0035001928268414964,-0.00021033627536470975,-0.00021381454956652846,-0.0004684677182300142,-0.0004684677182300142,-14.418404936367141,0.8549295465459286,0.8811228582875728,0.8807699773840935,-4971.439907444202,-4676.950198325253,0.0,0.0,0.855137088106835,2.9572938068682126,-249.13333333333333,0.9563208546507697,0.0,0.0,0.0,5.192055534130351,12.499421519475511,0.0,-0.0004006504678183404,0.006556112610875434,0.03711790393013101,1.3964519861164675,1.5452278306628549,2.3538921841373157,-1.052620341154421,-0.2564657487017745,26674000,-19051000,-20900000,28171000,0.0,3362500.0,0.0,0.0,1028.6788227767115,0.0,0.0,0.35482406356413165,0.0,-35.21349206349206,0.00019048091781773631,0.0,0.0,0.0,0.0,-0.00020114896662083885,6.2173316955532015e-06,0.0,2.9572938068682126,2.9572938068682126,2.811344291165248,0.0,0.0,0.0,1028.6788227767115,-1028.6788227767115,0.3972232934824528,-17.29425376012341,-17.111068260701888,-17.111068260701888,0.0,-1.052620341154421,-35.21349206349206,-1.5722048872839463,1.0,0.9894077245562394,-17.29425376012341,0.0,0.0,0.0,0.0,-249.13333333333333,0.0,-2.212534775077424,0.0,0.35482406356413165,0.0,1.732130928523714,0.061516927237787955,-0.47542916611319824,-0.47561964703101595,0.4292879649618195,-16.36367142306209,1.0004006504678182,0.0,0.0,-2495.9411764705883,-2495.9411764705883,-0.0004684677182300142,-0.0004684677182300142,0.0035001928268414964,-0.00020114896662083885,-0.00021381454956652846,-0.00021033627536470975,-0.00021033627536470975,6.2173316955532015e-06,0.0035001928268414964,0.8549295465459286,-0.0004684677182300142,0.0,INFIQ,2022-12-31,2022,FY,0.39558665231431644,0.3956639566395664,0.005301333096732693,0.005301333096732693,0.019729574477486633,0.05660377358490571,0.05660377358490571,0.04264763649454964,0.04264763649454964,0,-0.044635383327588755,-0.044770976396170226,-0.45700238112905106,-0.45700238112905106,-0.45700238112905106,0.34765976035529295,0.34765976035529295,0.34765976035529295,0.3979837184165744,0.3979837184165744,0.3979837184165744,-2.574402990306034,-2.574402990306034,-2.574402990306034,0,0,0,0,0,-0.5028483811995046,-1.8470517325674565,-0.36142061281337046,0.02414130881284166,-0.050162268943135316,3500000.0,2698745.0,18000000.0,-3500000.0,-2698745.0,-18000000.0,-0.55,-0.28,-0.13
0,IQV,197.27,1.513,1501344,35804505000,0.0,187.62-261.73,5.75,IQVIA Holdings Inc.,USD,0001478242,US46266C1053,46266C105,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.iqvia.com,"IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",Mr. Ari  Bousbib,Healthcare,US,88000,919 998 2000,4820 Emperor boulevard,Durham,NC,27703,52.56458,144.70542401405288,https://images.financialmodelingprep.com/symbol/IQV.png,2013-05-09,False,False,True,False,False,182100000.0,1572000000,13700000000,55280237000,84.3437671609006,7.71554091158704,14.15705656232839,10.768808347062054,9.401427786930258,38.25919824272378,-70.60955518945634,38.25919824272378,78.00109829763866,35804505000.0,47932505000.0,25.567876868327406,2.331174230093105,13.934393716058961,18.2582891381948,5.156145686809245,5.156145686809245,3.120808971938277,14.858185058896467,18.59290341349884,24.44288883222846,0.03911157759206691,0.05476964421097289,1.9394287354672026,0.4971302428256071,3.759454432734036,0.8054919908466819,3.151734104046243,1.8348754448398576,0.0,0.0,0.0,0.0,0.0,0.7293966151582045,0.23933281613653995,0.0401718861905072,0.5474711623779946,0.013217006315515333,81.49714233603974,0.10031413207746566,0.1910265125764786,-88.21252059308073,-1360000000,-12858000000,-14581000000,19237000000,3273000000.0,3373500000.0,0.0,77.234846018621,116.30416628004082,0.0,4.725846153846154,3.1383226557949913,0.0,0.21502085166622031,3.388248215266337,0.0,0.3773826785204823,0.0,0.0,25.567876868327406,-22.187235371293035,0.0,0.8054919908466819,0.8054919908466819,0.2248283752860412,77.234846018621,0.0,77.234846018621,116.30416628004082,-39.06932026141982,0.29832671397877464,0.14200143238492088,0.09753239143173384,0.09147730972068494,0.05807743658210948,0.05169242089771891,0.21502085166622031,0.10803447592629285,0.937917222963952,0.6868408986703347,0.14200143238492088,0.4971302428256071,1.9394287354672026,0.6382658359293873,0.6597978416914888,3.151734104046243,0.19079336885731202,3.9012487440792305,4.725846153846154,3.1383226557949913,0.0,19.895077720207254,0.565084621044886,14.15705656232839,10.768808347062054,9.401427786930258,0.16784946936649522,0.76066718386346,0.19079336885731202,2.114848236259229,4.178282009724473,4.178282009724473,5.156145686809245,5.156145686809245,2.331174230093105,25.567876868327406,18.2582891381948,13.934393716058961,13.934393716058961,-22.187235371293035,2.331174230093105,14.858185058896467,5.156145686809245,0.0,IQV,2023-12-31,2023,FY,0.039833448993754336,0.041964996022275255,0.09894385769872151,0.09894385769872151,0.2447296058661778,0.2697594501718212,0.27447552447552453,-0.02025586353944563,-0.022560335781741866,0.0,-0.04911504424778761,-0.05422446406052964,0.9846643020876477,0.5949208183242151,0.3729576074002283,2.6528518726623194,0.8992599090961154,0.14175110994094947,3.048068344238457,4.810928447489927,4.06599818253439,7.185565444468596,0.008898626066138341,0.06005691108065234,0.0,0.0,0.0,0.15304054054054053,-1.0,0.05304495401981292,0.08210987658631926,0.09376681269694874,0.0,-0.008691453404152583,15377937881.0,16069060130.0,17043567304.0,2973572073.0,3107211696.0,3295648361.0,11.11865,11.95714,13.3449
0,ISPC,3.0,1.593,446433,2887911,0.0,2.76-12.2,0.04,iSpecimen Inc.,USD,0001558569,US45032V1089,45032V108,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://ispecimen.com,"iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.",Ms. Leslie  Hoyt,Healthcare,US,53,781 301 6700,450 Bedford Street,Lexington,MA,02420,,0.0,https://images.financialmodelingprep.com/symbol/ISPC.png,2021-06-17,False,False,True,False,False,687141.0,1751854,1188375,2666083,15.121644611513503,-13.860263031895927,-6.324598590391201,-7.861518960446255,2.5494825661690976,6.861142036350618,5.74843154461748,6.861142036350618,1.2882275981203275,2887911.0,2324432.0,-0.2164461087856883,0.2779322321052033,-0.4743384037933763,-0.5346031041997256,0.4372449927586216,0.4372449927586216,0.22370307607705428,-0.3219586517924667,-0.5348574089870178,-0.43029323365615374,-4.620087677298643,-1.870546564627511,0.18335174433649545,0.07674075699673204,0.07804785820938936,0.7430880630431571,-469.86441330829604,0.4563115848405416,0.0,0.0,0.0,0.7398081477074407,0.3230234107377923,0.06787765121482414,-0.2430067850298132,0.1016371174921579,0.47253510854498093,0.03337811054537027,46.256758963073665,-1.7863873890102613,-0.9070749513744956,-5.176932754703911,-1610379,3949983,-1891816,-400880,2250232.5,4130351.5,0.0,58.101650398596746,207.12183306513677,0.0,6.282093494693834,1.7622478258253578,0.0,-1.3924846776068025,1.5369203700550542,0.0,0.2993253600959309,0.0,0.0,-0.2164461087856883,-0.018228820724294697,0.0,0.7430880630431571,0.7430880630431571,0.27948216190449143,58.101650398596746,0.0,58.101650398596746,207.12183306513677,-149.02018266654002,0.31222163815303333,-0.9391679214744105,-0.9165843655221755,-0.9165843655221755,-0.021277189990922887,-0.8455048341993939,-1.3924846776068025,-1.953281909620259,1.0,0.9759536548940249,-0.9391679214744105,0.07674075699673204,0.18335174433649545,0.0,0.15494272536801865,-469.86441330829604,-5.027493420481823,2.3892355446051092,6.282093494693834,1.7622478258253578,0.0,23.35461554022162,0.9224517305809731,-6.324598590391201,-7.861518960446255,2.5494825661690976,-0.41824806447148616,1.2430067850298132,-5.027493420481823,-5.027493420481823,-4.115111435581173,-4.115111435581173,0.4372449927586216,0.4372449927586216,0.2779322321052033,-0.2164461087856883,-0.5346031041997256,-0.4743384037933763,-0.4743384037933763,-0.018228820724294697,0.2779322321052033,-0.3219586517924667,0.4372449927586216,0.0,ISPC,2023-12-31,2023,FY,-0.045578272426788566,-0.095197488618042,-0.09653044222498897,-0.09653044222498897,-0.22772127848624496,0.9399120664386907,-0.20107632093933459,19.47247494531671,0.022278755808826024,0,0.0017481075060332915,-0.17129985758543487,-0.9882923278289053,-0.9882923278289053,-0.9937192191342265,0.9887768062447203,0.9887768062447203,0.8957339575538585,0.9892420339660559,0.9892420339660559,0.9914971292617565,1.002740125962884,1.002740125962884,1.001848885626759,0,0,0,-0.2508538595879873,-1.0,-0.3574067763486633,-0.976571501664374,0.05594386780523764,0.34282063647489897,-0.05609039528663631,11078000.0,12381000.0,37846000.0,-6842503.0,-7647322.0,-23376187.0,-17.6,-15.8,0.0
0,LAB,2.0,1.569,1761890,744518000,0.0,1.21-3.04,0.015,Standard BioTools Inc.,USD,0001162194,US34385P1084,34385P108,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.fluidigm.com,"Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.",Dr. Michael  Egholm Ph.D.,Healthcare,US,534,650 266 6000,2 Tower Place,South San Francisco,CA,94080,,0.0,https://images.financialmodelingprep.com/symbol/LAB.png,2011-02-10,False,False,True,False,False,371538000.0,210647000,89474000,595895340,0.41961252953937417,-0.3353331260866991,-0.38611393720157833,-0.3997087781061426,0.9859825912827221,1.3170469776981089,0.9679332934989153,1.3170469776981089,0.16803664766457266,744518000.0,623345000.0,-5.964218397805732,4.775551307872894,-5.1798182020968095,-5.013352905923627,1.5185487183574378,1.5185487183574378,3.998313042808944,-5.347571332978742,-4.345199921927281,-4.197411569824991,-0.16766656304334954,-0.1994673063646547,0.125342047235727,0.08999338262373834,1.0395226738500076,3.76078431372549,-115.98087431693989,1.1514339239534304,0.0,0.0,0.0,0.0,0.3544983386999525,0.190317795459981,-0.03520940218603614,0.03239855806853023,0.3004044248840252,0.1779130479403728,3.152318718860338,-0.23151784236405082,-0.22577424025515105,0.5973379573556407,332992000,359624000,261401000,534947000,33879000.0,11748000.0,42631000.0,82.68466729099049,49.733002444255995,194.10709831895045,4.414361355721041,7.3391909207395205,1.8804052152706126,-0.2863930574583705,0.013594840904564271,0.0,0.08238081550748269,0.0,0.0,-5.964218397805732,-0.223658189917715,0.0,3.76078431372549,3.407229614890354,1.7464411557434814,82.68466729099049,194.10709831895045,276.79176560994097,49.733002444255995,227.05876316568498,0.48565124244717833,-0.8168400661954305,-0.7982578799502251,-0.7991494592756988,-0.0011169144234632383,-0.1828053845781386,-0.2863930574583705,-0.22703075639480572,1.0011169063881076,0.9772511327318272,-0.8168400661954305,0.08999338262373834,0.125342047235727,0.0006106627017841971,0.11138128851011592,-115.98087431693989,-2.3389310985750154,1.392791820702875,4.414361355721041,7.3391909207395205,1.8804052152706126,2.15793261910694,0.2287499321388798,-0.38611393720157833,-0.3997087781061426,0.9859825912827221,-0.92016779771908,1.035209402186036,-2.3389310985750154,-2.35038912099615,-28.40150465254405,-28.40150465254405,1.5185487183574378,1.5185487183574378,4.775551307872894,-5.964218397805732,-5.013352905923627,-5.1798182020968095,-5.1798182020968095,-0.223658189917715,4.775551307872894,-5.347571332978742,1.5185487183574378,0.0,LAB,2023-12-31,2023,FY,0.08567811491811982,0.3616366629780573,0.34082010240523214,0.34082010240523214,0.6072762469883954,0.6131687242798355,0.6131687242798355,0.010918842985760808,0.010918842985760808,0,0.5156428331654918,0.5051451258114705,-0.519164015242666,-0.5284628591714722,-0.29942173251150045,-7.757172442957781,0.1396027259680076,-1.5553456162246886,-0.5187277563449209,0.366310755502207,-0.2814953236825218,-0.45911823550064035,0.13358256731455975,0.06818509924142364,0,0,0,0.13773148148148148,-0.043775904624412054,-0.17228100740437088,2.981652324985277,-0.04330037504261848,-0.3259909605693802,-0.23716865055159553,171200000.0,188166667.0,224212267.0,-85443624.0,-93911460.0,-111901336.0,-0.35667,-0.2,-0.0765
0,LBT.AX,0.017,1.685,1242819,29889571,0.0,0.009-0.038,0.0,LBT Innovations Limited,AUD,,AU000000LBT8,Q54261104,Australian Securities Exchange,ASX,Medical - Devices,https://www.lbtinnovations.com,"LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, Switzerland, the United States, the United Kingdom, and Germany. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; Automated Plate Assessment System Pharma, a technology that uses cutting-edge artificial intelligent image analysis algorithms to automatically detect microbial growth for environmental monitoring applications; and devices that can detect biofilms in the presence of mammalian tissue. The company was incorporated in 2004 and is headquartered in Adelaide, Australia.",Mr. Brenton John Barnes,Healthcare,AU,19,61 8 8227 1555,16 Anster Street,Adelaide,SA,5000,,0.0,https://images.financialmodelingprep.com/symbol/LBT.AX.png,2006-07-21,False,False,False,False,False,1553986346.0,2347000,3193000,22601808,0.000808243909756978,-0.002406713552938772,-0.0023635986310010988,-0.0023674596687865623,0.0015103092804137162,0.001559215759029584,0.001559215759029584,0.001559215759029584,0.0013713119201370382,29889571.0,30735571.0,-7.063574300000001,23.797429140127388,-7.192422510754153,-8.124373742864908,10.902916996285597,10.902916996285597,24.47099601910828,-7.594655547319002,-8.367974680098014,-8.354327534656155,-0.14157138546698658,-0.1230864103067923,0.719356170037144,0.21977052074139453,-0.20904373610081542,3.6192660550458715,-11.827319587628866,0.9820855614973262,0.0,0.0,0.0,0.25557324840764334,0.5294585987261147,0.0,-0.0016335420637081405,0.004777070063694267,0.025210084033613446,0.052547770700636945,0.009188752811577577,-0.8812289966394623,-0.47156726768377255,-0.0007615897031826302,3997000,2423000,15000,5438000,1227500.0,593000.0,1566500.0,452.7627388535032,38.13564297523196,141.52172094936998,0.8061617458279846,9.571098623853212,2.579109394313968,-1.5035175879396985,3.86103778546327e-06,0.0,0.05831465429865153,0.0,0.0,-7.063574300000001,-0.07063574300000001,0.0,3.6192660550458715,2.5589777195281784,1.5380078636959371,452.7627388535032,141.52172094936998,594.2844598028732,38.13564297523196,556.1488168276413,-2.322451433121019,-3.6536624203821657,-3.7221337579617835,-2.977707006369427,0.2,-0.47156726768377255,-1.5035175879396985,-0.716471506635441,0.8,1.0187404663325343,-3.6536624203821657,0.21977052074139453,0.719356170037144,0.4183869419107057,0.4183869419107057,-11.827319587628866,-2.1072862880091794,3.2732150226991332,0.8061617458279846,9.571098623853212,2.579109394313968,0.871616932685635,0.15836590593872146,-0.0023635986310010988,-0.0023674596687865623,0.0015103092804137162,-2.924363057324841,1.0016335420637081,-2.1072862880091794,0.0,-612.1666666666666,-612.1666666666666,10.902916996285597,10.902916996285597,23.797429140127388,-7.063574300000001,-8.124373742864908,-7.192422510754153,-7.192422510754153,-0.07063574300000001,23.797429140127388,-7.594655547319002,10.902916996285597,0.0,LBT.AX,2024-06-30,2024,FY,-0.41088180112570355,0.4814222222222222,0.3362274191289735,0.3362274191289735,0.8339548925590481,0.9163179916317993,0.9163179916317993,0.9913615749268596,0.9913615749268596,0,-1.6273247496423462,-1.1603053435114503,-0.9665827122780377,0.29632161651333017,-0.5120899671748728,-1.160105750502954,-0.4045645584599967,0.4005515590898382,-2.3600411133840726,0.734675925967824,0.7752680361738925,-0.981031677742888,-0.9746685063867236,-0.9575152659930685,0,0,0,0.17054845980465816,0.08590604026845637,0.07611940298507462,12.588146907493702,-0.05727782698553292,1.2542372881355932,2.571662571662572,,,,,,,,,
0,LH,228.61,1.036,581931,19120780373,2.88,191.97-247.99,1.64,Laboratory Corporation of America Holdings,USD,0000920148,US50540R4092,50540R409,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.labcorp.com,"Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.",Mr. Adam H. Schechter,Healthcare,US,67000,336 229 1127,358 South Main Street,Burlington,NC,27215,-55.93963,284.5496260411359,https://images.financialmodelingprep.com/symbol/LH.png,1990-03-29,False,False,True,False,False,84000000.0,1517300000,7719100000,24974120000,151.34285714285716,5.184523809523809,16.526190476190475,10.03809525,18.063095238095237,97.4452380952381,-21.877380952380953,97.26428571428572,82.68690476190476,19120780373.0,25322580373.0,44.09469575200919,1.5040573573878295,13.833194064255872,22.676447284539318,2.350400235000367,2.350400235000367,1.9918963857686742,17.895816530668423,18.241305556115833,30.031523177144777,0.02267846467575263,0.04409861859982779,0.826417957944726,0.36276695768972467,4.382897529599221,1.4390093786635405,5.774909654104285,3.185406149609913,0.015747342635930184,1.5747342635930184,0.5605051664753157,0.0,0.00015732175445220566,0.5385144392209537,0.39259472626422703,0.04287017800956516,0.8749397961149462,0.00915612610911837,106.51785115555006,0.052077577483618895,0.05070202808112324,-83.32916666666667,1497900000,-1837700000,-5517200000,14571000000,2235600000.0,710750000.0,462450000.0,63.876722673211255,25.81419613046828,18.869478212481805,5.71413160733549,14.139506733242548,19.343407162078243,0.05441947354938677,6.4880952261904765,3.5999999999999996,0.3531236627525066,0.015747342635930184,1.5747342635930184,44.09469575200919,-23.370188748564953,0.5605051664753157,1.4390093786635405,1.2974208675263774,0.4446951934349355,63.876722673211255,18.869478212481805,82.74620088569306,25.81419613046828,56.93200475522478,0.26492983449751434,0.08799005726511862,0.049446227424328235,0.03425681203196778,0.3052815781100859,0.023398253861652115,0.05441947354938677,0.07358968454985033,0.6928094177537385,0.5619524405506884,0.08799005726511862,0.36276695768972467,0.826417957944726,0.39579805210652036,0.4524801972899438,5.774909654104285,0.20559834123222748,2.2780960074416785,5.71413160733549,14.139506733242548,19.343407162078243,4.168131147540984,0.6830248488918738,16.526190476190475,10.03809525,18.063095238095237,0.10919702976527594,0.6074052737357729,0.20559834123222748,0.9916422601614401,2.547155967976433,1.7592193660616138,2.350400235000367,2.350400235000367,1.5040573573878295,44.09469575200919,22.676447284539318,13.833194064255872,13.833194064255872,-23.370188748564953,1.5040573573878295,17.895816530668423,2.350400235000367,3.5999999999999996,LH,2023-12-31,2023,FY,-0.18251236825123682,-0.23265147887163348,-0.5909577766503185,-0.5909577766503185,-0.6732077241810648,-0.658119658119658,-0.6583094555873926,-0.043907793633369926,-0.043668122270742356,0.3609874649451358,-0.32118206452272613,-0.4069877883310719,1.0601760895118755,0.24925270413246908,-0.028092732372705962,0.5956507172960632,0.18406664395198818,-0.30539846222776584,-0.28323233552056337,-0.44933024140359656,-0.6999224783380926,2.1228523918928897,0.31507451125472546,-0.06009638729258052,0.0,0.0,0.0,0.050768537024983726,0.008499787505312367,-0.17018025219423372,-0.18260948274240305,-0.05412317908147866,0,0.012421115897024942,,,,,,,,,
0,LUCD,0.781,1.416,434849,46346477,0.0,0.63-1.58,0.0101,Lucid Diagnostics Inc.,USD,0001799011,US54948X1090,54948X109,NASDAQ Global Market,NASDAQ,Medical - Devices,https://www.luciddx.com,"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.",Dr. Lishan  Aklog M.D.,Healthcare,US,70,212 949 4319,One Grand Central Place,New York,NY,10165,1.94238,-0.9632761871808547,https://images.financialmodelingprep.com/symbol/LUCD.png,2021-10-14,False,False,True,False,False,50374146.0,14489000,13066000,39631928,0.08315771745291722,-0.8897024279081575,-0.8783870996046266,-0.8895436162828447,0.2876277048944909,0.12581851015399845,0.1091035865898352,0.12581851015399845,0.2030803658686343,46346477.0,44923477.0,-0.877821590120041,11.063854873204793,-0.889129633565359,-1.0342887078777059,6.2073537434521935,6.2073537434521935,10.724155579889134,-1.0395584069977322,-1.0152657069246067,-1.0025324034813659,-1.1391836464893181,-0.966848030326016,1.6093404859577154,0.4513673776440393,0.03292914333317906,1.180714436100779,-1504.3666666666666,0.9872818956669196,0.0,0.0,0.0,4.415613372072898,1.5414183674906583,0.03725993450747854,-0.012701139034532634,0.13416092961588197,0.3570520965692503,1.0327049493208282,1.5870328490915022,-339.78956777479266,-2.060029417172274,-0.028114620543641573,2575000,5496000,564000,7217000,99500.0,1019000.0,667000.0,3.398186535733238,53.3172526791831,30.581085016870656,107.41023076923076,6.8458140969163,11.935482334869432,-5.619811912225705,0.011156516678218228,0.0,0.2200814530088231,0.0,0.0,-0.877821590120041,-0.10436323349204923,0.0,1.180714436100779,1.1350270194399608,1.016843287248228,3.398186535733238,30.581085016870656,33.97927155260389,53.3172526791831,-19.33798112657921,-0.8548581653994188,-10.773695577392116,-10.698976056093592,-10.698976056093592,-123.51396760230264,-1.9832728560049562,-5.619811912225705,-5.405557551802611,1.0,0.9930646340652767,-10.773695577392116,0.4513673776440393,1.6093404859577154,0.0,0.6167613979925021,-1504.3666666666666,-4.338039215686274,3.5654780687914167,107.41023076923076,6.8458140969163,11.935482334869432,1.1023681578947369,0.18537034250818657,-0.8783870996046266,-0.8895436162828447,0.2876277048944909,-10.562905362355064,1.0127011390345326,-4.338039215686274,-4.338039215686274,-78.73309608540926,-78.73309608540926,6.2073537434521935,6.2073537434521935,11.063854873204793,-0.877821590120041,-1.0342887078777059,-0.889129633565359,-0.889129633565359,-0.10436323349204923,11.063854873204793,-1.0395584069977322,6.2073537434521935,0.0,LUCD,2023-12-31,2023,FY,5.440318302387268,-0.09700339820821749,0.13688558152783464,0.13688558152783464,0.06239874668423208,0.1870967741935484,0.1870967741935484,0.15436367944517732,0.15436367944517732,0,-0.1055078322385043,-0.07992024319288726,0,0,0,-254.69774509277195,-254.69774509277195,-4.165153979614318,-40.43941360802599,-40.43941360802599,-4.6352581839093965,-0.9265732038060968,-0.9265732038060968,0.8485514574835069,0,0,0,1.6470588235294117,1.5045045045045045,-0.1611553723584238,-1.086864613150162,6.631315657828915,-0.36752136752136755,-0.1165021723297923,4565667.0,10924333.0,33469800.0,-913133.0,-2184866.0,-6693959.0,-0.89,-0.615,-0.406
0,MASS,2.06,0.976,231468,71734968,0.0,1.82-12.51,0.12,908 Devices Inc.,USD,0001555279,US65443P1021,65443P102,NASDAQ Global Market,NASDAQ,Medical - Devices,https://www.908devices.com,"908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.",Dr. Kevin J. Knopp Ph.D.,Healthcare,US,230,857 254 1500,645 Summer Street,Boston,MA,02210,,0.0,https://images.financialmodelingprep.com/symbol/MASS.png,2020-12-18,False,False,True,False,False,34670638.0,45025000,7179000,82461113,1.5910292738195357,-1.7360222791400608,-0.8633818621970556,-0.8848697852055679,2.0676285218633703,3.779538178674416,2.140687460092312,3.779538178674416,0.0,71734968.0,33888968.0,-1.1866207160776887,1.3004417533809505,-2.3859662684572727,-2.3382433586492386,0.5450401352269172,0.5450401352269172,0.6143535042239222,-0.5991366794547673,-1.132122937128349,-1.104630789791062,-0.8427292617184761,-0.42767148094357554,0.0,0.0,0.6690946378374556,4.235438214480131,0.0,0.49733339979065944,0.0,0.0,0.0,0.0,0.420978209637069,0.318706775183276,-0.02488808712500835,0.013505674196004496,0.22074074074074074,0.20443421195750697,12.150335627808097,-0.5030846215375945,-0.4955336192914715,1.3225239754745788,83209000,74219000,61683000,151179000,13823000.0,1934500.0,18211000.0,110.23050288241906,24.235283812193412,228.06744919411352,3.311243171859055,15.060686015831134,1.6004037458644087,-0.3948230679160749,0.021487923008512273,0.0,0.0,0.0,0.0,-1.1866207160776887,0.02200990037886035,0.0,4.235438214480131,3.5420328174819193,1.7507193405397,110.23050288241906,228.06744919411352,338.29795207653257,24.235283812193412,314.06266826433915,0.4826148435517204,-1.1993219970269389,-1.0949929299155217,-1.091131576084986,0.0035263732988973875,-0.3376036974921894,-0.3948230679160749,-0.43363156687313603,0.9964736267011026,0.9130099611530148,-1.1993219970269389,0.0,0.0,0.0,0.0,0.0,0.0,1.360533886858111,3.311243171859055,15.060686015831134,1.6004037458644087,4.947264573991031,0.30940695411228214,-0.8633818621970556,-0.8848697852055679,2.0676285218633703,-0.5426561763532867,1.0248880871250083,0.0,0.0,-40.17986577181208,-40.17986577181208,0.5450401352269172,0.5450401352269172,1.3004417533809505,-1.1866207160776887,-2.3382433586492386,-2.3859662684572727,-2.3859662684572727,0.02200990037886035,1.3004417533809505,-0.5991366794547673,0.5450401352269172,0.0,MASS,2023-12-31,2023,FY,0.0720780329548365,-0.026937708949775197,-0.20846758238652421,-0.20846758238652421,-0.14664188508064516,-0.1188118811881187,-0.1188118811881187,0.022830842017747002,0.023715527977093996,0,-0.1972766364070712,-0.1797170837867247,0.34221699534134586,0.34221699534134586,0.5813287834217945,-0.6596897299260176,-0.6596897299260176,-6.136077706517237,-1.8464537681267392,-1.8464537681267392,-3.443277244409427,2.943720949236596,2.943720949236596,0.007754026989212713,0,0,0,-0.10405661317651749,0.1937984496124031,-0.16326513786806382,-0.1511128736238014,-0.6389968423609425,0.24980029670204268,0.052348503840105746,56978600.0,65916600.0,84980333.0,-32716560.0,-37848673.0,-48794884.0,-1.676,-1.256,-0.97667
0,ME,3.27,1.261,339145,89382288,0.0,2.655-19.34,0.21,23andMe Holding Co.,USD,0001804591,US90138Q1085,90138Q108,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.23andme.com,"23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.",Ms. Anne  Wojcicki,Healthcare,US,560,650 938 6300,349 Oyster Point Boulevard,South San Francisco,CA,94080,6.56395,-2.313946688832079,https://images.financialmodelingprep.com/symbol/ME.png,2020-11-23,False,False,True,False,False,25519658.0,126601000,71688000,122448623,7.572985500040792,-24.111373279375453,-5.169622570960787,-5.341803561787544,4.960920714533087,3.994136598539056,2.8461980172304817,3.994136598539056,0.0,89382288.0,34469288.0,-0.13562064516653285,0.46249760943806273,-0.6325413422574605,-0.6556751197541097,0.8187000918286258,0.8187000918286258,0.1783570733726586,-0.08689378672642892,-0.2612754629454168,-0.2528538376332333,-7.37350864812705,-1.525145563514776,0.0,0.0,0.13843043437707186,1.2352467758504493,0.0,0.22160761139424642,0.0,0.0,0.0,0.6431232536479354,0.8912346062299493,0.09185228384378057,-0.03330629818005412,0.02273621028666046,0.226401483924155,0.46879850977957155,46.54935730237614,-4.642936980863849,-2.1244022773019013,-2.521996964065898,35953000,72634000,-28223000,135166000,26297500.0,8839000.0,14796500.0,46.89511538859567,21.68773704171934,49.64171201377819,7.783326621022956,16.829787234042552,7.35268759261754,-3.0343133931092128,0.17218099082675795,0.0,0.0,0.0,0.0,-0.13562064516653285,-0.04169138186119426,0.0,1.2352467758504493,1.1381067977046542,0.828372516047137,46.89511538859567,49.64171201377819,96.53682740237386,21.68773704171934,74.84909036065451,0.43517541136293075,-2.448789195901894,-3.18388699161751,-3.1838662941115596,6.500703701175653e-06,-1.9292710763287932,-3.0343133931092128,-2.8491195328256222,0.9999934992962988,1.3001882713897217,-2.448789195901894,0.0,0.0,0.0,0.0,0.0,0.0,3.129001559909349,7.783326621022956,16.829787234042552,7.35268759261754,2.764095082811293,0.6059522913688012,-5.169622570960787,-5.341803561787544,4.960920714533087,-0.6826399668839905,1.033306298180054,0.0,0.0,-30.024351388256715,-30.024351388256715,0.8187000918286258,0.8187000918286258,0.46249760943806273,-0.13562064516653285,-0.6556751197541097,-0.6325413422574605,-0.6325413422574605,-0.04169138186119426,0.46249760943806273,-0.08689378672642892,0.8187000918286258,0.0,ME,2024-03-31,2023,FY,-0.26662414980182914,-0.26111557221032594,0.008194166247442217,0.008194166247442217,-1.1392304335549452,0.8985948138490512,-1.0288280457771983,20.084282109701,0.05421409441095984,0,0.006475603119898422,0.01539375760491242,-0.9787316225383818,-0.9787316225383818,-0.9615561347047085,0.9284992659905474,0.9284992659905474,0.9055185379679275,0.8449092575744194,0.8449092575744194,0.8447663160184437,-0.9743510207841075,-0.9743510207841075,1.0135131272288598,0,0,0,3.783869267264101,0.2164535961744901,-0.5807682596398465,-0.9874761601323474,-0.10303151083184844,-0.07742726733634027,-0.127874495042622,166683018.0,198421589.0,251394751.0,-137232142.0,-163362891.0,-206976336.0,-12.58875,-10.64002,-7.80164
0,MLAB,132.08,0.865,34758,717381954,0.64,83.68-141.17,0.68,"Mesa Laboratories, Inc.",USD,0000724004,US59064R1095,59064R109,NASDAQ Global Select,NASDAQ,"Hardware, Equipment & Parts",https://www.mesalabs.com,"Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.",Mr. Gary M. Owens,Technology,US,736,303 987 8000,12100 West Sixth Avenue,Lakewood,CO,80228,-91.88949,223.9694893400432,https://images.financialmodelingprep.com/symbol/MLAB.png,1984-02-29,False,False,True,False,False,5413000.0,24337000,222855000,901450180,42.191021614631445,-45.38167374838352,7.412155920931092,6.610012931830778,4.496028080546831,29.82652872713837,-9.088675411047479,29.82652872713837,39.642711989654536,717381954.0,915899954.0,-2.9104259294690435,3.141176784306857,17.819376900453616,20.04980307434321,4.428272602833058,4.428272602833058,4.010421026359576,-3.9895109440405614,22.827873834803846,25.598098211291227,-0.3435923209296147,0.049875801587281075,1.269623600968715,0.45140476284854814,-0.8647120573925088,0.7046792403576323,1.2775926697209496,-0.16332927608680609,0.004845548152634767,0.48455481526347666,-0.014064668981603983,0.313350556090726,0.08260355547771259,0.46388224568265,0.10821992921589153,0.019012172694631756,0.1615507683149161,0.054952272528242405,174.5150434896376,0.030961902586254565,-1.0090408708153624,-41.24616663587659,-45252000,-49197000,-184669000,197469000,37901000.0,5823500.0,30752500.0,64.30252211226903,23.101363492231265,114.72751294789134,5.676293681960531,15.799933199732799,3.1814513417176675,-1.1418564329972622,0.802142989100314,0.64,0.285736209082282,0.004845548152634767,0.48455481526347666,-2.9104259294690435,-1.5706147370541672,-0.014064668981603983,0.7046792403576323,0.5106049729165307,0.15882660053514325,64.30252211226903,114.72751294789134,179.03003506016037,23.101363492231265,155.92867156792911,0.5857343024783256,0.053726245730799545,-1.1632761187494527,-1.0756239600665558,0.0753494009462903,-0.5409647256759554,-1.1418564329972622,0.04078200406822926,0.9246505990537097,-21.651915240423797,0.053726245730799545,0.45140476284854814,1.269623600968715,0.3922508224984378,0.5593983074668494,1.2775926697209496,0.19573425959352528,2.812605682219373,5.676293681960531,15.799933199732799,3.1814513417176675,7.120631060393477,0.5029310853604289,7.412155920931092,6.610012931830778,4.496028080546831,0.17568088273929416,0.8917800707841085,0.19573425959352528,0.3981186556723127,9.240442192538001,5.1458253174297806,4.428272602833058,4.428272602833058,3.141176784306857,-2.9104259294690435,20.04980307434321,17.819376900453616,17.819376900453616,-1.5706147370541672,3.141176784306857,-3.9895109440405614,4.428272602833058,0.64,MLAB,2024-03-31,2024,FY,-0.013205221836771955,-0.0033135616674021826,-7.919322056123787,-7.919322056123787,-274.3827956989247,-278.6470588235294,-278.6470588235294,0.012215748919376056,0.004663309084126096,-0.00017601798795908048,0.5771361183575743,0.7733691710397201,1.6226727309473605,0.49408486034846205,0.4909248170035306,1.2814518868555618,0.029549279366614563,0.09959423699624793,-19.06901576102653,-25.214310841715452,-72.73022447164428,0.4455481787579109,-0.06898393188351884,-0.6694010664984732,0.10848386885389133,-0.0020586965695881545,0.005991485737113652,-0.08216023125190948,-0.05678081519542751,-0.3249102491266666,-0.6349538731792381,0.3583971527908288,-0.05807711078574915,0.014642847392226276,235933333.0,250066667.0,270000000.0,-24116906.0,-25561604.0,-27599173.0,8.37333,8.62,10.925
0,MRVI,5.37,0.024,1766669,761702280,0.0,4.275-11.555,-0.06,"Maravai LifeSciences Holdings, Inc.",USD,0001823239,US56600D1072,56600D107,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.maravai.com,"Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.",Mr. William E. Martin III,Healthcare,US,580,858 546 0004,10770 Wateridge Circle,San Diego,CA,92121,,0.0,https://images.financialmodelingprep.com/symbol/MRVI.png,2020-11-20,False,False,True,False,False,141555000.0,578157000,561075000,1159240050,1.9562714139380453,-1.587086291547455,0.2111758680371587,-0.07569495955635619,4.084327646497828,4.331369432376108,1.6917735155946452,2.4382042315707677,4.051852636784289,761702280.0,744620280.0,-3.3835589334995104,2.750622129134768,25.429041916167666,-71.087473635091,2.2024406038129456,2.2024406038129456,2.6889364437382635,1.3578991250305454,24.9095199545044,-69.4932599160056,-0.29554679544645346,-0.014067175957514529,1.5116271657877962,0.40816529300626264,-0.031150955026059426,10.738255245805727,-3.774659027335687,-0.13305884447609723,0.0,0.0,0.0,0.0,0.06952910587895421,0.292320149583599,1.3584451209313217,0.14664162935143724,0.7241988122625863,0.1741008233424816,9.330965197565398,0.16530072761555312,-0.24836192343961255,-0.2830825474197308,615857000,239479000,14010000,1154060000,34066000.0,11015000.0,49851500.0,38.056640907121185,22.212244165400715,117.93733053862277,9.59096733972916,16.4323783442174,3.094864012378742,-0.5583400901530614,0.2868708275935149,0.0,0.6849434663632621,0.0,0.0,-3.3835589334995104,0.0520547528230694,0.0,10.738255245805727,9.94116158821018,9.142122989832545,38.056640907121185,117.93733053862277,155.99397144574397,22.212244165400715,133.78172728034326,0.4366279069767442,-0.70658312870143,1.5932615917954644,-0.8112812364581828,1.7323313826194566,-0.17576072882887464,-0.5583400901530614,-0.1610462446109958,-0.5091952511978531,-2.2548820189403425,-0.70658312870143,0.40816529300626264,1.5116271657877962,0.5993373754821963,0.6018517343571014,-3.774659027335687,0.05729668808927343,3.703468157848989,9.59096733972916,16.4323783442174,3.094864012378742,1.6828416031114217,0.2166458694351107,0.2111758680371587,-0.07569495955635619,4.084327646497828,0.1079481438682652,-0.3584451209313217,0.05729668808927343,5.495036764705882,0.7361357368006304,0.7361357368006304,2.2024406038129456,2.2024406038129456,2.750622129134768,-3.3835589334995104,-71.087473635091,25.429041916167666,25.429041916167666,0.0520547528230694,2.750622129134768,1.3578991250305454,2.2024406038129456,0.0,MRVI,2023-12-31,2023,FY,-0.6727693400120724,-0.8036507554156327,-1.0551151483065606,-1.0551151483065606,-1.2425880899925204,-1.2412868632707774,-1.46875,0.002843141152025095,-0.4833250431805987,0,-0.764497357162714,-0.883074734961562,0.5735982477388777,0.5735982477388777,-0.25488062704653547,458.661172041136,458.661172041136,-0.3923643717491955,-3.527251581623563,-3.527251581623563,-2.1341567151884355,0.9463080453789336,0.9463080453789336,2.4495332474009497,-1,-1,0,-0.6204517280368357,0.191068780126066,-0.34827138234643334,-0.1299080852529025,0.0439205005621414,-0.059284664380205784,0.17121438352455148,259771302.0,265581547.0,295139976.0,168700846.0,172474139.0,191669993.0,-0.08083,-0.062365,-0.020053
0,MTD,1230.74,1.159,135901,25971936998,0.0,1115.64-1546.93,24.72,Mettler-Toledo International Inc.,USD,0001037646,US5926881054,592688105,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.mt.com,"Mettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection, x-ray, checkweighing, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of networked scales and software, stand-alone scales, and automated packaging and labeling solutions for handling fresh goods. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.",Mr. Patrick K. Kaltenbach,Healthcare,US,16000,614 438 4511,1900 Polaris Parkway,Columbus,OH,43240,585.12858,645.6114241074671,https://images.financialmodelingprep.com/symbol/MTD.png,1997-11-14,False,False,True,False,False,21288202.0,71574000,2077485000,33931827539,176.72821781754985,37.37436350895205,46.20700231048165,41.742651587015196,3.362143970636881,-7.2506358216630975,-51.16806013020733,-7.2506358216630975,101.17909441107332,25971936998.0,27977847998.0,32.93005912208267,6.9033431266489576,26.635356947204897,29.227073062488685,-169.74235505289823,-169.74235505289823,7.436514445968956,23.972724856263977,28.442484452457833,31.48439054167264,0.030367391576573484,0.03421485271077123,-13.45931080056753,0.6257809139509637,1.718758086490099,1.0111935512182608,14.780705426762259,1.2363288086341315,0.0,0.0,0.0,0.0,0.04936917665233295,0.2816179030961845,0.09661632437154996,0.02526110871595699,0.7727860401200185,0.005076781671276526,78.08474706734972,0.4893149557474822,0.33361203066788825,-128.5594246052344,13264000,-1089276000,-2275949000,1738634000,635956000.0,201160500.0,371104000.0,61.81944678496188,47.44172583784726,87.88970325348588,5.904290946983845,7.6936492834924755,4.152932442464737,-5.16837780340062,4.4643507234664535,0.0,0.07998960571019324,0.0,0.0,32.93005912208267,17.6853788108597,0.0,1.0111935512182608,0.6940432146690881,0.06040163109889887,61.81944678496188,87.88970325348588,149.70915003844777,47.44172583784726,102.26742420060052,0.5851588926343074,0.30029509125714404,0.25390074918412664,0.21147932101899247,0.16707773608924323,0.23966091014353755,-5.16837780340062,0.5292047253684082,0.8329212170446552,0.8455041609944609,0.30029509125714404,0.6257809139509637,-13.45931080056753,1.0888460768038828,1.0802612613174758,14.780705426762259,0.4734878947381088,-21.508023815539705,5.904290946983845,7.6936492834924755,4.152932442464737,4.759618291928491,1.1332593134343105,46.20700231048165,41.742651587015196,3.362143970636881,0.261457977006166,0.90338367562845,0.4734878947381088,5.2935250505855,10.35021779709169,10.35021779709169,-169.74235505289823,-169.74235505289823,6.9033431266489576,32.93005912208267,29.227073062488685,26.635356947204897,26.635356947204897,17.6853788108597,6.9033431266489576,23.972724856263977,-169.74235505289823,0.0,MTD,2023-12-31,2023,FY,-0.03352289672524159,-0.028923217168491736,0.014403719816122726,0.014403719816122726,-0.09595851929279245,-0.06934777004382567,-0.06534756573808899,-0.028617909023692645,-0.032870519744223704,0,0.12432906862910577,0.16633325472401353,1.1826299291389801,0.48938527818527877,0.34225081463905377,2.8270029811810815,0.9729889518597458,0.45690481647539616,2.532026987389237,0.7759197479913231,0.43051976060161573,-1.2197859827106297,-1.2932714587693672,-1.5798193145894206,0,0,0,-0.06404434663572628,-0.1263974606854519,-0.0391822803548854,-7.22576238037871,0.03291331891147035,0.046081232145075146,-0.03660780788972584,3836231918.0,3945777868.0,4159597833.0,1135179353.0,1167595094.0,1230866558.0,40.45165,42.27476,47.17497
0,MXCT,4.24,1.16,517011,447246054,0.0,3.165-5.545,0.1,"MaxCyte, Inc.",USD,0001287098,US57777K1060,57777K106,NASDAQ Global Select,NASDAQ,Medical - Devices,https://maxcyte.com,"MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.",Mr. Maher  Masoud,Healthcare,US,143,301 944 1700,9713 Key West Avenue,Rockville,MD,20850,4.30077,-0.005770100224315302,https://images.financialmodelingprep.com/symbol/MXCT.png,2021-07-30,False,False,True,False,False,105109603.0,36958000,18319000,390237355,0.43384237689490657,-0.33997845087475026,-0.17893036852208452,-0.20194253801909992,1.4635389689370246,2.0293293277874906,2.0293293277874906,2.0293293277874906,0.021840059656585326,447246054.0,428607054.0,-12.471378668532251,9.807812416394377,-23.69636878871502,-21.070571324925446,2.089360234409429,2.089360234409429,9.399071380013595,-10.197160591929958,-22.789398478250465,-20.1924542897659,-0.08018359690442223,-0.04745955791037566,0.0,0.0,0.4434478492577084,9.812666704500312,-20.174463756752047,0.5262991464950328,0.0,0.0,0.0,0.6704524023595974,0.5143527554220302,0.0,-0.1286096356202113,0.05304269643209579,0.5547706422018348,0.29656147891493606,3.939972769760917,-0.22360909032914003,-0.1437380335623381,1.2095802511974096,155288000,213302000,137599000,187143000,4570500.0,1409000.0,10776000.0,36.499199578956606,71.22789578319556,396.92842942345925,10.000219298245614,5.124396782841823,0.9195612431444241,-0.16005123789454354,0.023012169497015414,0.0,0.0,0.0,0.0,-12.471378668532251,-0.12471378668532251,0.0,9.812666704500312,9.22285908858748,2.097383803416378,36.499199578956606,396.92842942345925,433.42762900241587,71.22789578319556,362.1997332192203,0.7904212626916076,-1.015602706081007,-0.7836450955022917,-0.7836450955022917,-0.029878914229746745,-0.1437380335623381,-0.16005123789454354,-0.20049482014450778,1.0,0.7716059545825847,-1.015602706081007,0.0,0.0,0.0,0.0,-20.174463756752047,0.0,1.1655399386784935,10.000219298245614,5.124396782841823,0.9195612431444241,1.4315178150996704,0.1834223609479832,-0.17893036852208452,-0.20194253801909992,1.4635389689370246,-0.4124317449178746,1.1286096356202113,0.0,0.0,-7.775467173805192,-7.775467173805192,2.089360234409429,2.089360234409429,9.807812416394377,-12.471378668532251,-21.070571324925446,-23.69636878871502,-23.69636878871502,-0.12471378668532251,9.807812416394377,-10.197160591929958,2.089360234409429,0.0,MXCT,2023-12-31,2023,FY,-0.06718028083097048,-0.0668256598686008,-0.765282067213684,-0.765282067213684,-0.9171330209139027,-0.9473684210526315,-0.9473684210526315,0.015396233868564152,0.015396233868564152,0,-0.4669652098032186,0.23674312464484473,1.5540070111960942,0.2277761617425197,0.06129222962102543,-15.365425903548866,-0.024859678890526853,-0.6610307845257952,-15.659919099603403,-1.1191955045915407,-1.017825035567646,64.32929357104229,8.369033483223351,3.7003140648357404,0,0,0,-0.4829530201342282,0.4251584933805706,-0.06411715332872382,-0.09969987500666642,0.16453037918843857,0.22048333538310172,0.28239541743102764,37624700.0,46300312.0,60228360.0,-21692155.0,-26693995.0,-34724075.0,-0.41427,-0.37671,-0.31574
0,MYGN,13.36,1.937,855188,1216230272,0.0,12.87-29.3,0.19,"Myriad Genetics, Inc.",USD,0000899923,US62855J1043,62855J104,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://myriad.com,"Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.",Mr. Paul J. Diaz J.D.,Healthcare,US,2700,801 584 3600,320 Wakara Way,Salt Lake City,UT,84108,20.98838,-7.628377401877387,https://images.financialmodelingprep.com/symbol/MYGN.png,1995-10-06,False,False,True,False,False,90900000.0,99900000,143100000,2532951000,9.06050605060506,-1.2761276127612762,-0.77007700770077,-1.1804180418041805,1.099009900990099,8.049504950495049,1.462046204620462,8.049504950495049,0.46204620462046203,1216230272.0,1259430272.0,-10.469172413793103,1.476724468188441,-17.348914285714287,-11.334858080149115,1.659729397293973,1.659729397293973,1.5291771151044198,-25.49453991902834,-17.991861028571428,-11.737467586206897,-0.09551853388931708,-0.088223424848284,0.05330053300533005,0.03606769629150097,-0.8744939271255061,1.900194426441996,-38.6,0.603448275862069,0.0,0.0,0.0,0.20847498785818358,0.12323943661971831,0.5537778599833534,-0.5328571428571428,0.045288975230694514,0.6065040650406504,0.05985915492957746,15.202776048099562,-0.14947984512531323,-0.24041450777202072,-1.5657315731573158,138900000,132900000,-56400000,910500000,121750000.0,19299999.5,26150000.0,55.70726080621661,42.518693427784335,37.63478945297127,6.552108194112967,8.58445945945946,9.698473282442748,-0.15387676593486768,0.41034103410341033,0.0,0.03206629607719549,0.0,0.0,-10.469172413793103,-0.3715529817444219,0.0,1.900194426441996,1.7303953337653921,0.6474400518470512,55.70726080621661,37.63478945297127,93.34205025918789,42.518693427784335,50.82335683140355,0.6914764448761535,-0.14060223409422049,-0.14157357940747936,-0.14084507042253522,0.005145797598627788,-0.10727827614907981,-0.15387676593486768,-0.12491909385113269,0.9948542024013722,1.0069084628670122,-0.14060223409422049,0.03606769629150097,0.05330053300533005,0.0506033476060724,0.0506033476060724,-38.6,-1.794871794871795,1.4777914445811124,6.552108194112967,8.58445945945946,9.698473282442748,4.766203703703703,0.7616757606584666,-0.77007700770077,-1.1804180418041805,1.099009900990099,-0.08499271491015056,1.532857142857143,-1.794871794871795,0.0,-1.876675603217158,-1.876675603217158,1.659729397293973,1.659729397293973,1.476724468188441,-10.469172413793103,-11.334858080149115,-17.348914285714287,-17.348914285714287,-0.3715529817444219,1.476724468188441,-25.49453991902834,1.659729397293973,0.0,MYGN,2023-12-31,2023,FY,0.11025943396226415,0.0852225020990764,-1.0808407437348424,-1.0808407437348424,-1.3508928571428571,-1.287769784172662,-1.287769784172662,0.02760715010544329,0.02729528535980149,0,-0.043273753527751646,-0.21503957783641162,-0.11481039328946535,-0.21442668396738068,0.2199354679745705,-1.5332335926180494,-2.1761510224577076,-2.71929826904082,-2.366499541169029,-51.81009766855703,-0.06185842420728243,-0.0037435484726444208,-0.36152825414824963,-0.19799234745321254,0,-1,0.0,0.125,0.0945273631840796,-0.04354717610744974,-0.13958121121985856,0.04896551724137931,0.03864168618266979,0.1130755780066058,840474280.0,881839880.0,962144717.0,-75135698.0,-78833649.0,-86012644.0,0.1277,0.14863,0.39378
0,NAUT,1.76,1.036,107120,220992640,0.0,1.74-3.455,-0.04,"Nautilus Biotechnology, Inc.",USD,0001808805,US63909J1088,63909J108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.nautilus.bio,"Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.",Mr. Sujal M. Patel,Healthcare,US,161,206 333 2001,2701 Eastlake Avenue East,Seattle,WA,98102,1.88193,-0.12192700870163867,https://images.financialmodelingprep.com/symbol/NAUT.png,2020-08-07,False,False,True,False,False,125452572.0,4409000,31567000,384697830,0.0654590007130344,-0.5596537311327503,-0.4681928641526776,-0.48637503422408906,1.1208140077032458,1.7810236684505758,1.7810236684505758,1.7810236684505758,0.05622842072938927,220992640.0,248150640.0,-3.1448016909272187,26.910940087676572,-3.759134610445631,-3.621820863395789,0.9881957388759098,0.9881957388759098,30.218051631758403,-3.12536228415975,-4.224847524939518,-4.066909944227182,-0.3179850745072445,-0.2761042132443868,0.017718878953068916,0.015244278101222931,-0.3420446101336289,16.648002770722698,-25.369951534733442,0.8365759720837488,0.0,0.0,0.0,3.820871894788115,5.978080857282026,0.0,-0.038834786822983976,0.2777642474427667,0.3569640062597809,1.5404286410131516,4.735717704729909,-0.33800041298036837,-0.2703462403351508,0.8317007641740498,135543000,223434000,107935000,169244000,0.0,1557000.0,0.0,0.0,84.93818466353679,0.0,0.0,4.29724277067922,0.0,-0.2884676619163933,0.01818217007141153,0.0,0.01791462376303573,0.0,0.0,-3.1448016909272187,-0.03144801690927219,0.0,16.648002770722698,16.648002770722698,0.5090048487647195,0.0,0.0,0.0,84.93818466353679,-84.93818466353679,0.22187043351193375,-9.561617145640525,-8.549683390160741,-8.549683390160741,0.021154764278592794,-0.2703462403351508,-0.2884676619163933,-0.3127763481807825,1.0,0.8941670911869587,-9.561617145640525,0.015244278101222931,0.017718878953068916,0.0,0.017410386423504683,-25.369951534733442,-14.83606946198535,1.1623298155159913,0.0,4.29724277067922,0.0,0.24367229459066497,0.03162061423774759,-0.4681928641526776,-0.48637503422408906,1.1208140077032458,-7.152459693132002,1.038834786822984,-14.83606946198535,-14.83606946198535,-25.750109162647963,-25.750109162647963,0.9881957388759098,0.9881957388759098,26.910940087676572,-3.1448016909272187,-3.621820863395789,-3.759134610445631,-3.759134610445631,-0.03144801690927219,26.910940087676572,-3.12536228415975,0.9881957388759098,0.0,NAUT,2023-12-31,2023,FY,0,-0.6700819672131147,-0.19701971140243327,-0.19701971140243327,0.0010197678067147787,0.0,0.0,0.0026442425289985184,0.0026442425289985184,0,-0.12891324280661923,-0.12514024516933306,0,0,0,0.9875143286926252,0.9875143286926252,0.11388046158683622,-1.0058469303684914,-1.0058469303684914,0.02224726647517059,2.053537582041385,2.053537582041385,3.1412821384910297,0,0,0,0,0,-0.12708683281341057,-0.15962837772847932,0.1417831706673701,0.2542737311531111,0.1138903877283589,122600.0,3607000.0,26162467.0,0.0,0.0,0.0,-0.22585499999999997,-0.75341,-0.6212
0,NEO,16.41,1.183,747017,2106403994,0.0,12.77-21.22,0.01,"NeoGenomics, Inc.",USD,0001077183,US64049M2098,64049M209,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://www.neogenomics.com,"NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.",Mr. Christopher Michael Smith BSc,Healthcare,US,2100,239 768 0600,9490 NeoGenomics Way,Fort Myers,FL,33912,28.73749,-12.327492918322621,https://images.financialmodelingprep.com/symbol/NEO.png,2004-03-16,False,False,True,True,False,126953000.0,361992000,606268000,2116832750,5.073672934077966,-0.6122580797618016,0.11820910100588407,-0.16944853607240476,3.05477617701039,7.153907351539546,0.29461296700353673,7.153907351539546,4.30910651973565,2106403994.0,2350679994.0,-26.80242293639358,3.2702144544943628,138.82179849403613,-97.9176270918557,2.29385134495326,2.29385134495326,3.649455525229849,-5354.624132118452,156.63890144599185,-109.27296364819635,-0.037310059705167674,-0.010212665785516925,0.5949945497186774,0.3292769349544303,-556.4373576309795,1.9913260865164673,-13.235990410548396,-0.19307070811033347,0.0,0.0,0.0,0.3972129330340093,0.04706746279408432,0.5306210244157769,2.433464383287799,0.056696133317187224,0.5021864686468647,0.04979677636706318,9.927277849519845,-0.05937343928975992,-0.10090574747858959,-1.7273203469000338,293835000,37402000,-142660000,1339123000,149004500.0,16850000.0,23835500.0,85.80915298128603,16.264858024075057,24.088024263945968,4.25362548537919,22.441019740825965,15.152757901623257,-0.08427989821745001,0.28765763707828884,0.0,0.25654148090264206,0.0,0.0,-26.80242293639358,-16.617502220564006,0.0,1.9913260865164673,1.9088142615196724,1.2212708244772372,85.80915298128603,24.088024263945968,109.897177245232,16.264858024075057,93.63231922115695,0.4246535572674572,-0.13714412576577584,-0.12394157592242415,-0.12067354118344775,0.026367542244435258,-0.04736303638206069,-0.08427989821745001,-0.06569247530127426,0.9736324577555647,0.9037322979046153,-0.13714412576577584,0.3292769349544303,0.5949945497186774,0.27236441306685166,0.37303860995864946,-13.235990410548396,0.02777119804581961,1.8069730568921285,4.25362548537919,22.441019740825965,15.152757901623257,3.691643741403026,0.39248899068984366,0.11820910100588407,-0.16944853607240476,3.05477617701039,0.023298526046469745,-1.4334643832877991,0.02777119804581961,0.07487626232387339,0.41093677263890027,0.41093677263890027,2.29385134495326,2.29385134495326,3.2702144544943628,-26.80242293639358,-97.9176270918557,138.82179849403613,138.82179849403613,-16.617502220564006,3.2702144544943628,-5354.624132118452,2.29385134495326,0.0,NEO,2023-12-31,2023,FY,0.16070335551509826,0.3018052539702814,0.2963352426734245,0.2963352426734245,0.39016984402079724,0.39655172413793105,0.39655172413793105,0.010344799826110758,0.010344799826110758,0,0.9704059521464398,0.6830746046818876,2.42308213877443,0.5598373182859501,0.15168567518768736,-1.3372451349882688,-1.0318165473466685,-2.157296336269705,-17.639911288914973,-25.311618552016316,-19.242132638468682,15.677126811917574,1.1437773799796815,0.17324623696509642,0,0,0,0.09619834434596654,-0.004984141368373357,-0.033795316643238,-0.06625727560941809,0.0012292774271272556,-0.09948558992283849,0.010512525870920603,661679004.0,727374346.0,799153120.0,14257858.0,15673461.0,17220150.0,0.098,0.19559,0.35147
0,NEOG,12.04,1.223,1681082,2609043920,0.0,11.46-20.89,0.02,Neogen Corporation,USD,0000711377,US6404911066,640491106,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.neogen.com,"Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.",Mr. John Edward Adent,Healthcare,US,2917,517 372 9200,620 Lesher Place,Lansing,MI,48912,6.72318,5.316815835118119,https://images.financialmodelingprep.com/symbol/NEOG.png,1989-08-23,False,False,True,False,False,216695348.0,120477000,891780000,4509297753,4.209591984411221,-0.10859947025720183,-0.02654879328558544,-0.576740576821243,0.5559740950230274,14.468201689313608,-2.2707132596127537,14.468201689313608,4.442559606771069,2609043920.0,3380346920.0,-110.8661024909701,2.8601696778882677,-453.5046045402398,-20.876192579434615,0.8321697650159862,0.8321697650159862,3.705712152721062,20.528007044391813,-587.5798574656701,-27.047752146394938,-0.009019889556246,-0.04790145502801654,0.28359634752831725,0.19744500155779046,4.6839314993623615,4.406670524659912,0.6297091892920751,0.24446521905409424,0.0,0.0,0.0,0.22630917157330802,0.022969768657935385,0.8054864869726301,-20.723796280201633,0.1306995513040466,1.0122343631933302,0.016566560586012483,5.945828653624383,0.008577371780483008,-0.026866363445397338,-4.718498848438593,417961000,-492053000,-827331000,4360488000,170322000.0,72262500.0,193931500.0,67.07772646100248,48.75614494908005,157.5357178561028,5.44144858893217,7.486235845372901,2.3169348828778022,-0.007486792212724413,0.5501917835356577,0.0,0.34078728732170976,0.0,0.0,-110.8661024909701,0.7224607880042198,0.0,4.406670524659912,2.7879761021770495,0.9819706738175387,67.07772646100248,157.5357178561028,224.6134443171053,48.75614494908005,175.85729936802522,0.49557717120935235,0.050775104993537594,-0.03461635016043648,-0.025798098879740057,0.25474237577983977,-0.005225870736034348,-0.007486792212724413,0.010573489139556268,0.7452576242201603,-0.6817583176803333,0.050775104993537594,0.19744500155779046,0.28359634752831725,0.2209388863363534,0.2209388863363534,0.6297091892920751,-0.006470377189361724,1.4363308531024574,5.44144858893217,7.486235845372901,2.3169348828778022,2.893279667091683,0.20256805590191626,-0.02654879328558544,-0.576740576821243,0.5559740950230274,-0.006306737893814836,21.723796280201633,-0.006470377189361724,0.0,-0.04825370730725357,-0.04825370730725357,0.8321697650159862,0.8321697650159862,2.8601696778882677,-110.8661024909701,-20.876192579434615,-453.5046045402398,-453.5046045402398,0.7224607880042198,2.8601696778882677,20.528007044391813,0.8321697650159862,0.0,NEOG,2024-05-31,2024,FY,0.1237465757671923,0.14273749553521942,0.5637211781953885,0.5637211781953885,0.5880629645824224,0.6375000000000001,0.6375000000000001,0.14612839830369387,0.14612839830369387,0,-0.14048942185824315,-2.0796635529135834,0.690297628754481,0.06968589018775116,-0.029425899232599664,-0.2636096336012468,-0.7352106770366064,-0.7860592020849185,-1.1513876863119916,-1.0750497185491419,-1.0761258361902533,3.6446234188862587,1.3627926480258399,0.8405684665726265,0,0,0,0.12888491579283928,0.4144247152721729,-0.0012293519806641092,-0.12473448733084681,0.006932222222222222,-0.13683321172088023,0.11787348751902009,935275000.0,980175000.0,1026868250.0,180737293.0,189413997.0,198437238.0,-0.0275,0.0825,0.1825
0,NTRA,161.88,1.529,1223395,21371559318,0.0,58.53-175.63,3.79,"Natera, Inc.",USD,0001604821,US6323071042,632307104,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.natera.com,"Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.",Mr. Steven Leonard Chapman,Healthcare,US,3282,650 249 9090,13011 McCallen Pass Building A,San Carlos,CA,78753,7.51816,36.2218,https://images.financialmodelingprep.com/symbol/NTRA.png,2015-07-01,False,False,True,False,False,123775000.0,892844000,475733000,15296125250,12.37693395273682,-1.734485962431832,0.19916784487982225,-0.26810745303978994,7.451698646738032,7.097758028681074,7.097758028681074,7.097758028681074,3.8659826297717634,21371559318.0,20954448318.0,-93.33024510214918,13.950513767049294,812.7818026934934,-644.0126357691728,22.807201843999888,22.807201843999888,13.678240103658398,-128.78085670563073,850.0100729352588,-631.4433725478378,-0.010714640242351322,-0.0015527645646356855,0.5304015252838564,0.292889078014541,2.563461042073823,4.387839398041245,-19.303883262897696,-0.11482816764949741,0.0,0.0,0.0,0.0,0.23345398526719127,0.0,2.346138244361512,0.03775371991997154,1.7214929904455756,0.16411317564810976,16.643215959465767,-0.18195942094286321,-0.13494227023276073,3.7522197535851345,1021149000,878525000,610143000,1251175000,321406000.0,30467000.0,44854500.0,73.11555496081803,15.66415398634241,27.420429648291567,4.992097785424732,23.301609542286414,13.31124291930055,-0.26225330838486566,0.4672752979196122,0.0,0.021803322493531868,0.0,0.0,-93.33024510214918,-3.327426129728797,0.0,4.387839398041245,4.226189054330228,2.962165246702232,73.11555496081803,27.420429648291567,100.53598460910959,15.66415398634241,84.87183062276718,0.5766344311680174,-0.15802683499188944,-0.13867574439196975,-0.1401385810940922,-0.010548612582080067,-0.13494227023276073,-0.26225330838486566,-0.18773492068046443,1.0105486125820802,0.877545540914536,-0.15802683499188944,0.292889078014541,0.5304015252838564,0.30497924490536993,0.34657670978567434,-19.303883262897696,0.05290457989874906,1.8109296832759454,4.992097785424732,23.301609542286414,13.31124291930055,6.659921052402772,0.9629201978444285,0.19916784487982225,-0.26810745303978994,7.451698646738032,0.016091856484035105,-1.3461382443615122,0.05290457989874906,0.3063539996768942,0.42623234261804727,0.42623234261804727,22.807201843999888,22.807201843999888,13.950513767049294,-93.33024510214918,-644.0126357691728,812.7818026934934,812.7818026934934,-3.327426129728797,13.950513767049294,-128.78085670563073,22.807201843999888,0.0,NTRA,2023-12-31,2023,FY,0.31985121101360364,0.3538077732535457,0.1752088570161171,0.1752088570161171,0.20627638969768108,0.32136445242369843,0.32136445242369843,0.16857369319567514,0.16857369319567514,0,0.4276838292379392,0.40284809202041744,5.25978452474891,1.1091728899968105,0.950435353510462,-2.2646630051178374,-0.7563970421358496,0.04680033350361726,-2.7377773746101757,-0.7031427447203752,-0.33323199942914417,2.423554082927408,10.945289187077783,0.10881069790113576,0,0,0,0.1387319188984594,0.1511890640004519,0.033865816071149406,-0.07200906218353771,0.007781932600665785,0.013472812603700837,0.05048667071022153,1631036125.0,1805564275.0,2126720987.0,-842576928.0,-932736422.0,-1098642763.0,-1.61271,-1.25777,-0.009672
0,OCX,2.19,1.002,68682,36869088,0.0,1.98-3.82,-0.02,OncoCyte Corporation,USD,0001642380,US68235C2061,68235C107,NASDAQ Global Market,NASDAQ,Biotechnology,https://oncocyte.com,"OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.",Mr. Joshua  Riggs,Healthcare,US,43,949 409 7600,15 Cushing,Irvine,CA,92618,1.80103,0.728967994404601,https://images.financialmodelingprep.com/symbol/OCX.png,2015-12-30,False,False,True,False,False,13714000.0,3363000,3991000,39712900,0.051698993729036025,-3.145982207962666,-1.4526031792329006,-1.4718535802829225,0.2452238588303923,0.7081085022604637,-3.4138836225754705,0.7081085022604637,0.015604491760245006,36869088.0,37497088.0,-0.69612599666234,52.00153455571227,-1.5076381707745594,-1.8265587317314838,3.092746370095768,3.092746370095768,52.88728913963329,-1.2162532598118716,-1.882289443301039,-1.8576709437701264,-1.4365215561473361,-0.5474776050874922,0.0,0.0,-0.020369769704832955,0.5272827282728273,-135.19158878504672,0.4617328017800853,0.0,0.0,0.0,15.078984485190409,13.750352609308885,0.8050729178534807,-0.013252346769740474,0.3723554301833568,0.19909502262443438,2.300423131170663,7.079772373594823,-3.583407772784788,-3.1521882077884125,-4.146802537552865,-4297000,-46818000,-55712000,55233000,147000.0,961500.0,116000.0,107.59520451339915,306.3330125120308,81.50144369586141,3.3923444976076556,1.19151376146789,4.478448275862069,-2.303224428784967,0.019250401050021876,0.0,0.0,0.0,0.0,-0.69612599666234,0.1535141013692217,0.0,0.5272827282728273,0.5017601760176018,0.36996699669967,107.59520451339915,81.50144369586141,189.09664820926056,306.3330125120308,-117.23636430277023,-0.46544428772919605,-40.80535966149506,-60.851904090267986,-60.851904090267986,-0.2028091971073614,-0.6144468497208614,-2.303224428784967,-0.4733010502895658,1.0,1.491272337630915,-40.80535966149506,0.0,0.0,0.0,0.0,-135.19158878504672,0.0,7.230563278756049,3.3923444976076556,1.19151376146789,4.478448275862069,0.23625458180606465,0.010097413694884356,-1.4526031792329006,-1.4718535802829225,0.2452238588303923,-28.09732016925247,1.0132523467697405,0.0,0.0,-75.45833333333333,-75.45833333333333,3.092746370095768,3.092746370095768,52.00153455571227,-0.69612599666234,-1.8265587317314838,-1.5076381707745594,-1.5076381707745594,0.1535141013692217,52.00153455571227,-1.2162532598118716,3.092746370095768,0.0,OCX,2023-12-31,2023,FY,0.5688935281837161,23.944444444444443,-0.39667722398177474,-0.39667722398177474,0.6217184095860566,0.7171945701357466,0.7171945701357466,0.3810469314079422,0.3810469314079422,0,0.4881276334269663,0.5270096978440331,0,0,-0.4711011610969326,-0.39384244626036186,0.5047201113554343,0.6158244571269194,0.6627506847824318,0.5638109895664665,0.6028456297219718,-0.6996136138199058,0.8494770760644021,-0.6729147117548337,0,-1,0,-0.7594433399602386,-1.0,-0.2517608975831993,-0.4595731557174262,-0.1904627539503386,0.2729763046158061,-0.4118107156824404,500000.0,1033333.0,5700000.0,-300000.0,-619999.0,-3420000.0,-2.79,-1.67333,-1.355
0,OMIC,19.55,1.514,28434,49105299,0.0,5.34-23.41,-0.42,"Singular Genomics Systems, Inc.",USD,0001850906,US82933R1005,82933R100,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://singulargenomics.com,"Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.",Mr. Andrew  Spaventa,Healthcare,US,255,858 333 7830,10931 North Torrey Pines Road,La Jolla,CA,92037,17.06269,-0.9026925411660588,https://images.financialmodelingprep.com/symbol/OMIC.png,2021-05-27,False,False,True,False,False,2501093.0,52620000,50492000,37064127,1.0659339736667128,-34.513710605723176,-32.158340373588665,-32.32826608206892,45.513301584547236,49.27965493486248,49.27965493486248,49.27965493486248,2.522497164239794,49105299.0,46977299.0,-0.5664415577720627,18.419091897974493,-0.6079293823277095,-0.6073179355891956,0.3967154401921252,0.3967154401921252,17.620892348087022,-0.5997204080069448,-0.5840695627307879,-0.580999542396359,-1.7654071921086023,-1.6465840071557247,0.041913787088346734,0.027692159248677305,0.02716641985395496,7.371798512124482,-81.36832895888014,0.9317555200296564,0.0,0.0,0.0,0.0,16.309077269317328,0.0,-0.005284032276112444,0.15941485371342837,0.062070979991237035,3.7261815453863467,195.62345042546454,-0.757763097360405,-0.46272601058155677,22.989248800424456,112201000,123253000,66512000,167275000,1167999.5,1690000.0,12426000.0,138.4150918979745,119.61170120146265,788.7254048406757,2.6369956844665525,3.05154091392136,0.4627719580983078,-0.5786975584248422,0.16992570848025243,0.0,0.10520249555959327,0.0,0.0,-0.5664415577720627,-0.0864227976715089,0.0,7.371798512124482,6.667045260946107,2.9882446476233744,138.4150918979745,788.7254048406757,927.1404967386502,119.61170120146265,807.5287955371875,-1.1541635408852213,-34.88522130532633,-32.37884471117779,-32.37884471117779,-0.04631176293413035,-0.46272601058155677,-0.5786975584248422,-0.5505084585242273,1.0,0.9281536278009548,-34.88522130532633,0.027692159248677305,0.041913787088346734,0.04022769216393213,0.04022769216393213,-81.36832895888014,-15.569299264421216,1.5135615360275205,2.6369956844665525,3.05154091392136,0.4627719580983078,0.04840759705124015,0.01429099817208163,-32.158340373588665,-32.32826608206892,45.513301584547236,-30.169167291822955,1.0052840322761125,-15.569299264421216,0.0,-189.24941176470588,-189.24941176470588,0.3967154401921252,0.3967154401921252,18.419091897974493,-0.5664415577720627,-0.6073179355891956,-0.6079293823277095,-0.6079293823277095,-0.0864227976715089,18.419091897974493,-0.5997204080069448,0.3967154401921252,0.0,OMIC,2023-12-31,2023,FY,2.8052287581699344,-22.25,-0.0996288253981837,-0.0996288253981837,-0.0741919769799821,-0.049973132724341736,-0.049973132724341736,0.023175708325848865,0.023175708325848865,0,0.1543963992927182,0.19866617981872073,0,0,0,-5.151889494613076,-5.151889494613076,-1.8193377698345377,-6.31593464921008,-6.31593464921008,-2.1499127623033742,7.893686138006757,7.893686138006757,4.306107841377501,0,0,0,-0.21272365805168986,-0.25514516217551175,-0.1905876972330208,-0.3279398208569155,0.2794507511386038,0.03387519210372519,0.15265318212593093,3354000.0,15194000.0,31272000.0,670799.0,3038799.0,6254399.0,-33.51,-31.95,-22.14
0,ONC.L,14.9,1.264,179866,16654177,0.0,9.35-31.0,0.1,Oncimmune Holdings plc,GBp,,GB00BYQ94H38,G6750T108,London Stock Exchange,LSE,Biotechnology,https://www.oncimmune.com,"Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",Mr. Martin John Gouldstone,Healthcare,GB,38,44 1157 840 500,MediCity,Nottingham,,NG90 6BH,,0.0,https://images.financialmodelingprep.com/symbol/ONC.L.png,2016-05-18,False,False,True,False,False,74142147.0,911000,5262000,20291561,0.0163739525913648,0.09523597961089528,-0.08262506884242238,-0.08275994489342209,0.012287208246073586,-0.017223671712662973,-0.03850711256041722,-0.017223671712662973,0.09465601259159652,16654177.0,21005177.0,1.5645347547089645,13.718432454695224,-1.8033267879529873,-2.7141748696219037,-8.650884810493343,-8.650884810493343,17.30245222405272,-15.675505223880597,-3.428856839699641,-3.423268741851369,0.6391676483952703,-0.36843609864360155,-4.106499608457322,0.8817891373801917,-3.247014925373134,1.1350877192982456,-1.0011273957158964,1.9179711959924859,0.0,0.0,0.0,0.0,0.46540362438220756,0.26534387085925676,-0.001632386549134835,0.008237232289950576,0.06493506493506493,0.0,0.19211207166955516,-0.4793606928632894,1.6161593041886015,-0.06285223976586489,385000,-2855000,-3989000,2358000,982000.0,975000.0,297500.0,590.494233937397,889.0,180.0,0.6181262729124236,0.41057367829021374,2.0277777777777777,-22.77741935483871,0.00013487605099971004,0.0,0.31487596174821486,0.0,0.0,1.5645347547089645,0.015645347547089645,0.0,1.1350877192982456,1.0087719298245614,0.3196491228070175,590.494233937397,180.0,770.494233937397,889.0,-118.50576606260302,0.3986820428336079,-1.4629324546952225,-2.457166392092257,5.816309719934102,-0.07073416024136775,1.187321338489995,-22.77741935483871,-0.5734581853406523,-2.3670801206838754,1.679617117117117,-1.4629324546952225,0.8817891373801917,-4.106499608457322,1.4280925243043916,1.3219057222082178,-1.0011273957158964,-1.168192219679634,-4.6570086139389195,0.6181262729124236,0.41057367829021374,2.0277777777777777,3.0734177215189873,0.2041365394316462,-0.08262506884242238,-0.08275994489342209,0.012287208246073586,-5.046128500823723,1.0016323865491348,-1.168192219679634,-6.225609756097561,-612.6,-612.6,-8.650884810493343,-8.650884810493343,13.718432454695224,1.5645347547089645,-2.7141748696219037,-1.8033267879529873,-1.8033267879529873,0.015645347547089645,13.718432454695224,-15.675505223880597,-8.650884810493343,0.0,ONC.L,2023-08-31,2022,FY,-0.7014770665975641,-0.456417295813315,0.5059399021663172,0.5059399021663172,1.4314550042052145,1.3773333333333335,1.3773333333333335,0.12335424252838123,0.12335424252838123,0,-0.09338270809853486,-0.015934475055845124,-0.23305448699796552,4.740229817340166,-0.7243716331282615,-1.223741669489457,0.21370079037829504,-0.33589104170184947,3.0453125094219007,1.4364548492075528,1.7896993915474666,1.246182286378253,-0.9288230204924335,-0.8880663486326218,0,0,0,0.0,-0.43099273607748184,-0.5111548936663383,1.2144684938092036,-0.50393037619315,-0.17270929466051418,-0.46412365286443563,,,,,,,,,
0,ONT.L,143.1,0.855,2305701,1418016966,0.0,85.0-212.59,5.1,Oxford Nanopore Technologies plc,GBp,,GB00BP6S8Z30,,London Stock Exchange,LSE,Biotechnology,https://nanoporetech.com,"Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.",Dr. Gurdial Singh Sanghera Ph.D.,Healthcare,GB,1281,44 84 5034 7900,Gosling Building,Oxford,,OX4 4DQ,,0.0,https://images.financialmodelingprep.com/symbol/ONT.L.png,2021-09-30,False,False,True,False,False,861574683.0,162017000,46704000,729030189,0.29204897145289027,-0.23360017880191125,-0.21035843273496002,-0.21625577524078665,0.3005578101463318,0.6715378381191361,0.627423264246496,0.6715378381191361,0.003580653030864418,1418016966.0,1302703966.0,-6.125851475539591,5.6355047094451205,-6.8026747556299805,-7.610633067157757,2.1309298132894328,2.1309298132894328,5.177226021572041,-7.540999921852162,-7.18774861992005,-6.991737135786255,-0.16324261271971435,-0.1313951140694603,0.0,0.0,0.6675156802190455,4.4516431357136375,-70.5868719611021,0.9005063001828444,0.0,0.0,0.0,0.0,0.5222794509224153,0.052595090589812814,-0.028034733046604077,0.020192991868755516,0.08846061840593336,0.07910278115586078,1.8787244552567524,-0.38614489933625384,-0.29396840698464166,0.24917892114989176,342510000,540572000,297668000,473563000,61059000.0,90569000.0,108024000.0,88.57148818465794,334.86988188577567,399.4080106971373,4.12096496830934,1.089975598714792,0.9138524772272828,-0.3292848430708972,0.005897342505826625,0.0,0.0,0.0,0.0,-6.125851475539591,-0.42880960328777107,0.0,4.4516431357136375,3.363031713879735,1.6327256603279217,88.57148818465794,399.4080106971373,487.9794988817952,334.86988188577567,153.10961699601955,0.6076734148842311,-0.8654271089173443,-0.7796198265652446,-0.799866466366216,-0.025969888285385854,-0.2785071119887415,-0.3292848430708972,-0.34929870938144625,1.0259698882853858,0.9008497868070655,-0.8654271089173443,0.0,0.0,0.0,0.0,-70.5868719611021,0.0,1.2490113726710221,4.12096496830934,1.089975598714792,0.9138524772272828,2.7043043688537804,0.348192009166225,-0.21035843273496002,-0.21625577524078665,0.3005578101463318,-0.7202847922677668,1.028034733046604,0.0,0.0,-35.67003824640066,-35.67003824640066,2.1309298132894328,2.1309298132894328,5.6355047094451205,-6.125851475539591,-7.610633067157757,-6.8026747556299805,-6.8026747556299805,-0.42880960328777107,5.6355047094451205,-7.540999921852162,2.1309298132894328,0.0,ONT.L,2023-12-31,2023,FY,-0.14569266325282096,-0.2691947338664082,-0.7121315204256745,-0.7121315204256745,-0.6974127986816808,-0.7272727272727273,-0.7272727272727273,0.012403932548797831,0.012403932548797831,0,-1.7801243242148743,-0.7964440466705232,0.0,3.9713785833876525,0.41993854655146523,-1.9511744210286293,-1.3569710475299852,-1.0504828053371464,-2.1913768077340317,-1.7716542768281274,-1.40394983232371,3.911129004867478,3.293536984535184,2.2996460052017706,0,0,0,-0.1785046502027634,0.15792834500216651,-0.056837684642367305,-0.08304078796558488,0.221625901812423,0.6014620153604145,-0.013966604635210579,181838495.0,233770912.0,301760257.0,-122079550.0,-156945028.0,-202590527.0,-0.17832,-0.1447,-0.10836
0,OPGN,0.724,-0.598,3850,7289304,0.0,0.661-9.9,0.0,"OpGen, Inc.",USD,0001293818,US68373L4068,68373L307,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://www.opgen.com,"OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.",Mr. Honjian  Tan,Healthcare,US,85,240 813 1260,9717 Key West Avenue,Rockville,MD,20850,-1.19,1.85556,https://images.financialmodelingprep.com/symbol/OPGN.png,2015-05-05,False,False,True,False,False,5760214.0,1633166,2241370,12071029,0.21976058528381065,-1.6146769894312953,-1.0961313242876045,-1.0962899989479558,0.28352523013901915,0.5184302180439824,0.5184302180439824,0.5184302180439824,0.05411378813356587,7289304.0,7897508.0,-0.4483868939353621,5.758344471935462,-0.6605047989761086,-1.1543087619450296,1.3965235335463753,1.3965235335463753,6.2388084697614605,-0.7238759860308346,-1.2508028649572986,-1.2506218264365112,-2.230216836231071,-0.8663193358378248,0.05592965670540732,0.03053497496995334,-0.055747239535293626,5.455332057114468,-145.0795239345894,0.6788548616610139,0.0,0.0,0.0,4.0899209080251655,0.2991394047404627,0.0,-0.00014475880474840557,0.0007220342089380567,0.0024210766109165655,0.5181930501442489,4.339895186900603,-6.757315826297505,-1.700398696411915,-0.1444547459521469,2627590,2986269,733796,4577801,24901.5,116118.5,0.0,7.0357770320444155,31.304219302323467,0.0,51.877709929920904,11.659770092810104,0.0,1.2018319991629325,0.00015867466035116056,0.0,0.022913161530922568,0.0,0.0,-0.4483868939353621,-0.013910352485123446,0.0,5.455332057114468,5.455332057114468,2.7691903357789487,7.0357770320444155,0.0,7.0357770320444155,31.304219302323467,-24.268442270279053,0.04328334391895521,-16.582278721004087,-7.347436699561092,-7.347436699561092,-0.015092219718876214,-1.700398696411915,1.2018319991629325,-4.301373978163807,1.0,0.4430896876829358,-16.582278721004087,0.03053497496995334,0.05592965670540732,0.0,0.05296721836558008,-145.0795239345894,-37.80333610743559,1.831658835824904,51.877709929920904,11.659770092810104,0.0,0.6490928417489185,0.23142747136746214,-1.0961313242876045,-1.0962899989479558,0.28352523013901915,-4.987843124243602,1.0001447588047485,-37.80333610743559,-37.80333610743559,-6908.042669584245,-6908.042669584245,1.3965235335463753,1.3965235335463753,5.758344471935462,-0.4483868939353621,-1.1543087619450296,-0.6605047989761086,-0.6605047989761086,-0.013910352485123446,5.758344471935462,-0.7238759860308346,1.3965235335463753,0.0,OPGN,2023-12-31,2023,FY,0.3110609356140641,0.8889503831281576,0.5461394209901012,0.5461394209901012,0.11088001963064942,0.7244335171772212,0.7244335171772212,2.2267302320628444,2.2267302320628444,0,0.29976755646953807,0.2813870602700415,-0.9980722879746403,-0.9778777722481555,-0.9186640199660765,0.997400262673785,0.9753442131552614,0.9386255510426899,0.9956180303622079,0.9507164344890534,0.8750148103880029,0.9914181630211532,-1.0666267618671361,-1.0547104929218032,0,0,0,-0.7991414773743516,-1.0,-0.927130160810622,-1.4729528726437122,-0.12098963540936261,-0.4209471293281221,-0.1786630985723843,,,,,,,,,
0,ORGS,1.32,1.318,34192,6823410,0.0,0.87-10.8,0.01,Orgenesis Inc.,USD,0001460602,US68619K2042,68619K204,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.orgenesis.com,"Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.",Ms. Vered  Caplan M.Sc.,Healthcare,US,146,480 659 6404,20271 Goldenrod Lane,Germantown,MD,20876,2.18039,-0.8603941867335211,https://images.financialmodelingprep.com/symbol/ORGS.png,2012-03-13,False,False,True,False,False,47152290.0,204000,17297000,227392213,-0.2728393467210182,-0.93189535439318,-0.3282979469289827,-0.33504205204031445,0.004326407052552485,-0.5074620978111561,-0.7140056188151201,-0.5067834457244812,0.3734283106928635,6823410.0,23916410.0,-1.4164680548917867,-0.5303855421686747,-4.020737906976744,-0.4319160653247246,-2.604662822229662,-2.604662822229662,-1.8590291488534785,-0.7808675068564712,-1.5449877260981912,-1.5138884668945434,-0.7059813290857424,-2.315264655062498,-0.6333277535989287,0.5097854279651026,-0.5580841060467546,0.06987711170906266,-37.30598181083266,0.21211290764593038,0.0,0.0,0.0,-2.597590361445783,-0.8772638942868247,0.32805605147034056,-0.02054263565891473,-0.024718227749708513,0.17482133040131942,-0.2468713563933152,3.259763123597369,10.532396335587489,-2.2027772207740126,-1.1105134024243573,-33530000,-33667000,-51096000,-6769000,818500.0,12375500.0,0.5,-39.63505635445006,2025.6338717572198,0.0,-9.209019327129564,0.18019050979008644,0.0,1.9951869593842941,0.006744105111331815,0.0,2.2179526072740754,0.0,0.0,-1.4164680548917867,0.026958585560843677,0.0,0.06987711170906266,0.06987711170906266,0.005658964187633499,-39.63505635445006,0.0,-39.63505635445006,2025.6338717572198,-2065.26892811167,1.1588029537504858,7.174115740380878,4.244073066459386,3.415546055188496,0.00010989010989010989,-1.4801428234580793,1.9951869593842941,14.5072302734989,0.8047802197802197,0.591581348844264,7.174115740380878,0.5097854279651026,-0.6333277535989287,-0.5285613765751935,-1.7272312257475462,-37.30598181083266,-1.022862428967887,-1.2423418145296283,-9.209019327129564,0.18019050979008644,0.0,-0.7557866290682645,-0.433354667025971,-0.3282979469289827,-0.33504205204031445,0.004326407052552485,1.203264671589584,1.0205426356589147,-1.022862428967887,-2.252947169262116,-48.679245283018865,-48.679245283018865,-2.604662822229662,-2.604662822229662,-0.5303855421686747,-1.4164680548917867,-0.4319160653247246,-4.020737906976744,-4.020737906976744,0.026958585560843677,-0.5303855421686747,-0.7808675068564712,-2.604662822229662,0.0,ORGS,2023-12-31,2023,FY,-0.9852879944482998,-1.367340391401989,-6.2795874049945715,-6.2795874049945715,-3.5493467006327553,-2.9791666666666665,-2.9791666666666665,0.1558631150332854,0.1558631150332854,0,0.4047103193708875,0.5465184788430637,0,-0.9912601198249298,-0.9490928622736328,-0.6152487423112166,0.3845195510875005,0.86027528958206,-0.5650136718909615,-0.1658586226443409,0.5722619386997373,-0.09585862792363442,-3.10099229657057,-1.2933141601988811,0,0,0,-0.9975679186358235,-0.7166666666666667,-0.8399612880520851,-1.30626469767834,0.11587411207576953,0.8447587354409318,1.143237387805633,,,,,,,,,
0,OSUR,3.64,0.046,670393,271522888,0.0,3.605-8.45,-0.15,"OraSure Technologies, Inc.",USD,0001116463,US68554V1089,68554V108,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.orasure.com,"OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.",Ms. Carrie  Eglinton Manner,Healthcare,US,638,610 882 1820,220 East First Street,Bethlehem,PA,18015,1.38968,6.67968,https://images.financialmodelingprep.com/symbol/OSUR.png,1986-11-17,False,False,True,False,False,74583000.0,278571000,11107000,51005409,2.475255755332985,0.15240738506093882,0.9201962913800732,0.8581714331684164,3.735046860544628,5.705924942681308,5.223884799485138,5.705924942681308,0.05230414437606425,271522888.0,4058888.0,23.883357086302457,1.4707759408922498,3.9556777549503868,4.242213702054527,0.6379333826794967,0.6379333826794967,0.021986046410850866,0.2660519140010488,0.05914073815039851,0.06341517068978986,0.041870160731027145,0.23572598417559554,0.002885575646493485,0.0026460669920380965,-17.531725222863138,12.60261301468471,-0.6150392817059483,6.037740828714701,0.0,0.0,0.0008797395970792645,0.2562942820618378,0.14292678699109485,0.07746856718058115,0.06740394282467106,0.025057959395922258,0.3873074346952445,0.06665330531059736,4.423410985543963,-0.003394923453721457,0.026550160814513248,3.750204470187576,322367000,389613000,311631000,406523000,32525500.0,9333000.0,38562500.0,53.29128117348818,42.63361617048253,172.96406017604176,6.849150404392669,8.561319277737189,2.1102649858502702,0.026615513306293234,0.06202485821165681,0.0,0.00452263899019813,0.0,0.0,23.883357086302457,-0.4094289786223278,0.0008797395970792645,12.60261301468471,11.203606392168155,10.026310106536135,53.29128117348818,172.96406017604176,226.25534134952994,42.63361617048253,183.62172517904742,0.5556843542131605,-0.008905163261326458,0.0770589127467337,0.06157237882694516,0.11865598200477998,0.024493357897798895,0.026615513306293234,-0.0037680408708666725,0.799029945170814,-8.653284671532846,-0.008905163261326458,0.0026460669920380965,0.002885575646493485,0.0,0.0028772730574306515,-0.6150392817059483,55.88843648208469,1.0905149624616686,6.849150404392669,8.561319277737189,2.1102649858502702,3.8298066550493735,0.39779781721020935,0.9201962913800732,0.8581714331684164,3.735046860544628,0.37175806556453533,0.9325960571753289,55.88843648208469,55.88843648208469,14.835927367055772,14.803925798101812,0.6379333826794967,0.6379333826794967,1.4707759408922498,23.883357086302457,4.242213702054527,3.9556777549503868,3.9556777549503868,-0.4094289786223278,1.4707759408922498,0.2660519140010488,0.6379333826794967,0.0,OSUR,2023-12-31,2023,FY,0.04643606492222804,0.21528478633404904,12.587529462181273,12.587529462181273,3.991636465012545,3.92,3.88,0.01162678435969933,0.02598441486794014,0,3.9995127325113344,2.1815211815211817,2.104015196740132,0.8588373803065468,1.1731270896473642,11.94198991318845,2.017752793542317,21.439178307864264,4.631741997932366,1.1918125868666414,4.309259534758253,1.0242352087574502,0.26624492749448697,-0.005539362263927683,0,0,0,-0.43258895150924476,-0.5052165599800482,0.0857573958642525,0.17077319167393984,0.07627321272017215,-0.0692386235063609,-0.21511528898879467,186035377.0,146022776.0,154409179.0,11376856.0,8929915.0,9442779.0,-0.17539,-0.20501,-0.11491
0,PACB,1.97,2.009,9501936,539512080,0.0,1.16-10.65,0.04,"Pacific Biosciences of California, Inc.",USD,0001299130,US69404D1081,69404D108,NASDAQ Global Select,NASDAQ,Medical - Devices,https://www.pacb.com,"Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.",Mr. Christian O.  Henry M.B.A.,Healthcare,US,796,650 521 8000,1305 O’Brien Drive,Menlo Park,CA,94025,0.876951,12.657,https://images.financialmodelingprep.com/symbol/PACB.png,2010-10-27,False,False,True,False,False,272915000.0,77982000,920752000,1306725500,0.6344356301412528,-1.444552333144019,-0.8538116263305425,-0.8779766593994467,1.7263506952714216,1.6603044904091018,-1.2911162816261474,1.6603044904091018,3.324734807540809,539512080.0,1382282080.0,-1.3637442928165586,3.1159193055611705,-2.3073005089735554,-2.2515977012933353,1.1865293452977344,1.1865293452977344,7.983286340508354,-4.3132425095327545,-5.93208284338549,-5.768810874201316,-0.7332752960121924,-0.44412907306913313,1.9710894637647256,0.6159392904530321,-2.6297609166422236,9.7377202193443,-26.208772669759597,0.5910562094155845,0.0,0.0,0.0,0.0,0.8778667837155711,0.555488354900376,-0.02830253456814495,0.038089022622395996,0.13364811737526852,0.41344637793320127,7.346014315285132,-0.2848387557680424,-0.6116373057798671,-1.7253622922888079,524237000,-352365000,-412696000,1379020000,30908000.0,14776000.0,67165500.0,61.94040324117657,31.05944756369382,169.2436094574387,5.892761120375727,11.751657824933687,2.156654547667219,-0.6867864936983454,0.02416503306890424,0.0,1.6554661760307572,0.0,0.0,-1.3637442928165586,-0.5114041098062091,0.0,9.7377202193443,8.642048769105122,1.2997649882494124,61.94040324117657,169.2436094574387,231.18401269861528,31.05944756369382,200.12456513492145,0.1812044101255003,-2.1533494660606305,-2.28105598133378,-2.276909215868597,-0.02849093827698135,-0.2718799049965105,-0.6867864936983454,-0.2682239191974418,0.9981820851837411,1.0593059869222146,-2.1533494660606305,0.6159392904530321,1.9710894637647256,0.6634231273760163,0.6634231273760163,-26.208772669759597,-0.2608963392241341,3.2001359457276406,5.892761120375727,11.751657824933687,2.156654547667219,3.5123945147679323,0.11940744194001318,-0.8538116263305425,-0.8779766593994467,1.7263506952714216,-1.3457813303147037,1.028302534568145,-0.2608963392241341,0.0,-35.3325246398787,-35.3325246398787,1.1865293452977344,1.1865293452977344,3.1159193055611705,-1.3637442928165586,-2.2515977012933353,-2.3073005089735554,-2.3073005089735554,-0.5114041098062091,3.1159193055611705,-4.3132425095327545,1.1865293452977344,0.0,PACB,2023-12-31,2023,FY,0.5628585235066716,0.07637401855817273,-0.0972642781453912,-0.0972642781453912,-0.03302125079985182,0.0833333333333334,0.0833333333333334,0.12993750231023746,0.129498997995992,0,0.01534130412482761,0.0432783608195902,0.7613819186725729,0.3569619165324829,0.7332659391223071,-1.1505170973677223,-1.0758667988366617,-10.062168788018031,0.042412305442510255,-0.5912954914876704,-8.114026881345938,1.5094343026599857,2.2714713451000375,0.42550666981491503,0,0,0,0.9490578090067071,0.124947897024672,-0.011925282640460057,0.10259890846951893,-0.024480685045546798,-0.030207253886010362,0.05572755417956656,155458336.0,191781607.0,252778187.0,-102399499.0,-126325425.0,-166503517.0,-1.36111,-0.68442,-0.55903
0,PAVM,0.582,0.693,66447,6441925,0.0,0.582-4.44,-0.0231,PAVmed Inc.,USD,0001624326,US70387R4039,70387R106,NASDAQ Capital Market,NASDAQ,Medical - Devices,https://www.pavmed.com,"PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.",Dr. Lishan  Aklog M.D.,Healthcare,US,107,212 949 4319,One Grand Central Place,New York,NY,10165,2.35059,-0.010587426794144763,https://images.financialmodelingprep.com/symbol/PAVM.png,2016-07-27,False,False,True,False,False,10005379.0,765000,34929000,46470616,0.40318312779555876,2.431092315443523,-4.549752688029109,-4.5731401079359415,0.07645887277233576,-0.938195344724073,-0.938195344724073,-0.48663823729216055,3.209073739235665,6441925.0,40605925.0,0.23939856018746916,1.5969075359444722,-0.1279190408593647,-0.14078863974123612,-1.1959602747997535,-1.1959602747997535,10.065920922161627,3.4443909576724066,-0.8920066121875138,-0.8874448159804178,4.177134562617737,-7.102845810840703,-6.582460258780037,1.0490998036006547,2.897955721435236,0.05671379503155204,-960.0172413793103,-2.249444087562386,0.0,0.0,0.0,6.7840852751611305,2.161378284581061,0.0,-0.005140371688414393,0.05800694100148736,0.1262135922330097,1.9048091224590977,5.15935129443072,884.1104481534295,0.79620294599018,-3.913594877315492,-35427000,-9387000,-37807000,-32593000,117500.0,848500.0,494500.0,1.4476945959345564,21.167997006734847,0.2731354452481916,252.125,17.24301075268817,1336.3333333333333,-0.48303835174382526,0.023387419906832116,0.0,4.975220760875049,0.0,0.0,0.23939856018746916,0.0022200751835773245,0.0,0.05671379503155204,0.05655403786244908,0.020369039060627845,1.4476945959345564,0.2731354452481916,1.720830041182748,21.167997006734847,-19.4471669655521,-0.9876053544868617,-13.8029251363411,2.4484382746653446,6.0297471492315315,432.58357800951705,0.79620294599018,-0.48303835174382526,7.9464820893392325,2.4626911005366003,-0.17738546362313895,-13.8029251363411,1.0490998036006547,-6.582460258780037,0.0,1.1791324888389865,-960.0172413793103,-1.4203432580450315,-6.27438899157938,252.125,17.24301075268817,1336.3333333333333,1.4234297812279464,0.1320458265139116,-4.549752688029109,-4.5731401079359415,0.07645887277233576,-11.284581060981656,1.0051403716884144,-1.4203432580450315,-1.4203432580450315,-194.53846153846155,-194.53846153846155,-1.1959602747997535,-1.1959602747997535,1.5969075359444722,0.23939856018746916,-0.14078863974123612,-0.1279190408593647,-0.1279190408593647,0.0022200751835773245,1.5969075359444722,3.4443909576724066,-1.1959602747997535,0.0,PAVM,2023-12-31,2023,FY,5.503978779840849,-0.22582638245288847,0.24340404940226776,0.24340404940226776,0.3664481607992576,0.3905522288755821,0.3905522288755821,0.2177587723035441,0.2177587723035441,0,0.2669437205043319,0.27917269906928643,0,0,0,-67.59633319644655,-0.21601901426566933,-0.038323301960642084,-8.291274400137953,0.2665509945019996,0.18256152052804528,-6.380931672286896,-3.7760703923620795,-13.414935496104112,0,-1,0,2.588235294117647,1.0651340996168583,-0.38645794738792144,-2.8038337325287492,0.3299396784671234,-0.4411868321133597,-0.19597740187875876,3012500.0,332000.0,2000000.0,-602499.0,-66399.0,-399999.0,2.5,-1.16,-0.62
0,PEB,13.55,1.85,1837895,1621840150,0.04,11.65-16.65,-0.04,Pebblebrook Hotel Trust,USD,0001474098,US70509V1008,70509V100,New York Stock Exchange,NYSE,REIT - Hotel & Motel,https://www.pebblebrookhotels.com,"Pebblebrook Hotel Trust (NYSE: PEB) is a publicly traded real estate investment trust (REIT) and the largest owner of urban and resort lifestyle hotels in the United States. The Company owns 53 hotels, totaling approximately 13,200 guestrooms across 14 urban and resort markets, with a focus on the west coast gateway cities.",Mr. Jon E. Bortz CPA,Real Estate,US,60,240-507-1300,4747 Bethesda Avenue,Bethesda,MD,20814,15.49474,-0.03974440599102397,https://images.financialmodelingprep.com/symbol/PEB.png,2009-12-09,False,False,True,False,False,119640463.0,133965000,2528428000,3977306325,12.117948757854606,0.029772536069172517,2.003201876609254,0.8058728425348872,1.1197298693168716,23.753652641748804,23.753652641748804,23.002259695367446,18.527979116897935,1621840150.0,4016303150.0,455.11742662829874,1.1186670616644951,6.764170979579745,16.8214505004408,0.5890725598028489,0.5890725598028489,2.7702520766700443,12.654436910609578,16.75805773916817,41.656413939739664,0.002197235134256274,0.05944790551645919,0.786469917707152,0.37821526909991776,7.544395887618429,0.553593886177754,1.513854385629658,41.45001729505361,0.002952029520295203,0.2952029520295203,14.71420550252667,0.033099116634949584,0.0,0.0,0.5977076240069431,0.09880624666763692,0.6145440973324524,0.009241293781129358,3.9254045836305855,-0.007785439572057642,0.0006224468451888022,-22.575428766102316,-157247000,2841898000,-2685675000,-157247000,62297000.0,219316500.0,-14750000.0,15.367141054920102,74.67766329481101,0.0,23.751978243418144,4.887673018892679,0.0,0.0012967755722723025,1.1973290340743665,0.04,1.3345125288703699,0.002952029520295203,0.2952029520295203,455.11742662829874,5.23123478883102,14.71420550252667,0.553593886177754,0.553593886177754,0.3803111985487621,15.367141054920102,0.0,15.367141054920102,74.67766329481101,-59.31052223989091,0.1777310892490466,0.0546421326571927,-0.011326413284066666,0.0024568956895344657,1.4831618050057853,0.0006224468451888022,0.0012967755722723025,0.014751432222177946,-0.21691736191462152,-0.20728351426407474,0.0546421326571927,0.37821526909991776,0.786469917707152,0.4402368659622034,0.4402368659622034,1.513854385629658,0.11073173391191693,2.0794240263720836,23.751978243418144,4.887673018892679,0.0,0.0,0.2533468750180207,2.003201876609254,0.8058728425348872,1.1197298693168716,0.16530866045384285,0.40229237599305695,0.11073173391191693,0.0,1.673058799712389,1.2248940770005263,0.5890725598028489,0.5890725598028489,1.1186670616644951,455.11742662829874,16.8214505004408,6.764170979579745,6.764170979579745,5.23123478883102,1.1186670616644951,12.654436910609578,0.5890725598028489,0.04,PEB,2023-12-31,2023,FY,0.02015818767417851,-0.07326771004726865,-0.6196253596507113,-0.6196253596507113,0.0819477294924748,-0.4307692307692308,-0.4307692307692308,-0.06623718482593366,-0.06623718482593366,0.08964633513827493,-0.15264130298301315,0.4579881729855187,0.46534928414483256,0.03274962762967568,2.4376489390010074,0.1097516067156067,0.04908877678158428,2.255126674170762,-1.917740127393582,-4.51090830877162,0.7869265268646641,-0.0530506847848397,-0.5559951132145345,-0.09033922744739312,-0.537871147163585,-0.7349271071260337,-0.3359928491134428,-0.029740598347253525,-1,-0.050308141790874436,-0.010376441835534328,-0.02484659461276104,1.0,0.14295557200091868,1440489308.0,1490275310.0,1528705548.0,161523781.0,167106345.0,171415573.0,-0.3,-0.37,-0.27
0,PGEN,0.7626,1.682,860882,223341899,0.0,0.65-1.93,0.0368,"Precigen, Inc.",USD,0001356090,US74017N1054,74017N105,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.precigen.com,"Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.","Dr. Helen  Sabzevari MPH, Ph.D.",Healthcare,US,202,301 556 9900,20374 Seneca Meadows Parkway,Germantown,MD,20876,0.81518,-0.052581534430198154,https://images.financialmodelingprep.com/symbol/PGEN.png,2013-08-08,False,False,True,False,False,275881170.0,24725000,5749000,242311056,0.01436488035772793,-0.5058844683020591,-0.27437900165495166,-0.27816686075385283,0.1037801891299794,0.20072410161229923,0.09310167852340194,0.20072410161229923,4.7121737232011887e-05,223341899.0,204365899.0,-1.5074588127988509,56.35677491799142,-2.7793672088617627,-2.9103334841914164,3.7992448035611095,3.7992448035611095,51.568483219783,-1.5014760047020792,-2.6998242839780175,-2.6630601850778617,-0.6633680413087584,-0.3436032349666732,0.0,0.0,0.13941664829916978,1.6267439668174963,-9992.692307692309,0.5423748283395061,0.0,0.0,0.0,0.0,13.70325510976533,0.3556915925917052,-0.013805207672796449,0.2636888720666162,0.19072805256433656,2.2376987130961394,1.5115297290955927,-2.3121090092968632,-2.5949463399215364,0.003913822752020371,13297000,25685000,6415000,61741000,872500.0,4583000.0,0.0,67.14231642694928,243.87905034413424,0.0,5.436213991769547,1.4966435185185185,0.0,-1.7775286996558015,0.0037878590989011683,0.0,0.0,0.0,0.0,-1.5074588127988509,0.003856289986229618,0.0,1.6267439668174963,1.6267439668174963,1.1653940422322775,67.14231642694928,0.0,67.14231642694928,243.87905034413424,-176.73673391718495,-0.6314660610648498,-32.77946000504668,-35.73101160736815,-35.216754731264196,0.014392452185650289,-1.6719457435848288,-1.7775286996558015,-2.0865591570561213,0.9856075478143497,1.0900427158307995,-32.77946000504668,0.0,0.0,0.0,0.0,-9992.692307692309,0.0,1.5074039295001445,5.436213991769547,1.4966435185185185,0.0,0.2113261878099504,0.047475860747058965,-0.27437900165495166,-0.27816686075385283,0.1037801891299794,-19.100681302043906,1.0138052076727964,0.0,0.0,-72.43643295352436,-72.43643295352436,3.7992448035611095,3.7992448035611095,56.35677491799142,-1.5074588127988509,-2.9103334841914164,-2.7793672088617627,-2.7793672088617627,0.003856289986229618,56.35677491799142,-1.5014760047020792,3.7992448035611095,0.0,PGEN,2023-12-31,2023,FY,-0.7686647590025641,-0.9948468643655809,-0.1919014556469989,-0.1919014556469989,-0.20215099590107424,0.025000000000000022,0.025000000000000022,0.2204792323145851,0.2204792323145851,0,-0.02897993696671535,0.02148094155983364,-0.9561242725021107,-0.9794664722324271,-0.9587811443633556,0.7912072289052933,0.7146625193224604,0.4063159903143851,0.5879724104661164,0.9002686292760843,0.36861242826560675,-0.9458865196271318,-0.8270273859724221,0.20518436872946766,0,0,0,-0.8859026369168357,-1.0,-0.30065238428165963,-0.2310142690148616,-0.8619797744068456,0.030612677549289802,-0.15812606757488648,4067000.0,25525000.0,165787333.0,-3653650.0,-22930764.0,-148937524.0,-0.660215,-0.208,0.093333
0,PRE,5.645,-0.21,13974,68966235,0.0,2.85-7.838,0.145,Prenetics Global Limited,USD,0001876431,KYG722451229,G72245106,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.prenetics.com,"Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.",Mr. Sheng Wu  Yeung,Healthcare,HK,320,852 2210 9588,"Unit 701-706, K11 Atelier King’s Road",Quarry Bay,,,,0.0,https://images.financialmodelingprep.com/symbol/PRE.png,2021-07-16,False,False,True,False,False,12722810.0,31939164,6487722,25439798,2.0090972041553714,-3.8520899864102347,0.29633815171334005,0.29633815171334005,3.3665721644825317,14.155368193032828,10.276388863780879,14.043974326426316,0.009775356230266742,68966235.0,43514793.0,-1.4654382477862564,2.6980657368727066,19.049184073539873,18.292198615796178,0.4019517459084139,0.4019517459084139,1.7023659772120125,-1.0459268508714896,11.54160780679498,11.54160780679498,-0.6823897230133277,0.054668114041603114,0.0,0.0,0.6117539518388234,1.401522027338322,-357.8932218380638,-0.07569587782600906,0.0,0.0,0.0,1.4662219485800483,0.4276416100206241,0.20932373127240583,0.0,0.0,0.0,0.30513467944313766,34.88867566453559,-0.24693926864246757,-0.262904925137121,0.032059132377202836,19802067,130744543,13449169,78391651,13856752.0,5217078.0,5905333.0,167.16050713573088,280.029025336605,286.17438111158754,2.1835301068070314,1.303436311865375,1.2754461059100748,-0.2536967110015729,0.0,0.0,0.0,0.0,0.0,-1.4654382477862564,-0.19737621399871175,0.0,1.401522027338322,1.220401613536417,0.6476231941226718,167.16050713573088,286.17438111158754,453.3348882473184,280.029025336605,173.30586291071342,0.5542958548139962,-1.7413461770933802,-1.9719813443430754,-1.917323849957604,0.008725080038738632,-0.20787268523752628,-0.2536967110015729,-0.238731181324167,0.9722829556464798,1.1324464774917222,-1.7413461770933802,0.0,0.0,0.0,0.0,-357.8932218380638,0.0,1.3194987125978117,2.1835301068070314,1.303436311865375,1.2754461059100748,2.7669600144705595,0.10841813981614154,0.29633815171334005,0.29633815171334005,3.3665721644825317,0.14749816539509905,1.0,0.0,0.0,0.0,0.0,0.4019517459084139,0.4019517459084139,2.6980657368727066,-1.4654382477862564,18.292198615796178,19.049184073539873,19.049184073539873,-0.19737621399871175,2.6980657368727066,-1.0459268508714896,0.4019517459084139,0.0,PRE,2023-12-31,2023,FY,-0.9211540010955417,-0.9328805849141931,-1.2502519539870036,-1.2502519539870036,0.6706602492713873,0.8514772424807028,0.8514772424807028,1.2184476600881973,1.2184476600881973,0,-1.9483506809283566,-2.7960026882391493,0.5492388717767648,0.5492388717767648,-0.7805405519606204,-3.8089543643975725,-3.8089543643975725,-2.1446871068453444,-1.0433233872737007,-1.0433233872737007,-20.01208905510925,7.030352529420941,7.030352529420941,3.3674772083609223,0,0,0,-0.8763061076137235,-0.3568181135627506,-0.17470836559538844,-0.6053473590355628,-0.6434953521302442,-0.24856055984228081,-0.5457249167711702,,,,,,,,,
0,PSNL,5.75,1.945,755768,406226575,0.0,1.12-7.2,0.49,"Personalis, Inc.",USD,0001527753,US71535D1063,71535D106,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.personalis.com,"Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.",Mr. Christopher M. Hall,Healthcare,US,223,650 752 1300,1330 O’Brien Drive,Menlo Park,CA,94025,2.99157,5.37157,https://images.financialmodelingprep.com/symbol/PSNL.png,2019-06-20,False,False,True,False,False,61051350.0,75800000,45156000,297812263,1.4330395642356804,-1.4978047168490132,-0.8316278018422197,-0.8951972397006782,2.3529537020884876,2.7314875101041993,2.7314875101041993,2.7314875101041993,0.007288946108480811,406226575.0,375582575.0,-3.838951724024802,4.643173141766393,-6.91415076223115,-7.43283214096207,2.1050800996635903,2.1050800996635903,4.292911966075735,-6.459302015615863,-7.397435102024739,-6.87213099006459,-0.26048777684330665,-0.1345382192191636,0.00246460503355101,0.0017133066818960593,0.5270181955766519,4.6762694642023455,-2061.3823529411766,0.5552311275876776,0.0,0.0,0.0,0.0,0.5832047457394643,0.0,-0.07643976995194202,0.04435986238269954,0.40943137461757567,0.13037067517059286,9.594414246038436,-0.4193379613988686,-0.3811919778895897,1.3902231482186718,133864000,166761000,97151000,200911000,13197500.0,11193000.0,6591500.0,56.21289533541359,75.72614107883818,51.63367161592428,6.493172035030429,4.82,7.069030510071857,-0.6912209355063043,0.06356943785845849,0.0,0.001011750646791141,0.0,0.0,-3.838951724024802,1.5739702068501675,0.0,4.6762694642023455,4.443138439568286,2.0816741273720925,56.21289533541359,51.63367161592428,107.84656695133788,75.72614107883818,32.120425872499695,0.3140966292905394,-0.8010949947993462,-1.0449770828332705,-1.0451942529918046,-0.00020782289114455724,-0.3811919778895897,-0.6912209355063043,-0.34445187100071756,1.0002078228911446,1.3044359153623353,-0.8010949947993462,0.0017133066818960593,0.00246460503355101,0.0024585456894695283,0.0024585456894695283,-2061.3823529411766,-123.53284671532846,1.4385078045826063,6.493172035030429,4.82,7.069030510071857,1.3048905991319522,0.3647092172564583,-0.8316278018422197,-0.8951972397006782,2.3529537020884876,-0.5803243836368001,1.076439769951942,-123.53284671532846,0.0,-13.082195310486988,-13.082195310486988,2.1050800996635903,2.1050800996635903,4.643173141766393,-3.838951724024802,-7.43283214096207,-6.91415076223115,-6.91415076223115,1.5739702068501675,4.643173141766393,-6.459302015615863,2.1050800996635903,0.0,PSNL,2023-12-31,2023,FY,0.12966009193352498,0.3638951310861423,0.048428560299832946,0.048428560299832946,0.04429245907426201,0.09274193548387095,0.09274193548387095,0.054051122196014184,0.054051122196014184,0,0.1989805362151695,0.44085940946815505,2.532651842424255,-0.1215598359747174,-0.24159320447443172,-88.6024784079261,-5.559353685983233,-0.07065499353600985,-1.0723701181172818,-1.4592069821649207,-1.129548660179142,1.6312144107487714,1.5494261390247817,-0.46101758061517334,0,0,0,0.06537675760124985,-0.3410545920148993,-0.23095661086436625,-0.43704087037038847,0.006413155190133607,-0.0020951596006901652,-0.22265472338163797,83405509.0,87477649.0,122552395.0,-56758423.0,-59529561.0,-83398336.0,-1.43798,-1.03865,-0.80736
0,QDEL,44.84,0.116,835931,3015790428,0.0,29.74-75.86,1.81,QuidelOrtho Corporation,USD,0001906324,US2197981051,219798105,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.quidelortho.com,"QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.",Mr. Brian J. Blaser,Healthcare,US,7100,858 552 1100,9975 Summers Ridge Road,San Diego,CA,92121,21.0447,107.355,https://images.financialmodelingprep.com/symbol/QDEL.png,1991-02-01,False,False,True,False,False,67300000.0,143700000,2755700000,5680880000,41.838038632986624,-27.73551263001486,1.4814264487369986,-1.438335794947994,2.135215453194651,47.35066864784547,-5.643387815750372,47.35066864784547,40.442793462109954,3015790428.0,5627790428.0,-1.6166998821386478,1.0710624100578898,30.26812437311936,-31.15486011523616,0.9469771236702547,0.9469771236702547,1.9987180551905388,-4.00954005984611,56.447246018054166,-58.1383314683712,-0.6185439926408309,-0.03209772075050833,0.7974079769040073,0.37363073620443754,-1.8609290396124252,1.3750608390927674,0.16989485334809076,-0.053412621879352834,0.0,0.0,-0.0069645344476588445,0.06126362893774195,0.08193344461412792,0.5244004646307215,1.9709127281845538,0.06978726391305892,0.42763873558215454,0.015910785950207763,171.89863012032484,0.0050028240367247035,-0.577072899276572,-43.557206537890046,385300000,-379800000,-2201800000,5491000000,324000000.0,242300000.0,589500000.0,43.348368078985686,54.94671457280312,128.2534559405639,8.420155502392344,6.642799352750809,2.8459272097053727,-0.5088252531723207,2.9197622436849926,0.0,0.8425983372078002,0.0,0.0,-1.6166998821386478,4.0843717931484775,-0.0069645344476588445,1.3750608390927674,0.8133943346636815,0.13988124209091793,43.348368078985686,128.2534559405639,171.60182401954958,54.94671457280312,116.65510944674647,0.41680576765990696,0.010903150193557552,-0.7102319139112832,-0.6629257378271833,0.0666066606660666,-0.27445560277014014,-0.5088252531723207,0.0053171221725726555,0.9333933393339334,-65.1400651465798,0.010903150193557552,0.37363073620443754,0.7974079769040073,0.4048001494209936,0.44364328363420513,0.16989485334809076,0.03923497697847389,2.1342140772586062,8.420155502392344,6.642799352750809,2.8459272097053727,1.8293269230769231,0.41400655776271483,1.4814264487369986,-1.438335794947994,2.135215453194651,0.03540860176865433,-0.9709127281845537,0.03923497697847389,0.2667201712145532,0.507379137442133,0.47589499033840094,0.9469771236702547,0.9469771236702547,1.0710624100578898,-1.6166998821386478,-31.15486011523616,30.26812437311936,30.26812437311936,4.0843717931484775,1.0710624100578898,-4.00954005984611,0.9469771236702547,0.0,QDEL,2023-12-31,2023,FY,-0.08211879975505205,-0.228099173553719,-0.8351309707241911,-0.8351309707241911,-1.018407144158921,-1.015527950310559,-1.0156903765690377,0.176056338028169,0.16376306620209058,0.0,-0.6834971196204677,-0.9047555077915099,7.939707718324255,2.656444863224526,0.13765751631514794,4.707084495326767,0.30916034373001033,-0.719428127039636,-1.7149109492111851,-1.0867323089420957,-1.007860237056983,10.714854747790504,6.493087504921733,1.3686556906603946,0,0,0,-0.16712141882673942,0.10246136233543217,-0.03305178527067007,-0.13741462885439756,-0.07455659008036251,0.29553805774278213,0.2289855072463768,2773331503.0,2767333097.0,2881438485.0,1111802511.0,1109397807.0,1155141583.0,1.80788,2.45626,3.35425
0,QGEN,44.67,0.404,970292,9909905490,1.31959,39.03-47.44,0.35,Qiagen N.V.,USD,0001015820,NL0015001WM6,N72482123,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.qiagen.com,"QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",Mr. Thierry  Bernard,Healthcare,NL,5800,31 77 355 6600,Hulsterweg 82,Venlo,,5912 PL,-38.47079,83.14079351162259,https://images.financialmodelingprep.com/symbol/QGEN.png,1996-06-28,False,False,True,False,False,222314000.0,972985000,1919841000,11077704980,8.844130374155474,0.4180258553217521,2.849168293494787,2.067355182309706,6.658887879305847,15.878415214516405,3.206829079590129,15.878415214516405,8.838759592288385,9909905490.0,10856761490.0,106.85941893622287,5.040197607129379,15.678259547528459,21.56192855992794,2.813253048022178,2.813253048022178,5.521770448597123,30.64639568790066,17.140180120301228,23.62209365929652,0.009358089440827224,0.046378040685027766,0.5438652303658307,0.30618511667177284,2.6727789555099517,2.17450166937216,2.578723498526773,6.815770501328914,0.029540855160062683,2.954085516006268,0.0,0.05800809084038341,0.09706923191945373,0.4492795042962765,0.27440046731185175,0.08839909387470285,0.8304807775006451,0.02279859259658606,12.220709156061616,0.017385512982789546,0.02691271618817269,-3.777556744064701,1325505000,712923000,-286130000,4902508000,357340500.0,77539500.0,321724500.0,64.15356168884341,29.141965379128052,118.64310815890195,5.689473668980644,12.524893062340226,3.07645345493769,0.025917944034052284,0.7818131111850806,1.31959,0.19372949640511658,0.029540855160062683,2.9540855160062685,106.85941893622287,3.7994460066212588,0.0,2.17450166937216,1.8894510565601719,0.8621412267581572,64.15356168884341,118.64310815890195,182.79666984774536,29.141965379128052,153.6547044686173,0.4966406838865736,0.059201779700067236,0.058067597272672716,0.04726590830719967,0.1860192167888518,0.014821384399884086,0.025917944034052284,0.02263893408100818,0.8139807832111482,0.9808420889854899,0.059201779700067236,0.30618511667177284,0.5438652303658307,0.2787950258428816,0.35227506887823207,2.578723498526773,0.32992836385929875,1.7762627925146615,5.689473668980644,12.524893062340226,3.07645345493769,2.587302548122727,0.31357451767464406,2.849168293494787,2.067355182309706,6.658887879305847,0.3221535835587288,0.7255995326881483,0.32992836385929875,1.1407510396086857,3.644308662432109,3.644308662432109,2.813253048022178,2.813253048022178,5.040197607129379,106.85941893622287,21.56192855992794,15.678259547528459,15.678259547528459,3.7994460066212588,5.040197607129379,30.64639568790066,2.813253048022178,1.31959,QGEN,2023-12-31,2023,FY,-0.08228135369396848,-0.11674369458088941,-0.16221916983404208,-0.16221916983404208,-0.19353939287967467,-0.19791666666666663,-0.1947368421052631,0.0025002531147841007,0.002098759380151076,0,-0.35764277245884035,-0.47581141063880916,0.5362524737949669,0.3334760493468563,0.05206823229910923,0.8057278008787292,0.30235336019642683,-0.06551480509474246,4.028850725578539,0.826832370594274,3.6404586076671066,0.42772319230832695,0.4725642877797503,0.5353921327326199,0,0,0,0.54607247584838,0.11293161247066712,-0.02744151908437617,0.09567164304761404,-0.1344784979451503,0.04557066033214122,-0.04102857048241148,1979511776.0,2084191053.0,2222292626.0,650810366.0,685226104.0,730630197.0,2.17629,2.28971,2.52196
0,QSI,1.3,2.928,10803790,185526701,0.0,0.612-2.58,0.01,Quantum-Si incorporated,USD,0001816431,US74765K1051,74765K105,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.quantum-si.com,"Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.",Mr. Jeffrey Alan Hawkins,Healthcare,US,159,203 458 7100,530 Old Whitfield Street,Guilford,CT,06437,0.44181,0.8581897780658246,https://images.financialmodelingprep.com/symbol/QSI.png,2020-11-13,False,False,True,False,False,142399000.0,42268000,13825000,97181397,0.015913033097142537,-0.6315634239004487,-0.6031151904156631,-0.6226448219439743,1.3788299075133954,1.4783811684070816,1.4783811684070816,1.4783811684070816,0.0,185526701.0,157083701.0,-2.058383925990171,81.87409576345985,-2.1554754724450707,-2.0924693336641704,0.8793402052061562,0.8793402052061562,69.32202162400706,-1.7757797510711177,-1.829043012004704,-1.771673971397636,-0.4858180183849605,-0.47790425594858177,0.0,0.0,0.32153879198272645,13.415982270890366,0.0,0.9549558565170013,0.0,0.0,0.0,4.458517210944396,25.86672506619594,0.0,-0.0323812628808961,1.2272727272727273,0.5918280485209619,3.5675198587819947,4.5834548249497615,-0.5690459309305194,-0.3803445913370042,1.2164551717357566,190486000,210520000,179894000,220417000,810000.0,1766000.0,4472500.0,164.62047661076787,241.64975399753996,459.1682041820418,2.2172211350293543,1.5104505341384116,0.7949156685406991,-0.3711794628393367,0.019529631528311293,0.0,0.0,0.0,0.0,-2.058383925990171,1.2967818733738066,0.0,13.415982270890366,13.149328640333724,2.755051492634598,164.62047661076787,459.1682041820418,623.7886807928096,241.64975399753996,382.13892679526964,-0.4351279788172992,-46.45984112974404,-39.66946160635481,-39.68843777581642,-0.13789727558932485,-0.3803445913370042,-0.3711794628393367,-0.47612974420203336,1.0004783571214027,0.8538441079807747,-46.45984112974404,0.0,0.0,0.0,0.0,0.0,0.0,1.1231901957058712,2.2172211350293543,1.5104505341384116,0.7949156685406991,0.075707460492466,0.00958325932316645,-0.6031151904156631,-0.6226448219439743,1.3788299075133954,-37.90070609002648,1.0323812628808962,0.0,0.0,-30.882056814095648,-30.882056814095648,0.8793402052061562,0.8793402052061562,81.87409576345985,-2.058383925990171,-2.0924693336641704,-2.1554754724450707,-2.1554754724450707,1.2967818733738066,81.87409576345985,-1.7757797510711177,0.8793402052061562,0.0,QSI,2023-12-31,2023,FY,0,1.1888544891640866,0.10230860538916837,0.10230860538916837,0.31964010975376306,0.3267326732673267,0.3267326732673267,0.014684335042562991,0.014684335042562991,0,-0.03838339222614841,0.01966416915923831,0,0,0,-1.9560850513767971,-1.9560850513767971,0.8901150538187957,-1.587723783880722,-1.587723783880722,0.9002372074435779,6.395111341321783,6.395111341321783,-0.7135247484014563,0,0,0,0,20.150485436893202,-0.23815727294787795,-0.2537393377299696,-0.1228361802132294,-0.06989814326552135,0.05527709476073388,3070500.0,8551500.0,20933000.0,1842300.0,5130900.0,12559800.0,-0.635,-0.79,-0.755
0,QTRX,10.5,1.362,398658,402979500,0.0,9.87-29.7,0.51,Quanterix Corporation,USD,0001503274,US74766Q1013,74766Q101,NASDAQ Global Market,NASDAQ,Medical - Devices,https://www.quanterix.com,"Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.",Dr. Masoud  Toloue Ph.D.,Healthcare,US,441,617 301 9400,Building 1,Billerica,MA,01821,8.48665,22.7666,https://images.financialmodelingprep.com/symbol/QTRX.png,2017-12-07,False,False,True,False,False,38338000.0,47002000,39576000,478699840,3.360399603526527,-1.035839115238145,-0.9167927382753404,-1.0500547759403203,7.743100839897751,8.783765454640305,8.653842140956753,8.783765454640305,1.3554697688976993,402979500.0,395553500.0,-10.136709307010475,3.1279699761703315,-11.452970297029703,-10.01017214397496,1.195387109801872,1.195387109801872,3.070328569987037,-8.966214071992022,-11.253940480254922,-9.825707330402166,-0.09865134430839476,-0.09989838192761666,0.11752268731885779,0.09622454338565677,0.16832895094750203,9.74256106982072,-4.75544794188862,0.8850725221595488,0.0,0.0,0.0,0.7880090971893411,0.22486823047247945,0.012110735056699929,-0.14535677705701605,0.03965660438869527,0.47792329279700657,0.14873749330518277,14.307961990876441,-0.1591341683064242,-0.09773890186484605,6.790612447180343,328187000,331771000,291190000,368772000,31130000.0,5593500.0,27189000.0,90.049444621248,45.165458690622025,176.1347318633456,4.053328718852253,8.081396947614465,2.0722772626308923,-0.11523509052434258,0.1332620376649799,0.0,0.0982084696616081,0.0,0.0,-10.136709307010475,1.081248992747783,0.0,9.74256106982072,8.987000186472734,1.2520844987879272,90.049444621248,176.1347318633456,266.1841764845936,45.165458690622025,221.01871779397158,0.5437744021237124,-0.4573433412765561,-0.3032732804992587,-0.3082487910518431,-0.016406030047861585,-0.0965552119196281,-0.11523509052434258,-0.15764590674490098,1.0164060300478617,0.6631194840461643,-0.4573433412765561,0.09622454338565677,0.11752268731885779,0.09427547847790771,0.10516358070619247,-4.75544794188862,-0.8881140084899939,1.2213379579037393,4.053328718852253,8.081396947614465,2.0722772626308923,3.618441748118189,0.3132379257357375,-0.9167927382753404,-1.0500547759403203,7.743100839897751,-0.27282253494888653,1.145356777057016,-0.8881140084899939,-7.769230769230769,-6.879624192601292,-6.879624192601292,1.195387109801872,1.195387109801872,3.1279699761703315,-10.136709307010475,-10.01017214397496,-11.452970297029703,-11.452970297029703,1.081248992747783,3.1279699761703315,-8.966214071992022,1.195387109801872,0.0,QTRX,2023-12-31,2023,FY,0.1659425261071728,0.5279435937364824,0.31311414237737883,0.31311414237737883,0.6656256463288521,0.6704980842911877,0.6704980842911877,0.016302224070120906,0.016302224070120906,0,0.60842724560822,0.6218207273575785,3.3311240457352094,0.9024029246959729,0.11502199354943674,0.34899015649510934,0.6149650568291856,0.363269488011169,0.12568196560530445,0.39065996541889997,0.19285947785967228,10.842772448571298,3.8842322413366874,0.32471093165538417,0,0,0,0.3363832360519535,0.3323603002502085,-0.021160804147407064,-0.048971862867478816,-0.05985851623435516,-0.03989957512553109,-0.03250672756317477,136648833.0,158411167.0,188426600.0,-66380818.0,-76952453.0,-91533250.0,-0.95167,-0.86167,-0.606
0,RGEN,144.46,0.959,589750,8093617082,0.0,113.5-211.13,-2.08,Repligen Corporation,USD,0000730272,US7599161095,759916109,NASDAQ Global Select,NASDAQ,Medical - Instruments & Supplies,https://www.repligen.com,"Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.",Mr. Olivier  Loeillot,Healthcare,US,1783,781 250 0111,Building 1,Waltham,MA,02453,70.19784,74.26215706994006,https://images.financialmodelingprep.com/symbol/RGEN.png,1986-04-29,False,False,True,False,False,56013038.0,783964000,672471000,8224367315,10.998028708958797,-0.37003884702700823,2.950795134518503,2.3432937167235957,13.996098551198026,36.003867528128005,11.574305253716108,36.003867528128005,9.637738270864723,8093617082.0,7982124082.0,-390.39144446760264,13.138284932787691,48.95629598615708,61.6633048798141,4.012346726004941,4.012346726004941,12.957299498565824,91.45945668289889,48.29367861183546,60.81386676317092,-0.0025615315452513373,0.016217100298939,0.25864561959571297,0.1842714944019806,-1.2774906903466055,10.442112839820608,-0.28526766125493636,-7.974669497249831,0.0,0.0,-0.014666859651662083,0.09899794329199897,0.0678664941650853,0.4834143749620228,0.2058771924517343,0.055237300599156214,0.49958157767239736,0.07712411510422332,17.313684375198324,-0.016277455487741458,-0.014174536850239696,2.820914659190598,1023204000,648312000,317612000,2721429000,126135500.0,21133500.0,186496500.0,76.4479987273409,23.823553681122217,203.53817120503652,4.774487312634663,15.320972046635763,1.7932754226838024,-0.010435436682772694,0.607501417794907,0.0,0.06444671087294712,0.0,0.0,-390.39144446760264,11.945978200708641,-0.014666859651662083,10.442112839820608,8.758328257940683,7.234409316575309,76.4479987273409,203.53817120503652,279.98616993237744,23.823553681122217,256.1626162512552,0.4688433898833342,-0.008442729529099902,-0.00423516272667211,-0.03364592481246946,-6.944039862016098,-0.007322361978404914,-0.010435436682772694,-0.0019105322821548717,7.944423150632426,0.5016343010959431,-0.008442729529099902,0.1842714944019806,0.25864561959571297,0.20549518908967562,0.20549518908967562,-0.28526766125493636,0.3168726646689941,1.403611667855085,4.774487312634663,15.320972046635763,1.7932754226838024,1.8676099208430472,0.21762998102198652,2.950795134518503,2.3432937167235957,13.996098551198026,0.26830218511021325,0.7941228075482657,0.3168726646689941,0.0,4.857264605618902,4.814254922521263,4.012346726004941,4.012346726004941,13.138284932787691,-390.39144446760264,61.6633048798141,48.95629598615708,48.95629598615708,11.945978200708641,13.138284932787691,91.45945668289889,4.012346726004941,0.0,RGEN,2023-12-31,2023,FY,-0.20307509581603322,-0.30826453897907863,-0.5915275802709378,-0.5915275802709378,-0.7764184578321027,-0.7761194029850746,-0.7716049382716049,0.0046880634691669676,-0.018762509790270648,0,-0.33800549734721036,0.934326354648011,4.325318158995376,1.5858465116669351,0.6449231386002255,1.4968152465636562,1.7305591046474362,0.7156918243914181,0.468276930870608,0.9653332461964219,-0.34561621632940503,9.783752716223137,100.4567354153033,27.268631322662014,0,0,0,0.06807917623680611,-0.15090000293775732,0.11873014087452637,0.02685141364509708,0.682906934681921,-0.027631099781500364,0.0105824518484541,634097879.0,696721450.0,798839369.0,167057906.0,183556562.0,210460304.0,1.54082,1.74385,2.25148
0,ROG.SW,247.4,0.145,1064500,200688685315,9.6,212.9-288.2,0.7,Roche Holding AG,CHF,,CH0012032048,H69293217,Swiss Exchange,SIX,Drug Manufacturers - General,https://www.roche.com,"Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.",Dr. Thomas  Schinecker,Healthcare,CH,103605,41 61 688 11 11,Konzern Hauptsitz,Basel,,4070,-216.31101,463.7110128967821,https://images.financialmodelingprep.com/symbol/ROG.SW.png,1995-08-03,False,False,True,False,False,799000000.0,4824000000,36175000000,231180900000,74.70963704630789,13.290362953692116,19.799749687108886,14.294117647058824,11.031289111389237,41.14643304130163,6.973717146433041,36.22277847309137,44.520650813516895,200688685315.0,232039685315.0,18.6149919954798,3.3620137254786995,12.49510745891277,17.57190134970668,6.829956464653444,6.829956464653444,3.887217685742047,13.184073029261365,14.667489590075855,20.316932432799227,0.05372014128412334,0.056909037906515025,1.190000691037247,0.3595619401582695,1.7813068181818181,1.264295650212414,15.684350132625994,1.4897824653922216,0.03880355699272433,3.880355699272433,0.7229494302665035,0.0,0.22121521786474127,0.2850520952957635,0.27806573957016434,0.0736937329335098,1.3022498519834222,0.014306535104618632,104.07599216302393,0.24511462135815998,0.1550626441984755,-51.306320400500624,7030000000,5572000000,-29281000000,58196000000,12576500000.0,3759000000.0,7847000000.0,74.433266882214,92.54761300152362,184.09884459116304,4.903721350529861,3.9439158738107163,1.9826305852737571,0.364557048938325,5.505632040050062,9.6,0.17161405958657594,0.03880355699272433,3.880355699272433,18.6149919954798,0.18614991995479802,0.7229494302665035,1.264295650212414,0.9656002105342306,0.181360201511335,74.433266882214,184.09884459116304,258.53211147337703,92.54761300152362,165.9844984718534,0.7361164625668001,0.2971705225068266,0.2206958939909202,0.17789355535824972,0.12418399878548657,0.11086171256759861,0.364557048938325,0.25639209678118724,0.80605738575983,0.7426574215006483,0.2971705225068266,0.3595619401582695,1.190000691037247,0.4954499494438827,0.5433791395169052,15.684350132625994,0.4593362562062658,3.3095846866146084,4.903721350529861,3.9439158738107163,1.9826305852737571,2.5015924901517055,0.6231912805629215,19.799749687108886,14.294117647058824,11.031289111389237,0.26502269947900087,0.7219342604298357,0.4593362562062658,2.6274705198472015,3.596271879972721,1.310036435905929,6.829956464653444,6.829956464653444,3.3620137254786995,18.6149919954798,17.57190134970668,12.49510745891277,12.49510745891277,0.18614991995479802,3.3620137254786995,13.184073029261365,6.829956464653444,9.6,ROG.SW,2023-12-31,2023,FY,-0.04487918964618132,-0.008100081000810009,-0.15295735900962862,-0.15295735900962862,-0.07430963690524113,-0.07340631036703148,-0.07920154539600764,-0.00125,0.005,0.020615011310471835,-0.10033538289547234,-0.14185035237666815,0.3195845584566491,0.08579456778071272,0.10894784572995461,0.08306191768368845,-0.13895009033577882,-0.05159360819967696,0.09307899654216652,0.1704263662911974,-0.1392887489214613,0.6125630241907287,0.13434684891847196,-0.13679815434795262,0.2661850576345236,0.11849794319281304,0.05480064366172005,-0.06389730275494014,-0.09947704822777455,0.026284443738584927,0.04028207991521497,0.1596594333936106,0.010676156583629894,0.23729940966159474,60753265682.0,64262123182.0,67131634642.0,21018418774.5,22088521184.0,23074845033.0,18.56405,20.47934,21.93464
0,RPID,0.9,1.079,66417,38730799,0.0,0.58-1.34,-0.1,"Rapid Micro Biosystems, Inc.",USD,0001380106,US75340L1044,75340L104,NASDAQ Global Select,NASDAQ,Medical - Devices,https://www.rapidmicrobio.com,"Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.",Mr. Robert G. Spignesi Jr.,Healthcare,US,193,978 349 3200,1001 Pawtucket Boulevard West,Lowell,MA,01854,1.01087,-0.010868732263837489,https://images.financialmodelingprep.com/symbol/RPID.png,2021-07-15,False,False,True,False,False,43668656.0,22044000,6454000,23275103,0.5992856752907624,-1.1082319547457564,-1.0016566573516712,-1.0402426857377978,1.393035773759559,1.9321180848799193,1.9321180848799193,1.9321180848799193,0.05003588844135711,38730799.0,23140799.0,-0.8121043578882114,1.4799693924340849,-0.8985114743604399,-0.8526130189759168,0.4658100387564743,0.4658100387564743,0.8842491020252198,-0.4739927285389484,-0.5290413799410164,-0.5094174921850922,-1.231368838606396,-1.1728650369438545,0.014139594420015882,0.01127141143013709,0.31932979660392047,5.523492462311558,-52.296370967741936,0.9038330406033681,0.0,0.0,-0.0001446430416365327,0.8658005349636989,0.5545662972869698,0.0,-0.03852221028325827,0.06438670233091326,0.5126254943717675,0.1607565915170042,6.941022082167529,-0.6067812046552561,-0.4572338274614287,1.2089563736516187,72014000,84373000,66464000,88997000,4501000.0,2254500.0,21341000.0,52.16278181123423,30.988808690580345,282.78452172645086,6.997326203208556,11.77844568484328,1.2907354255869758,-0.4804737722577154,0.03858602838612665,0.0,0.030802359641483253,0.0,0.0,-0.8121043578882114,-0.19003241974584215,-0.0001446430416365327,5.523492462311558,4.188505025125628,1.3846733668341709,52.16278181123423,282.78452172645086,334.9473035376851,30.988808690580345,303.95849484710476,-0.048223156285823465,-1.9823461979365686,-1.8477646159724876,-1.8492548719908293,-0.0008065183224418894,-0.4572338274614287,-0.4804737722577154,-0.5769158057449151,1.000806518322442,0.9321099502679363,-1.9823461979365686,0.01127141143013709,0.014139594420015882,0.0,0.013942453778369914,-52.296370967741936,-36.664710813076276,1.2544652910291207,6.997326203208556,11.77844568484328,1.2907354255869758,1.5409527174233058,0.24725300681197623,-1.0016566573516712,-1.0402426857377978,1.393035773759559,-1.6714176538020635,1.0385222102832583,-36.664710813076276,-36.664710813076276,-25.95905044510386,-25.8516548463357,0.4658100387564743,0.4658100387564743,1.4799693924340849,-0.8121043578882114,-0.8526130189759168,-0.8985114743604399,-0.8985114743604399,-0.19003241974584215,1.4799693924340849,-0.4739927285389484,0.4658100387564743,0.0,RPID,2023-12-31,2023,FY,0.3143640926866281,0.35772833723653397,0.10528480361916512,0.10528480361916512,0.13714107160477584,0.14685314685314682,0.14685314685314682,0.013417595343408787,0.013417595343408787,0,0.2300032452559482,0.2812351616707767,0.2571805198349483,0.2571805198349483,0.2589658348907853,-0.9651377471173892,-0.9651377471173892,-0.3072472725347534,-1.2845100992344394,-1.2845100992344394,-0.271861402374968,151.0208893653054,151.0208893653054,3.272770816110942,0,0,0,0.018609742747673783,-0.057865672346250056,-0.24756359821662732,-0.2908111039070527,-0.07806224899598393,-0.003575314783149386,-0.08502140482625022,27450000.0,32799999.0,42300000.0,-27450000.0,-32799999.0,-42300000.0,-1.075,-0.895,-0.75
0,RVTY,112.56,1.056,860509,13698777120,0.28,97.32-129.5,2.02,"Revvity, Inc.",USD,0000031791,US7140461093,714046109,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.perkinelmer.com,"Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",Dr. Prahlad R. Singh Ph.D.,Healthcare,US,11000,781 663 6900,940 Winter Street,Waltham,MA,02451,55.9505,56.609500673435335,https://images.financialmodelingprep.com/symbol/RVTY.png,1965-07-06,False,False,True,False,False,122810000.0,1229778000,3315143000,17774342500,22.160695383112124,2.2560947805553293,5.29828189886817,4.595488966696523,10.013663382460711,64.50371305268301,-11.401107401677388,64.50371305268301,26.747194853839265,13698777120.0,15784142120.0,49.89152094589473,5.033437545814801,21.24462271893183,24.272602326125323,1.745015824252897,1.745015824252897,5.799677801844901,19.158023284605264,24.257843493442262,27.967620860000142,0.02004348596797556,0.04119871394768703,0.40228026783641546,0.24955439567784363,2.5311145150092487,3.5590400325609792,3.272362075469774,2.5195330196898413,0.0024875621890547268,0.24875621890547267,0.12471171649144082,0.2776060009810568,0.07247033405534703,0.7299971017414063,0.13264543970787573,0.03171348732617933,0.20147811309479347,0.01852360139699547,57.2219016876705,0.029498729840920574,0.08036014160643135,-24.137832831202672,1760466000,-1400170000,-2399630000,11749574000,599788500.0,175639000.0,403001000.0,80.75584178897725,46.20403352540597,105.96385542168674,4.519796858210951,7.899743207469092,3.44457077885162,0.03517105795549209,0.7027929321716473,0.28,0.23262981593790613,0.0024875621890547268,0.24875621890547267,49.89152094589473,1.2725953168807929,0.12471171649144082,3.5590400325609792,2.9709509550251476,1.7876239206907578,80.75584178897725,105.96385542168674,186.71969721066398,46.20403352540597,140.515663685258,0.48795082223214303,0.11792890461519241,0.09294208641750763,0.10180613656530917,-0.02098463314449272,0.021697471138207466,0.03517105795549209,0.02656475688177843,1.0953717577199966,0.7881196448044867,0.11792890461519241,0.24955439567784363,0.40228026783641546,0.2868087041071718,0.28687579584721357,3.272362075469774,0.20418395704204667,1.6119943178870295,4.519796858210951,7.899743207469092,3.44457077885162,4.078843049770921,0.21312537603554405,5.29828189886817,4.595488966696523,10.013663382460711,0.23908464094975115,0.8673545602921242,0.20418395704204667,622.6622009569378,7.538894681960375,5.383588165210485,1.745015824252897,1.745015824252897,5.033437545814801,49.89152094589473,24.272602326125323,21.24462271893183,21.24462271893183,1.2725953168807929,5.033437545814801,19.158023284605264,1.745015824252897,0.28,RVTY,2023-12-31,2023,FY,-0.16946895092791822,-0.22621982782448752,-0.5953111556633306,-0.5953111556633306,0.21770831320199796,0.23281596452328157,0.23333333333333328,-0.011501724069596925,-0.012766361349722368,0.0008162275302773465,-0.8657389564731321,-0.9833315942360706,0.1429818499077551,-0.12216515112662828,-0.34977329219912234,-0.48193951140429014,-0.7398369050164597,-0.9085180203392136,2.731179469344434,1.5826763439410414,-0.1485146379785997,2.557453333192599,1.7001907222229418,0.8846341363865581,-0.003951898855984776,-0.0002768101512128528,0.001782325377970081,0.03268873004993635,0.05573888551824832,-0.039795563781340935,0.07729964249459055,-0.10931689892126714,-0.02273742537801703,-0.0028892828376794466,2755841796.0,2891313263.0,3078813667.0,838901442.0,880140097.0,937216798.0,4.84448,5.07726,5.72105
0,SCND,0.9,0.131,4471,9453240,0.0,0.182-2.73,-0.0102,"Scientific Industries, Inc.",USD,0000087802,US8087571084,808757108,Other OTC,PNK,"Hardware, Equipment & Parts",https://www.scientificindustries.com,"Scientific Industries, Inc. designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems worldwide. It offers vortex mixers to mix the contents of test tubes, beakers, and other containers by placing such containers on a rotating cup or other attachments; and various mixers and shakers, such as high speed touch mixers, mixers with an integral timer, cell disruptors, microplate mixers, vortex mixers incorporating digital control and display, multi-vessel vortex mixers, and orbital shakers. The company also provides benchtop multi-purpose rotators and rockers to rotate and rock various containers; refrigerated incubators and incubated shakers for shaking and stirring functions; and magnetic stirrers, including high/low programmable magnetic stirrers, four-place high/low programmable magnetic stirrers, large volume magnetic, and four-place general purpose stirrers. In addition, it offers bioprocessing systems comprising disposable sensors, such as coaster systems and other shaking products using vessels; and mechanical balances, moisture analyzers, pill counters, test stands, and force gauges, as well as pharmacy, laboratory, and industrial digital scales. The company's products are used for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, petrochemical companies, and other industries performing laboratory-scale research. The company markets its products under the Genie and Torbal brand names directly, as well as through laboratory equipment distributors and online. Scientific Industries, Inc. was incorporated in 1954 and is headquartered in Bohemia, New York.",Ms. Helena R. Santos CPA,Technology,US,63,631 567 4700,80 Orville Drive,Bohemia,NY,11716,3.13336,8.57336,https://images.financialmodelingprep.com/symbol/SCND.png,1994-04-04,False,False,True,False,False,10145211.0,796100,1331900,24782854,0.8187212666153518,-0.6619872174171636,-0.45718122570343783,-0.447669348621729,0.5642859473302231,1.3686654718171953,1.3573005036563557,1.3686654718171953,0.031946107380122504,9453240.0,9989040.0,-1.3595428677784398,1.1381081373930002,-1.9685847742658789,-2.081432062883942,0.6575748556037276,0.6575748556037276,1.2026149456423592,-1.5572836118732851,-2.153645810874908,-2.199405508950393,-0.7355413526857373,-0.4804384528479125,0.023341063275094703,0.019371805983084786,-0.0835308056872038,6.716758286616231,0.0,0.6906194163192376,0.0,0.0,0.0,0.2644080856238186,0.3340556940080182,0.006891605152266818,-0.020805484886378338,0.011617967517848328,0.17046458222928812,0.17221078484487304,4.515072376321593,-0.46461984628600017,-0.40420819490586934,0.6220200841559629,10503400,13770100,9495600,12974900,1331900.0,903450.0,5083100.0,57.93964676563008,57.19171748750578,392.46681050615354,6.299658703071672,6.382042995644232,0.9300149470709883,-0.5741397734558666,0.009511877081708798,0.0,0.03428454159632042,0.0,0.0,-1.3595428677784398,-0.09214679437164984,0.0,6.716758286616231,4.05856419746367,0.4332988624612203,57.93964676563008,392.46681050615354,450.4064572717836,57.19171748750578,393.2147397842778,0.4531609299189752,-0.8177484017770072,-0.8087911294109149,-0.8085623818639314,0.02801470697688266,-0.4014225516272676,-0.5741397734558666,-0.45606719845298527,0.9997171735214874,0.9890464202111214,-0.8177484017770072,0.019371805983084786,0.023341063275094703,0.0,0.02280868433090538,0.0,-14.311015118790497,1.2048986705460412,6.299658703071672,6.382042995644232,0.9300149470709883,3.5252100840336134,0.49646454080870267,-0.45718122570343783,-0.447669348621729,0.5642859473302231,-0.5584088802205608,0.9791945151136217,-14.311015118790497,-14.311015118790497,-48.064248704663214,-48.064248704663214,0.6575748556037276,0.6575748556037276,1.1381081373930002,-1.3595428677784398,-2.081432062883942,-1.9685847742658789,-1.9685847742658789,-0.09214679437164984,1.1381081373930002,-1.5572836118732851,0.6575748556037276,0.0,SCND,2023-12-31,2023,FY,0.06070296689449769,0.10047021267417282,-0.13326412107014088,-0.13326412107014088,-0.11542805234342393,0.22413793103448268,0.22413793103448268,0.4485700505054255,0.4485710846666121,0.0,-0.0802035802035802,-0.01333010960670535,-0.7766921904167692,-0.839563527585336,-0.5923831981860765,-25.008533597069317,-1.8891251542469416,-10.511601706163617,-15.47431162119345,-3.0727894002440808,-3.061920550849503,-0.6662014075465666,-0.6774899450490114,-0.6275617139386874,-1.0,-1.0,-1.0,0.004265366745372839,0.0050004115565067085,-0.0740873973391185,-0.35200093471865684,0.0,0.27747528299183266,0.07788849394943888,,,,,,,,,
0,SEER,2.31,1.457,258592,136212747,0.0,1.51-2.625,-0.01,"Seer, Inc.",USD,0001726445,US81578P1066,81578P106,NASDAQ Global Select,NASDAQ,Biotechnology,https://seer.bio,"Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","Dr. Omid C. Farokhzad M.D., Ph.D.",Healthcare,US,147,650 453 0000,3800 Bridge Parkway,Redwood City,CA,94065,,0.0,https://images.financialmodelingprep.com/symbol/SEER.png,2020-12-04,False,False,True,False,False,61186324.0,37622000,26499000,109414058,0.23305859982698093,-1.3508901106724438,-0.7328761897838478,-0.8302672342270472,4.046655916116157,5.634053125989396,5.634053125989396,5.634053125989396,0.020413058316757188,136212747.0,125089747.0,-1.7099836483739836,9.552086714732589,-3.151964864189822,-2.6813005058955532,0.4100067834547338,0.4100067834547338,8.772072634787703,-1.3494476304519023,-2.7895666339592347,-2.462348123068444,-0.5848009137110146,-0.3729533477509267,0.0,0.0,0.11999309578519261,18.362094138913996,-79.34587670136109,0.5425135501355014,0.0,0.0,0.0,0.0,3.1244742724035253,0.0,-0.13288880959814459,0.41788221724279223,0.6843918686114621,2.0604489523456486,13.086145331811826,-0.33709265195956634,-0.21557336004006009,3.5431528784111954,249719000,344727000,225405000,293741000,5798500.0,2682000.0,7258000.0,150.91445658586653,22.10483008310705,208.28396280753722,2.4185887042062415,16.512228260869566,1.7524152847873107,-0.22191242948281242,0.09739104444319943,0.0,0.0,0.0,0.0,-1.7099836483739836,1.0943895349593487,0.0,18.362094138913996,17.879927692414658,2.6157268998122785,150.91445658586653,208.28396280753722,359.19841939340375,22.10483008310705,337.0935893102967,0.14775590096464944,-6.949719982448807,-5.79635384266156,-5.79635384266156,-0.1725673151374371,-0.21557336004006009,-0.22191242948281242,-0.26854197772063265,1.0,0.834041350917732,-6.949719982448807,0.0,0.0,0.0,0.0,-79.34587670136109,0.0,1.112254044504782,2.4185887042062415,16.512228260869566,1.7524152847873107,0.323928921902685,0.037191200863795695,-0.7328761897838478,-0.8302672342270472,4.046655916116157,-3.144600501023878,1.1328888095981446,0.0,0.0,-7.5250881020305425,-7.5250881020305425,0.4100067834547338,0.4100067834547338,9.552086714732589,-1.7099836483739836,-2.6813005058955532,-3.151964864189822,-3.151964864189822,1.0943895349593487,9.552086714732589,-1.3494476304519023,0.4100067834547338,0.0,SEER,2023-12-31,2023,FY,0.03384405856315969,0.04227232275289232,-0.06405101043862807,-0.06405101043862807,0.027283899117219297,0.04929577464788722,0.04929577464788722,0.022694137531332682,0.022694137531332682,0,0.02821651859164199,0.06574706172144415,0,0,21.07786159382149,-3.2672082854841618,-3.2672082854841618,-1.7052941787447553,-3.5965519975177926,-3.5965519975177926,-1.6406085507646506,3.4492443416025607,3.4492443416025607,-0.12274299992521864,0,0,0,-0.043032202906811055,-0.02939269505078885,-0.10587605983657458,-0.13176160478102186,-0.05406038695855928,0.15769591894665588,0.0071585997163896055,14118778.0,19028104.0,28645551.0,-14118778.0,-19028104.0,-28645551.0,-1.39,-1.57,-1.32
0,SERA,8.78,1.044,90990,288025257,0.0,4.9-12.355,0.65,"Sera Prognostics, Inc.",USD,0001534969,US81749D1072,81749D107,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://seraprognostics.com,"Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.",Ms. Evguenia  Lindgardt M.B.A.,Healthcare,US,55,801 990 0520,2749 East Parleys Way,Salt Lake City,UT,84109,10.05532,-1.27532054472834,https://images.financialmodelingprep.com/symbol/SERA.png,2021-07-15,False,False,True,False,False,33522726.0,2684000,1100000,259893262,0.0028040679030696966,-0.9618549219416106,-0.43832950816708643,-0.46983052631220984,1.4841275139736547,1.6302671805389575,1.6006753150086899,1.6302671805389575,0.0009844068170351062,288025257.0,286441257.0,-9.128195738996268,3064.0984787234042,-20.030593050224578,-18.287317904761903,5.385620286545533,5.385620286545533,3047.247414893617,-9.16993491692544,-19.493756431196406,-18.186746476190475,-0.10955067448082126,-0.05468270444074285,0.0,0.0,0.05070909498351314,2.1134314779588124,-1089.1818181818182,0.45571270486641563,0.0,0.0,0.0,167.90425531914894,156.5212765957447,0.012556803078442045,-0.07186606778276848,11.23404255319149,1.0841889117043122,71.73404255319149,5.939849452033994,-0.656621697313034,-0.413336909843736,0.7595220627343969,26925000,53659000,26757000,30104000,90000.0,1165000.0,0.5,306.75531914893617,605.9879518072289,0.0,1.1898734177215189,0.602322206095791,0.0,-0.5173276697471442,0.0315010181451234,0.0,0.0,0.0,0.0,-9.128195738996268,8.945631824216335,0.0,2.1134314779588124,2.1134314779588124,0.11099164667934827,306.75531914893617,0.0,306.75531914893617,605.9879518072289,-299.23263265829274,-7.829787234042553,-382.3723404255319,-343.0212659574468,-343.0212659574468,0.0016127652156297362,-0.40814671966177646,-0.5173276697471442,-0.6556668308433208,1.0,0.897087026681134,-382.3723404255319,0.0,0.0,0.0,0.0,-1089.1818181818182,0.0,1.4455545186730343,1.1898734177215189,0.602322206095791,0.0,0.04298125285779607,0.001189858356223339,-0.43832950816708643,-0.46983052631220984,1.4841275139736547,-156.31914893617022,1.0718660677827685,0.0,0.0,-13.914772727272727,-13.914772727272727,5.385620286545533,5.385620286545533,3064.0984787234042,-9.128195738996268,-18.287317904761903,-20.030593050224578,-20.030593050224578,8.945631824216335,3064.0984787234042,-9.16993491692544,5.385620286545533,0.0,SERA,2023-12-31,2023,FY,0.1417910447761194,0.28,0.12772715324629808,0.12772715324629808,0.18091622030872148,0.18881118881118883,0.18881118881118883,0.008312783464894934,0.008312783464894934,0,0.21444669170759895,0.22838337900059322,7.363359361849233,7.363359361849233,11.043237481062897,-0.38433775938459297,-0.38433775938459297,-0.5858989128733622,-0.7446742242606544,-0.7446742242606544,-0.6503631447986076,1.6474169441033235,1.6474169441033235,1.549734683826334,0,0,0,0.8763291346311141,-1,-0.17955969706607983,-0.29677086956278637,-0.19636678200692043,0.06887110362257792,-0.21570371311501446,112000.0,4800000.0,17900000.0,-112000.0,-4800000.0,-17900000.0,-0.975,-0.995,-1.03
0,SHC,13.24,2.082,1236222,3750084360,0.0,10.71-17.44,-0.03,Sotera Health Company,USD,0001822479,US83601L1026,83601L102,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://soterahealth.com,"Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.",Mr. Michael B. Petras Jr.,Healthcare,US,3000,440 262 1410,9100 South Hills Boulevard,Broadview Heights,OH,44147,18.8375,-5.597501342925283,https://images.financialmodelingprep.com/symbol/SHC.png,2020-11-20,False,False,True,False,False,283059000.0,306738000,2357606000,6777953300,3.9584574240706,0.2499337593929181,0.8814982000219036,0.2525621866819285,1.08365393787161,1.6610070691975878,-3.484676339561717,1.6610070691975878,8.421463369827492,3750084360.0,5800952360.0,52.97403612925112,3.3468642015855745,15.019883193943008,52.4560688208141,7.971067821159896,7.971067821159896,5.177216810340596,15.919407126881543,23.248819247057583,81.14354958735487,0.018877172159585957,0.019063571145903502,4.750945948532743,0.7094015791093381,5.628145281905624,2.8823854308903174,2.3320049049662783,3.5390332321570406,0.0,0.0,0.0,0.0,0.0,0.46257658229315435,0.7134853064071455,0.15888411721079504,1.0754128801150162,0.03287617684254117,3.0562541086454567,0.06804030669932173,0.04180699146970964,-7.816577992573986,368076000,-986369000,-2114961000,2879902000,168591500.0,67620499.5,57700000.0,57.532412535018565,47.013566011425155,35.646560983335576,6.344249857032042,7.763716538994262,10.239416929185229,0.16023528172710558,0.6289360133399751,0.0,0.5956450003700716,0.0,0.0,52.97403612925112,0.674215005281378,0.0,2.8823854308903174,2.6080281481254186,1.5686954387149235,57.532412535018565,35.646560983335576,93.17897351835414,47.013566011425155,46.165407506928986,0.5097498654590857,0.31229735193136493,0.12010956048183051,0.06313918090241924,0.4742458017536038,0.022468056239692297,0.16023528172710558,0.11848909657320872,0.5256798930004458,0.3845999965706643,0.31229735193136493,0.7094015791093381,4.750945948532743,0.82463004172358,0.826115562735356,2.3320049049662783,0.11170429181110068,6.697117808079326,6.344249857032042,7.763716538994262,10.239416929185229,1.0617676211558107,0.3558496628965836,0.8814982000219036,0.2525621866819285,1.08365393787161,0.22268730103339918,0.28651469359285453,0.11170429181110068,10.89399227209221,1.4015705593653205,1.4015705593653205,7.971067821159896,7.971067821159896,3.3468642015855745,52.97403612925112,52.4560688208141,15.019883193943008,15.019883193943008,0.674215005281378,3.3468642015855745,15.919407126881543,7.971067821159896,0.0,SHC,2023-12-31,2023,FY,0.04543348673441023,0.03618286403688304,0.1141211999194685,0.1141211999194685,1.219959755105536,1.216867469879518,1.216867469879518,0.003256026505198218,0.01116045927110705,0.0,-1.5314846327362472,-4.794681062532041,0.2318386595255006,0.2318386595255006,0.29272364617291524,-2.0823368839495706,-2.0823368839495706,-2.2348933663416752,8.666671794632533,8.666671794632533,2.381279071744058,7.762451847241202,7.762451847241202,-0.016065286835339487,-1.0,-1.0,0.0,0.12716659067410752,0.39951541257235157,0.004078320431214627,0.2628380684151021,0.19121785913560718,0,-0.03681922885956844,1101396092.0,1159898237.0,1231976519.0,355690224.0,374583192.0,397860504.0,0.69323,0.78962,0.89826
0,SOPH,3.26,1.032,24101,213122826,0.0,2.7-7.37,0.16,SOPHiA GENETICS SA,USD,0001840706,CH1125843347,H82027105,NASDAQ Global Select,NASDAQ,Medical - Healthcare Information Services,https://www.sophiagenetics.com,"SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.","Dr. Jurgi  Camblong M.B.A., Ph.D.",Healthcare,CH,430,41 21 694 10 60,Rue du Centre 172,Saint-Sulpice,,1025,,0.0,https://images.financialmodelingprep.com/symbol/SOPH.png,2021-07-23,False,False,True,False,False,66383160.0,95787000,31673000,178184534,0.9714511933448182,-1.0755137296868664,-0.6587336457017111,-0.7510345696107266,1.4429412519681197,1.7098764204656722,1.2526218998914784,1.7098764204656722,0.19827317651042825,213122826.0,149008826.0,-3.0311096083814215,3.3048447152958693,-4.948889465828498,-4.274763735785877,1.906570533975878,1.906570533975878,2.3106442438903363,-2.2700572549177687,-3.407565596154536,-2.988781341032085,-0.32991218702051117,-0.23393105720172835,0.11595760613882844,0.07410702220620692,0.9767371151679151,3.7979261179520414,0.0,0.6136000477085848,0.0,0.0,0.0,0.7374550303932514,0.5424730182359508,0.17090446376289356,-0.14011873313483572,0.09501344436174172,0.739110615199035,0.18612765165612208,6.432526738480761,-0.5437820635009969,-0.4848493079984245,0.6363963390715356,86344000,83153000,53103000,138484000,9843000.0,5595000.0,6511000.0,55.252605135839225,103.21793389226173,113.91081237351835,6.606023355869699,3.536207190322031,3.2042612320518757,-0.5506571234651694,0.09230092390901548,0.0,0.06175781471666484,0.0,0.0,-3.0311096083814215,0.44167597150700677,0.0,3.7979261179520414,3.5880427738172394,3.1039209332469215,55.252605135839225,113.91081237351835,169.16341750935757,103.21793389226173,65.94548361709585,0.6781726832899144,-1.0589101848405904,-1.097584046644337,-1.1071207046272176,-0.00868877241067518,-0.40198639700914374,-0.5506571234651694,-0.4653351323357047,1.0086887724106752,1.0365223248934643,-1.0589101848405904,0.07410702220620692,0.11595760613882844,0.10390861220977508,0.10390861220977508,0.0,-3.3223538216076585,1.5647316905565296,6.606023355869699,3.536207190322031,3.2042612320518757,2.9600660974938036,0.3630917526237557,-0.6587336457017111,-0.7510345696107266,1.4429412519681197,-0.6780923737749659,1.1401187331348357,-3.3223538216076585,0.0,-7.136804463095622,-7.136804463095622,1.906570533975878,1.906570533975878,3.3048447152958693,-3.0311096083814215,-4.274763735785877,-4.948889465828498,-4.948889465828498,0.44167597150700677,3.3048447152958693,-2.2700572549177687,1.906570533975878,0.0,SOPH,2023-12-31,2023,FY,0.311417157275021,0.3730402508478915,0.14799084522277764,0.14799084522277764,0.09683358300266441,0.10294117647058831,0.10294117647058831,0.010166614682149062,0.010166614682149062,0,0.30699213901530825,0.2817431717076323,0,0,1.1658641353770305,0,0,-0.5097657881918325,0,0,-0.98000439809598,0,0,0.48594900730256674,0,0,0,1.2868100466235524,0.25717610550814585,-0.15453702868297806,-0.25089770121583943,0.11097174938780385,0.045178253371405956,-0.028055611716993924,65509214.0,76248446.0,95183039.0,-65509214.0,-76248446.0,-95183039.0,-0.88833,-0.775,-0.58667
0,STSS,1.88,1.189,196405,3379855,0.0,1.7-18.15,-0.01,"Sharps Technology, Inc.",USD,0001737995,US82003F1012,82003F101,NASDAQ Capital Market,NASDAQ,Medical - Instruments & Supplies,https://sharpstechnology.com,"Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.",Mr. Robert M. Hayes,Healthcare,US,57,631-574-4436,105 Maxess Road,Melville,NY,11747,1.64882,0.23118034405258703,https://images.financialmodelingprep.com/symbol/STSS.png,2022-04-14,False,False,True,False,False,1331000.0,2473197,2334142,4266555,0.0,-5.91390833959429,-5.660779864763336,-6.063214876033058,1.8581495116453794,4.8878309541697975,4.85760781367393,4.8878309541697975,1.9688437265214125,3379855.0,3240800.0,-0.3178946801412504,0.0,-0.33210971719681914,-0.41881001058346085,0.3846286865539358,0.3846286865539358,0.0,-0.390959012517251,-0.4301281916857633,-0.4015792045217561,-3.1456959253161116,-2.3877175204261722,0.35878397768849885,0.20740742452081937,0.01677511894766303,1.0147878579083531,-30.37309044690962,0.9571977683292401,0.0,0.0,0.0,0.0,0.0,0.00357449481059807,-0.07109179669302454,0.0,0.6555214521209807,0.0,25.502728196289457,-0.9802764020681869,-0.7019478277898469,-0.950606686701728,67820,6465476,-94180,6341642,0.0,911836.5,1952656.5,0.0,554.3417422057189,1183.8547160780938,0.0,0.6584385988103106,0.30831485911479234,-1.1040693612698336,0.40243501126972203,0.0,0.6906041827238151,0.0,0.0,-0.3178946801412504,0.00150277485157682,0.0,1.0147878579083531,0.5744487532693224,0.5392699176550495,0.0,1183.8547160780938,0.0,554.3417422057189,0.0,0.0,0.0,0.0,0.0,0.003796916297998383,-0.6994387189221015,-1.1040693612698336,-1.3045750538078855,0.9962032102616596,0.9083629063752117,0.0,0.20740742452081937,0.35878397768849885,0.0,0.2640478424678261,-30.37309044690962,-3.2279518555426363,1.7298511782662074,0.0,0.6584385988103106,0.30831485911479234,0.0,0.0,-5.660779864763336,-6.063214876033058,1.8581495116453794,0.0,1.0710917966930245,-3.2279518555426363,-3.2279518555426363,-14.066320539316445,-14.066320539316445,0.3846286865539358,0.3846286865539358,0.0,-0.3178946801412504,-0.41881001058346085,-0.33210971719681914,-0.33210971719681914,0.00150277485157682,0.0,-0.390959012517251,0.3846286865539358,0.0,STSS,2023-12-31,2023,FY,0,-0.36157366951229203,-0.15881563964268292,-0.15881563964268292,-13.619345159863313,-8.892004153686397,-8.892004153686397,0.6088074554250957,0.6088959694632741,0,-0.32241407370780045,-0.2811325977499962,0,0,0,-2.804865928576436,-2.804865928576436,-2.1797183771989914,-2.369894896950449,-2.369894896950449,-1.951169488514214,8.955831346415437,8.955831346415437,1.6207784330279897,0,0,0,0,8.198590988353319,-0.004255866893430012,-0.4884646376334987,0,-0.296100762275788,0.3194932996379606,44600000.0,63000000.0,72400000.0,0.0,0.0,0.0,-3.3,0.0,0.0
0,STVN,20.56,0.584,510758,5605483602,0.058,16.56-34.73,-0.78,Stevanato Group S.p.A.,USD,0001849853,IT0005452658,T9224W109,New York Stock Exchange,NYSE,Medical - Instruments & Supplies,https://www.stevanatogroup.com,"Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.",Mr. Franco  Stevanato,Healthcare,IT,5635,39 04 99 31 811,"Via Molinella, 17",Piombino Dese,PD,35017,36.65717,-16.09717179166849,https://images.financialmodelingprep.com/symbol/STVN.png,2021-07-16,False,False,True,False,False,272870175.0,77996000,361812000,5184018602,3.984462684498223,0.4203317566678,0.7871560788935618,-0.9653659547072156,0.28583556264439675,0.0,-0.18317502086844045,4.845699974355937,1.281187077334487,5369492742.3558,5653308742.3558,46.85447551269617,4.93864064563108,25.019719123153784,-20.38380291817035,4.064309409213407,4.064309409213407,5.199683038411271,20.159107190941,26.319993700473606,-21.46123233033587,0.02134267834732308,-0.04905855909294476,0.2602804165938739,0.15545591986423607,1.0120581463449145,1.8100913719629146,28.03225451436059,1.1975335476531996,0.0029449960049605923,0.2944996004960593,0.2144590395480226,0.08457830183248327,0.030726021257678253,0.022577481781680092,2.2286344104708804,0.440280977070926,3.9688826722170654,0.0018174442883193986,6.769640729491355,0.06799415611182966,0.05300527760576008,-7.302197830891559,386463000,-49983000,-1350319000,436446000,243222000.0,128471000.0,294684000.0,0.0,0.0,131.5952562281082,0.0,0.0,2.7736562127080497,0.08974192269759247,1.7542831238335226,0.058,0.06409450883231964,0.0029449652609866805,0.29449652609866805,46.85496465013758,-5.505458346391168,0.2144590395480226,1.8100913719629146,1.20935058619338,0.16349271896046838,0.0,131.5952562281082,131.5952562281082,0.0,131.5952562281082,0.2688814052574892,0.14032981168858205,0.14092561701796702,0.1054927075369847,0.257364697283574,0.051808551916283134,0.08974192269759247,0.08784771433605369,0.7485701306068088,1.004245750223817,0.14032981168858205,0.15545591986423607,0.2602804165938739,0.17287085308501574,0.20652579629645187,28.03225451436059,0.6241124406154204,1.6743036664102848,0.0,0.0,2.7736562127080497,0.0,0.4911102684336694,0.7871560788935618,-0.9653659547072156,0.28583556264439675,0.197556393728077,-1.2263971283359054,0.6241124406154204,3.167828107486284,0.4487052678095882,0.42677538855761155,4.064351838584001,4.064351838584001,4.938692202585309,46.85496465013758,-20.384015714943693,25.019980316588626,25.019980316588626,-5.505458346391168,4.938692202585309,20.159307076618468,4.064351838584001,0.058,STVN,2023-12-31,2023,FY,0.10333841618379587,0.06282989368355223,0.3155324852369623,0.3155324852369623,0.019475110081274633,0.03773584905660381,0.03773584905660381,0.0009530770481563581,0.0010504969596068078,0.0772077130455275,0.018489835430784123,-1.4081114520085534,0,0,0.6378549219490884,0,0,-0.32473003134548994,0,0,0.8530986536651846,0,0,2.6440285301187085,0,0,0.7221726192577186,0.5003874730745751,0.1970042194092827,0.2483380215828205,0.13647711007523455,0.8161664361668025,0.11072674418604651,0.021395348837209303,1135391549.0,1215886542.0,1367954826.0,275956443.0,295520717.0,332480850.0,0.49192,0.56644,0.72785
0,TBIO,0.47,1.758,528366,834645,0.0,0.346-15.462,0.07,"Telesis Bio, Inc.",USD,0001693415,US1920031010,89374L104,NASDAQ Global Select,NASDAQ,Medical - Devices,https://codexdna.com,"Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.",Mr. Eric  Esser,Healthcare,US,137,16179457361,29 Hartwell Ave,Lexington,MASSACHUSETTS,92121-2993,5.65791,43.0179,https://images.financialmodelingprep.com/symbol/TBIO.png,2021-06-18,False,False,True,False,False,1732238.0,3720000,16291000,19274761,7.812436859138294,-26.296040151526523,-13.193337174222018,-13.707122808759536,2.6058774833481313,2.2364132411366104,-0.15067213627688575,2.2364132411366104,4.680650118517201,834645.0,13405645.0,-0.017873413536475598,0.06167479494568831,-0.035624042180799856,-0.03515182931063971,0.2101579401135777,0.2101579401135777,0.9905893002290695,-0.4873362294605206,-0.5865776231731863,-0.5645908677809497,-55.9490215989926,-28.448021613979595,1.5067114093959733,0.2359623236447427,-0.45699432892249525,1.2251054616777308,-13.458388375165125,0.501723343066014,0.0,0.0,0.0,1.296164930170694,0.7821621222197591,0.1671585074988883,-0.03894285464251335,0.06576516662971994,0.2249747219413549,0.20815783639991134,36.3757924813675,-3.1478586997173372,-2.2109989321425103,-8.574456858699556,1491999,-261000,-12743001,17617999,1298000.0,1514500.0,1228000.0,34.0375378703909,60.84691826708352,44.789526574363556,10.723454833597465,5.9986604152712655,8.149226569608736,-2.802836617595028,0.5137862118253959,0.0,6.993392400361831,0.0,0.0,-0.017873413536475598,0.00044308041960170597,0.0,1.2251054616777308,1.059293753771877,0.5612552806276403,34.0375378703909,44.789526574363556,78.82706444475446,60.84691826708352,17.98014617767094,0.3382103007463238,-2.258479272888495,-3.255745215399394,-3.365920342865588,-0.00015887426236949615,-1.8414116505639326,-2.802836617595028,-1.6877795571262908,1.0338402178847026,1.4415652401518126,-2.258479272888495,0.2359623236447427,1.5067114093959733,0.6010709504685409,0.6010709504685409,-13.458388375165125,-3.915367483296214,6.3853897780072275,10.723454833597465,5.9986604152712655,8.149226569608736,1.1285964473355017,0.5470752314346929,-13.193337174222018,-13.707122808759536,2.6058774833481313,-1.6887608069164266,1.0389428108864969,-3.915367483296214,0.0,-25.67865168539326,-25.67865168539326,0.2101579401135777,0.2101579401135777,0.06167479494568831,-0.017873413536475598,-0.03515182931063971,-0.035624042180799856,-0.035624042180799856,0.00044308041960170597,0.06167479494568831,-0.4873362294605206,0.2101579401135777,0.0,TBIO,2023-12-31,2023,FY,0.002697284490614179,0.0868868226995832,-0.0011616650532429815,-0.0011616650532429815,0.015411276845949125,0.006060606060606067,-16.915151515151518,0.01311700318235927,-0.9437156881049653,0,0.10455895647681777,0.15135585762915962,0,28.207925449588203,3.096227644646705,-0.4619174006767695,-1.3615123924906776,-1.2070022389202395,-0.7878980386421688,0.2612211945746926,-1.5947421673897546,1.765580648384197,-0.6445638482601223,2.136085012378545,0,0,0,0.022902068022560246,0.8295454545454546,-0.13459600304810598,-0.3738738034255563,0.6045176646287395,-0.25421994884910487,-0.10398757120662869,,,,,,,,,
0,TECH,73.17,1.278,893080,11626127640,0.32,61.16-85.57,1.78,Bio-Techne Corporation,USD,0000842023,US09073M1045,09073M104,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.bio-techne.com,"Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.",Mr. Kim  Kelderman,Healthcare,US,3100,612 379 8854,614 McKinley Place N.E.,Minneapolis,MN,55413,33.95707,39.21293303446365,https://images.financialmodelingprep.com/symbol/TECH.png,1989-02-09,False,False,True,False,False,158531000.0,187540000,398918000,12882760830,7.390239133040225,0.9506784162088172,1.9143700601144256,1.5456283061357086,1.1829862929017039,13.490421431770443,4.226687524837414,13.490421431770443,2.0595593290902094,11626127640.0,11837505640.0,76.96608942884443,9.923443378269724,38.22145024333827,47.44777207914226,5.423848348257078,5.423848348257078,10.103864381665133,34.026380715854344,39.00498420031171,48.31043379051368,0.01299273494886999,0.021075805168091204,0.14658078694503543,0.11457713895783542,0.6075966104423212,4.563259878419453,17.58668100468546,2.013875432985176,0.004373377067104004,0.43733770671040045,0.334764318700568,0.0,0.08239713481429384,0.5367616502382844,0.1926178024099879,0.049895781089159784,0.5251823678441802,0.03254829794244022,16.987162235546073,0.07981873662932586,0.11891168571311349,-0.9432886943247693,506439000,670061000,51200000,2318188000,232541000.0,34763500.0,182386000.0,69.68877978664746,28.664512500715425,168.06964915380345,5.237571975251242,12.73351500364397,2.17171870017996,0.07364887432969346,0.3687417539787171,0.32,0.026963836086010835,0.004373377067104004,0.4373377067104004,76.96608942884443,-7.416732254052276,0.334764318700568,4.563259878419453,3.261327817178881,1.3195148035573567,69.68877978664746,168.06964915380345,237.75842894045093,28.664512500715425,209.0939164397355,0.6569962665865471,0.19542891577371452,0.15048199784564803,0.1286397366979008,0.14515433744370454,0.055084453057126476,0.07364887432969346,0.088269390093408,0.8548513346416944,0.7700088661387747,0.19542891577371452,0.11457713895783542,0.14658078694503543,0.12301888339860169,0.12784165635252545,17.58668100468546,0.9681069269662025,1.2793196642741917,5.237571975251242,12.73351500364397,2.17171870017996,3.4140983797645412,0.42820713467789123,1.9143700601144256,1.5456283061357086,1.1829862929017039,0.2590403403261573,0.8073821975900121,0.9681069269662025,22.505524657026324,5.191628123092668,2.786585279465479,5.423848348257078,5.423848348257078,9.923443378269724,76.96608942884443,47.44777207914226,38.22145024333827,38.22145024333827,-7.416732254052276,9.923443378269724,34.026380715854344,5.423848348257078,0.32,TECH,2024-06-30,2024,FY,0.019669183303979407,-0.00011691120593908926,-0.3086129843716549,-0.3086129843716549,-0.4107017033404262,-0.4088397790055249,-0.4034090909090909,0.00336558955076696,-0.006678817460072287,-0.0006984283479216182,0.17527211833658946,0.09232057515880249,2.0312755531644866,0.5555492754489683,0.22344840754627288,1.0454697878280228,0.5774733318024078,-0.16566015975500606,0.417673023929125,0.6767314682844234,0.17659484562046052,1.4340643561256259,0.7008392890061839,0.29399466358354487,0.03922765855090141,-0.0010316446775520457,-0.0014626522434989838,0.10493985389164545,0.04715156317365618,0.0246997375972641,0.04850937175981589,-0.07786752827140549,0.04509530450953045,0.0487554773269059,1222064202.0,1335184551.0,1483033928.0,448922724.0,490477247.0,544789406.0,1.8776,2.18287,2.49238
0,TEM,35.54,2.95,1883233,5416363526,0.0,22.89-79.49,2.51,"Tempus AI, Inc.",USD,0001717115,US88023B1035,71535D106,Nasdaq,NASDAQ,Medical - Diagnostics & Research,https://www.tempus.com,"Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.",Mr. Eric P. Lefkofsky,Healthcare,US,2300,(800) 976-5448,600 West Chicago Avenue,Chicago,IL,60654,,0.0,https://images.financialmodelingprep.com/symbol/TEM.png,2012-03-28,True,False,True,False,False,165612000.0,388006000,471545000,9457178200,3.8671231553269085,-4.4880684914136655,-1.1476281911938748,-1.2494807079197159,2.815756104630099,0.3244209356809893,-0.2048523053884984,0.3244209356809893,2.9762637973093735,5416363526.0,5499902526.0,-7.9187739821692205,8.457227236814575,-30.96821799317061,-26.17498539197012,109.54903365098274,109.54903365098274,8.587666839463994,-8.44862457948146,-28.937564918631384,-26.578693912301773,-0.1262821747724723,-0.03820441482679019,8.170544222751637,0.45175913424332736,-0.12832766497383952,2.6894624336948776,-12.846860028190957,0.2557064789428807,0.0,0.0,-0.0075678279292106425,0.0,0.47484862017169394,0.09020425468855482,-0.08875044854020551,0.02633805871569947,0.4643250110107906,0.7624624868450226,5.723681161294514,-1.4065160381278206,-0.840741837221771,-1.9587711035432216,426792000,-33926000,-238588000,587979000,131861000.0,38836500.0,34413999.5,82.9893105074308,57.92714942379904,42.69833613880616,4.3981567959564885,6.3010178065147775,8.548342464995295,1.8939347295559263,0.10185251672584113,0.0,0.08104828966754991,0.0,0.0,-7.9187739821692205,2.544566039603719,-0.0075678279292106425,2.6894624336948776,2.5464096271079093,1.5359274800095004,82.9893105074308,42.69833613880616,125.68764664623697,57.92714942379904,67.76049722243793,0.517645625989551,-1.0815608579699645,-1.1573694417293057,-1.1605703545363983,-0.0004829822942468444,-0.7649033464096949,1.8939347295559263,-0.963244740706542,1.0027656793860997,1.070091833668639,-1.0815608579699645,0.45175913424332736,8.170544222751637,0.8909552175192555,0.8909552175192555,-12.846860028190957,-0.4329535954367669,18.086063132817152,4.3981567959564885,6.3010178065147775,8.548342464995295,8.709586172194797,0.6590753791184364,-1.1476281911938748,-1.2494807079197159,2.815756104630099,-0.29676535892399314,1.0887504485402055,-0.4329535954367669,0.0,-11.267548687903052,-8.449784753024709,109.54903365098274,109.54903365098274,8.457227236814575,-7.9187739821692205,-26.17498539197012,-30.96821799317061,-30.96821799317061,2.544566039603719,8.457227236814575,-8.44862457948146,109.54903365098274,0.0,TEM,2023-12-31,2023,FY,0.6584816695148876,1.351826893049095,0.2714542083576389,0.2714542083576389,0.2611805625045288,0.15551711858371067,-1.136643434908684,-0.05883335801107957,-0.6273408173668669,0.06251109568306618,-0.27428004090271335,-0.3342569715029933,7.614170156446194,7.614170156446194,2.005610390887213,-0.8396763903650564,-0.8396763903650564,-0.10251433340891707,-0.45280402849591045,-0.45280402849591045,-0.0841001400281471,-5.794902027089318,-5.794902027089318,-5.242294361018782,0.06962930280264433,0.06962930280264433,0.06251109568306618,0.11976230210635515,0.2945426801902881,-0.10661361750115622,-13.27397383016401,0.12727323112308875,0.15302088513177522,0.2905694840070452,698480000.0,900300000.0,1167139360.0,-522679959.0,-673703996.0,-873382707.0,-1.51,-0.68,-1.17939
0,TKNO,7.73,0.359,231800,412068521,0.0,1.155-8.909,0.49,"Alpha Teknova, Inc.",USD,0001850902,US02080L1026,02080L102,NASDAQ Global Market,NASDAQ,Drug Manufacturers - Specialty & Generic,https://www.teknova.com,"Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.",Mr. Stephen  Gunstream,Healthcare,US,210,831 637 1100,2290 Bert Drive,Hollister,CA,95023,,0.0,https://images.financialmodelingprep.com/symbol/TKNO.png,2021-06-25,False,False,True,False,False,44520132.0,6145000,30586000,239918438,0.816417166058717,-0.7116330877006385,-0.32333686701557846,-0.34287858805090693,0.711835265897235,1.9601918520816606,1.6596985831039315,1.9601918520816606,0.32306732603578087,412068521.0,436509521.0,-10.862339221713883,11.337071037499657,-23.906955217783956,-26.9943348182116,3.943491547417152,3.943491547417152,12.009506176575783,-17.16244086655658,-30.32369023966655,-28.59544847690796,-0.09206120151366604,-0.03704480983637185,0.15337809964706423,0.1078574364015826,-0.9609577730596839,4.7257948348595535,-27.962925851703407,0.45435894198598575,0.0,0.0,0.0,0.6563402756761219,0.0956337524417421,0.10780102982296393,-0.060437651962486974,0.02393595069744408,0.13294621026894865,0.10790436624755825,5.602329074064319,-0.2741957590290379,-0.28614263780132043,0.04830960519164678,36211000,73890000,9099000,112862000,4601000.0,998999.5,9330500.0,46.24384405865683,11.674156934785461,91.88459519748064,7.892942453854506,31.265641025641024,3.972374250716706,-0.3731574335266924,0.019541721035328467,0.0,0.03248246181852848,0.0,0.0,-10.862339221713883,-0.5942338515408183,0.0,4.7257948348595535,3.9362074287478137,0.6322666941043317,46.24384405865683,91.88459519748064,138.12843925613748,11.674156934785461,126.45428232135203,0.16130629763116625,-0.7677937656477839,-0.8813932374061133,-0.8716537540924973,0.011050068672743165,-0.2552961667700787,-0.3731574335266924,-0.24398496240601503,0.9889499001123736,1.1479557100369082,-0.7677937656477839,0.1078574364015826,0.15337809964706423,0.11064458598726115,0.1329816299563848,-27.962925851703407,-1.075457601793052,1.4220447357565202,7.892942453854506,31.265641025641024,3.972374250716706,0.5744472365780032,0.29288713043618403,-0.32333686701557846,-0.34287858805090693,0.711835265897235,-0.3960436899881696,1.060437651962487,-1.075457601793052,-5.694224683544304,-16.54597701149425,-16.54597701149425,3.943491547417152,3.943491547417152,11.337071037499657,-10.862339221713883,-26.9943348182116,-23.906955217783956,-23.906955217783956,-0.5942338515408183,11.337071037499657,-17.16244086655658,3.943491547417152,0.0,TKNO,2023-12-31,2023,FY,-0.11434089811685176,-0.41084916456855114,-0.23234458382424283,-0.23234458382424283,0.22516221454453528,0.31360946745562135,0.31360946745562135,0.13303913751969434,0.13303913751969434,0,0.31335766423357664,0.5184791805433041,0.4981383638205765,0.4981383638205765,-0.03813169688434468,-8.108254314999822,-8.108254314999822,-7.163324699472899,-22.12825419111008,-22.12825419111008,-9.454445859775532,4.723103352249116,4.723103352249116,3.4065881957139674,0,0,0,-0.07821620359561056,-0.05331918020739773,-0.15548302585691673,-0.20444354812074592,-0.28012290238714255,-0.28047046658911723,-0.0712702608881412,37218880.0,41701740.0,50116875.0,-10131902.0,-11352247.0,-13643056.0,-0.58295,-0.38742,-0.36322
0,TLIS,1.72,1.561,5146,3135250,0.0,1.37-9.6,0.0,Talis Biomedical Corporation,USD,0001584751,US87424L2079,87424L108,NASDAQ Global Market,NASDAQ,Medical - Devices,https://talisbio.com,"Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.",Mr. Robert  Kelley MBA,Healthcare,US,99,650 433 3000,230 Constitution Drive,Menlo Park,CA,94025,8.71945,0.03055384579853127,https://images.financialmodelingprep.com/symbol/TLIS.png,2021-02-12,False,False,True,False,False,1822422.0,59867000,18800000,-25703982,0.16461609879599787,-27.999003523881957,-22.09038301776427,-22.077762450189912,32.85023995540001,26.68207473351397,26.68207473351397,26.68207473351397,2.2437174265894506,3135250.0,-37931750.0,-0.06143075765296123,10.450833333333334,-0.07786193650951365,-0.07792344973281969,0.06446275325957307,0.06446275325957307,-126.43916666666667,0.7022447598305056,0.9422164538725223,0.9427550639990058,-16.2784904208616,-12.833107407702736,0.06011187430592687,0.040206880424765126,0.7602888227397727,7.760004880429478,-43.048885077186966,0.7889703288519578,0.0,0.0,0.0,0.0,68.25666666666666,0.0,-0.0005713150181330419,0.07666666666666666,0.021043000914913082,11.613333333333333,129.6499473620531,-1.0050549948371414,-0.7018803559883905,19.640895467679822,55405000,48626000,39528000,63737000,3000.0,3704500.0,0.0,0.0,1411.5816326530612,0.0,0.0,0.25857519788918204,0.0,-0.7973373127798048,0.012620567574359835,0.0,0.9323020492783669,0.0,0.0,-0.06143075765296123,-0.005663879825833141,0.0,7.760004880429478,7.760004880429478,7.304416788677403,0.0,0.0,0.0,1411.5816326530612,-1411.5816326530612,-2.2666666666666666,-167.31666666666666,-170.08666666666667,-170.08666666666667,-0.032166150589895345,-0.7018803559883905,-0.7973373127798048,-0.7781808598049703,1.0,1.0165554338081482,-167.31666666666666,0.040206880424765126,0.06011187430592687,0.0,0.05670333081146094,-43.048885077186966,-13.772836127266507,1.4950643688561676,0.0,0.25857519788918204,0.0,0.03600576092174748,0.00412660421738951,-22.09038301776427,-22.077762450189912,32.85023995540001,-134.19333333333333,0.999428684981867,-13.772836127266507,-13.772836127266507,-1750.3478260869565,-1750.3478260869565,0.06446275325957307,0.06446275325957307,10.450833333333334,-0.06143075765296123,-0.07792344973281969,-0.07786193650951365,-0.07786193650951365,-0.005663879825833141,10.450833333333334,0.7022447598305056,0.06446275325957307,0.0,TLIS,2023-12-31,2023,FY,-0.8871851040525739,1.0782865583456425,0.41970140438947706,0.41970140438947706,0.4407990260179465,0.45364291433146525,0.45364291433146525,0.02363043768434439,0.02363043768434439,0,0.4683230806103699,0.47198553331171195,-0.9857331187575643,-0.9857331187575643,-0.9939899035494351,0.7896081632044278,0.7896081632044278,0.9023839680054453,0.759487809426797,0.759487809426797,0.8913677146203342,1.1099988842776825,1.1099988842776825,1.1015750167650262,0,0,0,-0.8376623376623377,0,-0.4407584618110934,-0.4672479510497946,-0.414329104877613,-0.4254775451426635,-0.30727491467995777,,,,,,,,,
0,TMO,524.05,0.792,1708995,200449125000,1.56,493.3-627.88,7.36,Thermo Fisher Scientific Inc.,USD,0000097745,US8835561023,883556102,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.thermofisher.com,"Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.",Mr. Marc N. Casper,Healthcare,US,122000,781 622 1000,168 Third Avenue,Waltham,MA,02451,-299.61147,823.6614713099478,https://images.financialmodelingprep.com/symbol/TMO.png,1980-03-17,False,False,True,False,False,382000000.0,4645000000,35313000000,265376439999,110.91623036649214,16.06282722513089,23.82198952879581,20.353403141361255,17.395287958115183,128.53141361256544,-36.3586387434555,128.25130890052355,96.27225130890052,200449125000.0,231117125000.0,32.62501629726206,4.7309210526315795,21.998582417582416,25.78123794212219,4.086118141737426,4.086118141737426,5.454735071984895,20.42753447056744,25.397486263736262,29.725675241157557,0.03065132568482185,0.038787896928958905,0.7207911495754409,0.35184926866207006,2.7106240056567086,1.6288610369152798,4.9008885850991115,1.4835343984349527,0.0029768151893903257,0.29768151893903255,0.09289439374185136,0.0,0.03169695539296672,0.6275955521900283,0.14560439560439561,0.031272126504602316,0.41341653666146644,0.0066792541892848716,215.29460946801484,0.08038287031376815,0.1641695205479452,-90.46596858638743,9182000000,-13889000000,-27482000000,81582000000,9613000000.0,2576500000.0,5314000000.0,84.38848241680434,38.07044226535922,79.32559535721434,4.325234789710086,9.587490406753645,4.601289134438305,0.130093711571895,3.468586387434555,1.56,0.17616938961444706,0.0029768151893903257,0.29768151893903255,32.62501629726206,-31.05133904057093,0.09289439374185136,1.6288610369152798,1.2569687007739196,0.31812889528114513,84.38848241680434,79.32559535721434,163.71407777401868,38.07044226535922,125.64363550865946,0.4103139013452915,0.1692235071984895,0.1613405711588388,0.14481944772244512,0.05485664131070802,0.061137459646885335,0.130093711571895,0.08360248592050185,0.8976009362200117,0.9534170153417015,0.1692235071984895,0.35184926866207006,0.7207911495754409,0.38904338500293056,0.41887195302769703,4.9008885850991115,0.25769546625888484,2.048579359895493,4.325234789710086,9.587490406753645,4.601289134438305,4.501699957501063,0.4221633254951975,23.82198952879581,20.353403141361255,17.395287958115183,0.21477460467311776,0.8543956043956044,0.25769546625888484,2.2108843537414966,6.867924528301887,4.802110817941952,4.086118141737426,4.086118141737426,4.7309210526315795,32.62501629726206,25.78123794212219,21.998582417582416,21.998582417582416,-31.05133904057093,4.7309210526315795,20.42753447056744,4.086118141737426,1.56,TMO,2023-12-31,2023,FY,-0.04581988199933207,-0.12241025641025641,-0.18277135708328368,-0.18277135708328368,-0.13741007194244603,-0.12408347433728151,-0.12414965986394565,-0.015306122448979591,-0.015228426395939087,0.16731765643682728,-0.0817129123880271,0.002315149761250181,2.0559702693276938,0.8323941193262674,0.3646807677103875,2.9022857247405134,0.927016340119001,0.04038750400837105,3.3947624568204118,1.1250842101179117,-0.03524535202682104,1.587987089158966,0.7643805579837188,0.38945000421180603,1.2579949001356447,1.0476644980326464,0.5921341922787164,0.025140553728651746,-0.09691160809371673,0.016180496942997714,0.07751458706254657,0.01243910925539318,-0.09109449354180829,0.18493054581170199,42808589984.0,44916189544.0,48195282622.0,12218221385.0,12819762291.0,13755665230.0,21.70086,23.4035,26.06258
0,TRIB,0.8,1.133,164058,9568938,0.0,0.75-3.55,0.039,Trinity Biotech plc,USD,0000888721,US8964385046,896438306,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.trinitybiotech.com,"Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.",Mr. John  Gillard,Healthcare,IE,380,353 1 276 9800,IDA Business Park,Bray,,A98 H5C8,3.60799,-1.577994448192187,https://images.financialmodelingprep.com/symbol/TRIB.png,1992-10-21,False,False,True,True,False,10387099.0,0,93715000,105140808,5.692349711887795,-1.957716971793568,-1.2027418820211495,-1.803486998631668,0.0,-2.536030512465511,-7.029392903639409,-2.536030512465511,8.639755912598888,9568938.0,103283938.0,-0.4086392525202853,0.16183702876858286,-0.6651468714597673,-0.510806545754182,-0.3154536177966745,-0.3154536177966745,1.7468151267610397,-9.995542243298171,-8.267345414819932,-5.51347616649508,-2.44714621474196,-1.957688303550509,-3.1065219041834333,0.8397676661946103,-9.069486112455241,1.6425108718899266,-1.6648544879898861,0.6143594295549545,0.0,0.0,0.0,0.0,0.07115192720753633,0.4789627075508487,-0.657968434961053,0.1390227645576471,4.317226365546219,0.0028244287719654303,10.569232443413362,-0.23613756016461124,-0.40050814409233254,-9.320191325797511,18025000,-73015000,-77709000,68465000,19573000.0,24191000.0,22380000.0,132.32152823583135,236.96021342636533,204.15206628530385,2.7584324702589225,1.5403429745535009,1.7878829572555495,0.7931895307563287,0.7913661937755672,0.0,8.551837204922846,0.0,0.0,-0.4086392525202853,-0.02607507611319914,0.0,1.6425108718899266,0.8652955015327582,0.0,132.32152823583135,204.15206628530385,336.47359452113517,236.96021342636533,99.51338109476984,0.34069037833815347,-0.22272395014122143,-0.3456458132494461,-0.3439207130414193,0.004990947790771635,-0.2086796790017035,0.7931895307563287,-0.18977690511874568,0.9950090522092283,1.551902312392916,-0.22272395014122143,0.8397676661946103,-3.1065219041834333,1.476519536903039,1.4747161650747882,-1.6648544879898861,-0.15266642633688532,-3.6992635335206137,2.7584324702589225,1.5403429745535009,1.7878829572555495,15.696044597823201,0.6067668247029124,-1.2027418820211495,-1.803486998631668,0.0,-0.21129093307625957,1.4994796685727743,-0.15266642633688532,-59.49047142857143,-1.5198297469379254,-1.5198297469379254,-0.3154536177966745,-0.3154536177966745,0.16183702876858286,-0.4086392525202853,-0.510806545754182,-0.6651468714597673,-0.6651468714597673,-0.02607507611319914,0.16183702876858286,-9.995542243298171,-0.3154536177966745,0.0,TRIB,2023-12-31,2023,FY,-0.24000053490953344,-0.11783381712626996,-1.4782369650875102,-1.4782369650875102,0.4142236964050534,0.48355263157894735,0.4041745730550284,0.1345796021500627,-0.01542945772008582,0.0,-11.548317046688382,-1.0674108437228182,-0.6429092291156239,-0.68013676335769,-0.6956691038663162,-1.5658395546599815,-1.910119554967554,-1.265679589289583,-2.3316774141665317,-6.488311308107797,-1.1812917125720757,-1.075000973358698,-1.296894282693382,-4.893837999227949,-1,0,0.0,-0.004760133878765341,-0.11420699462293916,-0.35469686441414056,-8.700486632977736,0.15740597696414166,0.05824069598840019,0.06809298498251388,62199000.0,68500000.0,77500000.0,-6697468.0,-7375948.0,-8345051.0,-1.74,-0.9,-0.49
0,TTOO,0.35,0.376,786712,7365050,0.0,0.31-8.38,0.0159,"T2 Biosystems, Inc.",USD,0001492674,US89853L3024,89853L104,NASDAQ Capital Market,NASDAQ,Medical - Diagnostics & Research,https://www.t2biosystems.com,"T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.","Mr. John J. Sperzel III, B.Sc.",Healthcare,US,113,781 761 4646,101 Hartwell Avenue,Lexington,MA,02421,3.17094,-0.181236862882056,https://images.financialmodelingprep.com/symbol/TTOO.png,2014-08-07,False,False,True,False,False,17892606.0,2083000,18944000,52109433,0.4290599144696977,-2.400656449932447,-2.045090580991947,-2.0465436952001292,0.1164168036785698,-0.654460283761907,-0.654460283761907,-0.654460283761907,0.9408355607897475,7365050.0,24226050.0,-0.1457934557899148,0.9593656376188616,-0.171141563729777,-0.2011319569610574,-0.5347918104184457,-0.5347918104184457,3.1556662758890193,-0.6132090515604829,-0.6620586466987319,-0.6615885630018024,-6.859018428378421,-4.971860340391443,-1.16532877882152,0.7546731556243779,-0.42678512668641,0.40049109883364026,-13.066185696361355,0.8518880663034875,0.0,0.0,0.0,0.0,1.6730493682428031,0.0,-0.0007105378224748579,0.0033867396118275367,0.10038610038610038,0.3578220659111632,5.945630478119788,-19.789882613227988,-2.375511558455923,-1.3565240300937718,-14649000,-11710000,-20006000,-6904000,1665000.0,2948000.0,4497000.0,96.65819981763708,112.62459689240691,102.32519788918205,3.776192818494835,3.240855106888361,3.5670588235294116,2.059724037066785,0.0014531142081818601,0.0,1.8528048010536249,0.0,0.0,-0.1457934557899148,-0.004469986856336624,0.0,0.40049109883364026,0.24395334561080417,0.08524657253939022,96.65819981763708,102.32519788918205,198.98339770681912,112.62459689240691,86.3588008144122,-0.7772567409144197,-5.425947635795232,-5.59515435717077,-5.59515435717077,0.08022535735903524,-2.375511558455923,2.059724037066785,6.556744844955139,1.0,1.031184731724883,-5.425947635795232,0.7546731556243779,-1.16532877882152,0.0,7.0485537190082646,-13.066185696361355,-2.6815183936684743,-1.5441502988898377,3.776192818494835,3.240855106888361,3.5670588235294116,0.9912201420271143,0.42456586660767615,-2.045090580991947,-2.0465436952001292,0.1164168036785698,-4.76644522599974,1.0007105378224748,-2.6815183936684743,-2.6815183936684743,-1407.3846153846155,-1407.3846153846155,-0.5347918104184457,-0.5347918104184457,0.9593656376188616,-0.1457934557899148,-0.2011319569610574,-0.171141563729777,-0.171141563729777,-0.004469986856336624,0.9593656376188616,-0.6132090515604829,-0.5347918104184457,0.0,TTOO,2023-12-31,2023,FY,-0.6775162519614436,-8.006861063464838,0.10531435777337417,0.10531435777337417,0.20976802903582137,0.9845550833816238,0.9845550833816238,50.173146677646415,50.173146677646415,0,0.049240553832783585,0.05179720609009575,-0.8554159387696763,-0.8935445222214827,-0.9963113062108634,0.9857435100531236,0.8136362150932389,0.9896439096807232,0.9870087091039748,0.8478701467052965,0.9905384358635081,0.9983259192347819,-1.382607943928346,-1.0298717861088627,0,0,0,-0.34350439204808136,0.10807082087836284,0.011805414207205373,0.9862927401509398,-0.1641251667595454,-0.4542264383772945,-0.19236273744470467,10551632.0,23125100.0,33299999.0,-10551632.0,-23125100.0,-33299999.0,-3.1,-1.19,-0.7
0,TWST,47.94,1.781,747803,2845545816,0.0,27.41-60.9,4.32,Twist Bioscience Corporation,USD,0001581280,US90184D1000,90184D100,NASDAQ Global Select,NASDAQ,Medical - Diagnostics & Research,https://www.twistbioscience.com,"Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.",Dr. Emily Marine Leproust Ph.D.,Healthcare,US,919,800 719 0671,681 Gateway Boulevard,South San Francisco,CA,94080,6.11429,35.2643,https://images.financialmodelingprep.com/symbol/TWST.png,2018-10-31,False,False,True,False,False,58554000.0,226316000,85026000,2504179720,5.345049014584828,-3.5646753424189637,-1.094613519144721,-1.181302729104758,4.7204119274515834,8.072702121118967,6.359941250811217,8.072702121118967,0.25333879837415035,2845545816.0,2704255816.0,-13.44863007004398,9.091955932441673,-43.796279838986486,-41.138438860777796,5.938532015765123,5.938532015765123,8.640512681564603,-15.303268138372824,-42.19202758448529,-39.09579031371982,-0.07435701590360792,-0.024308165980343504,0.0313208050113288,0.024099699994953795,0.7995540741662941,4.883756302284314,-7614.896551724138,0.30707242988415434,0.0,0.0,0.0,0.0,0.2902828988989501,0.16325125381924493,-0.07919618060972947,0.016218599628084123,0.16151202749140894,0.12326263523487574,25.44548387143652,-0.4546322466059849,-0.40605485240275935,2.9542174744680123,275770000,372400000,205142000,537408000,33445500.0,4128000.0,26281000.0,40.704962712557595,3.3121597096188746,48.926491710554146,8.9669655903504,110.2,7.460171110557355,-0.39494021052970174,0.08668920996003689,0.0,0.0052028682570331875,0.0,0.0,-13.44863007004398,-2.3351712212530935,0.0,4.883756302284314,4.5446581978987695,3.1872799481733938,40.704962712557595,48.926491710554146,89.63145442311173,3.3121597096188746,86.31929471349287,0.4260673410570846,-0.7055921578150262,-0.6645088729415223,-0.6669116284419792,-0.003615836594958985,-0.33976588862862045,-0.39494021052970174,-0.4064514822838233,1.003615836594959,0.9417747427908999,-0.7055921578150262,0.024099699994953795,0.0313208050113288,0.0,0.030369604548979065,-7614.896551724138,-4.329213103681189,1.2996346434970985,8.9669655903504,110.2,7.460171110557355,1.9397331250890926,0.5094616350030847,-1.094613519144721,-1.181302729104758,4.7204119274515834,-0.20479017426367685,1.0791961806097294,-4.329213103681189,-4.329213103681189,-12.626871552403466,-12.626871552403466,5.938532015765123,5.938532015765123,9.091955932441673,-13.44863007004398,-41.138438860777796,-43.796279838986486,-43.796279838986486,-2.3351712212530935,9.091955932441673,-15.303268138372824,5.938532015765123,0.0,TWST,2024-09-30,2024,FY,0.27687681806869596,0.4861304594947007,-0.016909269245115332,-0.016909269245115332,-0.020076435113235393,0.0,0.0,0.019882218511031027,0.019882218511031027,0,0.5501354633126044,0.5937222838951443,43.65187734863251,1.7240246983430683,0.9669740866225304,0.4623668384163724,0.6549932087860675,0.52508840064578,-0.5325763200531632,0.08236961792955398,-0.141330920444962,2.997332290645015,0.4712266868014811,-0.32315110880790965,0,0,0,-0.20790214233841686,-0.24904095062845025,-0.20875756533655845,-0.25657632822894033,-0.09613156300162647,-0.15007390498999007,0.15105039580895763,373278000.0,438517182.0,528235143.0,-314755157.0,-369766084.0,-445417987.0,-2.25167,-1.65917,-1.09875
0,TXG,14.04,1.873,2082733,1699604464,0.0,12.95-57.78,0.43,"10x Genomics, Inc.",USD,0001770787,US88025U1097,88025U109,NASDAQ Global Select,NASDAQ,Medical - Healthcare Information Services,https://www.10xgenomics.com,"10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.",Dr. Serge  Saxonov Ph.D.,Healthcare,US,1259,925 401 7300,6230 Stoneridge Mall Road,Pleasanton,CA,94588-3260,72.48975,-36.13975487860238,https://images.financialmodelingprep.com/symbol/TXG.png,2019-09-12,False,False,True,False,False,120733030.0,398159000,85876000,2413868817,5.2159959871793165,-1.5120220208173356,0.32443482947458535,0.20742459623518103,3.29784649652212,5.986795825467149,5.815674467873456,5.986795825467149,0.07808136679747042,1699604464.0,1387321464.0,-9.285579050238015,2.6988858375559555,43.27525507275976,67.86744655193068,2.3451609858274165,2.3451609858274165,2.2029962444997406,-10.585714992064462,35.417959254531524,55.39757473146189,-0.10769387612659086,0.014734604745072027,0.013025661175090342,0.010039518273736022,2.3828210841167135,4.898692621767641,-14852.5,-0.21457017491002514,0.0,0.0,0.0,0.1315219065555314,0.4010842518297147,0.022030424592181224,0.36065866734745977,0.022432960747479528,0.31498327759197325,0.23363022693384444,14.27143161180691,-0.25258860274755607,-0.19904506865954158,2.4254982252992408,472658000,702144000,378903000,811656000,87351500.0,23729000.0,91161000.0,48.41121695675855,44.53333022995997,159.80006517084072,7.539574977551632,8.19610835558947,2.2841041998936737,-0.2512107210176077,0.11701023323940433,0.0,0.005539524165429586,0.0,0.0,-9.285579050238015,-0.38279325880573045,0.0,4.898692621767641,4.122926547614138,3.284191858786654,48.41121695675855,159.80006517084072,208.21128212759928,44.53333022995997,163.6779518976393,0.6588767163747751,-0.2830202161834272,-0.2793488772403981,-0.2898817454104293,-0.03770506713355086,-0.194660021283992,-0.2512107210176077,-0.21826959227685935,1.0377050671335508,0.9870279975312798,-0.2830202161834272,0.010039518273736022,0.013025661175090342,0.0,0.01285817494492768,-14852.5,4.160382368560807,1.2974388630942828,7.539574977551632,8.19610835558947,2.2841041998936737,1.9782212616778392,0.6715152794750233,0.32443482947458535,0.20742459623518103,3.29784649652212,0.0621999768159392,0.6393413326525402,4.160382368560807,4.160382368560807,2.772704749769944,2.772704749769944,2.3451609858274165,2.3451609858274165,2.6988858375559555,-9.285579050238015,67.86744655193068,43.27525507275976,43.27525507275976,-0.38279325880573045,2.6988858375559555,-10.585714992064462,2.3451609858274165,0.0,TXG,2023-12-31,2023,FY,0.19813364987829415,0.03355865694669249,-0.5798659076835135,-0.5798659076835135,-0.5367409638554217,-0.493150684931507,-0.493150684931507,0.029039084976601345,0.029039084976601345,0,0.54778908528239,0.6083852190697477,-0.13916020188852252,-0.5166380984169355,0.7874264248789239,0.8595195426349594,0.9772663268843302,0.9397884621713762,-0.3447168940997339,0.7407788655137083,0.5942119741093477,1.6514144396346717,1.3850371689832741,-0.13437107487152986,0,0,0,0.10191822360403412,-0.09706109348393341,-0.062039106688176644,-0.10625217575182784,0.002038328990501807,0.01755957646226291,0.15095541401273885,599333902.0,632539270.0,691978152.0,-205620502.0,-217012657.0,-237405050.0,-1.42699,-1.25781,-0.89001
0,VCYT,40.89,1.668,770665,3168958644,0.0,18.61-46.0,1.82,"Veracyte, Inc.",USD,0001384101,US92337F1075,92337F107,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.veracyte.com,"Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.",Mr. Marc A. Stapley,Healthcare,US,815,650 243 6300,6000 Shoreline Court,South San Francisco,CA,94080,46.11192,-5.221923071875257,https://images.financialmodelingprep.com/symbol/VCYT.png,2013-10-30,False,False,True,False,False,77013831.0,274079000,19694000,2367165807,5.5227871990941475,-0.12034202012363208,0.8585990222976961,0.7333877469360016,3.558828283714389,15.27052978315025,3.9610027970170707,15.27052978315025,5.193872253933193e-05,3168958644.0,2914573644.0,-339.7815655578334,7.450570600308936,47.62409336383159,56.10663132734902,2.6777067057043884,2.6777067057043884,6.852483463467276,217.1975291750503,44.07739465247111,51.60272735964307,-0.0029430672566307676,0.01782320514246509,0.0,0.0,-18.957075788061704,5.075220798429878,2768.0,-7.134656883901597,0.0,0.0,0.0,0.37039858369128986,0.15970855404379178,0.6831181604067698,0.14583207307482912,0.022671754468872478,0.40960835952765273,0.08024808913528522,6.430236702906339,0.010678593626172761,-0.022938833901359056,2.8811350781913445,286541000,305052000,257875000,1195756000,49555500.0,10877000.0,19811000.0,41.8839797710489,24.033760503343366,50.61256451810592,8.71454914254103,15.18697001034126,7.211648006285602,-0.008291071353489667,0.12521127536169444,0.0,0.0,0.0,0.0,-339.7815655578334,-4.177642199481559,0.0,5.075220798429878,4.785601524611381,3.8979847254419524,41.8839797710489,50.61256451810592,92.49654428915483,24.033760503343366,68.46278378581147,0.6547206763673469,0.026031490768366285,-0.019210920436083898,-0.021790088190138973,-0.1342552931097785,-0.007268899884786211,-0.008291071353489667,0.00919060884463289,1.1342552931097785,-0.7379877167630058,0.026031490768366285,0.0,0.0,0.0,0.0,2768.0,0.0,1.0841628105118695,8.71454914254103,15.18697001034126,7.211648006285602,11.127037279267496,0.33358744679499397,0.8585990222976961,0.7333877469360016,3.558828283714389,0.15546480270659793,0.8541679269251709,0.0,0.0,6.857202115524214,6.857202115524214,2.6777067057043884,2.6777067057043884,7.450570600308936,-339.7815655578334,56.10663132734902,47.62409336383159,47.62409336383159,-4.177642199481559,7.450570600308936,217.1975291750503,2.6777067057043884,0.0,VCYT,2023-12-31,2023,FY,0.21756211724714705,0.27285410917447195,-1.0884350429639005,-1.0884350429639005,-1.0351203501094093,-1.0,-1.0,0.01530810880858996,0.01530810880858996,0,4.868878566688785,34.7879684418146,-0.0555194522323043,0.9997679367900552,1.2522813299463416,1.1321346487241517,2.6667336614924153,4.337363706315608,0.8334874715138941,-0.6486329288632904,-0.5211518880385133,0.05897086193428174,5.671471688982984,0.8165639201137443,0,0,0,-0.08275595738397583,0.12830558276199805,-0.035900389304250525,-0.04356421414965486,-0.1418671015083571,0.4113489151047952,0.05833017383012213,,,,,,,,,
0,VNRX,0.6759,1.103,271674,64864636,0.0,0.43-1.23,0.0949,VolitionRx Limited,USD,0000093314,US9286611077,928661107,American Stock Exchange,AMEX,Medical - Diagnostics & Research,https://www.volition.com,"VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.",Mr. Cameron  Reynolds MBA,Healthcare,US,101,646 650 1351,13215 Bee Cave Parkway,Austin,TX,78738,1.09464,-0.3746401826603646,https://images.financialmodelingprep.com/symbol/VNRX.png,2012-03-02,False,False,True,False,False,87886012.0,5414146,5886241,53291588,0.014630621764928872,-0.3399029301727788,-0.15762054375615542,-0.16535060209581476,0.06160418338244771,-0.2576097092674998,-0.2614249808035436,-0.24468089415639885,0.06119166039756133,64864636.0,65336731.0,-1.9885088947495329,50.44585002492559,-4.288146607625217,-4.463570993816751,-2.762373426541297,-2.762373426541297,50.81300283786233,-2.2882618342397416,-4.716554121340472,-4.4960575639768905,-0.5028893773824217,-0.2240358675565527,-0.2358637646863183,0.39999361211584467,-0.016533991739430775,0.22460562974717166,-98.02921175662863,0.4625666277828597,0.0,0.0,0.0,10.020202562242044,12.238063907508552,0.02644339565726399,-0.04931297938061053,0.5312650924268972,0.5290486317527536,0.9682087870296704,1.3679453351006936,1.8122920521001684,-2.4198334281899654,-0.3376184682267754,-23478536,-22975599,-28519604,-17599222,239436.5,2916699.5,0.0,88.7390099912352,899.1540367868278,0.0,4.113185396547147,0.4059371198558435,0.0,1.7909260632935047,0.0077727386242079114,0.0,0.07819393297759353,0.0,0.0,-1.9885088947495329,-0.1988508894749531,0.0,0.22460562974717166,0.22460562974717166,0.17880579641451536,88.7390099912352,0.0,88.7390099912352,899.1540367868278,-810.4150267955926,0.21545822260692923,-23.3189962568837,-23.48718606779917,-23.232295635415962,0.0068235720133780755,-2.3558448154236644,1.7909260632935047,1.7037227554718044,0.9891476811378158,1.007212566487111,-23.3189962568837,0.39999361211584467,-0.2358637646863183,-0.21724969175387995,-0.308667164029324,-98.02921175662863,-2.7311876271805655,-0.5896688285562128,4.113185396547147,0.4059371198558435,0.0,0.23193106788323603,0.10140387555297586,-0.15762054375615542,-0.16535060209581476,0.06160418338244771,-10.773331871239288,1.0490422006893847,-2.7311876271805655,-11.225157223530898,-20.27863683274412,-20.27863683274412,-2.762373426541297,-2.762373426541297,50.44585002492559,-1.9885088947495329,-4.463570993816751,-4.288146607625217,-4.288146607625217,-0.1988508894749531,50.44585002492559,-2.2882618342397416,-2.762373426541297,0.0,VNRX,2023-12-31,2023,FY,1.5304250763727512,1.8789983095793903,-0.13239815819171208,-0.13239815819171208,-0.166847914946592,0.09090909090909098,0.09090909090909098,0.2869746869584558,0.2869746869584558,0,-0.18230815784164964,-0.136445534773305,0.0,0.0,35.68617827910017,0.10940726257865538,0.45975890065078456,0.3026470429100745,-0.44755238133961517,0.13579137030352725,-0.0960828996772718,-2.743065259823494,-1.2831880273218306,-1.3034931060036203,0,0,0,2.3414177305843626,-1.0,0.5277625307911089,-1.16489244460204,0.17784748277817322,0.341669587687301,-0.014313907665333499,1457000.0,9400000.0,27100000.0,-1457000.0,-9400000.0,-27100000.0,-0.305,-0.16667,-0.04
0,VRCI.L,2.625,1.817,334319,6366701,0.0,2.27-13.0,0.0,Verici Dx plc,GBp,,GB00BM8HZD43,,London Stock Exchange,LSE,Medical - Diagnostics & Research,https://www.vericidx.com,"Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.","Ms. Sara jane Barrington A.C.A., A.C.I.M.",Healthcare,GB,19,44 207 9338780,Avon House,Penarth,,CF64 2EZ,-0.27394,2.898938565348318,https://images.financialmodelingprep.com/symbol/VRCI.L.png,2020-11-03,False,False,True,False,False,222662702.0,7015000,458000,12607044,0.019459927329903686,-0.021597689944497307,-0.025019906567019023,-0.025082781938036484,0.03150505197767698,0.04428671668594051,0.0349272686001987,0.04428671668594051,0.0,8011983.872420001,1454983.8724200008,-1.5294934358670305,1.8490615906808219,-1.320289702582041,-1.434553961042077,0.7459014230893978,0.7459014230893978,0.3357913391230097,-0.3888251930571889,-0.2611710415401186,-0.260516360325873,-0.6538112400810179,-0.6970807841021107,0.0,0.0,1.7522715125601283,4.540334855403349,0.0,1.1584529008109794,0.0,0.0,0.0,1.864297253634895,0.41310870066928224,0.17214604328432181,-0.0025130138215760187,0.0032310177705977385,0.01879194630872483,0.09000692360950842,0.14670051960358427,-0.5481533300398939,-0.47984434244661744,0.026475022296280227,6978000,7777000,6704000,10135000,1500000.0,661000.0,193000.0,126.35587352873297,80421.66666666666,0.0,2.8886666666666665,0.0045385779122541605,0.0,-0.7167449139280125,6.28753710174594e-05,0.0,0.0,0.0,0.0,-1.5294934358670305,-0.047597835724182,0.0,4.540334855403349,4.540334855403349,3.5591070522577373,126.35587352873297,0.0,126.35587352873297,80421.66666666666,-80295.31079313792,0.9993076390491576,-1.1400876990537734,-1.109854604200323,-1.109854604200323,-0.0941983780411728,-0.3972410375020651,-0.7167449139280125,-0.4874198322644302,1.0,0.9734817813765182,-1.1400876990537734,0.0,0.0,0.0,0.0,0.0,0.0,1.2276645370652064,2.8886666666666665,0.0045385779122541605,0.0,4.038210624417521,0.3579216917231125,-0.025019906567019023,-0.025082781938036484,0.03150505197767698,-1.2857142857142858,1.002513013821576,0.0,0.0,-397.92857142857144,-397.92857142857144,0.7459014230893978,0.7459014230893978,1.8490615906808219,-1.5294934358670305,-1.434553961042077,-1.320289702582041,-1.320289702582041,-0.047597835724182,1.8490615906808219,-0.3888251930571889,0.7459014230893978,0.0,VRCI.L,2023-12-31,2023,FY,0,0,0.225927542557835,0.225927542557835,0.2310942864688793,0.25652173913043486,0.25652173913043486,0.03432401221674524,0.0343205689196441,0,0.2888359157727453,0.35029887482419125,0,0,0,-1.8451325640989846,-1.8451325640989846,-1.8451325640989846,0.37381705668115983,0.37381705668115983,0.37381705668115983,-0.9076746696253025,-0.9076746696253025,-0.9076746696253025,0,0,0,0,0,-0.4796924152394268,-0.7011097511825143,2.4615384615384617,-1.0,-0.18090883109459846,,,,,,,,,
0,WAT,368.16,0.973,487585,21859941792,0.0,279.24-397.02,7.53,Waters Corporation,USD,0001000697,US9418481035,941848103,New York Stock Exchange,NYSE,Medical - Diagnostics & Research,https://www.waters.com,"Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",Dr. Udit  Batra Ph.D.,Healthcare,US,7900,508 478 2000,34 Maple Street,Milford,MA,01757,161.9247,206.23530168048063,https://images.financialmodelingprep.com/symbol/WAT.png,1995-11-17,False,False,True,False,False,59314000.0,330514000,1904828000,22768985620,48.979111171055735,10.497369929527599,12.680075530228951,10.45522136426476,5.588191657955964,27.027329129716424,-4.979886704656574,27.027329129716424,32.42059210304481,21859941792.0,23434255792.0,35.07164198952527,7.524556172889014,29.03452736715304,35.24995411043618,13.621767738611279,13.621767738611279,8.066461281305214,22.478600567474395,31.15818221367733,37.78859290387186,0.028513064780333545,0.02836883125768206,1.1391985148764985,0.4047876372566839,1.510113053637649,2.0191706288907407,8.394296463973044,1.2079288064872054,0.0,0.0,0.0,0.059092362623991146,0.062130763090473565,0.42079696428333946,0.17546063985661595,0.04542455166640449,0.6897966650985312,0.012955282469355251,79.89747882029155,0.20608555884805135,0.2382727473112848,-30.6068634723674,831684000,-295377000,-1260797000,3449429000,639811000.0,86516000.0,520960500.0,84.119636631124,28.336497103365417,155.46610826741122,4.339058210636054,12.880914626411265,2.3477785870356884,0.45934991438476175,2.2248541659641905,0.0,0.08354313187916837,0.0,0.0,35.07164198952527,8.034594346691252,0.0,2.0191706288907407,1.383179746090878,0.4050218126562423,84.119636631124,155.46610826741122,239.5857448985352,28.336497103365417,211.2492477951698,0.5805778502774558,0.27954626736616084,0.24628185768224464,0.21432340601009175,0.1297637267028659,0.13800829857124491,0.45934991438476175,0.21975522110196505,0.8702362732971342,0.881005709726236,0.27954626736616084,0.4047876372566839,1.1391985148764985,0.5325352027660076,0.5325352027660076,8.394296463973044,0.41183125183436203,2.814311530354644,4.339058210636054,12.880914626411265,2.3477785870356884,4.039027123371089,0.6439254635807093,12.680075530228951,10.45522136426476,5.588191657955964,0.25888741602404286,0.824539360143384,0.41183125183436203,0.0,5.699283901034365,5.699283901034365,13.621767738611279,13.621767738611279,7.524556172889014,35.07164198952527,35.24995411043618,29.03452736715304,29.03452736715304,8.034594346691252,7.524556172889014,22.478600567474395,13.621767738611279,0.0,WAT,2023-12-31,2023,FY,-0.005228879566184694,0.02170760204063874,-0.0637958770086845,-0.0637958770086845,-0.09257582072892456,-0.07881355932203402,-0.07587382779198641,-0.015153788447111778,-0.017586315492864366,0,-0.014472068678565415,0.03262923132611716,1.2450595620717826,0.5921993394315188,0.3137294425598882,0.7977447494345352,0.29974076197213584,-0.1984833226286247,1.0637489911260751,0.40958739680077116,0.2942507130093096,-0.05656787192433437,-0.04342148304023119,4.2084403071656675,0,0,0,-0.028668182799090322,0.13281692304316342,0.4100016059958805,1.3153003639333343,0.4789884618668727,-0.007066235314149498,0.11851811326604116,2942605122.0,3108424081.0,3295571283.0,997153757.0,1053344442.0,1116762579.0,11.79627,12.9127,14.21458
0,WGS,77.4,2.18,629690,2126286360,0.0,2.466-89.11,2.1,GeneDx Holdings Corp.,USD,0001818331,US81663L2007,81663L200,NASDAQ Global Market,NASDAQ,Medical - Healthcare Information Services,http://www.genedx.com,"GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.",Ms. Katherine A. Stueland,Healthcare,US,1000,800 298 6470,North Tower,Stamford,CT,06902,131.80146,-54.4014636196062,https://images.financialmodelingprep.com/symbol/WGS.png,2020-11-04,False,False,True,False,False,27095986.0,57894000,116101000,1208160645,9.862272589010047,-3.0815265404993935,-2.03613184624468,-2.2139072554879533,4.298053593620841,7.547280250292423,1.5646228928521,7.547280250292423,2.042590367444093,2126286360.0,2184493360.0,-25.11742118159934,7.956824733935067,-38.013255449420896,-35.4451950390078,10.255349931785176,10.255349931785176,8.174642477584683,-38.06400696985538,-39.59495677076725,-36.41550576782023,-0.039813004399216964,-0.028212568696532485,0.2544437435513763,0.12727228255552295,-1.0142359296044607,2.405032194667839,-16.481582125603865,0.6607542785968358,0.0,0.0,0.0,0.37565674255691767,0.16374032661248072,0.3965022991879464,-0.08731036232803466,0.01802580567904561,0.14062180703546928,0.020136362955977666,22.875439864555997,-0.210941553766937,-0.3384089748474065,-1.9794075771961206,108668000,42395000,-18329000,327162000,32336500.0,8578000.0,10546000.0,52.55886359213855,26.925177632601,32.14189349402713,6.944594594594594,13.55608512524939,11.355896007428042,-0.40057185485824764,0.17777540924327315,0.0,0.024471774347459015,0.0,0.0,-25.11742118159934,-0.8517260866843087,0.0,2.405032194667839,2.265780559075276,0.7485454216337825,52.55886359213855,32.14189349402713,84.70075708616568,26.925177632601,57.77557945356468,0.5423271513464158,-0.20427125899980542,-0.31518777972368167,-0.31245603005673056,0.008667054507461977,-0.20422903825457392,-0.40057185485824764,-0.16466766013671275,0.991332945492538,1.5429864253393666,-0.20427125899980542,0.12727228255552295,0.2544437435513763,0.20283392129728886,0.20283392129728886,-16.481582125603865,-1.0602875043240958,1.9992078278345826,6.944594594594594,13.55608512524939,11.355896007428042,4.739093424132794,0.6536248899324919,-2.03613184624468,-2.2139072554879533,4.298053593620841,-0.20645665873336627,1.0873103623280347,-1.0602875043240958,0.0,-11.453394228773096,-11.453394228773096,10.255349931785176,10.255349931785176,7.956824733935067,-25.11742118159934,-35.4451950390078,-38.013255449420896,-38.013255449420896,-0.8517260866843087,7.956824733935067,-38.06400696985538,10.255349931785176,0.0,WGS,2023-12-31,2023,FY,-0.1368931459687934,3.2662429906542054,0.7548693031699149,0.7548693031699149,0.6798298662974972,0.8651873951146747,0.8651873951146747,1.37492296296195,1.37492296296195,0,0.4355501245476336,0.44266621086311797,-0.6908663215998648,-0.6908663215998648,-0.9999927756202472,-1.8797636815512244,-1.8797636815512244,0.9999876287282619,-0.697942452978924,-0.697942452978924,0.9999954385724876,0,0,1.0000044182853707,0,0,0,-0.2428591204835956,-0.3577021587998536,-0.03517319764860208,-0.6215672842628233,0.6546474358974359,-0.32408384858995626,-0.42434410865593275,288197667.0,336559333.0,395047400.0,-218362902.0,-255005786.0,-299321287.0,-0.325,0.49,1.33667
0,WST,331.4,1.003,605771,24000750220,0.81,265.0-413.7,4.39,"West Pharmaceutical Services, Inc.",USD,0000105770,US9553061055,955306105,New York Stock Exchange,NYSE,Medical - Instruments & Supplies,https://www.westpharma.com,"West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.",Mr. Eric M. Green,Healthcare,US,10600,610 594 2900,530 Herman O. West Drive,Exton,PA,19341-0645,162.04216,169.35783680158727,https://images.financialmodelingprep.com/symbol/WST.png,1980-03-17,False,False,True,False,False,72800000.0,490900000,304800000,21665548000,39.50961538461539,6.862637362637362,9.648351648351648,4.417582417582418,6.743131868131868,37.80357142857143,36.14010989010989,37.80357142857143,2.8516483516483517,24000750220.0,23814650220.0,48.290472377902326,8.344313951952161,34.347835990888385,74.62919844527363,8.766367501180916,8.766367501180916,8.279612773354657,32.01324132275843,33.90468425398633,74.05052929104478,0.02070801859576754,0.013399581140259874,0.0736165110279423,0.0551277516258061,-0.25016803333781423,3.002129719264279,115.16,1.4059247397918335,0.0024441762220881115,0.2444176222088111,0.11729383506805445,0.0,0.023989152730939052,0.03295148431335202,0.5421412300683371,0.1323923095643709,2.5285524568393094,0.0054931683065048845,76.40173125560705,0.16005776932365007,0.1405740011254924,2.221497242445055,1034100000,2631000000,627600000,2866100000,513149999.5,218000000.0,410200000.0,66.5332196346,43.73604359207223,78.22960628238688,5.4859813188746545,8.345519393669193,4.665752741774676,0.18349938019374684,5.230769230769231,0.81,0.008441402795449783,0.0024441762220881115,0.24441762220881116,48.290472377902326,-11.444841953562825,0.11729383506805445,3.002129719264279,2.2253630203291386,0.9504356243949661,66.5332196346,78.22960628238688,144.76282591698688,43.73604359207223,101.02678232491465,0.3491986232312346,0.20018774119528562,0.20470743628967772,0.1736953725272051,0.17866847686594511,0.1359418791325406,0.18349938019374684,0.18229595390362818,0.8485054362236845,1.0225772820423757,0.20018774119528562,0.0551277516258061,0.0736165110279423,0.06856872102074661,0.06856872102074661,115.16,3.466929911154985,1.3353802550779406,5.4859813188746545,8.345519393669193,4.665752741774676,1.6811619615407096,0.7826453701940084,9.648351648351648,4.417582417582418,6.743131868131868,0.2442026214233564,0.45785876993166286,3.466929911154985,0.0,1.8445378151260505,1.5985434683659536,8.766367501180916,8.766367501180916,8.344313951952161,48.290472377902326,74.62919844527363,34.347835990888385,34.347835990888385,-11.444841953562825,8.344313951952161,32.01324132275843,8.766367501180916,0.81,WST,2023-12-31,2023,FY,0.021788077176209775,-0.006160887167752156,-0.07901907356948229,-0.07901907356948229,0.012800819252432157,0.013959390862944203,0.019404915912030977,-0.0013440860215053765,-0.006596306068601583,0.05502247719317444,0.07251381215469613,-0.0566681838871188,1.0192957518737686,0.7083495490146692,0.3665841517899263,2.298779538733394,1.67609026357344,0.6345389419413646,3.949806385271139,1.8526118104402165,0.7048104667246701,1.9774452703015732,1.0522021813273283,0.5451549775073327,0.9923263895863885,0.3466303072540864,0.17865147474837914,0.009065825778478517,0.047974927675988426,0.05880889183808892,0.07448229861565156,-0.027996225228059137,0.16923076923076924,0.11517828968128747,2884905898.0,3055616448.0,3318820781.0,793118050.0,840049778.0,912409888.0,6.65563,7.51558,8.78378
0,XGN,5.15,1.346,81541,90832095,0.0,1.3-6.22,0.44,Exagen Inc.,USD,0001274737,US30068X1037,30068X103,NASDAQ Global Market,NASDAQ,Medical - Diagnostics & Research,https://www.exagen.com,"Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.",Mr. John  Aballi,Healthcare,US,174,760 560 1501,1261 Liberty Way,Vista,CA,92081,1.53913,-0.019129946359114715,https://images.financialmodelingprep.com/symbol/XGN.png,2019-09-19,False,False,True,False,False,18254937.0,22035000,23270000,57642755,3.0540231390554786,-0.9272560075118309,-0.28994896010870924,-0.31596931832742015,1.2070707228406212,0.704905199070257,0.704905199070257,0.704905199070257,1.2319954870290706,90832095.0,92067095.0,-5.554021713829976,1.62924602249287,-17.76174675042509,-15.747589285714286,7.30594696534038,7.30594696534038,1.6513980915140536,-7.154732281628847,-17.394123370489325,-15.961701629680997,-0.180049710196472,-0.06350178315275014,1.5739042586260492,0.46446508427932576,-0.09597451041342867,4.0511564315825455,-6.884219937416183,0.31269569327110536,0.0,0.0,0.0,0.97429642517623,0.08600742587576904,0.0,-0.08974116757982241,0.008520026546609029,0.2615638766519824,0.03754192749905831,3.8349211938050205,-0.47652262410520796,-0.38818942781791077,-0.0910301689893534,26780000,12868000,4820000,34265000,10545000.0,1717500.0,1437000.0,61.45638643253036,17.55800792303339,0.0,5.939171194204751,20.788235294117648,0.0,-0.9257567885367388,0.026020358218710918,0.0,0.22297184712077817,0.0,0.0,-5.554021713829976,-1.7958003541383574,0.0,4.0511564315825455,4.0511564315825455,2.5105389085108807,61.45638643253036,0.0,61.45638643253036,17.55800792303339,43.898378509496965,0.5879715162059873,-0.2762282290900612,-0.3035102509372029,-0.3036178723251601,-0.024864015129129485,-0.38818942781791077,-0.9257567885367388,-0.4421729642816125,1.000354588972283,1.0987662337662338,-0.2762282290900612,0.46446508427932576,1.5739042586260492,0.6063748432290232,0.6114851604722079,-6.884219937416183,-0.2613439984199872,3.3886384830587506,5.939171194204751,20.788235294117648,0.0,7.448363393453574,1.2785460382983602,-0.28994896010870924,-0.31596931832742015,1.2070707228406212,-0.09494000107621388,1.0897411675798223,-0.2613439984199872,-12.309302325581395,-11.143157894736841,-11.143157894736841,7.30594696534038,7.30594696534038,1.62924602249287,-5.554021713829976,-15.747589285714286,-17.76174675042509,-17.76174675042509,-1.7958003541383574,1.62924602249287,-7.154732281628847,7.30594696534038,0.0,XGN,2023-12-31,2023,FY,0.15330421614028927,0.3797367558199447,0.4367492909113331,0.4367492909113331,0.5000949627534977,0.516245487364621,0.516245487364621,0.03495532347192552,0.03495532347192552,0,0.5500871080139372,0.5806593165487357,-0.9477777050761277,-0.9942272706843897,-0.10408651351232372,0.9936041423087543,0.9944587906169879,0.2651428424398086,0.9946709151543963,0.989463129671945,-0.01594231568035114,-0.8472273946362037,1.0120100215479222,-0.6118225145019441,0,0,0,0.07799901267072569,0.5994428969359331,-0.33955764836872687,-0.4835723842318331,-0.3124547114576389,-0.5073916565411097,-0.08823868660848168,55525000.0,65150000.0,73800000.0,-25660709.0,-30108873.0,-34106444.0,-0.89383,-0.66638,-0.45097
